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D. Miklavčič, “Early cost-effectiveness analysis of elec-
trochemotherapy as a prospect treatment modality for
skin melanoma”, Clinical Therapeutics, in preparation for
submission.
Acknowledgements
I would like to thank all my co-workers from the Laboratory of Biocybernetics at
the University of Ljubljana, especially the head of the laboratory at the time of
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Abstract
The first observations of the effects of pulsed electric fields on biological material
date more than 250 years back. But in the past two decades applications of
electroporation emerged in medicine, food processing, and biotechnology. The
phenomenon of electroporation leads to increased cell membrane permeability. Due
to exposure to high voltage electric pulses, the cell membrane becomes permeable to
molecules, which otherwise can not cross the membrane. A pulsed power generator
termed as electroporator and electrodes are used to expose cells to a pulsed electric
field. Electroporator generates electrical pulses with a specific shape, amplitude,
duration, number, repetition rate and sequence (bursts of pulses). By applying
electrical pulses to the electrodes, which are in direct contact with the tissue, an
electric field is generated in tissue with specific distribution and intensity.
In order to properly understand the current situation and trends of development
on the electroporation field, a thesis begins with a review of commercially available
devices, their characteristics, limitations, and weaknesses. Also, expert opinion
about the electroporation devices used in skin electroporation was provided. The
electroporation device manufacturers are currently hindering the development of
electroporation field by concealing the output pulse parameters of their devices,
designing them in a way to disable output pulse measuring, specifying charac-
teristics which device cannot deliver, and making devices that do not warn the
user when pulse delivery fault occurs. The quality of the pulse delivery was
evaluated, by checking if the delivered pulses were adequately addressed and
measured in the electroporation studies, with the focus on the field of nanosecond
electroporation, where the delivery and measuring are the most challenging. Addi-
tionally, recommendations for standardization, mainly focusing on the evaluation
of electroporators proper or improper operation were proposed and electronic
emulator of the biological load during electroporation, which enables constant and
sustainable testing and unbiased comparison of different electroporators operation,
was developed.
Secondly, we developed a high-frequency high voltage generator by using and
improving the latest pulse generator designs. The developed 4 kV pulse generator,
generates high voltage pulses with minimized switching time between positive and
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negative pulse. The minimal pulse duration is 200 ns and maximal repetition rate
2 MHz, it is also able to generate asymmetrical bipolar pulses. The developed
device was tested in first in vivo high-frequency electrochemotherapy (HF-ECT),
in which HF-ECT with bleomycin and cisplatin was proved to be as effective as
well established ”classical” ECT with bleomycin and cisplatin.
Third, the cost-effectiveness of electrochemotherapy of stage IV and IIIc skin
melanoma was calculated for patients treated at the Institute of Oncology in
Ljubljana using the Cliniporator device and associated electrodes. The probability
of ECT (with hospitalization) being cost-effective for the patient with stage IV and
IIIc skin melanoma is just above 50 %, which implies the prices of the device and
electrodes should be reduced for successful implementation into clinical practice.
However, if patients have bleeding lesions the ECT can be assumed cost-effective
(probability rises to 0.97).
Keywords: electroporation, standardization, electroporator design, cost-
effectoveness analysis.
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I.1 Simbolični prikaz različnih načinov uporabe elektroporacije. Ko celico
izpostavimo pulzirajočemu električnemu polju, se celična membrana
polarizira, s tem pa se zvǐsa njena prepustnost. Elektroporacija je
lahko reverzibilna (vnos ali ekstrakcija molekul in zlivanje celic) ali
ireverzibilna (celična smrt) [8]. . . . . . . . . . . . . . . . . . . . . . . 9
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troporacijskih pulzov. . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
I.3 Štirje osnovni koncepti vezij za generiranje elektroporacijskih pulzov. 13
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troporacijske pulze, ki elektroporirajo celično membrano in s tem
omogočijo transport kemoterapevtika v celico, kar poveča toksičnost
in učinkovitost terapije. . . . . . . . . . . . . . . . . . . . . . . . . . . 17
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I.6 Najprej se vbrizga DNK, nato (0,5-2 minute) dovede elektroporacijske
pulze, ki sprožijo interakcijo med permeablizirano celično membrano
in plazmidno DNK. Tvori se DNK-membranski kompleks, DNK se
s še neznanim postopkom prenese v citoplazmo in nato v jedro. V
primeru uspešne transfekcije pride do ekspresije transfeciranih genov. 20
I.7 Graf stroškovne učinkovitosti; terapiji 1 in 3, ki ležita v ravnini pod
premico MAX ICER, sta stroškovno učinkoviti, medtem ko je terapija
2 stroškovno neučinkovita. . . . . . . . . . . . . . . . . . . . . . . . . 24
III.1 Priporočamo, da raziskovalci v svoja poročila vključijo vsaj dve mer-
itvi uporabljenih elektroporacijskih pulzov: a) slika, ki zajema celotno
sekvenco dovedenih pulzov; b) slika, ki natančno prikazuje en sam
pulz, v kolikor to ni mogoče, je potrebno električne pulze ustrezno
besedno opisati. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
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III.2 Amplituda napetosti ne sme biti nižja od 90 % ali vǐsja od 110 % pred-
nastavljene napetosti. Kar pomeni, da mora biti tudi padec napetosti
med prvim in zadnjim pulzom pri največjem številu impulzov v tem
območju. Odstopanje trajanja pulza od vnaprej nastavljene vrednosti
ne sme biti večje od 8 %. . . . . . . . . . . . . . . . . . . . . . . . . . 30
III.3 Shema vezja elektronskega emulatorja elektroporacijskega bremena. . 32
III.4 Povprečje petih meritev toka pri ponavljalni frekvenci 4717 Hz (ze-
lena), (a) numerično modeliran tok s pomočjo programskega okolja
Matlab (oranžna, prva vrstica), (b) modeliran tok s pomočjo pro-
gramskega okolja PSpice (modra, druga vrstica) in (c) izmerjen tok
skozi prototipa (vijolična, tretja vrstica). Rumena krivulja v tretji
vrstici je dodatna meritev toka prototipa emulatorja pri napetosti
200 V, s tem želimo pokazati odziv, ko je napetost nižja od pragovne
napetosti. V prvem stolpcu je predstavljen tok pri 500 V, v drugem
750 V in tretjem pri 1000 V. . . . . . . . . . . . . . . . . . . . . . . . 32
III.5 Meritev monopolarnega (a) in bipolarnega (b) pulza, generiranega na
80 Ω uporu. Začetna polnilna napetost kondenzatorja je bila nastavl-
jena na 500 V, nato pa smo jo dvignili vse do 4 kV s korakom po 500
V. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
III.6 a) Slika prikazuje generiranje simetričnih bipolarnih pulzov različnih
dolžin. Polnilna napetost kondenzatorja je bila nastavljena na 4 kV,
prožitveni pulz pa je bil nastavljen na 260, 400 in 800 ns za obe polpe-
riodi. b) Slika prikazuje asimetrično generiranje bipolarnih pulzov ek-
vivalentnega naboja. Amplituda pozitivne polperiode in trajanje so
bili nastavljeni na 4 kV 200 ns, trajanje prožilnega signala negativne
polperiode pa na 260 ns, 400 ns in 800 ns in hkrati polnilna napetost
negativne polperiode na 4 kV, 2 kV in 1 kV. . . . . . . . . . . . . . . 34
III.7 Osem 200 µs dolgih sekvenc s ponavljalno frekvenco 1 Hz, vsaka
sekvenca je bila sestavljena iz 50 bipolarnih pulzov tipa 1-1-1-1 µs
(trajanje pozitivne polpreiode-pavza med polperiodama-trajanje neg-
ativne polperiode-pavza med bipolarnimi impulzi) amplitude 1950 V,
je bilo dovedenih s pomočjo ploščatih elektrod na tumor, ki se je
nahajal na boku mǐske. . . . . . . . . . . . . . . . . . . . . . . . . . . 35
III.8 : (a) Ravnina stroškovne učinkovitosti. (b) Verjetnost, da je elek-
trokemoterapija stroškovno učinkovita za vse bolnike in bolnike s kr-
vavečimi tumorji. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
Seznam uporabljenih simbolov
V doktorski disertaciji so uporabljene naslednje veličine in simboli:
Veličina / oznaka Enota
Ime Simbol Ime Simbol
čas t sekunda s
frekvenca f hertz Hz
jakost električnega polja E - V/m
tok I amper A
napetost U volt V
transmembranska napetost VTN volt V
dvižni čas tR sekunda s
čas padanja tF sekunda s
čas med polperiodama tIPD sekunda s
amplituda A - -
časovna konstanta τ sekunda s
dolžina pulza pri polovični amplitudi tFWHM sekunda s
impedanca bremena ZL ohm Ω
upornost R ohm Ω
kapacitivnost C farad F
induktivnost L henry H
dolžina pulza tp sekunda s
napetost V volt V
dielektričnost ε - F/m
magnetna permeabilnost µ - H/m
Ključne besede: elektroporacija, standardizacija, razvoj elektroporatorjev,
analiza stroškovne učinkovitosti.
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I Uvod
Elektroporacija je “temeljna” tehnologija [1], ki se je že dobro uveljavila v medicini
[2], živilski industriji [3] in genski transfekciji. Tehnologija veliko obeta tudi na
drugih področjih, kot sta proizvodnja biomase [4] in transdermalni vnos učinkovin
v telo [5]. Ko celico izpostavimo visokonapetostnim električnim pulzom, se prepust-
nost celične membrane poveča. Ločimo med reverzibilno in ireverzibilno elektro-
poracijo: če se celična membrana po izpostavljenosti električnim pulzom povrne v
prvotno stanje oziroma ohrani svoje fiziološko delovanje, gre za reverzibilno elektro-
poracijo; v primeru, ko se membrana ne povrne v prvotno stanje, se celična vsebina
razlije in celica odmre, elektroporacija je takrat ireverzibilna [6, 7]. Elektroporacijo
izkorǐsčamo za vnos večjih in manǰsih molekul v celico, ki v normalnih razmerah
težko ali ne morejo prehajati skozi membrano, za ekstrakcijo posameznih snovi iz
celice ter fuzijo oziroma zlivanje celic in povzročitev celične smrti (Slika I.1).
Slika I.1: Simbolični prikaz različnih načinov uporabe elektroporacije. Ko celico
izpostavimo pulzirajočemu električnemu polju, se celična membrana polarizira, s
tem pa se zvǐsa njena prepustnost. Elektroporacija je lahko reverzibilna (vnos ali
ekstrakcija molekul in zlivanje celic) ali ireverzibilna (celična smrt) [8].
Elektrokemoterapija je aplikacija, ki združuje vnos kemoterapevtika (v celice)
z elektroporacijo, poveča se učinkovitost protitumorskega delovanja, odmerek ke-
moterapevtika pa je zato manǰsi in lokalno omejen [9]. Genska elektrotransfekcija
omogoča nevirusni način vnosa DNA in se vse bolj uveljavlja na področju genskih
cepiv in terapij [10]. Ireverzibilna elektroporacija (kraǰse IRE) se v medicini izkorǐsča
9
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za netermično ablacijo malignega ali normalnega tkiva, celična smrt je v primeru
ustrezne uporabe IRE posledica permeabilizacije celične membrane in ne povečanja
temperature tkiva [11]. V biotehnologiji elektroporacijo poznajo pod imenom polzi-
rajoče električno polje (ang.: Pulsed Electric Field (PEF)) in jo izkorǐsčamo za
ekstrakcijo posameznih snovi iz celice, prezervacijo živil (PEF ohrani barvo in okus
živila ter ohranja nivo antioksidantov), podalǰsanje roka uporabe predvsem tekočih
živil [12] in kot tretma, ki olaǰsa rezrez živil (za razrez živila, predhodno tretiranega
s PEF, je potrebno manj sile, obenem je rez gladkeǰsi; noži imajo dalǰso življenjsko
dobo, porabi se manj energije in tako npr. krompirček pri cvrtju vsrka veliko manj
olja, kar pomeni dodaten prihranek).
I.I Elektroporacija kot fenomen
Elektroporacija je fenomen, pri katerem se zaradi izpostavljenosti pulzirajočemu
električnemu polju celici poveča permeabilnost in prevodnost celične membrane.
Vsaka biološka celica je obdana s celično membrano, ki jo sestavljajo predvsem
lipidi, in sicer fosfolipidi, glikolipidi in holesterol. Ko lipide obdamo z vodno raz-
topino, zaradi svojih dielektričnih lastnosti, spontano izoblikujejo lipidni dvosloj,
skozi katerega večje molekule, voda in njene raztopine ne morejo prosto prehajati
[13]. Poleg lipidov se v membrani nahajajo tudi druge molekule, ki omogočajo
selektivni transport v celico in iz nje. V zadnjih letih se je pojavilo kar nekaj teo-
retičnih razlag elektroporacije. Med vsemi se je najbolj uveljavila in se zdi najbolj
verjetna tista teorija, ki temelji na izoblikovanju vodnih por v celični membrani. Ko
celico izpostavimo visokonapetostnim električnim pulzom, se na membrani inducira
napetost, ki sproži reorganizacijo celične membrane in formiranje hidrofilnih por. S
tem je omogočen ionski in molekulski transport molekulam, ki drugače ne morejo
prosto prehajati skozi membrano [14]. Predlagana teorija še ni bila eksperimentalno
dokazana, vendar molekularna dinamika nudi prepričljivo potrditev [15].
Za lažje razumevanje procesa elektroporacije celico modeliramo kot elektrolit
(prevodni medij), ki je obdan z dielektrično plastjo. Dielektrična plast predstavlja
lipidni dvosloj, ki ima lastnosti izolatorja. Vsaka celica ima mirovni transmem-
branski potencial med -90 in -40 mV, ki je posledica negativno nabite citoplazme
[16]. Celico izpostavimo električnemu polju tako, da preko elektrod na celično
suspenzijo ali tkivo dovedemo električne pulze ustrezne jakosti in trajanja. Zaradi
nizke prevodnosti membrane se električno polje skoncentrira predvsem v celični
membrani, ki se polarizira, na njen pa se vzpostavi transmembranska napetost
VTN , ki je vsota mirovnega potenciala in pritisnjene napetosti. Napetost VTN
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je pogojena z obliko celice ter položajem oziroma orientacijo elektrod. Časovna
konstanta celične membrane je v milisekundnem območju [17], torej, ko celico
izpostavimo kraǰsim pulzom (nanosekundno območje), se celična membrana obnaša
kot kondenzator. Posledično se pritisnjena napetost pojavi tudi v notranjosti celice,
kar pomeni, da jo lahko izkorǐsčamo za znotrajcelično manipulacijo [18].
I.II Dozimetrija pri elektroporaciji
Lokalno električno polje,je tisto polje, ki ga celica “čuti” in je poglavitni razlog za
elektroporacijo celične membrane. Porazdelitev električnega polja in intenziteta sta
pogojeni s tipom aplikatorja oziroma s geometrijo elektrod in karakteristiko dove-
denih električnih pulzov. Zato se za različne aplikacije uporablja različne oblike,
amplitude, trajanja, ponavljalne frekvence in sekvence električnih pulzov. Ustrezen
opis elektroporacijskih pulzov je ključen za pravilno poročanje in razumevanje elek-
troporacijskih študij [8].
Slika I.2: Opis kvadratnih (a), eksponentno padajočih (b) in bipolarnih (c) elektro-
poracijskih pulzov.
Eksponentno padajoče pulze definiramo z maksimalno vrednostjo AMAX in
časovno konstanto τ . Vrednost časovne konstante je pogojena s karakteristiko
izhodne stopnje in je definirana kot čas, v katerem amplituda pade na 37 % AMAX
(Slika I.2b). Kvadratne pulze opǐsemo z amplitudo (tj. tista vrednost, ki se na-
jbolje približa vsem točkam v visokemu nivoju) in dolžino pulza. Dolžina pulza pa
12 Uvod
je definirana kot FWHM (ang.: Full Width at Half Maximum). FWHM je čas, ki
preteče, medtem ko amplituda doseže 50 % vrednosti v fazi vklopa in ponovno pade
na 50 % AMAX v fazi izklopa. Pri elektroporacijskih pulzih ponavadi podamo še
dvižni čas tR (ang.: rise time) in čas padanja tF (ang.: fall time). Dvižni čas je
definiran kot čas, pri katerem pulz naraste od 10 % do 90 % amplitude. Za čas
padanja pulza pa velja ravno obratno- amplituda pade od 90 % do 10 % amplitude
(Slika I.2a).
V zadnjem času se na področju elektroporacije vse bolj uveljavlja uporaba bipo-
larnih pulzov, zato ker področje občutljivosti, preklica in vzbujalnih učinkov elektro-
poracijskih pulzov še ni dovolj dobro raziskano. Učinek občutljivosti je definiran kot
dvig oziroma upad vnosa molekul v celico v primeru apliciranja dvakratne namesto
enojne polovične doze. Pri uporabi kraǰsih pulzov, dolgih nekaj sto nanosekund,
so odkrili, da pride do preklica bioloških učinkov [19, 20, 21, 22]. Efekt preklica je
definiran kot upad vnosa v celico, ko to izpostavimo enemu monopolarnemu pulzu,
ki mu skoraj strnjeno sledi drugi monopolarni pulz nasprotne polaritete (torej gre
za en bipolarni pulz), v primerjavi z enim samim monopolarnim pulzom. Vsako
polperiodo bipolarnega pulza opǐsemo enako kot kvadratni elektroporacijski pulz,
čas med polperiodoma imenujemo tIPD (ang: Inter Pulse Delay), pavzo med dvema
bipolarnima pulzoma pa opredelimo s tPAUSE.
Posebej zasnovane naprave, ki se uporabljajo za generiranje elektroporacijskih
električnih pulzov, imenujemo elektroporatorji. Ker se električne karakteristike bi-
oloških bremen močno razlikujejo, poleg tega se tudi njihova prevodnost zaradi elek-
troporacije med dovajanjem pulzov spreminja, razvoj elektroporatorjev proizvajal-
cem predstavlja velik izziv [23, 24, 8].
I.II.I Generiranje električnih pulzov
Elektroporator je naprava, ki je zgrajena iz visokonapetostnega pulznega gener-
atorja, merilnega sistema in zaščite. Obstaja več vrst elektroporatorjev, ki jih
ločimo glede na karakteristike generiranih električnih pulzov in namen uporabe.
Generiranje eksponentnega pulza je precej enostavno, potrebujemo le kondenzator
in vir električne napetosti (Slika I.3a). Kondenzator priključimo na želeno napetost,
ga napolnimo in s tem določimo maksimalno amplitudo pulza. Nato odklopimo vir
in priključimo breme ZL, skozenj se kondenzator začne prazniti. Vsa energija, ki jo
želimo prenesti na breme, mora biti že pred preklopom shranjena v kondenzatorju.
Napetost na kondenzatorju pada eksponentno, kondenzator se tako izprazni v
času 5τ , vendar ne smemo pozabiti, da se impedanca biološkega bremena med
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dovajanjem pulza niža, kar pomeni, da se spreminja vrednost τ . Torej je dolžina
generiranega pulza odvisna od karakteristik posameznega biološkega bremena. Za
zmanǰsanje omenjenega vpliva dodamo bremenu še soupor, ki pa mora imeti (vsaj
10-krat) nižjo vrednost od bremena ZL. Vendar ne smemo pozabiti, da se na
dodanem uporu lahko porabi tudi do 90 % energije. V kolikor želimo generirati
kvadratne pulze, potrebujemo večje kondenzatorje, ki jih nato le delno izpraznimo.
Problem lahko rešimo z vzporedno vezavo večih kondenzatorjev in pripadajočih
preduporov - tako sestavimo Marxov generator (Slika I.3b). Vsi kondenzatorji se
tako hkrati napolnijo skozi upore in ob sklenitvi stikala hkrati izpraznijo skozi
breme ZL. Vsa stikala morajo preklopiti hkrati, na breme se tako prenese maksi-
malna dovedena napetost, pomnožena s številom kondenzatorjev. Vlogo stikalnih
elementov pri elektroporatorjih v večini prevzamejo močnostna MOSFET ali IGBT
stikala. Paziti moramo, da je padec napetosti na stikalu pri prenosu čim manǰsi,
enako velja tudi za breme, kar pomeni, da mora biti kapacitivnost kondenzatorja
čim večja. Polnjenje kondenzatorja z veliko kapacitivnostjo pa je dolgotrajno, kar
nas dodatno omejuje, saj novega pulza ne moremo generirati, dokler kondenzator
ni povsem poln. [8, 23, 25].
Slika I.3: Štirje osnovni koncepti vezij za generiranje elektroporacijskih pulzov.
Za generiranje kraǰsih pulzov v nanosekundnem območju se uporablja drugačne
rešitve, kot sta Blumline generator (Slika I.2c) in generator z diodno odpiralnim
stikalom (Slika I.2d). Kot pri ostalih vezavah tudi tukaj obravnavamo delovanje
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v dveh fazah. V fazi polnjenja se skozi upor R polni valovna linija, ki se nato po
preklopu izprazni preko bremena ZL. Impedanca valovodne linije Z0 mora biti enaka
oziroma čim bolj podobna impedanci bremena ZL. Z0 je enaka (L/C)
0.5, kjer je C
kapacitivnost in L induktivnost, na 1 m dolžine valovodne linije. Dolžina pulza
(tp) je tako enaka 2l(εµ)
0.5, kjer l predstavlja dolžino linije, ε dielektričnost in µ
magnetno permeabilnost izolatorja v valovodni liniji. Amplituda izhodnega pulza
je enaka napajalni napetosti (Vizh = Vvh). Glavna slabost Blumline generatorja je
nizka ponavljalna frekvenca pulzov (do 10 kHz, ker se generator polni preko nizko-
prevodnega upora) in konstantna dolžina pulza, ki je odvisna od dolžine valovodne
linije. V kolikor pa vežemo dve stikali na koncu valovodnih linij, lahko nadgradimo
Blumlein-ov generator v Blumleinov generator z variabilno dolžino pulza [26].
Generatorji z diodnim odpiralnim stikalom (ang.: Diode Opening Switch - DOS),
imajo zelo hiter cikel polnjenja in praznjenja, kar pomeni, da omogoča generiranje
večjega števila pulzov v kraǰsem času. Pulz oblikuje s pomočjo polprevodnǐske
diode, ki ima dolgo, a na koncu naglo povratno okrevanje. Gre za ne prav pogosto
uporabljeno polprevodnǐsko diodo, ki jo uporabimo kot nabojno krmiljeno stikalo
(ang.: charge controlled switch). Njena posebnost je, da je sposobna zelo hitro
preklopiti in delovati pri relativno velikih močeh [27, 28, 29].
I.II.II Dovajanje električnih pulzov, merjenje in standardizacija
Pri elektroporaciji je za zagotavljanje kakovosti poskusov in terapij ključnega pom-
ena merjenje. A v zadnjem času se povečuje število neuspešnih ponovitev objavl-
jenih študij [30]. Opisi uporabljene opreme in metod so velikokrat pomanjkljivi ali
napačni. V številnih prispevkih s področja elektroporacije raziskovalci ne poročajo
dovolj podrobno, da bi lahko druge skupine ponovile ali nadgradile njihove študije
[18, 31]. Eden izmed glavnih problemov je, da raziskovalci ne nadzorujejo dova-
janja pulzov in posledično o meritvah pogosto sploh ne poročajo. Na trgu pa je
na voljo vse več elektroporacijskih naprav, večnamenskih ali zasnovanih za posebne
aplikacije. Zdi se, da bolj kot raste trg, oziroma se povpraševanje na trgu povečuje,
manj izvemo o napravah s strani proizvajalcev. Nekatere so namerno izdelane tako,
da ne omogočajo merjenja. Na področju genske elektrotransfekcije, kjer se naj-
pogosteje uporabljajo vnaprej programirani postopki elektroporacije, smo že dosegli
kritično točko. Raziskovalci pogosto ne poznajo niti osnovnih parametrov elek-
tričnih pulzov, kot so oblika, dolžina, ponavljalnja frekvenca pulza, še manj pa je
znanega o jakosti električnega polja. Raziskovalci poznajo samo zaporedno številko
izbranega programa, ki je nameščen na njihovo napravo. Torej je prehajanje med
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napravami različnih proizvajalcev skoraj nemogoče. Omejevanje ključnih informacij
o karakteristikah električnih pulzov ovira razvoj novega znanja, onemogoča primer-
javo rezultatov ali protokolov ter zavira celoten razvoj področja genske elektrotrans-
fekcije. Kakovostno elektroporacijo je mogoče zagotoviti le z ustreznimi meritvami,
saj elektroporatorji ne delujejo vedno v skladu s tehničnimi specifikacijami. Na tem
področju še ni nikakršne regulative, ki bi zagotavljala in urejala kakovost elektropo-
racijskih naprav.
Merjenje električnih pulzov in ovrednotenje generiranega električnega polja pred-
stavlja poseben izziv pri uporabi zelo kratkih nanosekundnih (od 1 do 20 ns) elek-
troporacijskih pulzov zaradi končne hitrosti potovanja pulzov (20 cm/ns) in s tem
povezanih odbojev pulzov. Nanosekundni elektroporatorji so običajno sestavljeni iz
generatorja nanosekundnih pulzov in valovodne linije ali mreže za oblikovanje pulzov
(ang.: Pulse Forming Network (PFN)) in sistema za dovajanje elektroporacijskih
pulzov, kot so različne komore ali elektrode [32, 33, 18]. Nanosekundni pulzi potujejo
približno 20 cm/ns v koaksialnem kablu. Torej je potrebno pri uporabi nanosekund-
nih pulzov vedno upoštevati, da se pulzi ob spremembi impedance odbijejo oziroma
se njihova moč v prenosni liniji zniža. Skratka, ko ujemanje impedance ni zagotovl-
jeno, so odboji prisotni in odvisni od bremena. Če je impedanca bremena večja, so
odboji pozitivni in se prǐstevajo k amplitudi. V primeru nižje impedance bremena
se amplituda zaradi odbojev zniža. Pulzi lahko zaradi odbojev postanejo bipolarni,
kar pa lahko privede do efekta preklica biološkega učinka [18].
I.III Uporaba elektroporacije v medicini
Ker je tkivo zelo nehomogen prevodnik, pri ex vivo ali in vivo elektroporaciji tkiv
električnega polja ne obravnavamo več kot homogenega. Nekateri biološki materiali
so anizotropni, zato je potrebno upoštevati tudi smer električnega polja. Neho-
mogenost tkiv se razlikuje od tkiva do tkiva in je odvisna od frekvence (pri vǐsjih
frekvencah je nižja). Ker se med elektroporacijo spremeni prevodnost biološkega
bremena, se sočasno spreminja tudi porazdelitev električnega polja [34]. Tumorji
imajo zaradi celične nekroze večinoma vǐsjo vsebnost vode [35]. Pri elektroporaciji
tkiva moramo torej dobro poznati značilnosti posameznega tkiva, najpogosteje in
najenostavneje tkivo opǐsemo s specifično prevodnostjo in relativno dielektričnostjo.
Vsiljena napetost se porazdeli po tkivu, največji padec napetosti pa je na najmanj
prevodnem delu tkiva, ki je v primeru elektroporoacije z neinvazivnimi elektrodami
ponavadi koža, saj je njena prevodnost kar 10–100-krat nižja od prevodnosti tkiva, ki
se nahaja pod njo. Zato je potrebno dodatno pozornost posvetiti neželenemu rezis-
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tivnemu gretju, ki lahko v primeru prevelikega padca napetosti poškoduje zdrave
celice [36, 37]. Za določitev lokalne porazdelitve električnega polja znotraj tumorjev
ali tkiva se zato uporabljajo različne numerične metode [38, 39]. V primeru elektro-
poracije globoko ležečih tumorjev in tumorjev v notranjih organih, ki so obdani s
tkivi, ki imajo različne električne lastnosti, je potrebno terapijo vnaprej individual-
izirano začrtati [40]. Posamezni tumorji se prav tako razlikujejo po obliki, velikosti in
lokaciji. Vsak tumor se zato analizira individualno in na podlagi analize optimizira
položaj igelnih elektrod ter karakteristiko dovedenih električnih pulzov [39, 41, 42].
Terapija bo uspešna le, če bo celoten tumor izpostavljen ustreznemu električnemu
polju [35, 43], kar pa je trenutno mogoče zagotoviti s pomočjo numeričnega modeli-
ranja distribucije električnega polja [44]. Takšni izračuni električnega polja temeljijo
na podlagi realnih vhodnih podatkov. V določenih primerih se uporablja tudi
slikovno vodeno vstavljanje elektrod [38, 45, 46]. V primeru ireverzibilne elektro-
poracije pa je pri načrtovanju terapije potrebno upoštevati tudi izračune povečanja
temperature [47]. Tudi pri in vivo elektroporaciji je za zagotavljanje kakovosti ter-
apije potrebno meriti in s tem nadzorovati dovedene električne pulze. Večinoma
merimo napetost in tok dovedenih pulzov, v raziskovalne namene pa se uporablja
tudi elektroimpedančna tomografija (EIT), vendar nam nobena od teh meritev ne
poda informacije o porazdelitvi električnega polja znotraj tkiva. Medtem ko MR-
EIT (magnetnoresonančna električnaimpedančna tomografija) omogoča rekonstruk-
cijo porazdelitve električnega polja z uporabo MR slikanja in numeričnih algoritmov,
tako lahko izmerimo porazdelitve gostote električnega toka in električne prevodnosti
med elektroporacijo [48]. Generiranje homogenega električnega polja znotraj hetero-
gene strukture tkiv še vedno predstavlja velik izziv. Porazdelitev električnega polja
je predvidoma možno izbolǰsati z uporabo visokonapetostnih, visokofrekvenčnih,
bipolarnih električnih pulzov.
I.III.I Elektrokemoterapija
Elektrokemotrapija ali kraǰse ECT (ang.: Electrochemotherapy (ECT)), vodilna
aplikacija v medicini na področju elektroporacije, je antitumorska terapija, pri
kateri celice oziroma tkivo izpostavimo visokonapetostnim električnim pulzom, ki
permeabilizirajo celično membrano in s tem omogočijo vnos že prej vbrizganega
(intratumorsko ali intravenozno) kemoterapevtika (bleomicin ali cisplatin) v celico
in s tem zvǐsajo njuno toksičnost [49, 50] (Slika I.4). Permeabilizirane celice
so v primeru ustrezne porazdelitve električnega polja večinoma tumorske celice.
Prav tako je potrebno za uspešno terapijo zagotoviti dovolj visoko koncentracijo
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vbrizganega kemoterapevtika v tumorju [51]. ECT je zelo učinkovita terapija,
saj z enim samim tretmajem doseže med 50 in 70 % popolnih odzivov in 80 %
objektivnih odzivov [52]. ECT je torej primerljiva, če ne celo bolj učinkovita kot
standardne terapije kožnega raka [53]. V večini se uporablja v skladu s standardnim
operativnim postopkom (ang.: Standard Operating Procedures (SOP)) za zdravl-
jenje kožnih in podkožnih tumorjev oziroma metastaz, ki je bil vzpostavljen leta
2006 [54]. Ker SOP predpisuje priporočila le za obravnavo manǰsih kožnih tumorjev
(< 3 cm premera), je bil leta 2018 nadgrajen. Posodobitev vsebuje smernice za
zdravljenje primarnih in metastatskih tumorjev kože tudi večjih od 3 cm [55].
Britanski nacionalni inštitut za odličnost v zdravstvu in oskrbi (ang.: National
Institute for Health and Care Excellence (NICE)) je prepoznal ECT kot sestavni del
multidisciplinarnega zdravljenja bolnikov s kožnimi metastazami, ki niso kožnega
izvora, in melanomom (IPG 446, http://www.nice.org.uk/guidance/ipg446). Prav
tako je v slovenskih smernicah za zdravljenje kožnega melanoma ECT eden od
možnih načinov zdravljenja pri recidivih na ekstremitetah, kjer ni možna preprosta
ekscizija (> 3 - 5 zasevkov), ali pri zelo hitro ponavljajočih se recidivih (prej kot v
3 - 6 mesecih) [56]. V zadnjih letih pa se vse več pozornosti posveča tudi uporabi
ECT za zdravljenje globoko ležečih tumorjev, predvsem metastaz v jetrih, zlasti
kadar se nahajajo v bližini večjih žil in zato posledično niso primerne za odstranitev
v sklopu kirurškega posega [9].
Slika I.4: ECT: Po injiciranju kemoterapevtika (8 - 28 minut) dovedemo elektro-
poracijske pulze, ki elektroporirajo celično membrano in s tem omogočijo transport
kemoterapevtika v celico, kar poveča toksičnost in učinkovitost terapije.
Parametri električnih pulzov, optimizirani in vitro, se preslikajo tudi v optimalne
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parametre in vivo. Trenutno je pod imenom “klasični” elektroporacijski pulzi defini-
rana sekvenca osmih monopolarnih pravokotnih pulzov, dolžina vsakega pulza je 100
µs, ponavljalna frekvenca pa 1 Hz ali 5 kHz. Prednosti vǐsje ponavljalne frekvence
so kraǰse trajanje elektroporacije, občutek samo ene aplikacije električnih impulzov
in enkratno krčenja mǐsic. Ker se mǐsično krčenje pojavi le enkrat, se izognemo
tudi neželenemu premiku elektrod med samo sekvenco. Prav tako bolniki poročajo,
da je bolečina v primeru 5 kHz manǰsa kot pri 1 Hz [57, 58]. Amplituda napetosti
je najpogosteje nekje med 200 in 1000 V. Odvisna je od elektrod in ciljnega tkiva,
zagotoviti pa mora, da je električno polje med elektrodama vǐsje od 400 V/cm. ECT
skoraj nima stranskih učinkov, po terapiji se lahko pojavi lokalna bolečina, ki zbledi
v nekaj dneh. Do večjih zapletov pa lahko pride, če dovedeni elektroporacijski pulzi
zmotijo ritem srčne mǐsice. Pri elektroporaciji kože je to skoraj nemogoče oziroma
je zelo malo verjetno, vendar se verjetnost poveča pri tretiranju globoko ležečih tu-
morjev, ki se lahko nahajajo tudi v bližini srca. V kolikor je amplituda dovedenih
električnih pulzov vǐsja od mejne vrednosti fibrilacije ali če so električni pulzi dove-
deni med pozno atrijsko ali ventrikularno sistolo, lahko zmotijo srčni ritem. Rizično
območje za ventrikle je v bližini T-vala, za atrije pa v bližini S-vala [59]. Zato je
za zmanǰsanje tveganja dovajanje elektroporacijskih pulzov sinhronizirano s srčnim
ritmom [60].
I.III.II Ireverzibilna elektroporacija
Slika I.5: Pri IRE celici dovedemo elektroporacijske pulze, ki povzročijo celično
smrt, domnevno odmrejo zaradi izgube homeostaze.
Ireverzibilna elektroporacija (kraǰse IRE) se uporablja za “netermično” ablacijo
tkiv in tumorjev. Pri IRE celice domnevno odmrejo zaradi izgube homeostaze (Slika
I.5) in ne zaradi dviga temperature [61], kljub temu pa se lahko temperatura v bližini
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elektrod z uporabo vǐsjih napetosti in večjega števila pulzov znatno povǐsa [62, 63].
Pri IRE se srečamo s skoraj enakimi izzivi kot pri ECT, za uspešno terapijo mora
biti celotno tumorsko tkivo izpostavljeno ustrezni jakosti električnega polja, ki mora
biti vǐsja, kot je prag ireverzibilne elektroporacije. Poleg tega je treba paziti, da
je elektroporacija zdravega tkiva čim manǰsa, saj se s tem izognemo nepotrebnim
termičnim poškodbam. Uporablja se predvsem v kliničnih študijah za zdravljenje
globoko ležečih tumorjev, operativno ali perkutano v jetrih, trebušni slinavki, led-
vicah, pljučih in drugih organih [11]. IRE nima SOP, različne raziskovalne skupine
uporabljajo različne protokole, ki se od vrste tumorjev in stopnje rakavega obolenja
nekoliko razlikujejo. Za vsak posamezen tumor je potrebno izdelati individualni
načrt zdravljenja. IRE je lahko tudi minimalno invaziven v kombinaciji z ultraz-
vokom, računalnǐsko tomografsko usmeritvijo ali slikanjem z magnetno resonanco
[64]. Pri IRE je varnost še pomembneǰsa kot pri ECT, saj se ponavadi tretira veliko
več tkiva (tudi do 50 cm3), hkrati je število dovedenih pulzov veliko večje (pon-
avadi dovedemo vsaj 90 pulzov) [65]. Za prečkanje praga IRE mora biti električna
poljska jakost veliko vǐsja kot pri ECT, tipično imajo pulzi amplitude tudi do 3000
V in dosegajo tokove tudi do 50 A. Zaradi vǐsjih električnih polj in operacije, ki
je lahko blizu srca, morajo biti elektroporacijski pulzi sinhronizirani z refraktarno
dobo srčnega ritma [66]. Čas terapije je v primerjavi z referenčnimi postopki izjemno
kratek - traja le nekaj minut. Dejanski čas je mogoče izračunati iz števila aplici-
ranih pulzov in povprečnega srčnega utripa. “Klasična” IRE temelji na uporabi
monopolarnih električnih pulzov, ki jih običajno spremlja signifikantna mǐsična kon-
trakcija, zato se za zmanǰsanje te uporablja živčno-mǐsična zaviralna sredstva, prav
tako so pacienti v splošni anasteziji. Toda pred kratkim so v seriji večih študij av-
torji pokazali, da se lahko z uporabo visokofrekvenčnih bipolarnih sekvenc pulzov, t.
i. H-FIRE (ang.: High-Frequency IrReversible Electroporation), izognemo neželeni
mǐsični kontrakciji. Arena et al. so z uporabo H-FIRE pulzov ponavljalne frekvence
250 ali 500 kHz dosegli enake rezultate ablacije in natančnosti kot pri “klasični” IRE
[67].
I.III.III Genska elektrotransfekcija
Genska elektrotransfekcija je obetavna nevirusna metoda vnosa genov [68].
Uporablja se za zdravljenje rakavih in drugih genskih obolenj [69] ter za DNK
cepljenje [70]. In vitro pa se električni impulzi pogosto uporabljajo za transfekcijo
bakterijskih in evkariontskih celic [71]. Metoda vnosa genov z elektroporacijo se
uspešno uporablja že od leta 1982, vendar so natančni molekularni mehanizmi
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Slika I.6: Najprej se vbrizga DNK, nato (0,5-2 minute) dovede elektroporacijske
pulze, ki sprožijo interakcijo med permeablizirano celično membrano in plazmidno
DNK. Tvori se DNK-membranski kompleks, DNK se s še neznanim postopkom
prenese v citoplazmo in nato v jedro. V primeru uspešne transfekcije pride do
ekspresije transfeciranih genov.
prenosa DNK še vedno neznanka [68, 72]. Do prenosa DNK lahko pride le v primeru
reverzibilne elektroporacije, saj mrtve celice ne morejo izražati transfeciranih genov.
Osnovni koncept ostaja enak, najprej se lokalno vbrizga DNK, nato pa dovede
elektroporacijske pulze (to so ponavadi dalǰsi pulzi v milisekundnem območju,
nižjih napetosti (nekaj 100 V)), kar sproži interakcijo med permeabilizirano celično
membrano in plazmidno DNK. Tvori se DNK-membranski kompleks, DNK se s
še neznanim postopkom prenese v citoplazmo in nato v jedro. V primeru uspešne
transfekcije pride do ekspresije transfeciranih genov (Slika I.6) [73]. V sklopu
nekaterih študij so raziskovalci pokazali, da se genska transfekcija poveča, če
dovedemo kratke visokonapetostne in dolge nizkonapetostne pulze v sklopu ene
sekvence. Visokonapetostni pulzi so ključni za permeabilizacijo celične membrane
in tvorbo pore, medtem ko nizkonapetostni pulzi elektroforetsko vlečejo negativno
nabito DNK v celico. V eni od študij predlagajo uporabo osmih visokonapetostnih
pulzov dolžine 100 µs z amplitudo 1300 V/cm, ki jim sledi en dalǰsi 100 ms
dolg nizkonapetostni pulz 100 V/cm [74], kasneje pa je skupina prof. Miklavčiča
pokazala, da kratki visokonapetostni pulzi niso samo ključni, ampak tudi zadostni
za uspešen vnos DNK v primeru optimalne koncentracije plazmidne DNK. Vendar,
kljub temu mislijo, da je elektroforetska sila nizkonapetostnih pulzov ključna pri
in vivo aplikacijah, saj smo omejeni s koncentracijo plazmida [68]. Parametri
elektroporacijskih pulzov so odvisni od vrste antigena tumorja in ciljnih tkiv,
ciljne celice v specifičnem tkivu pa so različne [72]. Različne raziskovalne skupine
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uporabljajo različne pulze, v nekaterih študijah so pokazali, da sprememba smeri
električnega polja oziroma orientacije dovajanja pulzov poveča ekspresijo, saj do
vnosa DNK pride le v delu membrane, ki je obrnjen proti katodi [75, 73]. V zadnjih
nekaj letih pa se na področju genske elektrotransfekcije vse več pozornosti posveča
tudi nanosekundni elektroporaciji [76]. Z večjimi pulzi dosežemo večjo ekspresijo, a
hkrati manǰse preživetje, medtem ko je pri nižjih pulzih preživetje vǐsje, ekspresija
pa nižja.
I.IV Vrednotenje novih tehnologij v medicini
Svetovna zdravstvena organizacija (WHO) definira vrednotenje novih tehnologij v
medicini (ang.: Health Technology Assessment (HTA)) tako: “HTA se nanaša na sis-
tematično vrednotenje lastnosti, učinkov in/ali vplivov zdravstvene tehnologije. Je
multidisciplinarni postopek za vrednotenje družbenih, ekonomskih, organizacijskih
in etičnih vprašanj zdravstvene intervencije ali inovativne tehnologije. Glavni na-
men ocenjevanja je informiranje strategov in odločevalcev.” [77]. Ocenjuje oziroma
evalvira se sisteme, splošno opremo, instrumente, strojno in programsko opremo ter
postopke, standarde, norme, kadrovske veščine, strokovno znanje, zdravila, javne
zdravstvene programe ipd. HTA se trenutno uporablja večinoma za farmacevtske
izdelke, vendar se predvsem v tujini počasi uveljavlja tudi na področju biomedicin-
skih naprav, za kar pa je potrebno obstoječe metode nekoliko modificirati [78].
Nova zdravila se lahko vpelje v klinično prakso, ko proizvajalci pridobijo zado-
voljive dokaze o njihovi učinkovitosti, medtem ko je za uporabo medicinske naprave
potrebno dokazati le, da je za uporabo varna, ne pa tudi učinkovita. Rezultat HTA
zagotavlja informacije o stroških/ekonomski učinkovitosti, prihrankih, uspešnosti,
varnosti, etičnih in družbenih vplivih in izbolǰsavah zdravljenja/zdravil. Če je anal-
iza uspešno zaključena, mora odgovoriti na vprašanje, ali resnično potrebujemo to
tehnologijo in zakaj. Formalni dokaz HTA je mogoče najti v sistematičnih pregledih,
metaanalizah in kliničnih študijah [79]. S pomočjo odločitvene multikriterijske anal-
ize lahko na podlagi kakovosti prilagojenih življenjskih let (ang.: Quality Adjusted
Life Years (QALY)) ocenimo stroškovno učinkovitost nove terapije ali tehnologije.
Ena od pogosto uporabljenih analiz je analiza stroškovne učinkovitosti (ang.: Cost-
Effectiveness Analysis (CEA)); njen osnovni koncept in načela so predstavljeni v
naslednjem podpoglavju. V zadnjih letih pa se vse več pozornosti posveča zgodnjemu
vrednotenju novih tehnologij v medicini (eHTA) (ang.: early Health Technology As-
sessment (eHTA)), ki zajema primere z omejenimi kliničnimi dokazi in na podlagi
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teh napoveduje s pomočjo statističnih metod [80, 81]. Stroški, vključeni v eHTA, se
ocenjujejo za najslabši primer (najvǐsji strošek), negotovost pa se količinsko določi s
pomočjo statističnih tehnik. Rezultat eHTA obvešča nosilce odločanja o tveganju in
priložnostih, pri čemer tveganje predstavlja potencialni strošek, priložnost pa poten-
cialno učinkovitost. eHTA predvideva, da bo HTA narejena, ko bo na voljo zadostna
količina podatkov. Njen glavni doprinos pa je, da omogoča hitreǰso implementacijo
medicinskih pripomočkov ali naprav, ki lahko potencialno rešijo življenje ali znatno
izbolǰsajo kakovost življenja, v klinično prakso.
I.IV.I Stroškovna analiza v medicini
Trenutno je na voljo več metod vrednotenja tehnologij in terapij v medicini, ena
teh je tudi analiza stroškovne učinkovitosti (CEA),ki meri inkrementalno vrednost
stroškovnega vložka, potrebnega za umestitev nove tehnologije, in vpliv nove
tehnologije na zdravje bolnikov, slednje je definirano s kakovostjo življenja [82].
Pri CEA predvidevamo, da se ljudje v svojem življenju gibljejo skozi različna
zdravstvena stanja, vsakemu od teh stanj pa je pripisana posebna vrednost -
kakovost življenja (ang.: Quality of Life (QoL)). QoL opisuje kakovost vsakod-
nevnega življenja posameznika, vključno s socialnimi, čustvenimi in fizičnimi vidiki.
Za oceno kakovosti življenja se uporabljajo indikatorji zdravstvene oskrbe, ki nam
povedo, kako zdravstvena oskrba vpliva na paciente, imenovani zdravstvenemu
stanju prilagojena življenjska leta (ang.: Health Adjusted life Years (HAYs)). Eno
od meril je “kakovostni prilagojena življenjska leta” (ang.: Quality Adjusted Life
Years (QALY)), to je splošen indeks (ni specifičen za bolezensko stanje) in združuje
dolžino življenja s kakovostjo življenja. QALY se uporablja pri analizah stroškovne
učinkovitosti za določitev inkrementalnega razmerja stroškov (nova tehnologija ali
terapija v primerjavi z referenčno) in pridobljenega QALY. Indeks je definiran kot
utežena življenjska leta, oziroma čas s kakovostjo življenja pridobljeno skozi ta čas
[83]. QoL je normaliziran na standardizirano lestvico in ima vrednost med 0,0
(smrt) in 1,0 (popolno zdravje). Nekateri avtorji navajajo, da je mogoče doseči
tudi negativne vrednosti, ki opisujejo stanja, slabša od smrti (npr. demenco ali
komo pogosto štejemo za enaki ali slabši od smrti [84]). Orodje (vprašalnik)
za ocenjevanje EuroQol (EQ-5D), je standardiziran instrument, ki se uporablja
kot merilo zdravstvenih rezultatov, je široko uporabljeno in prevedeno v večino
jezikov [85, 86]. Zdravstveno stanje se meri v petih dimenzijah: mobilnost (sposob-
nost hoje); samooskrba (sposobnost pranja ali oblačenja); običajne dejavnosti
(kot so “delo, študij, gospodinjska opravila, družinske ali zasebne dejavnosti”);
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bolečina/nelagodje; tesnoba/depresija. Anketiranci ocenjujejo vsako dimenzijo;
obstajata dve različici s tristopenjsko (EQ-5D-3L-vsako dimenzijo ocenjuje s tremi
vrednostmi: “0” - ni težav; “1” - nekaj težav; “2” - veliko težav) in petstopenjsko
lestvico (EQ-5D-5L). Na podlagi samoocene bolnikovih telesnih, socialnih in
kognitivnih sposobnostih se izračuna končna vrednost indeksa. EQ-5D-3L torej
definira 243 (35) potencialnih zdravstvenih stanj, ki skupaj z dvema dodatnima
stanjema, enim za smrt in enim za nezavest, skupno definira 245 zdravstvenih stanj.
Primer: eno leto popolnega zdravja je vredno 1 QALY, vsako leto nepopolnega
zdravja pa manj kot 1 QALY, odvisno od bremena bolezni, ki ga čuti bolnik [87].
Tako bo intervencija, ki ustvari šest dodatnih let zdravstvenega stanja vrednosti
0,65 QALY, ustvarila več QALY kot primerljiva tehnologija, ki v zdravstvenem
stanju ocenjenih na 0,5 QALY ohrani bolnika 7 let.
Rezultat CEA predstavimo z inkrementalnim razmerjem stroška (ang.: Incre-
mental Cost Ratio (ICER)). ICER je opredeljen kot dodatni strošek na dodatno
korist, ki se meri s QALY. Ker ima QALY normalno porazdelitev in ima vsota
dveh normalnih spremenljivk tudi normalno porazdelitev, ICER lahko izračunamo
kot razmerje dveh spremenljivk [88] s pomočjo naslednje enačbe (Enačba I.1), kjer
zdravljenje B predstavlja zlati standard oz. referenčno merilo in zdravljenje X novo
terapijo (npr. elektrokemoterapijo):
ICER =
cenaterapijaX − cenaterapijaB
koristterapijaX − koristterapijaB
(I.1)
ICER za lažje razumevanje prikažemo kot distribucijo vzorčne populacije v grafu
stroškovne učinkovitosti (Slika I.7), v katerem ponazorimo razmerje med inkremen-
talnimi stopnjami koristi in skupnim, dodatnim stroškom potrebnega za zagotavl-
janje želenega izida. Vsak od kvadrantov koordinatnega sistema predstavlja en
možen izid, če je nova terapija X bolj učinkovita in ceneǰsa v primerjavi z referenčno
terapijo B, se nahajamo v četrtem kvadrantu, kar seveda pomeni, da je vredna im-
plementacije v klinično prakso. Vendar se rezultati CEA novih terapij pogosteje
nahajajo v I. kvadrantu, torej je nova terapija X bolj učinkovita in hkrati dražja. V
tem primeru se je potrebno odločiti, ali pridobljena korist upraviči dodaten strošek
[89]. Maksimalen ICER (ang.: Maximum acceptable ceiling ratio (max ICER)) je
mejna oziroma maksimalna vrednost, ki jo je odločevalec pripravljen plačati za en
pridobljen QALY. V grafu stroškovne učinkovitosti jo ponazorimo kot mejno pre-
mico, če se ICER nahaja v ravnini pod premico, potem je nova terapija X stroškovno
učinkovita in je sprejeta, v nasprotnem primeru pa zavrnjena zaradi stroškovne
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Slika I.7: Graf stroškovne učinkovitosti; terapiji 1 in 3, ki ležita v ravnini pod
premico MAX ICER, sta stroškovno učinkoviti, medtem ko je terapija 2 stroškovno
neučinkovita.
neučinkovitosti [90]. Maksimalen ICER določi odločevalec, WHO pa predlaga, da
se mejno vredneost določi v skladu z BDP posamezne države.
II Namen
Namen te doktorske disertacije je precej vsestranski, združuje tri različne tematike s
skupno glavno temo, tj. elektroporacija. Glavna tema prvega doprinosa k znanosti
je pregled in predstavitev delovanja in uporabe na trgu razpoložljivih komercialnih
elektroporacijskih naprav. Pri testiranju smo zaznali očitno potrebo po razvoju elek-
tronskega emulatorja biološkega bremena. Zato se je namen razširil še na razvoj elek-
tronskega vezja, ki se na elektroporacijske pulze odzove enako kot biološko breme.
Poleg tega smo se zaradi pregleda poglobili tudi v merjenje dovedenih elektroporaci-
jskih pulzov, to je nujno za zagotavljanje kakovosti elektroporacije. S tem se splošni
namen prvega doprinosa k znanosti razširi na področje dozimetrije v elektroporaciji.
Med drugim smo se osredotočili tudi na merjenje nanosekundnih pulzov, ki je med
najbolj zahtevnimi na področju elektroporacije. Zaključimo, da je standardizacija na
področju elektroporacije nujna. Elektroporacija je vsestranska tehnologija, zato bi
bilo za vsako aplikacijo ali podpodročje potrebno določiti poseben standard. Kljub
temu se lahko za elektroporatorje na splošno definira nekatere minimalne osnovne
tehnične zahteve in dovoljena odstopanja. Namen je bil tako tudi napisati priporočila
za standardizacijo elektroporacijskih naprav.
Namen drugega doprinosa k znanosti je bil razviti nov vsestranski vi-
sokofrekvenčni, visokonapetostni elektroporator. Nedavne raziskave na področju
uporabe visokofrekvenčnih pulzov v medicini t. i. H-FIRE (ang.: High-
Frequency IrReversible Electroporation) so vzbudile zanimanje za raziskovanje učinka
občutljivosti in preklica bioloških učinkov. Učinek občutljivosti je definiran kot dvig
oziroma upad vnosa molekul v celico v primeru apliciranja dvakratne namesto eno-
jne polovične doze elektroporacijskih pulzov. Pri uporabi kraǰsih bipolarnih pulzov
(dolžine nekaj sto nanosekund), so raziskovalci odkrili, da pride do preklica bioloških
učinkov [19, 20, 21, 22]. Efekt preklica je definiran kot upad vnosa v celico, ko to
izpostavimo enemu monopolarnemu pulzu, ki mu skoraj strnjeno sledi drugi monopo-
larni pulz nasprotne polaritete (torej gre za en bipolarni pulz), v primerjavi z enim
samim monopolarnim pulzom [91]. Eden od poglavitnih izzivov na področju elek-
troporacije še vedno ostaja enakomerna elektroporacija heterogene strukture tkiv –
uporaba visokofrekvenčnih bipolarnih pulzov bi lahko rešila tudi ta problem [92]. Za
študijo vseh zgoraj opisanih efektov (tudi in vivo) potrebujemo pulzni generator, ki
bo generiral bipolarne pulze nastavljive amplitude vse do 4 kV, ob tem bo morala biti
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najvǐsja pavza med posameznimi pulzi in dolžina pozitivnega in negativnega pulza
1 µs. Visokofrekvenčne pravokotne pulze je najlažje generirati tako, da s pomočjo
silicijevih tranzistorjev vklapljamo in izklapljamo naelektrene kondenzatorje. Glede
na popis in pregled elektroporatorjev [8, 93, 94] ter ekonomski oceni [95, 96], ki
sta bili do sedaj narejeni, sem prǐsla do zaključka, da obstajajo zanimiva področja,
ki jih je še potrebno raziskati. Razvoj bipolarnega elektroporatorja z maksimalno
napetostjo 4 kV in minimalnim časom trajanja pulza 1 µs omogoča raziskavo bi-
oloških učinkov zelo visokih in hkrati kratkih električnih pulzov tako in vitro kot in
vivo. Predvidevamo, da je lahko glavna prednost teh specifičnih pulzov zmanǰsanje
krčenja mǐsic in bolečine, ki ju povzroča električno polje [97, 67, 98]. Trenutno za
zmanǰsanje mǐsične kontrakcije pred terapijo pacientom vbrizgajo relaksatorje mǐsic,
vendar je potrebno med samim tretmajem za vzdrževanje nevromuskularne blokade
spremljati živčno-mǐsično delovanje. [99, 100]. Poročajo, da je mejna vrednost, ki
sproži kontrakcijo mǐsic, dvakrat nižja kot mejna vrednost elektroporacije [98]. Prav
tako poročajo, da bipolarni pulzi [101] in H-FIRE pulzi [67] zmanǰsajo kontrakcijo
mǐsic. Pokazali so tudi, da IRE lahko izvedemo tudi pri dolžini pulza 1 µs, in sicer
s povečanjem števila pulzov in povečanjem električne poljske jakosti [67]. Glede na
nove raziskave [102] se namen razširi tudi na in vivo poskuse z razvito napravo. V
prvi visokofrekvenčni elektrokemoterapiji (HF-ECT) in vivo ocenimo učinkovitost
terapije in mǐsične kontrakcije, ki so prisotne med dovajanjem pulzov.
Namen tretjega doprinosa k znanosti je opredelitev proračuna za razvoj nove
klinične elektroporacijske naprave. Zato se v zadnjem delu osredotočamo na vred-
notenje tehnologij v zdravstvu, natančneje na analizo stroškovne učinkovitosti.
Nekaj stroškovnih analiz elektroporacije je že narejenih [9, 96], vendar zaradi po-
manjkanja podatkov niso najbolj objektivne, saj ne vključujejo podatkov o dvigu
kakovosti življenja. Osredotočamo se na elektrokemoterapijo kožnega melanoma
in bazalnoceličnega karcinoma (BCC), saj se terapiji na teh dveh vrstah rakavega
obolenja izvajata najdlje in imata dobre rezultate.
III Rezultati in razprava
V sklopu te doktorske disertacije so predstavljeni trije izvirni prispevki k znanosti:
1. Ocene elektroporatorjev in predlog standardizacije elektroporatorjev kot
samostojnih medicinskih naprav.
2. Razvoj novega bipolarnega visokofrekvenčnega visokonapetostnega pulznega
generatorja - elektroporatorja.
3. Ocena cenovne učinkovitosti elektrokemoterapije v terapiji bazalnoceličnega
karcinoma in kožnih metastaz melanoma.
Rezultati in razprava so sestavljeni iz osmih znanstvenih člankov in enega
poglavja iz knjige. V sklopu razširjenega slovenskega povzetka so povzeti rezul-
tati vsakega od prispevkov. Prvi prispevek k znanosti je sestavljen iz knjižnega
poglavja, ki je izšlo leta 2017, in petih znanstvenih člankov. Članek 1 in 4 sta v
recenzijskem postopku, članek 2 in 3 sta že sprejeta v objavo, medtem ko je članek
5 že objavljen. Drugi prispevek k znanosti je predstavljen v članku 6, ki je v recenz-
ijskem postopku, tretji prispevek k znanosti pa je sestavljen iz dveh člankov, članek
7 je bil objavljen leta 2019, članek 8 pa je v postopku oddaje v recenzijo.
III.I Dozimetrija pri elektroporaciji
Merjenje je nujno za kvalitetno elektroporacijo, saj se lahko le s pomočjo meritev
prepričamo, da smo elektroporacijske pulze res dovedli in da naprava deluje v
skladu sprednastavljenimi vrednostmi. Težave nastopijo predvsem takrat, ko
naprave niso sposobne generirati tistega, kar obljubljajo v tehničnih specifikacijah.
Če so biološka bremena bolj prevodna, se ponavadi zaplete, ker naprave niso
zmožne generirati tako visokega toka ali nimajo dovolj velike zaloge energije
in posledično dovedeni pulzi ne ustrezajo prednastavljenim karakteristikam.
Tipična prevodnost suspenzije v elektroporacijski kiveti je nekje med 100 in 50
Ω, vendar se lahko v primeru uporabe bolj prevodnega medija spusti tudi pod
10 Ω. Velike variacije karakteristik bioloških bremen predstavljajo ogromen izziv
pri načrtovanju in razvoju elektroporacijskih naprav ter rezultirajo v različnih
rešitvah. Prav tako je potrebno za izbolǰsanje ponovljivosti že objavljenih študij
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zelo podrobno poročati o vseh karakteristikah uporabljenih električnih pulzov.
Priporočamo, da raziskovalci v svoja poročila vključijo vsaj dve meritvi, eno
ki natančno prikazuje en sam pulz in drugo pri večji časovni skali, ki zajema
celotno sekvenco pulzov (Slika III.1). V kolikor grafična predstavitev meritve ni
mogoča, je potrebno električne pulze ustrezno besedno opisati (v pomoč je slika I.2).
Slika III.1: Priporočamo, da raziskovalci v svoja poročila vključijo vsaj dve meritvi
uporabljenih elektroporacijskih pulzov: a) slika, ki zajema celotno sekvenco dove-
denih pulzov; b) slika, ki natančno prikazuje en sam pulz, v kolikor to ni mogoče, je
potrebno električne pulze ustrezno besedno opisati.
Najlažji način merjenja elektroporacijskih pulzov je merjenje napetosti in toka s
pomočjo osciloskopa. Vendar je potrebno izbrati ustrezne sonde in osciloskop (maksi-
malna amplituda, pasovna širina, časa vzpona ...). Pri večini aplikacij se uporabljajo
mikro- ali milisekundni pulzi, zato so primerni že osciloskopi in sonde z nekaj MHz
pasovne širine. Merjenje je bolj zahtevno, ko dosežemo nanosekundno področje, kjer
so potrebne GHz pasovne širine in hitri časi vzpona ter prav tako visoke, nekaj de-
set kilovoltne, maksimalne napetosti. Paziti je potrebno na parazitne induktivnosti
in kapacitivnosti ter odboje signala, zato morajo biti sonde nameščene čim bližje
elektrod in brez kakršnihkoli dodatnih priključnih žic. Poudariti je potrebno, da se
pasovna širina sond konča pri –3 dB, kar pomeni, da ima sonda na koncu pasovne
širine napako 29 %. Napaka 29 % je sprejemljiva za elektroniko, vendar pa ima
lahko amplituda, ki odstopa za 29 %, drugačen biološki učinek [103, 104].
V sklopu te doktorske disertacije sta predstavljena dva pregleda elektroporatorjev,
prvi je predstavljen v knjižnem poglavju (Table 12.1. in 12.2, priloženi na strani
76-83) in zajema pregled na trgu dostopnih komercialnih elektroporatorjev ter elek-
trod in njihovih tehničnih specifikacij, ki jih podajajo proizvajalci. Kontaktirali smo
25 proizvajalcev, vendar jih je bilo le 13 pripravljenih sodelovati, ostali pa se niso
odzvali ali niso želeli razkriti parametrov pulzov, ki jih generirajo njihove naprave.
Nekateri so nas obvestili, da so karakteristike električnih pulzov predmet njihove
III.II Predlogi za standardizacijo 29
intelektualne lastnine. Z rastjo elektroporacijskega trga na žalost vse več proizva-
jalcev prikriva parametre izhodnih impulzov svojih naprav. Pri drugem pregledu,
ki je objavljen v tabeli članka 1 (Table 1 in 2, priloženi na straneh 111-121), pa
smo predstavili elektroporatorje, ki se najpogosteje uporabljajo pri elektroporaciji
kože, in različne tipe elektrod. V tabeli je pripisano tudi strokovno mnenje, v sklopu
katerega komentiramo naprave na podlagi zbranih tehničnih specifikacij in testiranj,
ki smo jih opravili v sklopu te doktorske disertacije.
III.II Predlogi za standardizacijo
Standard za elektroporatorje bi moral definirati naslednje zahteve:
• največjo dovoljeno odstopanje oziroma toleranco generiranih pulzov v primer-
javi s prednastavljenimi vrednostmi pri obremenitvi in brez obremenitve;
• protokol testiranja elektroporatorja, ki oceni, če naprava deluje v skladu s
tolerancami;
• preizkusna bremena za posamezne aplikacije;
• navodila za pripravo tehnične dokumentacije naprave (ki se lahko glede na
aplikacijo razlikujejo), specifikacije morajo biti navedene skupaj s pogoji, pod
katerimi jih naprava doseže;
• predpulz, če se uporablja (amplituda, oblika, trajanje in pavza med predpul-
zom in pred nastavljeno sekvenco elektroporacijskih pulzov);
• kako zagotavljati varnost naprave, kot so galvanska ločitev, omejitve toka, en-
ergije in napetosti, opozorila, v primeru, če je bilo dovajanje pulzov prekinjeno
ali pa je prǐslo do okvare;
• največja dovoljena odstopanja oziroma tolerance geometrije elektrod in elek-
troporacijskih kivet.
V sklopu doktorske disertacije smo določilo sprejemljive tolerance in predlagali
rešitev, ki bi omogočila nepristransko testiranje in oceno elektroporacijskih naprav.
Predlagamo, da proizvajalci naprav določijo aplikacije, za katere je njihova naprava
izdelana, in nato navedejo tehnične specifikacije in tolerance v skladu s tipičnim
bremenom za aplikacije, npr. napetost: 200-1000 V (za bremena z impedanco večjo
od 50 Ω in za pulze do 1 ms (NMAX = 10); 200-2000 V (za bremena, večja od 100
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Ω, in za trajanje pulzov do 100 µs (NMAX = 10)); kjer je NMAX največje število
pulzov. Na podlagi pregleda literature [105, 106, 107, 108], naših izkušenj in glede na
trenutno stanje tehnologije smo opredelili tolerance amplitude napetosti in trajanja
pulza. Z razpoložljivimi elektronskimi komponentami in obstoječimi rešitvami vezij
je zahteve mogoče enostavno izpolniti. Objavljene permeabilizacijske funkcije in
preživetja celic [105, 106, 107, 108] kažejo, da lahko več kot 15 % odstopanje povzroči
bistveno drugačen učinek elektroporacije, vendar v primeru in vivo elektroporacije
lahko pride do dodatnih napak, ki so posledica mǐsičnega krčenja med dovajanjem
pulzov, vstavitve elektrod in drugih okolǐsčin, ki skupno napako zlahka pripeljejo
na 15 %. Zato menimo, da morajo proizvajalci slediti najsodobneǰsim trendom in
priporočamo, da je toleranca amplitude napetosti 10 %, torej izmerjena amplituda
napetosti ne sme biti nižja od 90 % ali vǐsja od 110 % prednastavljene napetosti.
Kar seveda pomeni, da mora biti tudi napetost od prvega do zadnjega impulza v
tem območju. Trajanje pulza se definira kot FWHM odstopanje od prednastavljene
vrednosti in ne sme biti večje od 8 % [106, 107], kot je prikazano na sliki (Slika
III.2).
Slika III.2: Amplituda napetosti ne sme biti nižja od 90 % ali vǐsja od 110 %
prednastavljene napetosti. Kar pomeni, da mora biti tudi padec napetosti med
prvim in zadnjim pulzom pri največjem številu impulzov v tem območju. Odstopanje
trajanja pulza od vnaprej nastavljene vrednosti ne sme biti večje od 8 %.
Predlagane tolerance morajo biti izpolnjene od maksimalnih pa vse do minimal-
nih nastavitev, te so: največja amplituda pulza, največja dolžina pulza, največje
število pulzov in minimalna ponavljalna frekvenca pulzov, ko kot breme upora-
bimo tipično breme aplikacije, za katero je naprava narejena. Predlagamo, da se
sestavi seznam aplikacij in za vsako razvije tipičen emulator biološkega bremena.
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Postopek razvoja emulatorja smo podobno opisali v članku 4. Poleg tega je treba
standardizirati tudi elektrode in določiti dovoljena odstopanja razdalj med elektro-
dama, ustrezne materiale, v primeru večkratne uporabe pa tudi določiti sterilizaci-
jske postopke in vzdrževanje. Klinični elektroporator se mora nenehno samotesti-
rati in kalibrirati. Odstopanja, določena v sklopu tega doktorata se nanašajo na
“klasično” elektroporacijo in niso ekvivalentna za nanosekundno elektroporacijo.
III.II.I Emulator biološkega bremena
Razvili smo analogno elektronsko vezje, ki ima impedanco ekvivalentno govejim
jetrom med “klasično” (ne nanosekundno) elektroporacijo z igelnimi elektrodami.
Analizirali in parametrizirali smo natančne meritve toka in napetosti med elektro-
poracijo tkiva govejih jeter ex vivo tako, da smo poiskali enačbo (Enačba III.1) za
tok v odvisnosti od časa t in števila pulzov N, ki je primerna za opis analognega
elektronskega vezja (spominski tok Imem se izračuna s pomočjo enačbe III.2, končni
tok pa s enačbo III.3). Z metodo najmanǰsih kvadratov smo poiskali vrednosti
posameznih elementov v ekvivalentnem vezju (Slika III.3). Predlagano vezje oziroma
emulator biološkega bremena smo simulirali, razvili in ovrednotili (Slika III.4).
I(t, N) =
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

Uamp
R1
+ Uamp
R2
∗ e−(t−(N−1)∗Tper)/τ1 , Uamp < Uth
Uamp
R1
+ Uamp
R2
∗ e−(t−(N−1)∗Tper)/τ1 + (Uamp−Uth
R3
− Imem(N))∗
∗(1 − e−(t−(N−1)∗Tper)/τ2) + Imem(N), Uamp > Uth
(III.1)
Imem(N) = IM0(N) ∗ e−Tpause/τ3 (III.2)
IM0(N) =



I((N − 1) ∗ Tper − Tpause), N > 1
0, N = 1
(III.3)
Predlagani elektronski emulator biološkega bremena natančno simulira tok med
elektroporacijo. Predlagana rešitev je potrditev koncepta z ogromno potenciala.
Za vsako biološko breme je torej potrebno pridobiti natančne meritve napetosti in
toka in nato razviti model, v skladu s postopki, ki so opisani v članku 4. Z vidika
standardizacije elektroporacijskih naprav bi bilo smiselno vsako komponento v pred-
laganem vezju nadomestiti s komponento nastavljive vrednosti. Posamezne konden-
zatorje z nizom kondenzatorjev z različnimi vrednostmi in prav tako Zener diodo
z Zener diodami z različnimi prebojnimi napetostmi, s tem bi definirali en vses-
transki emulator za posamezno aplikacijo. Glavna prednost predstavljenega procesa
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Slika III.3: Shema vezja elektronskega emulatorja elektroporacijskega bremena.
oziroma koncepta emulatorja je, da omogoča trajnostno, ponovljivo in nepristransko
testiranje ter primerjanje delovanja različnih elektroporacijskih naprav in predstavlja
prvi korak proti standardizaciji elektroporatorjev.
Slika III.4: Povprečje petih meritev toka pri ponavljalni frekvenci 4717 Hz (zelena),
(a) numerično modeliran tok s pomočjo programskega okolja Matlab (oranžna, prva
vrstica), (b) modeliran tok s pomočjo programskega okolja PSpice (modra, druga
vrstica) in (c) izmerjen tok skozi prototipa (vijolična, tretja vrstica). Rumena
krivulja v tretji vrstici je dodatna meritev toka prototipa emulatorja pri napetosti
200 V, s tem želimo pokazati odziv, ko je napetost nižja od pragovne napetosti. V
prvem stolpcu je predstavljen tok pri 500 V, v drugem 750 V in tretjem pri 1000 V.
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III.III Razvoj novega visokofrekvenčnega visokonapetost-
nega pulznega generatorja
Razvito napravo smo najprej preizkusili na 80 Ω uporu in nato še in vivo na
mǐsih pri prvi visokofrekvenčni elektrokemoterapiji in vivo. Meritev generiranih
monopolarnih in bipolarnih pulzov z minimalnim trajanjem pulza je prikazana na
sliki (Slika III.5). Začetna polnilna napetost kondenzatorja je bila nastavljena na
500 V, nato pa smo jo dvignili vse do 4 kV s korakom po 500 V. Zato, da smo
dosegli želenih 4 kV, smo bili prisiljeni povečati širino pulza prožilnega signala na
260 ns, kar pomeni, da se minimalno trajanje izhodnega pulza elektroporatorja
poveča iz predvidenih 100 ns na 200 ns. Na sliki (Slika III.5b) je prikazan bipolarni
pulz, zakasnitev med prožilnim signalom pozitivne in negativne polperiode je bila
nastavljena na 200 ns. Poleg simetričnega generiranja pulzov različnih dolžin (Slika
III.6a) naprava omogoča tudi generiranje asimetričnih bipolarnih pulzov, ki so
prikazani na sliki (Slika III.6b). Širino pulza pozitivne in negativne polperiode je
mogoče, (vsakega posebej oziroma neodvisno) spreminjati od 200 ns pa vse do 1
ms (Slika III.6b). Enako velja tudi za amplitudo pulza (Slika III.6b), ki jo lahko
spreminjamo na območju od 0 do 4 kV.
Slika III.5: Meritev monopolarnega (a) in bipolarnega (b) pulza, generiranega na
80 Ω uporu. Začetna polnilna napetost kondenzatorja je bila nastavljena na 500 V,
nato pa smo jo dvignili vse do 4 kV s korakom po 500 V.
Izvedli smo tudi in vivo meritve toka in napetosti pulzov, uporabljenih pri vi-
sokofrekvenčni elektrokemoterapiji na mǐsi, prikazane so na Sliki III.7. Naprava
tudi pri in vivo pogojih deluje v skladu s pričakovanji. V sklopu in vivo poskusov
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Slika III.6: a) Slika prikazuje generiranje simetričnih bipolarnih pulzov različnih
dolžin. Polnilna napetost kondenzatorja je bila nastavljena na 4 kV, prožitveni pulz
pa je bil nastavljen na 260, 400 in 800 ns za obe polperiodi. b) Slika prikazuje
asimetrično generiranje bipolarnih pulzov ekvivalentnega naboja. Amplituda pozi-
tivne polperiode in trajanje so bili nastavljeni na 4 kV 200 ns, trajanje prožilnega
signala negativne polperiode pa na 260 ns, 400 ns in 800 ns in hkrati polnilna
napetost negativne polperiode na 4 kV, 2 kV in 1 kV.
smo primerjali “klasično” elektrokemoterapijo z visokofrekvenčno elektrokemoter-
apijo. Preko ploščatih elektrod (razdalja med elektrodama je 6 mm) smo v primeru
“klasične” elektrokemoterapije dovedli osem monopolarnih pulzov dolžine 100 µs,
ponavljalne frekvence 1 Hz in amplitude 780 V, pri visokofrekvenčni elektrokemoter-
apiji pa smo en monopolarni pulz nadomestili s sekvenco bipolarnih pulzov 1-1-1-1 µs
(trajanje pozitivne polperiode - pavza med polperiodama - trajanje negativne polpe-
riode - pavza med bipolarnimi impulzi), ponavljalna frekvenca sekvenc je enaka kot
ponavljalna frekvenca pulzov pri “klasični” elektrokemoterapiji, amplitudo napetosti
pa smo zvǐsali na 1950 V. V nasprotju z do sedaj objavljenimi študijami nismo opazili
razlike v mǐsični kontrakciji. Pri “klasični” elektrokemoterapiji z bleomicinom je bilo
50 % (3/6 mǐsi) popolnih odgovorov, pri visoko-frekvenčni z bleomicinom pa 86 %
(7/6 mǐsi) popolnih odgovorov. Razlika med skupinama sicer ni signifikantna, pri
obeh terapijah se je preživetje živali znatno podalǰsalo, v primerjavi z nezdravljeno
kontrolno skupino in kontrolno skupino mǐsi, ki smo jim dovedli le elektroporacijske
pulze. Živali so dobro prenašale obe vrsti elektrokemoterapije, po zdravljenju se
njihova telesna teža ni spremenila za več kot 5 %, prav tako nismo opazili smrtnosti,
povezane z zdravljenjem.
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Slika III.7: Osem 200 µs dolgih sekvenc s ponavljalno frekvenco 1 Hz, vsaka
sekvenca je bila sestavljena iz 50 bipolarnih pulzov tipa 1-1-1-1 µs (trajanje pozitivne
polpreiode-pavza med polperiodama-trajanje negativne polperiode-pavza med bipo-
larnimi impulzi) amplitude 1950 V, je bilo dovedenih s pomočjo ploščatih elektrod
na tumor, ki se je nahajal na boku mǐske.
III.IV Stroškovna analiza elektrokemoterapije
V sklopu članka 7 smo predstavili osnovne koncepte in postopke vrednotenja
tehnologij v zdravstvu (ang.: Health Technology Assessment) in analize stroškovne
učinkovitosti ter predstavili študijo stroškovne analize (ang.: Cost-Effectiveness
Analysis) elektrokemoterapije, kot terapije za zdravljenje bazalnoceličnega karci-
noma in kožnega melanoma. Nekaj stroškovnih analiz elektrokemoterapije je že
bilo narejenih, vendar zaradi pomanjkanja podatkov o učinkovitosti zdravljenja, v
smislu povečanja kakovosti življenja bolnikov (ang.: Quality of Life), zaključki ne
morejo biti točni. Da bi izdelali čim bolj relevantno analizo v sedmem članku pred-
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stavljamo dva splošna Markova modela in njuni poenostavljeni različici. Modela
sta zasnovana posebej za analizo elektrokemoterapije bazalnoceličnega karcinoma
in kožnega melanoma. Dodatno so opredeljeni tudi potrebni podatki za uspešne
izračune. Manjkajoče podatke smo skušali zbrati v okviru različnih študij, ki še
vedno tečejo, vključno z randomiziranimi kliničnimi študijami. Predstavljeno je tudi
priporočilo za poročanje, ki bi olaǰsalo zbiranje podatkov. S tem prispevkom smo
predvsem želeli dvigniti splošno ozaveščenost o pomembnosti številčnega poročanja
o kakovosti življenja in uporabnosti oziroma pomenu vprašalnikov EQ-5D, ki na
prvi pogled morda nista samoumevna, vendar sta bistvenega pomena za analizo
stroškovne učinkovitosti.
V sklopu članka 8 predstavljamo stroškovno učinkovitost zdravljenja kožnega
melanoma IV in IIIc stadija v Sloveniji z napravo Cliniporator (IGEA, Ital-
ija). Pacientom, vključenim v študijo, je elektrokemoterapija izbolǰsala kakovost
življenja za 0,29 QALY v celotni življenjski dobi, pri zvǐsanju stroškov za 6.568
e. Pričakovana dodatna neto korist za zdravje (ang.: incremental net health
benefit) elektrokemoterpije je v primerjavi s paliativno terapijo -0,037 QALY, kar
pomeni, da je pri uporabljenem pragu stroškovne učinkovitosti 20.000 e(prag
za Slovenijo, na podlagi GDP) elektrokemoterapija nekoliko manj učinkovita kot
paliativna terapija, čeprav je negotovost stroškovne učinkovitosti precej velika.
Za podskupino bolnikov s krvavečimi tumorji elektrokemoterapija zvǐsa kakovost
življenja za 0,34 QALY s stroški vǐsjimi za 4.863 e. Izračun torej kaže, da je
elektrokemoterapija stroškovno učinkoviteǰsa samo za bolnike s krvavečimi tumorji,
s pričakovano dodatno neto koristjo za zdravje 0,10. Rezultati verjetnostne analize
občutljivosti (ang.: probabilistic sensitivity analysis) kažejo veliko negotovost
stroškov in QALY elektrokemoterapije za obe skupini bolnikov, vendar kljub veliki
razpršenosti simulacija ostaja v drugem kvadrantu ravnine stroškovne učinkovitosti,
kar pomeni, da je velika verjetnost, da je elektrokemoterapija bolj učinkovita in
dražja v primerjavi s paliativno terapijo (Slika III.8 a). Ob predpostvki, da je prag
stroškovne učinkovitosti za Slovenijo (izračunano na podlagi GDP) 20.000 e, je
verjetnost, da bo elektrokemoterapija stroškovno učinkovita 0,3 za celoten vzorec
in 0,91 za bolnike s krvavečimi tumorji (Slika III.8 b).
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Slika III.8: : (a) Ravnina stroškovne učinkovitosti. (b) Verjetnost, da je elektroke-
moterapija stroškovno učinkovita za vse bolnike in bolnike s krvavečimi tumorji.
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IV Zaključek
Elektroporacija je vsestranska tehnologija, ki je že uveljavljena na številnih po-
dročjih. Merjenje napetosti in toka dovedenih elektroporacijskih pulzov je ključno
za doseganje učinkovite elektroporacije, saj le tako lahko zagotovimo kakovost
aplikacije. Najbolj zahtevno je natančno merjenje visokonapetostnih kratkih
nanosekundnih pulzov. Poudariti je potrebno, da se pasovna širina sond konča pri
-3 dB, kar pomeni, da ima sonda na koncu pasovne širine napako -29 %. Napaka -29
%, je sprejemljiva za elektroniko, vendar pa ima lahko amplituda, ki odstopa za 29
% drugačen biološki učinek [103, 104]. Ker sta permeabilizacija in preživetje celic
sigmoidni funkciji napetosti, lahko ima že več kot 10 % razlika v napetosti bistveno
drugačen biološki učinek [103, 104]. Pri uporabi merilnih sond se moramo vedno
zavedati napake. Pri komercialno dostopnih sondah je merilna napaka navedena v
podatkovnem listu, vendar je včasih kljub temu spregledana, prototipne sonde pa
je pred uporabo potrebno pravilno umeriti in ovrednotiti merilno napako.
Na področju elektroporacije se v zadnjem času pojavlja vse več neuspešnih
ponovitev že objavljenih raziskav [30]. Mislimo, da je poglavitni razlog za nastalo
situacijo neustrezno oziroma površno poročanje o metodah objavljenih raziskav, ki
opisujejo/uporabljajo elektroporacijo. Prav tako raziskovalci pogosto v poročila ne
vključujejo meritev dovedenih pulzov [18, 31], kar pomeni, da je nepristranskost
nekaterih raziskav vprašljiva. Raziskovalce na področju elektroporacije je potrebno
vzpodbuditi k večji ponovljivosti raziskav, kar pa je mogoče doseči le z ustreznim
merjenjem, standardiziranimi poročili in pravilno uporabo elektroporatorjev ter
elektrod. Če navedemo primer: elektroporacija kože je obetavna metoda zdravl-
jenja, pri kateri s transdermalnim vnosom zdravil, gensko elektrotransfekcijo,
elektrokemoterapijo ali ireverzibilno elektroporacijo zdravimo različna kožna
obolenja. Objavljenih je bilo že ogromno in vitro in in vivo študij, pri katerih
so raziskovalci uporabljali različne geometrije elektrod, karakteristike pulzov in
elektroporatorje. Rezultate študij, pri katerih so uporabili električne pulze različnih
karakteristik, je včasih težko (če ne celo nemogoče) primerjati. Razlogi za počasno
umestitev elektroporacije kože za transdermalni vnos v klinično prakso so torej
nestandardni parametri pulzov, nestandardne geometrije elektrod, elektroporatorji,
ki se ne ujemajo s svojimi tehničnimi specifikacijami ali tehničnih specifikacij celo
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nimajo, pomanjkljivo poročanje o karakteristikah uporabljenih električnih pulzov in
porazdelitvi električnega polja, neustrezno merjenje napetosti in toka ter bistveno
drugačna struktura kože živali in ljudi. Kljub temu je bilo večkrat pokazano, da
lahko elektroporacija zniža stroške in olaǰsa postopke zdravljenja. Iz objavljenih
študij lahko sklepamo, da so terapije, ki temeljijo na elektroporaciji, varne in
imajo malo ali pa so povsem brez stranskih učinkov. Klinične študije, ki temeljijo
na elektroporaciji, so zelo vzpodbudne, zato verjamemo, da bo elektroporacija v
prihodnosti nepogrešljiva pri genskem zdravljenju, zdravljenju raka, zdravljenju
okužb, intrakardialni ablaciji in cepljenju. Vendar pa so nadaljnji razvoj standard-
nih protokolov za zdravljenja, ki temeljijo na elektroporaciji, regulacija razvoja
elektroporatorjev in usposabljanje uporabnikov bistveni za uspešno vključitev v
klinično prakso. Prav tako imajo terapije, ki temeljijo na elektroporaciji, velik
potencial za uporabo v klinični praksi tudi pri socialnoekonomsko prikraǰsanih
populacijah. Trenutno je cena elektroporacije relativno visoka, predvsem zaradi
dragih elektroporatorjev in elektrod, vendar bi lahko razvili nizkocenovne različice
elektroporatorjev, saj tehnološko ni težko razviti elektroporatorja, bolj zahtevno
je zagotavljanje kakovosti in varnosti, ker se karakteristike bioloških bremen
precej razlikujejo že od vzorca do vzorca in še bolj pa od tkiva do tkiva. Zaradi
velikih razlik v karakteristikah bioloških bremen lahko dovedeni pulzi odstopajo od
prednastavljenih. Nizka impedanca bremena (tkiva ali celične suspenzije) zahteva
velike moči/tokove, kar pogosto vodi do občutnega padca napetosti na bremenu.
Protokoli, pri katerih se dovede večje število pulzov (ali dalǰse pulze), lahko privedejo
do neželenega padca napetosti na bremenu. Z umestitvijo specifičnega standarda
za posamezno aplikacijo bodo elektroporacijske naprave varneǰse, zdravljenje bolj
učinkovito in bolj ponovljivo, kar bo omogočilo hitreǰsi in učinkoviteǰsi napredek na
področju elektroporacije, poleg tega tudi pri zdravljenju in terapijah, ki temeljijo
na elektroporaciji. Z uvedbo posebnega standarda za klinične elektroporatorje se
bo izbolǰsala kakovost medicinskih elektroporatorjev, kar bo doprineslo k bolǰsemu
in bolj učinkovitemu zdravljenju raka. Da lahko začnemo razmǐsljati o predlogu
standarda za elektroporacijo, je potrebno najprej določiti tehnične specifikacije in
tolerance, nato pa še protokole testiranja. V okviru člankov 2 in 3 smo predlagali
minimalne tehnične zahteve in tolerance, v sklopu članka 4 pa smo razvili elek-
tronski emulator biološkega bremena, ki omogoča vzpostavitev standardiziranih
postopkov testiranja. Ker so biološka bremena nelinearna in uporno kapacitivna,
ad hoc biološka bremena (npr. gomoljnice) in upori niso primerni za testiranje
elektroporacijskih naprav, ker niso primeren približek terapevtskega biološkega
bremena. Zato smo razvili elektronski emulator biološkega bremena, ki omogoča
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trajno testiranje elektroporacijskih naprav in objektivno primerjavo delovanja
različnih elektroporatorjev ali delovanje elektroporatorja skozi življenjsko dobo.
Razvoj emulatorja je prvi korak k standardizaciji in uveljavitvi standardiziranega
protokola za testiranje ali oceno elektroporatorjev, ki omogoča splošen napredek na
področju elektroporacije. Določitev karakteristik biološkega bremena je pomemben
korak pri razvoju elektroporatorjev, ki pa je prepogosto zanemarjen. Neustrezna
karakterizacija biološkega bremena lahko privede do neoptimalnih rešitev in zvǐsa
zahtevnost razvoja. Na podlagi objavljenega članka 4 lahko s kvalitetnimi merit-
vami natančno določimo karakteristiko biološkega bremena in razvijemo emulator,
ki olaǰsa in zvǐsa kakovost razvojnega procesa elektroporatorja.
Elektroporacijska naprava, razvita v okviru te doktorske disertacije, deluje v
skladu s pričakovanji, maksimalna izhodna napetost je 4 kV, teoretični maksimalni
tok 131 A, minimalna dolžina pulza 200 ns in maksimalna ponavljalna frekvenca
2 MHz. Naprava generira asimetrične bipolarne pulze, kar pomeni, da lahko
uporabnik hkrati nastavi asimetrijo trajanja pulzov in napetostno amplitudno
asimetrijo. Tako omogoča raziskovanje še neznanih učinkov, nadaljno razisko-
vanje oziroma nadgradnjo raziskav učinka občutljivosti in preklica ter in vivo
raziskave visokofrekvenčne elektroporacije. Naprava je bila testirana in vivo pri
prvi visokofrekvenčni elektrokemoterapiji na mǐsih. Spremljali smo učinkovitost
terapije in krčenje mǐsic med dovajanjem električnih pulzov. Rezultati kažejo, da je
učinkovitost HF-ECT z bleomicinom in cisplatinom primerljiva s “klasično” ECT z
bleomicinom in cisplatinom. V nasprotju z do sedaj objavljenimi študijami krčenje
mǐsic ostaja signifikantno tudi v primeru visokofrekvenčne elektroporacije, ven-
dar smo bili prvi, ki smo električne pulze dovajali prek kože s ploščatimi elektrodami.
Razvili smo dva splošna Markova modela za CEA, - enega za kožni melanom in
drugega za bazalno celični karcinom (BCC) - in njuni reducirani verziji, ki sta ses-
tavljeni samo iz stanj, ki so pomembna za uporabo nove tehnologije, kar je v našem
primeru elektrokemoterapija. Ker je elektrokemoterapija nova tehnologija, še vedno
ni v uporabi pri vseh pacientih, a se z vǐsanjem števila študij povečuje njena vero-
dostojnost in se zato njena uporaba postopoma dviga po lestvici stopnje rakavega
obolenja. Realna analiza stroškovne učinkovitosti za določeno vrsto raka olaǰsa
nakup opreme in napredovanje kliničnih študij. Poleg tega lahko napoved stroškovne
učinkovitosti vpliva tudi na naslednji krog zbiranja sredstev. Vendar je za vsako
obolenje potrebno razviti specifični model, zato da vključimo vse specifične pojave
pri določeni vrsti raka. Elektrokemoterapijo je potrebno primerjati z uveljavljenimi
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terapijami, ki pa so odvisne od vrste rakavega obolenja, lokacije in velikosti tumorja.
V sklopu doktorske disertacije smo za elektrokemoterapijo kožnega melanoma
IV in IIIc stadija ocenili stroškovno učinkovitost. Rezultati kažejo, da elektroke-
moterapija sicer zvǐsa kakovost življenja pacientov po posegu, vendar je verjetnost,
da je terapija stroškovno učinkovita, dokaj nizka (približno 30 %), kar pomeni, da
bi bilo potrebno znižati, ceno za uspešno implementacijo v klinično prakso. Razen
v primeru, ko obravnavamo paciente, ki imajo krvaveče tumorje, se izkaže, da je
terapija stroškovno učinkovita (verjetnost naraste na 0,91). Stroškovno učinkovitost
bi najlažje zagotovili z znižanjem cene elektrode, ki predstavlja skoraj polovico
celotnega stroška posega.
V Izvirni prispevki k znanosti
Ocene elektroporatorjev in predlog standardizacije elektroporatorjev kot
samostojnih medicinskih naprav
Proizvajalci elektroporatorjev s prikrivanjem parametrov generiranih pulzov ovirajo
razvoj elektroporacijskega področja. Nekateri namerno načrtujejo naprave tako,
da merjenje dovedenih pulzov ni mogoče, tehnične specifikacije izhodnih pulzov
ne sovpadajo z zmogljivostmi naprave in uporabnika ne obvestijo o napakah pri
dovajanju pulzov. Posledično poročila študij ne vsebujejo potrebnih podatkov
za reprodukcijo poskusov. Zato je za bolǰsi vpogled v trenutno stanje in trende
razvoja na elektroporacijskem področju narejen nov pregled komercialno dostopnih
elektroporatorjev, njihovih značilnosti, omejitev in slabosti. Prav tako je podano
strokovno mnenje o napravah za elektroporacijo kože. Pri kakovosti merjenja in
dovajanju pulzov smo se osredotočili na področje nanosekundne elektroporacije,
kjer je merjenje najbolj zahtevno. S popisom in analizo smo poudarili in dvignili
ozaveščenje o pomembnosti merjenja, saj lahko samo z ustreznim merjenjem
zagotavljamo kakovost ter spodbujamo proizvajalce, naj ne prikrivajo parametrov
generiranih pulzov. Tako smo pripravili priporočila za standardizacijo, ki se osre-
dotočajo predvsem na oceno pravilnega ali nepravilnega delovanja elektroporatorjev,
in razvili elektronski emulator biološkega bremena med elektroporacijo, ki omogoča
trajno testiranje in nepristransko primerjavo delovanja različnih elektroporatorjev.
Razvoj novega bipolarnega visokofrekvenčnega visokonapetostnega
pulznega generatorja - elektroporatorja
Nedavne raziskave na področju preklica, občutljivosti in vzbujalnih učinkov
elektroporacijskih pulzov so nas motivirale, da razvijemo visokofrekvenčni, vi-
sokonapetostni, bipolarni generator pravokotnih pulzov. Generator razvit v
sklopu te doktorske disertacije temelji na nadgradnji že obstoječih rešitev pulznih
generatorjev. Naprava generira visokonapetostne pulze z maksimalno napetostjo
4 kV in minimalnim časom preklopa med pozitivno in negativno polperiodo.
Minimalna dolžina pulza je 200 ns maksimalna ponavljalna frekvenca pa 2 MHz.
Nova naprava omogoča raziskave vnosa snovi in vzbujanje celic v in vivo pogojih,
možnost generiranja homogenega električnega polja znotraj heterogene strukture
tkiva, zmanǰsanje živčnega in mǐsičnega vzbujanja ter občutka bolečine z vi-
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sokofrekvenčnimi bipolarnimi pulzi. Od že obstoječih naprav se razlikuje predvsem
v tem, da generira tudi asimetrične bipolarne pulze, ki jih potrebujemo za raziskave
efekta občutljivosti in preklica. Razvit elektroporator smo preizkusili v prvi in
vivo visokofrekvenčni elektrokemoterapiji (HF-ECT), pri kateri se je izkazalo, da je
HF-ECT z bleomicinom in cisplatinom enako učinkovita kot uveljavljena “klasična”
ECT z bleomicinom in cisplatinom.
Ocena cenovne učinkovitosti elektrokemoterapije v terapiji bazalno-
celičnega karcinoma in kožnih metastaz melanoma
Nekaj stroškovnih analiz terapij, ki uporabljajo elektroporacijo, je že bilo narejenih,
vendar nobena ne vključuje kakovosti življenja (QoL), ki pa je ključnega pomena
pri vrednotenju novih tehnologij v medicini (ang.: Health Technology Assessment
(HTA)). Glavni razlog je najverjetneje neustrezno zbiranje podatkov o kakovosti
življenja pacientov. Sklepamo, da v sklopu kliničnih študij zbiranje podatkov ni
bilo sistematično izvedeno. V naši študiji stroškovne analize elektroporacije smo
se osredotočili na elektrokemoterapijo kožnega melanoma in bazalno celičnega
karcinoma (BCC). Za omenjena tipa rakavega obolenja smo se odločili, ker se
terapiji na teh dveh vrstah raka izvajata najdlje in imata dobre rezultate. Razvili
smo dva Markova modela, za vsako vrsto obolenja posebej, nato pa definirali
potrebne podatke in jih zbrali za primer kožnega melanoma IV in IIIc stadija.
Izračunali smo stroškovno učinkovitost elektrokemoterapije kožnega melanoma
IV in IIIc stadija za paciente zdravljene na Onkološkem inštitutu v Ljubljani
z napravo Cliniporator in pripadajočimi elektrodami ter podali predloge, kako
izbolǰsati stroškovno učinkovitost. Realna stroškovna analiza dviga ozaveščenje o
novi terapiji in pripomore k bolj racionalni porabi sredstev ter podaja informa-
cijo o predvidenem stroškovnem okviru za uspešno implementacijo v klinično prakso.
High voltage pulse generation for
electroporation based technologies
and therapies
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1 Introduction
1.1 Electroporation - The phenomenon
The first observations of effects of pulsed electric fields on biological material dates
more than 250 years back. But in the past two decades applications of electropora-
tion emerged in medicine, food processing and biotechnology [1]. The phenomenon
of electroporation leads to increased cell membrane permeability. Due to exposure to
high voltage electric pulses, cell membrane becomes permeable to molecules, which
otherwise can not cross the membrane [14]. Several theoretical descriptions of the
electroporation phenomenon have been proposed. The most established and likely
is that electroporation is based on the aqueous pores, which form in the lipid bilayer
[109, 110, 7]. When cells are exposed to pulsed electric field, voltage is induced across
their membranes. If the induced voltage is higher than the electroporation thresh-
old voltage, the rearrangement of membrane components is triggered, which leads
to the formation of hydrophilic pores in the bilayer, the presence of which increases
the ionic and molecular transport to otherwise impermeable membranes [111, 7].
Electroporation is reversible, if the cell afterwards fully recovers. However, when
the damage of electroporation is too excessive, the electroporation is irreversible [6]
and the cell dies presumably due to a loss of cell homeostasis [11]. Experimental
observation of the pore formation was not successful with known techniques, but
molecular dynamic (MD) simulation provides convincing corroboration [112, 113].
1.2 Electroporation applications in medicine
Electroporation is a platform technology, which is already well established in
medicine, food processing and biotechnology [3, 2]. The technology holds great
promise also in other fields, such as biomass production [114] and transdermal
transport [115, 116]. However, hereinafter only those which relate to PhD topic
are presented, i.e. ElectroChemoTherapy (ECT) and IrReversible Electroporation
(IRE).
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1.2.1 Electrochemotherapy
ECT is an antitumor therapy [49, 50]. Locally applied high voltage electric pulses
lead to a transient permeabilization of cells in tissue, which in case of a proper ap-
plication, covers all tumor cells [51]. Diffusion of chemotherapeutic drug (bleomycin
or cisplatin) is thou enabled and higher cytotoxicity is reached [117]. For a suc-
cessful application, a sufficiently high drug concentration and appropriate electric
field distribution within the tumor should be delivered to the targeted area [35].
Electrochemotherapy is a highly efficient treatment, with complete response rates,
based on a single treatment between 60 to 70 % and objective response rates up
to 80 % [52]. Additionally it is comparable if not even more efficient than other
similar skin targeted therapies [53]. At the beginning ECT was mainly used in
treatment of cutaneous tumors and skin metastases, following Standard Operating
Procedures (SOP) [54], later it was demonstrated that ECT can be successfully used
also for treatment of deep-seated tumours. Recently new strategies were developed
which enable treatment of deep-seated tumours, including bone metastases, liver
malignancies, and pancreatic, prostate and gastrointestinal tumors [9].
1.2.2 Irreversible Electroporation
IRE is used as “non-thermal” ablation of normal and tumor tissue, as cells primar-
ily die due to the membrane permeabilization and not due to increase of tissue’s
temperature [61]. It was shown that IRE does not cause the denaturation of pro-
teins and is not affected by decreased blood flow, additionally rapid activation of
the immune system, no scarring and the potential ability to treat tumors near large
blood vessels was observed [11]. However a local temperature increases around the
electrodes, can be significant at higher amplitudes, due to high number of pulses
delivered to limited volume of tissue [62, 63]. Also muscle contractions associated
with the high voltage pulses are present during treatment [67]. But recently in a
series of studies, authors showed that by applying bursts of high-frequency, bipo-
lar pulses also termed as H-FIRE (High-Frequency IrReversible Electroporation)
pulses, muscle contractions can be avoided during IRE without compromising the
non-thermal mechanism of cell death [67] and additionally the electric field distribu-
tion is more homogeneous. Even the transmembrane transfer of molecules may be
achieved with bursts of short microsecond long pulses, however H-FIRE pulses need
considerably larger voltage amplitudes for cell disruption in comparison to longer
monopolar pulses. [118]. Even more, the most resent research claims it is possible
to use H-FIRE in electrochemotherapy, but again, at the expense of higher electric
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fields than in classical ECT [102].
1.3 Dosimetry in electroporation
A pulsed power generator termed as electroporator and electrodes are used to expose
the cell to pulsed electric field [23]. Electroporator generates electrical pulses with
specific shape, amplitude, duration, number, repetition rate and sequence (bursts
of pulses) [24, 119]. By applying electrical pulses to the electrodes, which are in
direct contact with the tissue, an electric field is generated in tissue with specific
distribution and intensity [43].
1.3.1 Electric pulse generators
Different applications require particular pulse shapes, voltage amplitudes, pulse
width, pulse repetition rates and number of pulses or bursts of pulses [23, 24]. For the
introduction of small molecules, pulses which generate the electric fields strengths
of approximately 1 kV/cm, with pulse widths from µs to ms range are used. For
the introduction of large molecules different protocols have been established, higher
electric field strengths of few kV/cm, with pulse widths in rage from few to hundred
µs, or low voltage pulses with few hundred V/cm and ms pulse widths, or even the
combination of both. For electroporation of the cell organelle membranes, pulses
with widths in ns range and amplitudes of tens of kV/cm or more are used [111].
Therefore specific pulse generators, i.e. electroporators have to be designed and de-
veloped for each application. When designing an electroporation device one should
always keep in mind that, biological sample as a load has resistive–capacitive nature
and can vary from sample to sample and in addition the impedance of a biological
sample decreases during the pulse delivery [105, 120].
Micro- and millisecond square wave pulses are usually generated by a capacitor
discharge circuit, with fast power MOSFET or IGBT used as switches. To minimise
a voltage drop on the load, all the required energy must be generated and stored in
the capacitor before the pulse delivery. Meaning large capacitor or capacitor banks
are needed, but this is resulting in difficult voltage modification. Additionally,
low impedance of a load (tissue or cell suspension) require large power/currents,
which quite often leads to significant voltage drop on the load. Also when using
protocols in which many pulses are delivered to the load, with higher pulse
repetition rates, significant amplitude voltage drop, with each successive pulse can
be observed, if the energy storage is not sufficient. To achieve efficient electric field
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that enables electroporation, high voltages and currents are required, therefore
generator construction is challenging. The most complicated circuit designs are
required, for generation of high power and short duration pulses, with fast switches.
To generate high voltage square wave pulses three different circuit concepts are
used, i.e. Marx generator, transistors in series or modular square wave generator
[121, 122, 123, 124]. For the generation of high frequency and high voltage
square wave pulses Radio Frequency MOSFET (RF-MOSFET) or Silicon Carbide
MOSFET (SiC MOSFET) are mainly used. For the bipolar pulse generation a
H-bridge solution is the most established. Short rise time of high voltage pulses
is provided by modular generator and short fall times can be achieved by short
circuiting of the load [125]. Modular generator is capable of delivering currents
of several amperes and has a capability to generate various pulse duration [122],
amplitudes and pulse repetition rates. The topology is simple as it consists of n
individually controlled voltage sources, which are at any time available for the
participation in the output pulse formation. On the output we have a series of n
transistors that connect sources in series, sources that do not participate in output
pulse formation, have no current, since the load current is pushed through diode.
The output pulse rise and fall time depend only on the speed of transistors, there
are no additional pulse repetition rate limits. For the generation of bipolar pulses,
a transistor bridge that enable polarity change is added at the output. Diagonal
bridge transistors in case of proper control change the polarity of the output voltage
[125].
1.3.2 Electric pulse delivery and standardization
We distinguish between prototype and commercially available electroporators.
A considerable number of electroporation devices can be found on the market,
some designed for specific applications and some for multifunctional laboratory
use. Several reviews have been published in which commercially available electro-
porators were described but not really compared [94, 93, 8]. Even more, as the
electroporation market grows more and more manufacturers conceal the output
pulse parameters of their devices, claiming that it is their intellectual property. We
have already reached a critical point on the field of gene transfection, where pre-
programmed electroporation procedures are most commonly used by researchers,
without even knowing basic pulse parameters such as amplitude. Pre-programmed
and concealed operation of electroporation devices limits researchers, restricts and
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hinders sharing, comparing and reproduction of results, consolidation of knowledge
and the development of new knowledge. Failed efforts to confirm other group’s pub-
lished papers work are unfortunately increasing in electroporation as in biomedical
research in general [30]. In the field of electroporation, this may be because in some
studies the determination and description of the electric fields to which the cells
were exposed during experimental work were not adequately reported, or at least
were not reported in sufficient detail. Measurement of electroporation pulses is
crucial to adequately determine and control the quality and the delivery of pulses.
Very short (from 1 to 20 ns) electroporation pulses are the one most challenging to
be measured, because of finite pulse propagation speed (20 cm/ns in transmission
line) and associated pulse reflections [18].
While all of the currently present problems could be avoided, or could be at
least reduced with the implementation of a particular standard for electroporators.
A clinical electroporator is a medical device, therefore it must comply with medical
device standards. In Europe, it is regulated by a Medical Device Regulation - MDR
(EU 2017/745) and in the USA by Code of Federal Regulation - CFR (Title 21).
The usability, safety, and risk management are strictly defined, however, none of the
existing regulative directly addresses the operation or electroporators performance
requirements [126, 127, 128]. Even more, a laboratory electroporator is not classified
as a medical device and therefore the regulation is even less strict.
1.4 Health Technology Assessment
Screening and evaluation of medical technologies is becoming crucial, as in the most
developed countries health care expenditures are constantly increasing, while at
the same time budgets are decreasing [129]. In Slovenia, health care spending is
around 8.6 % of GDP which is under the European average, that was in year 2012
evaluated to 10.2 % of GDP. Moreover, projections show that Slovenian population
is aging and that in 2050 29.8 % of the Slovenian population will be older than
65 years, what will most likely result in a significant rise of health care expenses.
Simulations show that the increase of health care expenses pre year will rise from
0.6 %/year in 2016 to 2.8 %/year by the year 2060 [130]. Independently from the
relative or absolute expenditure per year, the health care national budget is in
any case limited. Therefore, decision makers have to select carefully how to invest
public money, as the introduction of a new technology will result in the exclusion
of an old one. Health Technology Assessment (HTA) is a systematic evaluation
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of the properties and effects of a health technology, addressing mainly the clinical
effectiveness, safety and cost-effectiveness. HTA helps health technology decision
makers allocate resources, thus allowing better management of health technologies
and innovations, and provides guidelines for competitors, developers and researchers.
Health technology is evaluated by systematic tools and modelling for instance cost-
effectiveness can be evaluated by Cost-Effectiveness Analysis (CEA) [131, 82].
1.4.1 Cost-Effectiveness Analysis
CEA compares health care expenses with treatment outcomes in term of their util-
ity to patient measured in Quality Adjusted Life Years (QALY) [132]. QALY is
a generic measure of disease burden that includes both the Quality of Life (QoL)
and the quantity of life lived. In HTA it is assumed that people in their lives
move through different health states and each of them has a specific value attached.
QALY in CEA represents years of life subsequent to a health care intervention that
are weighted or adjusted for the QoL experienced by the patient during those years
[83, 133]. QoL is normalized to a standardized scale with range from 0.0 (death) to
1.0 (perfect health) and linear distribution in between. Widely used standardized
instrument for measuring QoL is an EuroQol five dimensions questionnaire (EQ-5D)
[85]. For the CEA analysis, data collection methods such as: systematic literature
review; meta-analysis; modelling; group judgment; unstructured literature review
and expert’s opinions can be used [54]. However, it can happen that for a specific
new technique or an innovation, there is not even a single primary study (empirical
research study) available. In this case a potential source of bias must always be
considered and documented [133]. In order to incorporate conditionality and uncer-
tainty of collected data, regardless of the reliability of the data, decision models are
used to simulate adjustments of projections of existing primary data. With mod-
eling patients conditions, treatment efficacy, treatment and maintaining costs and
incidence of the disease projections to a future costs and outcomes of the treatments
or innovations, can be made. Decision making trees, fuzzy logic and state transition
modeling, such as Markov model and Monte Carlo simulation are most often used.
Decision trees are not appropriate for modeling of diseases with a recurrent health
states. In such cases a state transition models should be used, where the probability
of transition between all the states and remaining in each state is incorporated. In
the Markov model for HTA each state represents a specific state of health, or stage
of disease, between which patients migrates. There is always one state that repre-
sents death, which is considered an absorbing state, as it does not have a feedback
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connection. Other health states are defined accordingly to the disease studied. The
model’s structure should be as simple as possible, as it is not necessary to model the
full complexity of the disease. Model complexity (i.e. number of parameters and
model order) should every time be limited by the quantity and quality of available
data [134]. More aggregated structure that however still includes fundamental dis-
ease process and interventions is often the best solution. The innovation cannot be
cost-effective by itself; therefore, CEA always includes a comparison of a new to a
benchmark technology.
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2 Aim
The aim of this thesis is quite versatile, it combines three different topics, with a
common main topic called electroporation.
The main topic of the first aim was to review currently available commercial electro-
poration devices, their operation, and usage. Thought testing and evaluation of the
devices, a need for an electronic emulator of the biological load becomes apparent.
Therefore the aim extended to the development of an electronic circuit that behaves
in the same way as biological load, during electroporation. Additionally, due to
the review, the focus moved also on the measurement of delivered pulses during
electroporation, which enables quality assurance. Dosimetry in electroporation and
measurement of nanosecond pulses, which is the most challenging, becomes an area
of interest. This topic concluded with the idea that standardization, in the field of
electroporation, is necessary. Electroporation is a platform technology and a specific
standard for each application or field should be established. Nevertheless, some ba-
sic technical specifications and tolerances can be applied to all electroporators. The
aim was to write the recommendations for the standardization of electroporation
devices.
The second aim was to develop a new versatile high voltage electroporator. Re-
cent insights on H-FIRE raised interest in the exploration of the sensitization and
cancelation effects described below. The sensitization effect is defined as a total
molecular increase or decrease of uptake in comparison to applying a single dose to
a split dose. For pulses of short duration (in a scale of a few hundred nanoseconds),
a cancellation of biological effects have been detected [19, 20, 21, 22]. Cancellation
effect is defined as a decrease of uptake when one monopolar pulse closely followed
by a second monopolar pulse of the opposite polarity (actually one bipolar pulse)
is used instead of only one monopolar pulse [91]. However, uniform electroporation
of the heterogeneous structure of tissues is a technological challenge that could be
overcome by electroporation with high-frequency, bipolar pulses [92]. To allow us
to study all the above-described effects in vivo, the output voltage of the new gen-
erator should reach 4 kV, and the shortest pulse duration and pause between the
bipolar pulses should be 1 µs. The simplest way to generate high-frequency square
wave pulses is to connect and disconnect the charged capacitor to the load by the
silicon transistor. According to the electroporators review [8, 93, 94] and economic
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evaluations [95, 96] that have been done by now, we came to the conclusion, we have
identified the need to develop. The development of a bipolar pulse generator with
a maximum voltage of 4 kV and a minimum duration time lower than 1 µs, would
enable an evaluation of biological effects of very high and at the same time short
electric pulses. Both in vitro and in vivo, we believe advantage of those specific pulse
characteristics might be in the reduction of an electric field induced muscle contrac-
tion and pain sensation [97, 67, 98]. In order to reduce movement, muscle relaxants
are currently administered prior to treatment and local or general anaesthesia is
used, but the dosage of those relaxants, need to be monitored throughout the proce-
dure [99, 100]. It was shown that the electric field threshold for muscle contraction is
two times lower than the threshold for electroporation [98]. It was already reported
that bipolar pulses [101] and H-FIRE pulses [67] reduce muscle contraction. It was
also shown that IRE can be performed with a phase duration of 1 µs by increasing
the number of pulses and electric field strength [67]. An additional aim becomes
apparent, which included in vivo experiments with the developed device. The feasi-
bility of High-Frequency electrochemotherapy (HF-ECT) and evaluation of muscle
contractions present during the pulse delivery were researched.
In order to define the budget for the development of a new clinical electropo-
ration device, the focus, in the scope of the third aim, is on to Heath Technology
assessment, in more detail to the Cost-Effectiveness Analysis (CEA). A few CEA
have already been done for electroporation [9, 96], but due to the lack of information
obtained, especially about QoL increase, results are inadequate and not accurate.
Electrochemotherapy of skin melanoma and basal cell carcinoma (BCC), as these
two therapies are used for the longest time and are also very successful are econom-
ically evaluated.
3 Results and Discussion
Three original scientific contributions were made in this thesis:
1. Evaluation of electroporators and recommendations for standardization of elec-
troporator as a standalone medical device;
2. Development of a novel bipolar high-frequency high-voltage pulse generator -
electroporator;
3. Cost-effectiveness analysis of electrochemotherapy for treatment of basal cell
carcinoma and skin melanoma;
The results and discussion section consists of eight papers and a book chapter,
which presents the work done in the scope of this thesis.
The first scientific contribution is addressed in a book chapter, which was
publishes in 2017 and five scientific papers. Paper 1 and 4 were submitted to the
SCIE ranking journals and are under the review process. Paper 2 and 3 were
accepted for publication and paper 5 is already published.
Book chapter (Pirc, Reberšek and Miklavčič) published in Dosimetry in bioelec-
tromagnetics, titled Dosimetry in electroporation-based technologies and treatments
provides a brief introduction in electroporation field. The physical dosimetry of
pulse delivery is described in detail, with the focus on measuring. We discuss why
measuring is necessary and provide basic guidelines on how to measure and report.
A review of commercially available electroporators for ECT IRE and GET and
different electrodes for electroporation, at the time of writing, is presented in two
tables. We contacted 25 manufacturers, but only 13 were pleased to cooperate,
others did not want to disclose the output pulse characteristics of their devices. As
the electroporation market grows more and more manufacturers conceal the output
pulse parameters of their devices, claiming that it is their intellectual property. We
concluded the field of electroporation is in need of promoting reproducible research,
which can only be achieved by adequate measurements, standardized reports, and
proper use of electroporators and electrodes.
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Paper 1 (Dermol-Černe, Pirc, and Miklavčič), titled Mechanistic view of skin
electroporation – models and dosimetry for successful applications: an expert review
contains a more recent and focused review of electrode configurations and pulse
generators, prototypes as well as commercially available models, used in skin
electroporation. An expert opinion about each of the reviewed devices is given and
the conclusion that electrode configuration and electroporators are not adequately
reported and therefore a comparison of studies is difficult, if not impossible, is
made. For each skin electroporation treatment, systematic studies determining the
optimal parameters should be performed and treatment parameters standardized.
Paper 2 (Pirc, Reberšek and Miklavčič), titled Functional requirements and
quality assurance necessary for the successful incorporation of electroporation based
therapies into clinical practice provides recommendations for the development of
clinical electroporators. Electroporation based therapies have a huge potential for
implementation into clinical practice in socioeconomically disadvantaged popula-
tions. But currently, the price of electroporators and electrodes is relatively high,
however, custom low budget devices can be developed. Functional requirements for
a medical electroporator and safety guidelines, with the focus on medical device
standard and FDA requirements are described. Quality assurance, the importance
of measurement during the pulse delivery and additionally, recommendations for
standardization are also addressed in the paper.
Paper 3 (Cvetkoska, Pirc, Reberšek, Magjarević, and Miklavčič), titled Towards
standardization of electroporation devices and protocols proposes guidelines for the
design of clinical electroporators and define minimal requirements for their safe
and efficient use which can be incorporated within the particular standard in the
future. In the paper, we describe the electroporator’s output parameters and define
tolerances on the base of the standard operating procedure for electrochemotherapy.
Paper 4 (Pirc, Balosetti, Miklavčič and Reberšek), titled Electronic emulator of
biological load during electroporation, in detail describes an innovative method for
the evaluation of clinical, laboratory and prototype electroporation devices during
the development process, or to evaluate their final performance considering at
least from the perspective of output pulse parameters. We developed an analog
electrical circuit that has equivalent impedance as the beef liver tissue during high
voltage pulse delivery and or electroporation. An equivalent circuit was simulated,
build and validated. Proposed emulator facilitates standard implementation, it
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enables the development of standardized testing protocols, which are fundamental
for quality assurance.
Paper 5 (Pirc, Miklavčič and Reberšek), titled Nanosecond Pulse Electroporator
with Silicon Carbide MOSFETs, Development and Evaluation, is focused on
nanosecond electroporation, which is studied for more than a decade, but it is still
not entirely understood, we believe one of a contributing reason for this situation,
is also a unique, group-specific, prototype hardware equipment and challenging
measuring methods. In the scope of this paper, we improve the performance of
the high-voltage nanosecond pulse generator by introducing Silicon carbide (SiC)
MOSFETs. The developed generator can deliver from 500 V to more than 6 kV,
approximately 8 ns pulses to a 50 Ω load. The measurement and evaluation process
are described in detail. Additionally, we emphasize on the size of an error which
occurs during measurements.
Second scientific contribution is addressed in a one scientific paper, which is
ready for submission to the SCIE ranking journal.
Paper 6 (Pirc, Miklavčič, Uršič, Serša and Reberšek), titled High frequency
and high voltage asymmetric bipolar pulse generator for electroporation based
technologies and therapies, describes the development and evaluation process of
an electroporator that generates as well, symmetrical as asymmetrical (duration
and amplitude) bipolar pulses. The voltage amplitude can reach up to 4 kV, while
the maximal theoretical load current is 131 A, the minimal pulse duration is 200
ns. The device was also evaluated in vivo, the first in vivo use of HF-EP (high
frequency) in electrochemotherapy was performed and the desired performance
was reached. Additionally, the acceleration of mice leg during the pulse delivery
was measured in order to evaluate muscle contractions. The design proposed in
this paper enables faster development and spread of the technology and in vivo
experiments, due to the high maximal current of developed device.
Third scientific contribution is addressed in two scientific paper, paper 7 was
published in 2018 in slovenian medical journal, while paper 8 is ready for submission
to SCIE ranking journal.
Paper 7 (Pirc, Pecchia, Reberšek, Serša, Snoj, Grošelj, Miklavčič), titled Study
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design of a medical device pre-market assessment: a case study on electrochemother-
apy, consists of two parts: the first part presents basic principles and concepts of
health technology assessment and cost-effectiveness analysis, and the second part
reports study design of an early cost-effectiveness analysis of electrochemotherapy
for the treatment of basal-cell carcinoma and skin melanoma. Two general Markov
models and their reduced versions, designed specifically to assess electrochemother-
apy of basal-cell carcinoma and skin melanoma, were developed in the scope of
this paper. The data required for successful calculations have been identified, some
of which were missing at the time of writing, therefore recommendations for data
collection process and follow-up reporting were made. With this paper, we tried
to raise awareness about the importance of numeric quality of life reporting and
usefulness/meaning of EQ-5D questionnaire that might not be self-evident at first
sight but are crucial for cost-effectiveness analysis.
Paper 8 (Pirc, Federici, Bošnjak, Perić, Reberšek, Pecchia, Glumac, Čemažar, Snoj,
Serša, and Miklavčič), titled Early cost-effectiveness analysis of electrochemotherapy
as a prospect treatment modality for skin melanoma, describes a study of an early
cost-effectiveness analysis of electrochemotherapy with Cliniporator in patients with
stage IV and IIIc skin melanoma in Slovenia. In the whole patient population, ECT
of skin melanoma stage IV and IIIc is expected to increase the quality of life by
0.29 QALYs, at the higher cost of 6,568 e. At the cost-effectiveness threshold
of 20,000 e, the probability of ECT being cost-effective compared to standard of
care is estimated to be 0.3 and 0.91 for the whole patient sample and the patients
with bleeding lesions respectively. For the whole sample population, a reduction in
the price of the electrodes by half is expected to increase the probability of being
cost-effectiveness from 0.3 to approximately 0.64.
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12.1  Introduction
Electroporation is a platform technology that is already established in medicine and 
food processing (Haberl et al., 2013a). It is based on increased cell membrane permeabil-
ity due to exposure to electric pulses (Weaver, 1993; Kotnik et al., 2012). If the cell is able 
to fully recover afterwards, we call it reversible electroporation; when the damage is too 
great and the cell dies, we call it irreversible electroporation (IRE). Electrochemotherapy 
(ECT) is an antitumor therapy in which locally applied high-voltage (HV) pulses trig-
ger a transient permeabilization of tumor cells. Diffusion of a chemotherapeutic drug 
(bleomycin or cisplatin) is enabled, resulting in higher cytotoxicity. Effectiveness is 
accomplished if sufficient drug concentration and electric field in the tumor are achieved. 
ECT is a highly efficient treatment, with complete response rates of between 60% and 
70% on a single treatment and with objective response rates up to 80% (Mali et al., 2013), 
To measure is to know. 
If you cannot measure it, you cannot improve it.
Lord Kelvin
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and is comparable to, if not more efficient than, other similar skin-directed technologies 
(Spratt et al., 2014). It is used in the treatment of cutaneous and subcutaneous tumors, 
following standard operating procedures (SOPs; Mir et al., 2006).
If the exposure of the cell to electric field is too excessive, it dies, presumably due 
to a loss of homeostasis. IRE is used as an ablation method for normal and tumor tis-
sues. It is called “nonthermal” ablation, because cells primarily die due to membrane 
 permeabilization and not due to the increase in the temperature of the tissues. However, 
we should not overlook local temperature increases around the electrodes, which can be 
significant at higher amplitudes, increased duration, or number of pulses (Garcia et al., 
2014; Kos et al., 2015). Considerable research has also been undertaken in the area of 
gene transfection and biopharmaceutical drugs stimulating an immune response. Gene 
electrotransfer (GET) is a nonviral method for delivering DNA molecules into cells. 
DNA vaccination using electric pulses and clinical trials of GET of DNA with interleu-
kin-12 in patients with metastatic melanoma also has shown great promise in clinical 
practice (Heller et al., 2001; Haberl et al., 2013a; Lambricht et al., 2016).
Many of its biotechnological applications such as inactivation of microorganisms and 
extraction of biomolecules have only recently started to emerge, while nonthermal food 
pasteurization is already being used in the industry (Toepfl et al., 2006; Kotnik et al., 
2015). Electroporation is more commonly termed as pulsed electric field (PEF) treatment 
in food technology. Food preserved by PEF maintains color and flavor, and the anti-
oxidant levels also stay unaffected (Haberl et al., 2013). It is efficient for increasing the 
shelf life of liquid food (Toepfl et al., 2006). A combination of mild preheating to 60°C 
and subsequent electroporation reduces the energy needed for efficient disinfection to 
40 kJ/L (Gusbeth and Frey, 2009).
Microalgae are currently the most intensely investigated feedstock for biomass 
 production with electroporation; they are getting implemented in biofuel applications 
(Golberg et al., 2016; Postma et al., 2016). A combination of grape fermentation and 
 electroporation led to an increased content of polyphenolic compounds and less  acidity, 
thereby resulting in a slightly smoother taste and color intensity in wine (Mahnič-
Kalamiza et al., 2014). Overall, it is a fast-growing field with great potential.
12.1.1  Electroporation—The Phenomenon
Electroporation is a phenomenon in which cells that are exposed to a high enough elec-
tric field increase permeability and conductivity of their membranes. Each biological cell 
is surrounded by a membrane that mainly consists of phospholipids. Lipids in aqueous 
conditions spontaneously form a two-molecule thick layer as a result of their dielectric 
properties. Water and water-soluble molecules cannot pass the entirely intact barrier only 
by diffusion (Deamer and Bramhall, 1986). In addition, biological membrane also contains 
glycolipids, cholesterol, and various proteins, which enable selective transport of some 
molecules from intracellular space to the cell interior and vice versa (Kotnik et al., 2012).
Several theoretical descriptions of the electroporation phenomenon have been pro-
posed. The most established and likely one is that electroporation is based on the aque-
ous pores formation in the lipid bilayer (Freeman et al., 1994; Weaver and Chizmadzhev, 
1996; Kotnik et al., 2012). When cells are exposed to a high pulsed electric field, voltage 
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is induced across their membranes. This results in the rearrangement of their mem-
brane components, leading to the formation of hydrophilic pores in the bilayer, the 
presence of which increases the ionic and molecular transport to otherwise imperme-
able membranes (Pucihar et al., 2008; Kotnik et al., 2012). Experimental observation of 
the pore formation was not successful with known techniques, but molecular dynamic 
(MD) simulation provides convincing corroboration. From the electrical point of view,
a cell can be modelled as an electrolyte (conductive media), surrounded by an electri-
cally  insulated/dielectric shell. Each cell under physiological conditions has a resting
transmembrane voltage in the range of −90 to −40 mV (Kotnik et al., 2010). This is a
result of ion imbalance in the cytoplasm, controlled by Na+–K+ pumps and K+ leak
channels. Na+–K+ pumps export Na+ ions out of the cell and simultaneously import K+
ions; meanwhile, K+ ions can freely cross the membrane through K+ leak channels, to
achieve electrical and concentration equilibrium. Applied electric pulses cause local
field distortion in the cell and their surroundings. Due to low-membrane conductiv-
ity in the vicinity of the cell, the electrical field concentrates mainly in the cell mem-
brane, resulting in electrical potential difference across the membrane. The induced
transmembrane voltage superimposes to the resting potential. It can affect transport
through the membrane, stimulate cells, and if high enough, lead to the electropora-
tion of cell membrane. Increased cell permeabilization is observed with electric field
increase; induced transmembrane voltage is dependent on position, cell shape, and ori-
entation. Delay between external and inducted voltage is in the microsecond range and
is determined by the membrane time constant τm (Isokawa, 1997). If cells are exposed
to electric field in low conductivity medium, delay significantly increases (Kotnik et al.,
2010). When short, intense electric pulses (nanosecond pulses, tens of kV/cm, with a
period similar to τm or shorter) are applied, the outer membrane acts as a short cir-
cuit because of cell frequency response, and the applied voltage also appears across
the interior of the cell (Kotnik and Miklavčič, 2006). Nanosecond pulses can induce a
high enough voltage to cause electroporation of internal organelles (Batista Napotnik
et al., 2016). Because organelle interior is electrically more conductive then cytosol, and
organelle membrane dielectric permittivity is lower than a cell membrane permittivity,
a voltage induced on organelle membrane can exceed the one induced on the cell mem-
brane, resulting in increase of induced voltage amplitude (Kotnik et al., 2010; Retelj
et al., 2013). But at the same time, pulses also cause plasma membrane permeabilization
(Kotnik et al., 2006; Batista Napotnik et al., 2010).
12.1.2  Physical Dosimetry in Electroporation
The local electric field, i.e., the one “felt” by the cell is the one that leads to membrane 
electroporation. Applicator/electrode characteristic and applied pulse characteristics 
define the electric field distribution and intensity. For various applications, different 
pulse shapes, voltages, duration, repetition frequencies, and sequences are needed. 
Therefore, special pulse generators have been designed called electroporators. Because 
biological load characteristics vary considerably, and in addition their conductivity 
changes due to electroporation during the pulse delivery, development of these devices 
is challenging.
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12.1.2.1  Dosimetry of Pulse Delivery
The electroporation signal is, as mentioned before, characterized by pulse amplitude, 
shape and duration, number of pulses, pulse repetition frequency, and pulse orienta-
tion sequence. Most common pulse shapes that are used in electroporation are square 
wave (also bipolar), exponential decay, and bell-shaped pulses. When designing an 
 electroporation device, one should always keep in mind that a biological sample as a 
load has a resistive–capacitive nature and can vary from sample to sample, and in addi-
tion the impedance of a biological sample decreases during pulse delivery (Pliquett et al., 
2000; Pavlin et al., 2005). The most simple and inexpensive way to generate pulses is by a 
capacitor discharge circuit (Figure 12.1). When we are dealing with higher voltages, it is 
more efficient and easier to use smaller capacitors and connect them in to a Marx genera-
tor (Figure 12.1c). The main problem here becomes simultaneous switching; the switching 
element must be chosen with respect to their maximum operating voltage and response 
rate. The generated pulses have typical capacitor discharge-exponentially decay shape 
(Reberšek and Miklavčič, 2011; Reberšek et al., 2014). Micro- and millisecond square 
pulses are usually generated by an HV power supply switching circuit (Figure  12.2a), 
with fast-power MOSFET (Metal-Oxide-Semiconductor Field-Effect Transistor) or 
IGBT (Isolated-Gate Bipolar Transistor) used as the switch. All the required energy must 
be generated and stored in the capacitor before delivery. To minimize a voltage drop, a 
very large capacitor is needed, resulting in difficult voltage modification. We also have 
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FIGURE 12.1 Panel (a) is capacitor discharge circuit, a built-in resistance R is added to limit the 
decrease of time constant τ = ⋅ ≥ τ ≈C Z I Z R RC* * 10 ,L F L , resulting in 90% energy dissipation 
through R. Panel (c) is a proposed Marx bank circuit. Capacitors C are charged in parallel through 
resistor R and then switched to series building up the voltage to n U*  and discharged through the 
load ZL, by switching all switches simultaneously. The maximum applied voltage is equal to the 
load power supply voltage multiplied by the number of capacitors and time constant. In panel 
(b), a generated pulse shape is presented, the discharge time is time constant dependent.
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some time limitations; pulses can be generated after the capacitor is recharged to the 
preset voltage. Low impedance of a load (tissue or cell suspension) requires large power/ 
currents, which quite often leads to a significant voltage drop. Protocols in which a larger 
number of pulses are delivered can result in reduced amplitude of pulses (Figure 12.2). 
This is one of the main reasons why we need to measure when using devices for electro-
poration. Furthermore, we focus on measuring and quality control.
To achieve an efficient electric field that enables electroporation, we are dealing with 
HV and currents; therefore, generator construction can be challenging. The shorter the 
pulses, the more complicated the circuit designs that are required; it is really challenging 
to generate high-power and short-duration pulses. HV switches with short rise times 
are needed; spark gaps, UV lasers, SiC MOSFETs, or IGBTs can be used, depending 
on the application. With nano- and picosecond pulses, pulse-forming networks are a 
common solution, e.g., a transmission line (Figure 12.3a). Transmission lines operate 
in both charging and discharging phases. Generated energy should be stored in a large 
capacitor and then discharged to the load. After pulse generation, a new pulse can be 
delivered when the capacitor is recharged, resulting in repetition frequency limitation 
(Bertacchini et al., 2007; Syamsiana and Putri, 2011; Reberšek et al., 2014).
Electrodes, together with the biological sample, present the load for the pulse genera-
tor. The main problem that we encounter here is that electrodes get polarized where they 
get in touch with the sample due to water molecules and hydrated ions that are present in 
the surrounding area. It is a frequency-dependent phenomenon, which can be modeled as 
a capacitor in series with a resistor (Chafai et al., 2015). In a cell suspension, a  counterion 
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FIGURE 12.2 High-voltage power supply switching circuit (a). The variable power sup-
ply VCC defines the amplitude of the output pulse. Switches control pulse duration and 
pulse repetition frequency. The voltage drop that occurs during pulse is proportional to 
( )( )= C Zload impedance voltage drop pulse duration/ * (b).L  In (c) C an example of reduced ampli-
tude is shown, that can occur in a case of low impedance load that requires too high current.
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layer is formed at each electrode and electric field driving charge transport is reduced, 
resulting in lower suspension conductivity. At the contacts with tissue, electrodes stimu-
late the release of electrolytes, resulting in the development of a poorly conductive region 
where wounds can occur. Luckily, polarization decreases with increasing frequency.
Electrodes must be user friendly; the wires connecting them should be long enough to 
enable easy handling and smooth application. But each additional wire/connection has 
some parasitic properties resulting in route losses—the higher the frequencies, the more 
the parasitic characteristics are manifested. In worst cases, when dealing with nanosec-
ond pulses, the generated pulses at the end of electrodes can completely differ from the 
ones at the output stage of the electroporator. At high frequencies, reflection on the lines 
must also be taken into account. The thickness of the wire must be compatible with the 
output current (Kolb et al., 2006; Batista Napotnik et al., 2016).
Different electrodes are available on the market, and they need to be chosen consid-
ering the targeted load and pulse generator restrictions. Electrode geometry and posi-
tion also determine electric field distribution. In vitro, four main groups of electrodes 
are present: single-cell chambers, macroelectrodes (two-plate electrodes separated for 
at least 1 mm), microelectrodes (glued onto cover glass, with separation of 100 μm), and 
flow-through chambers (polyethylene or polypropylene used as insulating materials, 
combined with stainless steel electrodes) (Reberšek et al., 2014). When using nano- or 
picosecond pulses, impedance matching must be ensured. For in vivo use macroplate 
and needle electrodes are commonly used. Electrochemotherapy standard operating 
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FIGURE 12.3 Concept of Blumlein transmission line (a) and diode opening switch (DOS)  circuit 
(b), commonly used in nanosecond pulse generator designs. The Blumlein  transmission line genera-
tors have a variable high-voltage power supply V, a charging resistor R, and two  transmission lines. 
T1 and T2 are charged when the switch is turned off and then discharged through the load when 
switched. The pulse duration cannot be modified as it equals twice the electrical length of the trans-
mission line, if the impedance of the load is twice the impedance of the transmission line. The DOS 
generators can be composed of more accessible electrical components than Blumlein generators. 
Pulse is formed by a diode that must be forward and reverse pumped with adequate sinusoidal cur-
rent. Diode should stop conducting when the majority of the total energy is stored in L2. That means a 
current must be maximized at the time of switching. High  voltage is switched by diodes, which means 
MOSFET-s does not need to withstand the whole output amplitude, and does not need to be faster 
than the output pulse. Pulse duration is determent with diode reverse recovery time. But finding the 
appropriate matching of capacitors and inductors values in LC oscillator for optimal switching can be 
challenging. (From Reberšek, M., et al., IEEE Electr. Insul. Mag., 30(3), 8–18, 2014; Sanders, J. M., et al., 
IEEE Trans. Dielectr. Electr. Insul., 16(4), 1048–1054, 2009.)
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procedure (ESOP) (Mir et al., 2006) describes three different types of electrodes that were 
developed within the Cliniporator project and are compatible with the Cliniporator gen-
erator (Table 12.1). According to SOP, plate electrodes are recommended for treatment of 
small and superficial tumor nodules. For treatment of thicker and deeper-seated tumor 
nodes, needle electrodes are more suitable. During the development of Cliniporator, 
voltage characteristics—sequences—were determined and acquired for better efficacy 
(Ongaro et al., 2016). Sometimes, large volumes need to be treated; lately, a new type of 
electrode that covers larger surfaces has become a subject of study (Ongaro et al., 2016).
12.1.2.2  Measuring
When dealing with electroporation, measuring is crucial for achieving effective electropora-
tion. Quality assurance can only be provided by appropriate measurements. Unfortunately, 
failed efforts to confirm other group’s published work are  increasing (Kaiser, 2016). The 
description of the used equipment and the process are flawed. In many papers describ-
ing/using electroporation, insufficient detail is reported, and quite often measurements 
are not reported (Batista Napotnik et al., 2016; Campana et al., 2016). The electroporation 
field needs to promote research reproducibility, and to improve this, we further need to try 
and answer the following questions: “Why measuring is necessary?”, “How to measure?”, 
“Which data are significant for researches?”, and “Which electroporator to choose?”
For electroporation, you need an electroporator. A considerable number of electropora-
tion devices can be found in the market, some are designed for specific applications and 
some are multifunctional. Most often, they are compatible with different electrodes. It seems 
however that as the market grows, manufacturers tell us less about their devices. We have 
already reached a critical point in the field of gene transfection, where preprogramed elec-
troporation procedures are most commonly used so that quite often the researcher does not 
even know basic pulse parameters, such as pulse shape, repetition rate, and even less about 
applied voltage amplitude/electric field strength (see Tables 12.1 and 12.2). The researchers 
are only aware of the program number they used on their device. This limited information 
availability restricts and hampers the development of new knowledge. In this case, preengi-
neering of electroporation devices limits researchers and hampers the sharing and compar-
ing of results or protocols and even the further development of gene transfection field.
The most complicated of all are nanosecond electroporation systems. They usually 
consist of nanosecond pulse generator, transmission line or delivery system, and electro-
poration chamber/electrodes (Pakhomov et al., 2009; Ibey et al., 2010; Batista Napotnik 
et al., 2016). When using nanosecond pulses, it should always be taken into account that 
pulses reflect on impedance change and lose power in the transmission line. If the imped-
ance matching is not guaranteed, reflections are present and load dependent. When load 
impedance is higher, reflections are positive and add to amplitude that would be present 
on a matched load. In case of lower load impedance, amplitude on the load will be lower. 
Pulses can become bipolar and cancelation effect can occur. Nanosecond pulses travel 
approximately 20 cm/ns in coaxial cable (Batista Napotnik et al., 2016).
12.1.2.3  Why Is Measuring Necessary?
For quality assurance! To be sure that the pulses are delivered and the device operates 
according to its specifications.
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The first and most logical answer is because we want to know if our pulses were 
successfully delivered and we need to know what was delivered. If the current flows 
through a load, a delivery was more or less successful. But we still do not know 
 anything about the pulse shape and voltage amplitude, or how many pulses were actu-
ally delivered. Due to the nature of electric discharge circuits that are commonly used 
in electroporation devices, amplitude of successive pulses can be lower with each suc-
cessive pulse delivered (Figure 12.4), if the pulse repetition rate is in the higher half of 
device operation range. Low-conductivity media in cuvettes is used for two reasons—
to reduce heating of the sample due to the current flow and to facilitate pulse gen-
eration. With lower resistant loads, problems can occur because the pulse generators 
cannot deliver “what they promise,” i.e., high currents. A typical cuvette resistance 
with a low conductivity media is somewhere between 100 and 50 Ω. But high conduc-
tive media can have a resistance between 10 and 15 Ω, and even lower, requiring even 
up to 10 × higher currents. This large variation of load characteristics represents a 
great challenge in electroporator design resulting in different solutions. Because of 
software or hardware errors, devices can have an unexpected delay during genera-
tion, one or more pulses may be omitted, a voltage amplitude may deviate from the 
expected value, etc. In the case of clinical medical devices with CE certification, these 
errors should not occur, or if they do, an alarm must be triggered. But when we are 
dealing with self-developed or commercial devices not classified as medical devices, 
monitoring is necessary. Also, electronic components and, consequently, devices are 
aging, and their characteristics may change with time. Built-in measurement systems 
are usually comfortable solutions, but some manufacturers are taking shortcuts. If 
the measurement system is a part of the device, it needs periodic calibration; so if this 
is not part of the unit maintenance, the measurement system is questionable.
The second reason why measuring is necessary is the reproducibility of research 
results. For research reproducibility, at least similar, if not exactly the same, pulses are 
needed. Different research groups have different electroporation devices whose output 
pulses may derogate from specified shapes/parameters. If we know exactly what kind of 
pulse is needed, a custom setting might lead us towards better matching. Not reporting 
pulse parameters hinders the comparison of results and hinders progress of research.
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FIGURE 12.4 An example of output pulse measurements, we used a SENNEX electroporator 
with surface pin electrodes. The biological load was simulated with a 100 Ω resistor. Amplitude of 
each successive pulse is lower, due to improper operation. The last pulse does not even reach 50% of 
the preset amplitude. Panel (a) shows output voltage measured on 100 Ω load and (b) output current.
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12.1.2.4  How and What to Measure and How to Report
Only correct measurement will upgrade our research, reduce resources used, and help 
advance the field by contributing to enhancing/improving reproducibility. The easiest 
way is to measure applied voltage and current. We need an adequate measurement from 
our oscilloscope and probes. What is appropriate depends on what we want to measure. 
First, we need to know what pulses are expected—at least amplitude, repetition frequency, 
and pulse duration. All oscilloscopes have limitations; a bandwidth tells us how fast it fol-
lows the signal changes, or more theoretically said, the maximum frequency range that 
it can measure (Figure 12.8). Closely related to frequency bandwidth is rise time speci-
fication. The specified rise time of an oscilloscope defines the fastest rising pulse it can 
measure. If not specified, it can be calculated as Rise time = 0.35/Bandwidth. For most 
applications, micro- or millisecond pulses are used; oscilloscopes and probes with a few 
MHz bandwidth are thus suitable. Measurement gets complicated when we reach the 
nanosecond HV pulses, where GHz range bandwidths and high rise times are needed. To 
minimize stray inductance and capacitances and reflections on lines, probes should be 
located as close to the electrodes as possible, with no additional connecting wires.
For the adequate presentation of pulses delivered, we propose to attach at least two 
measurements to your publications. One of a single pulse zoomed and another with 
reduced time scale, where all delivered pulses are displayed (if the number of pulses is 
low enough to keep a measurement meaningful) (Figure 12.5). If attaching the measure-
ment does not appear to be suitable, an adequate description of a pulse, common nota-
tions, and pulse parameters are required. But in some cases when pulses strongly deviate 
from classical forms, an image tells us a lot more. An example of pulse characteristics 
determination is given in Figure 12.7.
Exponential decay pulses (Figure 12.6a) are best described by their maximum value, 
AMAX, and time constant, τ. The value of time constant depends on circuit output stage 
characteristics. It is defined as the time maximum amplitude AMAX, which drops to 37% 
of AMAX. Square wave pulses are described with amplitude at high stage (that is choose 
to best fit the high level) and time tFWHM (Full Width at Half Maximum-FWHM). tFWHM 
is best described as the time passed between when the pulse reaches 50% of maximal 
amplitude at the rising and falling phase. Other pulse shapes are best described if we 
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FIGURE 12.5 An example of proposed measurements to accompany the report. For the adequate 
presentation of pulses delivered, we propose that you attach at least two measurements to your 
publications. One of a single pulse zoomed and another with reduced time scale, where all deliv-
ered pulses are displayed (if the number of pulses is low enough to keep a measurement meaning-
ful) The example measurements were made with the help of a CHEMIPULSE IV electroporator.
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define their rise (tR) and fall times (tF) and maximum amplitude AMAX. Rise time is time 
required for a pulse to rise from 10% to 90% of its steady value. Similarly, fall time is the 
time taken for the amplitude of a pulse to decrease from a specified value (usually 90% of 
the peak value exclusive of overshoot or undershoot) to another specified value (usually 
10% of the maximum value exclusive of overshoot or undershoot) (Reberšek et al., 2014).
12.1.3  Biophysical Dosimetry in Electroporation
Biological cells can be electroporated in suspension, attached, or in tissue. We distin-
guish in vitro and in vivo electroporation; the connection between them is not taken for 
granted. New applications of medical electroporation are first demonstrated in vitro, if 
their efficacy is shown also in vivo in an appropriate animal model, human clinical stud-
ies can be done (Hofmann., 2000). Electric pulse parameters for effective in vivo applica-
tion can be determined from in vitro experiments considering application specifications 
(Maček-Lebar et al., 2002).
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FIGURE 12.6 (a) Exponential decay pulse, (b) square wave pulse, and (c) Gaussian or  bell-shaped 
pulse.
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FIGURE 12.7 Pulse characteristics: a presentation of useful terms for description.
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12.1.3.1  Electroporation In Vitro
Cell membrane electroporation and consequently increased membrane permeability is 
controlled by the electric field strength. Because cells are in suspension and we usually 
work with low cell volume fractions, we can assume the surrounding field is  homogenous 
and uniform throughout all the conducting media (Susil et al., 1998; Kotnik et al., 2010). 
But induced transmembrane voltage is not uniform on the cell surface, it is dependent 
on cell size, membrane characteristics and orientation to the field, frequency, and time 
and space (Teissié and Rols, 1993). In vitro, we are dealing with dilute cell suspensions, 
where the local field outside cells does not affect other cells. If volume fractions are 
higher than 10%, the induced transmembrane voltage cannot be easily estimated by 
Schwan’s equation; local cell fields influence each other, and therefore approximate ana-
lytical or numerical calculations are needed (Pavlin et al., 2005). Even if we increase cell 
volume fraction of cells, there is still a big difference between tissue and a dense suspen-
sion. Plated cells are permeabilized with lower electroporation parameters than when 
in suspension (Towhidi et al., 2008). In tissues, cells form specific structures and are in 
contact with each other (Kotnik et al., 2010). In vitro experiments can be performed in 
electroporation chambers, especially with short pulse durations (nano- and picosecond 
pulses); chamber characteristics such as frequency responses can have a great impact on 
the results. Results are different when using different cuvettes; pulses are usually applied 
through two electrodes; the field delivered in is consequently different. From in vitro 
to in vivo, one needs to keep in mind that electric pulses are much larger compared to 
diameters of the cells (Maček-Lebar et al., 2002).
12.1.3.2  Electroporation In Vivo
In case of ex vivo electroporation of tissues, or in vivo electroporation, the electric field 
can no longer be considered homogenous because tissue is a highly inhomogeneous 
conductor. Some biological materials are also anisotropic, and therefore electric field 
orientation must also be considered. Tissue inhomogeneity is frequency dependent, it 
varies from tissue to tissue and is smaller at higher frequencies. Tumors mostly have a 
higher water content as a result of cellular necrosis (Miklavčič et al., 2006). In preclinical 
and clinical studies a few years ago, authors often considered the treated tissues as being 
linear electric conductors (i.e., with constant tissue conductivities) (Čorović et al., 2013).
Cell membranes have low electric conductivity in comparison to cytoplasm and 
extracellular medium. Electroporation changes the conductivity of cells, and thereby 
the field distribution is changed (Sel et al., 2005). To analyze tissue electroporation, 
we need to know the characteristics of the treated tissue. A macroscopic description is 
the most common and is described by specific conductivity and relative permittivity. 
Applied voltage rests among the most resistive tissue, which in the case of external 
electroporation is the skin. Skin conductivity is 10–100 times lower than the tissue 
underneath. Restive heating occurs and should be considered so as to avoid dam-
aging healthy cells (Lacković et al., 2009; Kos et al., 2012). Numerical methods are 
used to define the local electric field distribution within the tumors (Miklavčič et al., 
2010; Edhemovic et al., 2011). For deep-seated tumors and tumors in internal organs, 
which are surrounded by tissues with different electric properties, individualized 
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patient-specific treatment planning is required (Miklavčič and Davalos, 2015). Tumors 
vary in shape, size, and location. The shape and position of the used long-needle elec-
trodes and even the applied voltage (Hjouj and Rubinsky, 2010; Edhemovic et al., 2011; 
Pavliha et al., 2012) are analyzed and optimized for each tumor; coverage of the whole 
tumor with a sufficiently high electric field (which is one of the two prerequisites for 
successful treatment) (Miklavčič et al., 1998, 2006) can currently only be assured by 
means of numerical modeling of electric field distribution (Pavliha and Kos, 2013). 
Electric field calculations based on real input data are performed. Image-guided 
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FIGURE 12.8 Current measurement examples, in (b) an oscilloscope with a too low bandwidth 
was used, consequently current spike was not detected. The spike is clearly visible in (a), that was 
captured by a faster oscilloscope.
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FIGURE 12.9 Symbolic representation of different electroporation applications. When exter-
nally applied electric field reaches the cell membrane threshold value, the cell gets permeabilized. 
We  distinguish reversible and irreversible electroporation. The result of irreversible electropora-
tion is cell death, which we exploit for nonthermal ablation, so-called IRE. In case of reversible 
electroporation, cell membrane can fully recover after the electroporation process. During the 
electroporation process, molecules are introduced into the cell at electrochemotherapy and gene 
electrotransfer.
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insertion of electrodes is used (Kos et al., 2010; Miklavčič et al., 2010; Grošelj et al., 
2015). Nonthermal IRE is also an electroporation-based application that is used for 
ablation of pathological tissue, it similarly requires a specific treatment planning. But 
in that case, calculations of temperature increase should also be considered (Županič 
and Miklavčič, 2011) as the conductivity increases with  temperature. It is also neces-
sary to measure in vivo, the voltage and current measurement of applied pulses and 
electrical impedance tomography (EIT) are common, but they do not tell us, how 
the electrical conductivity of tissue affects the electric field distribution. MR-EIT 
(Magnetic Resonance-Electrical Impedance Tomography) enables reconstruction of 
electric field distribution by measuring the electric current density distribution and 
electric conductivity during electroporation by using MR imaging and numeric algo-
rithms (Kranjc et al., 2015).
12.2  Applications
Further on We will focus on three main applications (Figure 12.9). The most estab-
lished ECT, IRE, is used for tissue ablation and gene electrotransfection. In each 
section, we review pulses used, their characteristics, and main principles. For each 
application, we tried to discover if researches report adequate data. At the end of 
the chapter, a review of commercially available electroporation devices can be found, 
including their characteristics. We have summarized all the important parameters, 
so as to help researchers select the appropriate device for their application. Table 12.2 
describes their specifications and limitations. We focused on devices available for 
ECT, IRE, and gene electrotransfer. After a detailed review of the manufacturer’s 
Internet pages and literature, we wrote to all the listed producers and asked them to 
kindly review the data we found in  literature, device specifications, and on the Internet 
and update if necessary. We wrote to 25  producers: 13 were pleased to cooperate, the 
data they provided can be found in Tables  12.1 and 12.2. Three producers (LONZA, 
MaxCyte, and Ichor Medical Systems) replied to our email and informed us that the 
requested information was confidential. The data collection lasted for 1 month, with 
one reminder email. We contacted producers through their official emails published 
on their homepages. In addition, we also wrote directly to employees, whose contact 
information we have in our database. There have been no responses from BIO-RAD, 
Eppendorf, NEPA GENE, Oncosec, Scientz, Sigma-Aldrich, Thermo Fischer, and 
Tritech Research. Overall, the ones that do not specify their pulse parameters did not 
change their mind, only Inovio is excluded. We could not find any technical specifica-
tions or generated pulse descriptions of their devices, but in the end they provided all 
the missing data. Most of the producers who did not cooperate sell devices that are 
mainly used in the biopharmaceutical drug industry. When we are working with a 
device that has a CE mark, a small derogation from the specification is allowed. But 
due to aging and the huge diversity in biological load characteristics, control with an 
external measuring system is required for quality assurance. Noncertified devices can 
generate pulses that highly deviate from the preset values, so the use of an external 
measuring system is necessary.
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12.2.1  Electrochemotherapy
One of the leading applications on the electroporation field is ECT. It is highly effec-
tive, with complete response rates between 60% and 70% and objective response rates of 
about 80% (Mali et al., 2013). It is suitable for treatment of cutaneous and subcutaneous 
tumors of different histotypes, both skin and nonskin cancers, as well as metastases. 
European Standard Operating Procedures of Electrochemotherapy (ESOPE) have been 
established in 2006; it increased reproducibility and improved clinical practice results 
(Campana et al., 2016). SOP however only defines ECT for smaller skin tumors (<3 cm in 
diameter); we still do not have any guidelines for internal or larger tumor ECT. National 
Institute for Health and Care Excellence (NICE) has recognized ECT as an integral part 
of the multidisciplinary treatment for patients with skin metastases of nonskin origin 
and melanoma (NICE interventional procedure guidance IPG 446, http://www.nice.
org.uk/guidance/ipg446) (Campana et al., 2016). Lately, ECT has been introduced into 
the treatment of deep-seated tumors, it is really suitable for treatment of liver metas-
tases, especially when they are located close to major blood vessels and consequently 
not manageable with surgery (Edhemovic et al., 2014). Recently, recommendations for 
improving the quality of reporting clinical ECT studies has been released (Campana 
et al., 2016), on initiative of the Steering Committee of the COST TD 1104 Action. Really 
good guidelines could raise the level of research even higher. That is a good example 
for other, high-quality applications. Standardized reporting enables faster and greater 
progress (Miklavčič et al., 2014).
But the main challenge is still the successful use of the application, the presence of a 
cytotoxic agent within tumor tissue, and adequate coverage of the tumor with electric 
pulses above the threshold of reversible membrane electroporation are crucial. Some 
studies have been conducted that have introduced the method for the determination of 
effective electrical parameters for ECT from a systematic in vitro study performed on 
cells in culture (Maček-Lebar et al., 2002; Larkin et al., 2007). It has been proven that 
ECT parameters optimized in vitro are applicable in vivo. Currently, eight or two groups 
of four 100 μs square wave pulses with a repetition frequency of 1 Hz or 5 kHz are most 
commonly used. In the ESOPE clinical study, a 5-kHz electric pulse repetition frequency 
was used based on preliminary data assuming that higher electric pulse frequency has 
a comparable effect as lower pulse repetition frequency in ECT (Marty et al., 2006). The 
advantages of a higher frequency are shorter duration of electroporation, the sensation 
of only one application of electric pulses and also muscle contraction is obtained only 
right after the electric pulses, delivery, therefore an electrode displacement due to mus-
cle contraction during pulse’ delivery is avoided. Patients report less pain is associated 
with 5 kHz than with 1-Hz repletion frequency electroporation (Županič et al., 2007; 
Serša et al., 2010). Pulse voltage amplitude is most commonly somewhere between 200 
and 1000 V. It is electrode and target tissue dependent, which means it should be set to 
the value that ensures the electric field between the electrodes is higher than 400 V/cm. 
From Table 12.1 various implementations of electrodes and associated voltage amplitudes 
can be observed. Within a Cliniporator project, a clinical electroporator was designed, 
which is classified as a medical device and it is for now the only one with a medical 
device CE mark. SOP bases on the use of Cliniporator with associated electrodes, but 
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new electric pulse generators are coming to the market, with new electrodes that might 
have a completely different design, we always need to keep in mind that the voltage 
amplitude must be optimized specifically for each electrode configuration.
As with all treatments ECT also has some side effects. Transient lesions and some 
localized pain can appear in areas that are in direct contact with the electrodes (Mir 
and Orlowski, 1999). A problem can also occur if electroporation pulses interfere 
with heart muscle rhythm. There is very little chance for this phenomena when the 
 application is used for skin treatment (Mali et al., 2008). But deep-seated tumors, which 
can be located close to the heart, are also treated with ECT, and even in an open surgery 
the probability of electroporation pulses interfering with the heart is increasing. The 
most dangerous possible interference is induction of ventricular fibrillation (Wiggers 
and Wegria, 1940; Han, 1973; Reilly, 1998). Fibrillation can occur if the amplitude of the 
applied electric pulses is greater than the threshold level for fibrillation, and if electrical 
pulses are delivered during late atrial or ventricular systole. The vulnerable period for 
ventricles is near the peak of the T wave, and for atria in the S wave (Mali et al., 2005). 
The delivery of electric pulses must be synchronized with the ECG so as to reduce the 
risk (Mali et al., 2015).
12.2.2  Irreversible Electroporation
IRE as a nonthermal tissue ablation is a promising application for ablation of tumors 
tissue that is located near bile ducts or blood vessels (Scheffer et al., 2014). IRE causes 
cell death due to cell membrane electroporation and not due to tissue’s temperature 
increase; however, a local temperature increase occurs around the electrodes, when a 
greater number of pulses are administered. IRE has almost the same main challenges as 
ECT, the tumor tissue should be covered with an adequate electric field, but in case of 
IRE, the electric field should be above the IRE threshold (Rubinsky et al., 2007). In addi-
tion, the magnitude should be selected to minimize the electroporation of healthy tissue, 
so as to avoid significant thermal damage (Shafiee et al., 2009; Županič and Miklavčič, 
2011). It is mainly used for the treatment of deep-seated tumors either during open sur-
gery or percutaneously in liver, pancreas, kidney, lung, and other organs.
IRE does not have an SOP, treatment protocols vary with research groups, tumor 
types, and stages of development. An individual treatment plan required for each spe-
cific tumor and is crucial for successful outcome. IRE can be minimally invasive in 
combination with ultrasound, computed tomography guidance, or magnetic resonance 
imaging (Jourabchi et al., 2014). In comparison to ECT, safety is even more important, 
because with IRE we are ablating about 50 cm3 of tissue and the number of applied 
pulses is at least 90 (Bertacchini et al., 2007). To achieve IRE threshold, applied electric 
fields should be higher, i.e., delivered pulses should have amplitudes up to 3000 V and 
currents up to 50 A (Bertacchini et al., 2007). A Cliniporator VITAE or NanoKnife elec-
troporator is used (their specifications can be found in Table 12.2). Higher electric fields, 
open surgery, and proximity of the heart raises the risk, delivered pulses might interfere 
with cardiac activity if delivered at inappropriate heart rhythm phase (Thomson et al., 
2011). Pulses should be synchronized with the refractory period of the cardiac rhythm. 
The overall time for the procedure is extremely short in comparison to benchmark 
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treatments. It lasts only a few minutes, actual time can be calculated from the number 
of delivered pulses and average heart rate, because pulse delivery is coupled to the heart 
rate (Davalos et al., 2005; Bertacchini et al., 2007; Rubinsky et al., 2008).
Traditional IRE is based on the use of a series of unipolar electric pulses, normally 
accompanied by a significant muscle contraction; therefore, general anesthesia and 
neuromuscular blocking agents are necessary to prevent muscle contraction (Rubinsky 
et al., 2008). Researchers are investigating different techniques to minimize the con-
tractions. According to the Golberg and Rubinsky approach, surrounding a central 
energized  electrode with a series of grounded electrodes reduces the volume of tis-
sue exposed to electric fields with the potential to induce contraction (Golberg and 
Rubinsky, 2012). This procedure requires that at least 16 grounded electrodes be sur-
rounded by one superficially inserted, energized electrode. Arena (Arena et al., 2011) 
uses high-frequency IRE named H-FIRE. H-FIRE utilizes high frequency, bipolar bursts 
to eliminate muscle contraction, without sacrificing the efficiency of cell death due to 
nonthermal electroporation. He showed that H-FIRE at 250 or 500 kHz has the same 
ablation and precision outcomes as traditional IRE (Arena et al., 2011)
Treatment plans have been developed that can help clinicians. Electrode configura-
tion and pulse parameters are proposed, but a proper electrode placement can be in 
some cases really challenging (Edd and Davalos, 2007; Kos et al., 2015). Clinical studies 
are going on all around the world trying to specify the optimal parameters for specific 
cancer types. Each set of pulse specifications, number of pulses, voltage amplitude, and 
pulse duration have an effect on IRE outcomes. Pulse length is responsible for ther-
mal effects in tissue. The maximal duration can be calculated for each electric field that 
would not induce thermal effects or at least minimize them. Typical IRE pulses con-
sist of a series of 100-μs pulses separated by at least 100 μs. The pause between pulses 
enables a cooldown. Davalos (Davalos et al., 2005) showed that the threshold for IRE in 
most cell types is at least 800 V/cm. Rubinsky (Rubinsky et al., 2008) proposed that for 
prostate cancer cells a field of 250 V/cm is sufficient with use of 90 pulses to ensure com-
plete ablation of that region. Raffa demonstrated that performing IRE in the presence of 
fibril boron nitride nanotubes lowers the necessary voltage threshold required to cause 
tumor cell death. IRE at 800 V/cm was 2.2 times more effective at causing cell destruc-
tion when performed in the presence of fibril boron nitride nanotubes (Raffa et al., 2012). 
Contradictory to recent guidelines for ECT, there are no specific guidelines on how to 
report clinical cases and studies.
12.2.3  Gene Transfection
Gene electrotransfer is a promising non-viral gene delivery method (Kandušer et al., 
2009). It is used for treatment of cancer and other diseases (Shibata et al., 2006; Daud et al., 
2008), for DNA vaccination (Chiarella et al., 2010; Sardesai and Weiner, 2011), and genetic 
modification of organisms (Golden et al., 2007; Grewal et al., 2009). “Cancer immu-
noediting” is a process combining the immune system and tumors. The immune system 
can protect the host against tumor growth, or promote cancer development by selec-
tion of tumor variants with reduced immunogenicity (Zou et al., 2005). Immunotherapy 
can include cancer vaccines based on plasmid DNA (pDNA) vectors (Serša et al., 2015). 
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Electroporation is used to promote antigen, oligonucleotides, and immunomodulatory 
molecule delivery in to tumor tissue. They can stimulate the immune system or act on 
immunosuppressor genes (Serša et al., 2015). In vitro electric pulses are frequently used 
for the transfection of bacterial and eukaryotic cells. In vivo the technique is termed 
DNA electrotransfer, electrogenetherapy, or also gene electrotherapy. It has been suc-
cessfully used since 1998. However, exact molecular mechanisms of DNA transport are 
unknown (Kandušer et al., 2009; Serša et al., 2015). DNA transfer can only be achieved 
by reversible electroporation, because dead cells are not able to express transferred 
genes (Andre et al., 2010). The DNA must be injected before electroporation; the appli-
cation requires sufficiently intense electric fields, which means sufficiently long pulses 
should be applied, but we also need to ensure reversible electroporation. Permeabalized 
cell membrane should interact with the plasmid; thus a DNA–membrane complex is 
formed. DNA, then, with an as yet unknown process, is transferred into the cytoplasm 
and transported to the nucleus. In cases where the application is successful, the process 
is followed by gene expression (Golzio et al., 2002; Faurie et al., 2010).
Initially, we thought one of the most important mechanisms for efficient gene elec-
trotransfer was electrophoretic movement of DNA during the pulse. A long millisecond, 
square, or exponential decaying pulses were used with 400–600 V/cm and up to 20 ms 
long (Bettan et al., 2000). Some studies showed that DNA transfection is enhanced in 
a combination of short HV and long low-voltage (LV) pulses. It was suggested that HV 
pulses are crucial for permeabilization of the cell membrane and pore formation, while 
LV pulses electrophoretically drag negatively charged DNA into the cell. Eight HV 
pulses 100 μs with amplitude 1300 V/cm followed by one longer 100 ms LV pulse 100 V/cm 
(Šatkauskas et al., 2002) were proposed. Further, Miklavčič’s group showed that short 
HV pulses are not only crucial but also sufficient for successful DNA delivery, at optimal 
plasmid concentrations. They suggested that electrophoretic force of LV pulses is crucial 
in in vivo conditions where suboptimal plasmid concentration is the limiting factor for 
efficient transfection (Kandušer et al., 2009). As induced electric field is tissue depen-
dent, it is important to define targeted tissue. In comparison to ECT, where targeted 
tissue is always tumor, a definition in the case of gene electrotransfer is more compli-
cated. Electroporation parameters depend on the type of tumor antigen and target tis-
sues, and the target cells in specific tissue are different (Serša et al., 2015). Electric pulse 
parameters have to be experimentally or numerically optimized for given electrodes’ 
positions and geometry (Županič et al., 2010). Gene electrotransfer efficiency is electro-
poration media dependent, divalent cations such as Ca2+ and Mg2+ are necessary for the 
formation of DNA–membrane complex during the pulses. They act as a bridge between 
negatively charged DNA and the negatively charged cell plasma membrane, and thus 
improve DNA–membrane binding (Haberl et al., 2013a).
Classical gene electrotransfection parameters are hard to define; for example, 
8 × 5 ms, 700 V/cm, 1 Hz are efficient in vitro. Studies show that more than 30% of cells 
can express the gene coded by plasmid DNA, while preserving cell viability to a large 
extent (Golzio et al., 2002; Chopinet et al., 2012). In the case of skin tumors, rate signifi-
cantly decreases in vivo (Rols and Teissié, 1998; Čemazar et al., 2009). A lot of studies 
have been performed and parameters described to enable better gene transfer. In other 
studies, electric field direction and orientation changes during the pulse delivery have 
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been shown to increase the area, making DNA entry into the cell more competent. The 
introduction of DNA only occurs in the part of the membrane facing the cathode. It was 
shown that the percentage of cells expressing genes increases when electric field direc-
tion and orientation change (Pavlin et al., 2011). Also, a new prospect was presented, 
involving nanosecond electric pulses (pulse duration: 4–600 ns). Very short HV pulses 
(several tens of kV/cm) are able to disturb membranes of internal organelles, due to cell 
membranes charging time. We can conclude there is an option short nanosecond pulses 
can effect the nuclear envelope. Combination of medium or long electrical pulses with 
short HV nanosecond pulses enhance gene expression by increasing the number of plas-
mids entering the nucleus (Beebe et al., 2003; Chopinet et al., 2013; Guo et al., 2014).
Overall, we can say that the field of gene electrotransfer is complex and many known 
and as yet unknown factors mutually affect the process.
Longer electric pulses are optimal for higher transfection efficiency, but they reduce 
viability. Shorter pulses enable lower transfection efficiency and preserve viability. The 
number of studies is increasing, fields and applications are spreading, with insufficient 
and incomplete data and pulse parameters. There are no standard procedures or report-
ing guidelines defined that would in the future enable a proof of concept. In compar-
ison to ECT, a greater variety of pulses are being used, for each tissue specific pulse 
parameters are optimal, for each application a specific procedure seems to be required. 
One of the problems is that electroporation device manufacturers produce devices with 
preprogramed procedures. Users only select the “appropriate program” and the device 
ensures optimal transfection. Pulse parameters and characteristics stay unknown due 
to the device patent. The field is getting more and more chaotic and is in need of a more 
consistent, explicit, and well-defined research with guidelines on reporting; including 
electric pulse protocols.
12.3  Conclusion
Electroporation is a platform technology, which is already established in medicine and 
food processing. When we are dealing with electroporation, measuring is crucial for 
achieving effective electroporation. Quality assurance can only be provided by appro-
priate measurements, i.e., measuring the voltage and current using an oscilloscope.
Due to the huge variation in biological load characteristics, delivered pulses may 
significantly deviate from the pre-set. Low impedance of a load (tissue or cell suspen-
sion) requires large power/currents, which quite often leads to significant voltage drop. 
Protocols in which a larger number of pulses (or long pulses) are delivered can result 
in reduced amplitude of pulses. The delivered pulse shape repetition frequency, pulse 
duration, and amplitude must be always monitored. The measurement probes should 
be located as close to the load as possible, the oscilloscope bandwidth should be high 
enough, and in the case of nanosecond application, the reflections and losses must be 
considered.
One of the leading applications in the electroporation field is ECT that already has 
well-established protocols, reporting guidelines, and good research reproducibil-
ity. Unfortunately, failed efforts to confirm other published paperwork are increasing 
(Kaiser, 2016). We believe the main reason for this situation is flawed descriptions of the 
3.1 Book chapter 79
251Dosimetry in Electroporation-Based Technologies and Treatments
TA
BL
E 
12
.1 
Va
rio
us
 Im
pl
em
en
ta
tio
ns
 o
f E
le
ct
ro
de
s, 
w
ith
 A
ss
oc
ia
te
d 
Vo
lta
ge
 A
m
pl
itu
de
s, 
Pr
ov
id
ed
 b
y 
th
e 
M
an
uf
ac
tu
re
rs
Pr
od
uc
er
D
ev
ic
e
Ty
pe
 o
f 
el
ec
tr
od
es
 
N
um
be
r 
of
 o
ut
pu
t 
ch
an
ne
ls
N
um
be
r o
f 
el
ec
tr
od
es
El
ec
tr
od
es
’ g
eo
m
et
ric
 d
es
cr
ip
tio
n 
Pu
lse
 
nu
m
be
r
Pu
lse
s 
am
pl
itu
de
A
ng
io
dy
na
m
ic
s
N
an
oK
ni
fe
 
N
ee
dl
e
/
1–
6 
Pr
ob
e 
ou
tp
ut
s
Pr
ob
es
 sp
ac
ed
 1.
5 c
m
 ap
ar
t w
ith
 th
e 
ac
tiv
e 
el
ec
tr
od
e 
le
ng
th
 se
t a
t 2
 cm
90
 (P
ul
se
s f
or
 
ea
ch
 p
ai
r o
f 
el
ec
tr
od
es
)
(1
00
–3
00
0)
 V
Bi
on
m
ed
 T
ec
hn
ol
og
ie
s
SE
N
N
EX
N
ee
dl
e/
pi
n 
su
rf
ac
e
/
4
Li
ne
ar
 la
yo
ut
 fo
r s
m
al
l t
um
or
s a
nd
 
pe
nt
ag
on
 la
yo
ut
 fo
r l
ar
ge
r, 
m
or
e 
ex
te
ns
iv
e 
tu
m
or
s. 
Pi
n 
el
ec
tr
od
es
 
ar
e 
3 m
m
 th
ic
k 
at
 th
e 
to
p 
an
d 
ne
ed
le
 0
.3
 m
m
.
8
10
00
 V
IG
EA
C
lin
ip
or
at
or
 
EP
S0
2 
N
ee
dl
e
7
7
H
ex
ag
on
al
 co
nfi
gu
ra
tio
n 
(d
ia
m
et
er
: 
0.
7 m
m
/le
ng
th
: 
10
 m
m
/2
0 m
m
/3
0 m
m
)
H
V:
 4
H
V:
 7
30
 V
N
ee
dl
e
2
8 
(2
 ×
 4
)
Li
ne
ar
 co
nfi
gu
ra
tio
n 
(d
ia
m
et
er
: 
0.
7 m
m
/le
ng
th
: 
10
 m
m
/2
0 m
m
/3
0 m
m
)
H
V:
 8
H
V:
 4
00
 V
Pl
at
e
2
2
Li
ne
ar
 co
nfi
gu
ra
tio
n 
(1
0 m
m
 ×
 30
 m
m
 ×
 0
.8
 m
m
) 
H
V:
 8
H
V:
 9
60
 V
N
ee
dl
e
2
6 
(2
 ×
 3)
Fi
ng
er
 co
nfi
gu
ra
tio
n 
w
ith
 o
rt
ho
go
na
l 
lin
ea
r n
ee
dl
es
 (d
ia
m
et
er
: 0
.7
 m
m
/
le
ng
th
: 5
 m
m
/1
0 m
m
)
H
V:
 8
H
V:
 4
00
 V
(C
on
tin
ue
d )
80 Results and Discussion
252 Dosimetry in Bioelectromagnetics
TA
BL
E 
12
.1 
(C
on
tin
ue
d)
 
Va
rio
us
 Im
pl
em
en
ta
tio
ns
 o
f E
le
ct
ro
de
s, 
w
ith
 A
ss
oc
ia
te
d 
Vo
lta
ge
 A
m
pl
itu
de
s, 
Pr
ov
id
ed
 b
y 
th
e 
M
an
uf
ac
tu
re
rs
Pr
od
uc
er
D
ev
ic
e
Ty
pe
 o
f 
el
ec
tr
od
es
 
N
um
be
r 
of
 o
ut
pu
t 
ch
an
ne
ls
N
um
be
r o
f 
el
ec
tr
od
es
El
ec
tr
od
es
 g
eo
m
et
ric
 d
es
cr
ip
tio
n 
Pu
lse
 
nu
m
be
r
Pu
lse
s 
am
pl
itu
de
N
ee
dl
e
2
6 
(2
 ×
 3)
Fi
ng
er
 co
nfi
gu
ra
tio
n 
w
ith
 
lo
ng
itu
di
na
l l
in
ea
r n
ee
dl
es
 
(d
ia
m
et
er
: 0
.7
 m
m
/le
ng
th
: 
5 m
m
/1
0 m
m
)
H
V:
 8
H
V:
 4
00
 V
Pa
rt
ia
lly
 
iso
la
te
d 
ne
ed
le
s
7
7
H
ex
ag
on
al
 co
nfi
gu
ra
tio
n 
(d
ia
m
et
er
: 0
.7
 m
m
/le
ng
th
: 4
0 m
m
)
H
V:
 4
H
V:
 7
30
 V
C
lin
ip
or
at
or
 
V
IT
A
E
N
ee
dl
e
2–
6
2–
6
Si
ng
le
 lo
ng
 n
ee
dl
e/
di
am
et
er
: 
1.2
 m
m
/a
ct
iv
e 
pa
rt
: 1
–4
 cm
; s
oft
 
tis
su
es
 c
us
to
m
 g
eo
m
et
ry
 E
C
T
H
V:
 4
 +
 4
 
(p
ol
ar
ity
 
ex
ch
an
ge
)
H
V:
(5
00
–3
00
0)
 V
N
ee
dl
e
2–
6
2–
6
Si
ng
le
 lo
ng
 n
ee
dl
e/
di
am
et
er
: 
1.8
 m
m
/a
ct
iv
e 
pa
rt
 1–
4 c
m
; b
on
es
 
cu
st
om
 g
eo
m
et
ry
 E
C
T
H
V:
 4
 +
 4
 
(p
ol
ar
ity
 
ex
ch
an
ge
)
H
V:
(5
00
–3
00
0)
 V
In
tr
ac
el
TS
S2
0 
O
vo
dy
ne
Si
lv
er
, t
un
gs
te
n,
 
an
d 
pl
at
in
um
 
el
ec
tr
od
es
/
2
El
ec
tro
de
s. 
Si
lv
er
 el
ec
tro
de
s a
re
 
av
ai
la
bl
e m
ad
e f
ro
m
 0
.8
 m
m
 d
ia
m
et
er
 
sil
ic
on
 ru
bb
er
 in
su
lat
ed
 si
lv
er
 w
ire
, 
th
e e
xp
os
ed
 p
ol
e b
ei
ng
 fl
at
te
ne
d 
in
to
 
a “
pa
dd
le”
 sh
ap
e a
pp
ro
xi
m
at
ely
 
2  ×
 1 m
m
. S
ilv
er
 w
ire
 le
ng
th
 ex
te
nd
in
g 
be
yo
nd
 th
e e
le
ct
ro
de
 h
ol
de
r i
s 4
0 m
m
. 
Tu
ng
ste
n 
ele
ct
ro
de
s a
re
 p
ro
du
ce
d 
fro
m
 0
.5
 m
m
 o
.d
. t
un
gs
te
n 
ro
d 
/
/
(C
on
tin
ue
d)
3.1 Book chapter 81
253Dosimetry in Electroporation-Based Technologies and Treatments
TA
BL
E 
12
.1 
(C
on
tin
ue
d)
 
Va
rio
us
 Im
pl
em
en
ta
tio
ns
 o
f E
le
ct
ro
de
s, 
w
ith
 A
ss
oc
ia
te
d 
Vo
lta
ge
 A
m
pl
itu
de
s, 
Pr
ov
id
ed
 b
y 
th
e 
M
an
uf
ac
tu
re
rs
Pr
od
uc
er
D
ev
ic
e
Ty
pe
 o
f 
el
ec
tr
od
es
 
N
um
be
r 
of
 o
ut
pu
t 
ch
an
ne
ls
N
um
be
r o
f 
el
ec
tr
od
es
El
ec
tr
od
es
 g
eo
m
et
ric
 d
es
cr
ip
tio
n 
Pu
lse
 
nu
m
be
r
Pu
lse
s 
am
pl
itu
de
In
ov
io
C
EL
LE
C
TR
A
 
5P
SP
 
N
ee
dl
e 
el
ec
tr
od
es
, 
in
tr
am
us
cu
la
r
/
5
A
n 
ar
ra
y 
co
ns
ist
in
g 
of
 5
 n
ee
dl
e 
el
ec
tr
od
es
, a
dj
us
ta
bl
e 
fr
om
 1
3, 
19
, 
an
d 
25
 m
m
 in
 le
ng
th
 d
ep
en
di
ng
 o
n 
BM
I, 
fo
rm
in
g 
a 
pe
nt
ag
on
 o
n 
a 
1-
cm
 ci
rc
le
3
M
ax
 2
00
 V
C
EL
LE
C
TR
A
 
20
00
–5
P
N
ee
dl
e 
el
ec
tr
od
es
, 
in
tr
am
us
cu
la
r
/
5
A
n 
ar
ra
y 
co
ns
ist
in
g 
of
 5
 n
ee
dl
e 
el
ec
tr
od
es
, a
dj
us
ta
bl
e 
fr
om
 1
3, 
19
, 
an
d 
25
 m
m
 in
 le
ng
th
 d
ep
en
di
ng
 o
n 
BM
I, 
fo
rm
in
g 
a 
pe
nt
ag
on
 o
n 
a 
1-
cm
 ci
rc
le
3
M
ax
 2
00
 V
C
EL
LE
C
TR
A
 
20
00
–3
P
N
ee
dl
e 
el
ec
tr
od
es
, 
in
tr
ad
er
m
al
 
/
5
A
n 
ar
ra
y 
co
ns
ist
in
g 
of
 3
 n
ee
dl
e 
el
ec
tr
od
es
, 3
 m
m
 in
 le
ng
th
, 
fo
rm
in
g 
an
 is
os
ce
le
s t
ria
ng
le
, 
3-
m
m
 sp
ac
in
g 
(s
ho
rt
 si
de
) a
nd
5-
m
m
 sp
ac
in
g 
(lo
ng
 si
de
s)
2 
Se
ts
 o
f 2
 
pu
lse
s
M
ax
 2
00
 V
Le
ro
y 
BI
O
TE
C
H
EL
EC
TR
O
ve
t 
S1
3
/
A
ll 
ar
e 
co
m
pa
tib
le
 w
ith
 p
la
te
 a
nd
 n
ee
dl
e 
el
ec
tr
od
es
EL
EC
TR
O
ve
t E
Z
EL
EC
TR
O
 ce
ll 
B1
0
/
8 
(2
 ×
 4
)
N
ee
dl
e 
el
ec
tr
od
es
 a
re
 sp
ec
ia
lly
 d
es
ig
ne
d 
an
d 
m
an
uf
ac
tu
re
d 
fo
r t
he
 tr
ea
tm
en
t o
f s
ub
cu
ta
ne
ou
s 
tu
m
or
s. 
8 
m
m
 b
et
w
ee
n 
th
e 
tw
o 
ro
w
s o
f f
ou
r 
ne
ed
le
s. 
Ea
ch
 n
ee
dl
e 
sp
ac
ed
 2
 m
m
 ap
ar
t
EL
EC
TR
O
 ce
ll 
S2
0
M
IL
LI
PU
LS
ES
/
2
10
-m
m
 le
ng
th
/1
0-
m
m
 sp
ac
in
g 
be
tw
ee
n 
el
ec
tr
od
es
ce
nt
er
s/
3 m
m
82 Results and Discussion
254 Dosimetry in Bioelectromagnetics
TA
BL
E 
12
.2
 
A
 R
ev
ie
w
 o
f C
om
m
er
ci
al
ly
 A
va
ila
bl
e 
El
ec
tr
op
or
at
io
n 
D
ev
ic
es
, I
nc
lu
di
ng
 Th
ei
r C
ap
ab
ili
tie
s a
nd
 C
ha
ra
ct
er
ist
ic
s
Pr
od
uc
er
D
ev
ic
e
Pu
lse
 
de
sc
rip
tio
n
Pu
lse
 n
um
be
r
Pu
lse
s a
m
pl
itu
de
Pu
lse
s d
ur
at
io
n
Pu
lse
s r
ep
et
iti
on
 
fr
eq
ue
nc
y
Pu
lse
 se
qu
en
ce
s
M
ax
im
um
 
vo
lta
ge
M
ax
im
um
 c
ur
re
nt
A
ng
io
dy
na
m
ic
s
N
an
oK
ni
fe
 
Sq
ua
re
 w
av
e 
90
 (P
ul
se
s f
or
 
ea
ch
 p
ai
r o
f 
el
ec
tr
od
es
)
(1
00
–3
00
0)
 V
(2
0–
10
0)
 μs
EC
G
 sy
nc
hr
on
iz
ed
, 
90
, 1
20
, 2
40
 pp
m
/
30
00
 V
50
 A
BE
X
 C
o.
, L
td
. 
C
U
Y2
1E
D
IT
Sq
ua
re
 w
av
e
/
(1
–5
00
) V
T 
= 
0.
1–
99
9.
9 m
s
/
/
/
I <
 5.
0 A
 (1
–1
25
 V
)
I <
 2.
2 A
 (1
26
–2
50
 V
)
I <
 1.
0 A
 (2
51
–5
00
 V
)
C
U
Y2
1E
D
IT
 II
Sq
ua
re
 w
av
e 
ex
po
ne
nt
ia
l
/
(1
–2
00
) V
 (S
qu
ar
e)
(1
–4
00
) V
 
(E
xp
on
en
tia
l; 
PP
)
(1
–3
50
) V
 
(E
xp
on
en
tia
l; 
D
P)
T 
= 
0.
05
–1
00
0 m
s 
(S
qu
ar
e)
 
T 
= 
0.
01
–9
9.
9 m
s 
(E
xp
on
en
tia
l)
/
/
/
I <
 1 A
 (S
qu
ar
e)
I <
 10
 A
 (E
xp
on
en
tia
l)
G
en
om
e 
ed
ito
r
Sq
ua
re
 w
av
e
/
(1
–2
00
) V
T 
= 
0.
10
–1
00
0 m
s
/
/
/
C
U
Y2
1V
itr
o-
EX
Ex
po
ne
nt
ia
l
/
1–
90
0 V
 (P
P)
1–
50
0 V
 (D
P)
T 
= 
0.
01
–9
9.
9 m
s
/
/
/
I <
 50
 A
LF
30
1
Sq
ua
re
 w
av
e 
sin
us
 (A
C
)
/
0–
12
00
 (S
qu
ar
e 
w
av
e)
 
0–
75
 V
rm
s (
A
C
)
T 
= 
0–
10
0 μ
s 
(S
qu
ar
e)
 fA
C
 =
 1 
M
H
z; 
T 
= 
0–
10
0 s
 
(P
re
fu
sio
n)
/0
–1
0 s
 
(P
os
t-
fu
sio
n)
/
/
/
R 
> 
50
 Ω
(C
on
tin
ue
d)
3.1 Book chapter 83
255Dosimetry in Electroporation-Based Technologies and Treatments
TA
BL
E 
12
.2
 (C
on
tin
ue
d)
 
A
 R
ev
ie
w
 o
f C
om
m
er
ci
al
ly
 A
va
ila
bl
e 
El
ec
tr
op
or
at
io
n 
D
ev
ic
es
, I
nc
lu
di
ng
 Th
ei
r C
ap
ab
ili
tie
s a
nd
 C
ha
ra
ct
er
ist
ic
s
Pr
od
uc
er
D
ev
ic
e
Pu
lse
 
de
sc
rip
tio
n
Pu
lse
 n
um
be
r
Pu
lse
s a
m
pl
itu
de
Pu
lse
s d
ur
at
io
n
Pu
lse
s r
ep
et
iti
on
 
fr
eq
ue
nc
y
Pu
lse
 se
qu
en
ce
s
M
ax
im
um
 
vo
lta
ge
M
ax
im
um
 c
ur
re
nt
Bi
on
m
ed
 
Te
ch
no
lo
gi
es
SE
N
N
EX
Sq
ua
re
 w
av
e
8
10
00
 V
10
0 μ
s
10
0 m
s
10
 Im
p/
s
10
00
 V
/
BT
X
-H
ar
va
rd
 
Ap
pa
ra
tu
s
A
gi
le
Pu
lse
 in
 vi
vo
 
sy
st
em
/
3 
G
ro
up
s o
f p
ul
se
s: 
fr
om
 1 
to
 10
 
pu
lse
s i
n 
ea
ch
 
gr
ou
p 
(5
0–
10
00
) V
(0
.0
50
–1
0)
 m
s
(0
.2
00
–1
00
0)
 m
s
/
10
00
 V
At
 m
ax
 v
ol
ta
ge
 a
nd
 
m
in
im
um
 re
sis
ta
nc
e:
 
10
00
 V
/1
0 Ω
 =
 10
0 A
A
g i
le
Pu
lse
 M
A
X
 
sy
st
em
/
3 
G
ro
up
s o
f p
ul
se
s: 
fr
om
 1 
to
 10
 
pu
lse
s i
n 
ea
ch
 
gr
ou
p 
(5
0–
12
00
) V
H
V:
 (0
.0
50
–1
0)
 m
s
(0
.2
00
–1
00
0)
 m
s
(1
–5
00
0)
 H
z
12
00
 V
At
 m
ax
 v
ol
ta
ge
 a
nd
 
m
in
im
um
 re
sis
ta
nc
e:
 
12
00
 V
/1
0 Ω
 =
 12
0 A
EC
M
 2
00
1
Sq
ua
re
 w
av
e 
1–
9
H
V:
 (1
0–
30
00
) V
LV
: (
10
–5
00
) V
 
H
V:
 (1
–9
9)
 μs
LV
: (
0.
01
–0
.9
9)
 m
s
(0
.0
1–
0.
99
) m
s
(1
–9
9)
 m
s 
30
00
 V
/
A
C
(0
–1
50
) V
 (V
pp
)
D
ur
at
io
n:
 (0
–9
9)
 s
Po
st
 fu
sio
n—
ra
m
p:
 
1–
9 s
1 m
H
z
EC
M
 8
30
Sq
ua
re
 w
av
e 
1–
99
H
V:
 (5
05
–3
00
0)
 V
LV
: (
5–
50
0)
 V
 
H
V:
 (1
0–
60
0)
 μs
LV
: (
10
–9
99
)  μ
s; 
(1
–9
99
) m
s; 
(1
–1
0)
 s1
00
 m
s–
10
 s
/
30
00
 V
50
0  A
 li
m
it 
at
 10
0 μ
s
EC
M
 6
30
 
Ex
po
ne
nt
ia
l 
de
ca
y 
w
av
e
1–
99
H
V:
 (5
0–
25
00
) V
LV
: (
10
–5
00
) V
 
 10
 μs
–1
0 s
/
/
25
00
 V
60
00
 A
 in
 L
V
 m
od
e
G
em
in
i S
C
2
Sq
ua
re
 w
av
es
 
an
d 
ex
po
ne
nt
ia
l 
de
ca
y 
w
av
es
LV
: 1
–1
0
H
V:
 1–
2
Ex
po
ne
nt
ia
l d
ec
ay
: 
1
(1
0–
30
00
) V
50
 μs
–1
00
 m
s
10
0 m
s–
30
 s
/
30
00
 V
/
(C
on
tin
ue
d)
84 Results and Discussion
256 Dosimetry in Bioelectromagnetics
TA
BL
E 
12
.2
 (C
on
tin
ue
d)
 
A
 R
ev
ie
w
 o
f C
om
m
er
ci
al
ly
 A
va
ila
bl
e 
El
ec
tr
op
or
at
io
n 
D
ev
ic
es
, I
nc
lu
di
ng
 Th
ei
r C
ap
ab
ili
tie
s a
nd
 C
ha
ra
ct
er
ist
ic
s
Pr
od
uc
er
D
ev
ic
e
Pu
lse
 
de
sc
rip
tio
n
Pu
lse
 n
um
be
r
Pu
lse
s a
m
pl
itu
de
Pu
lse
s d
ur
at
io
n
Pu
lse
s r
ep
et
iti
on
 
fr
eq
ue
nc
y
Pu
lse
 se
qu
en
ce
s
M
ax
im
um
 
vo
lta
ge
M
ax
im
um
 c
ur
re
nt
G
em
in
i X
2
Sq
ua
re
 w
av
es
 
an
d 
ex
po
ne
nt
ia
l 
de
ca
y 
w
av
es
Sq
ua
re
 w
av
e:
 L
V
 
m
od
e-
1–
12
0 
(1
0 
pe
r s
am
pl
e)
H
V
 m
od
e-
1–
36
 (3
 
pe
r s
am
pl
e)
;
Ex
po
ne
nt
ia
l d
ec
ay
: 
1–
12
 (R
  i
nt
er
na
l 
<1
00
 Ω
) a
nd
 
1–
24
  (
R 
in
te
rn
al
 >
 10
0 Ω
)
(5
–3
00
0)
 V
10
 μs
–1
 s
10
0 m
s–
30
 s
/
30
00
 V
/
EC
M
 3
99
Ex
po
ne
nt
ia
l 
de
ca
y 
w
av
es
1
(2
–2
50
0)
 V
M
ax
. a
t 5
00
 V
: 
12
5 m
s;
M
ax
. a
t 2
50
0 V
: 5
 m
s1
00
 m
s–
10
 s
/
25
00
 V
/
C
yt
o 
Pu
lse
 S
ci
en
ce
, 
In
c. 
O
nc
oV
et
/
/
(5
0–
10
00
) V
(0
.0
5–
10
) m
s
(0
.2
–1
00
0)
 m
s
(1
–5
00
0)
 H
z
/
/
IG
EA
C
lin
ip
or
at
or
 
EP
S0
2
Sq
ua
re
 w
av
e
LV
: 1
–1
0
H
V:
 1–
10
LV
: (
20
–2
00
) V
H
V:
 (1
00
–1
00
0)
 V
LV
: (
1–
20
0)
 m
s
H
V:
 (5
0–
10
00
) μ
s
LV
: (
0.
45
–5
00
) H
z
H
V:
 (1
–5
00
0)
 H
z
24
 C
on
fig
ur
at
io
ns
10
00
 V
 
LV
: 5
 A
H
V:
 2
0 A
C
lin
ip
or
at
or
 
V
IT
A
E
Sq
ua
re
 w
av
e
H
V:
 4
 +
 4
 (p
ol
ar
ity
 
ex
ch
an
ge
); 
4–
8
H
V:
 (5
00
–3
00
0)
 V
10
0  μ
s
H
V:
 (1
–5
00
0)
 H
z
C
os
tu
m
30
00
 V
50
 A
In
ov
io
C
EL
LE
C
TR
A
 
5P
SP
 
Sq
ua
re
 w
av
e
3
M
ax
 2
00
 V
52
 m
s
1 H
z
/
M
ax
 2
00
 V
0.
5 A
 C
on
st
an
t c
ur
re
nt
(C
on
tin
ue
d)
3.1 Book chapter 85
257Dosimetry in Electroporation-Based Technologies and Treatments
TA
BL
E 
12
.2
 (C
on
tin
ue
d)
 
A
 R
ev
ie
w
 o
f C
om
m
er
ci
al
ly
 A
va
ila
bl
e 
El
ec
tr
op
or
at
io
n 
D
ev
ic
es
, I
nc
lu
di
ng
 Th
ei
r C
ap
ab
ili
tie
s a
nd
 C
ha
ra
ct
er
ist
ic
s
Pr
od
uc
er
D
ev
ic
e
Pu
lse
 
de
sc
rip
tio
n
Pu
lse
 n
um
be
r
Pu
lse
s a
m
pl
itu
de
Pu
lse
s d
ur
at
io
n
Pu
lse
s r
ep
et
iti
on
 
fr
eq
ue
nc
y
Pu
lse
 se
qu
en
ce
s
M
ax
im
um
 
vo
lta
ge
M
ax
im
um
 c
ur
re
nt
C
EL
LE
C
TR
A
 
20
00
–5
P
Sq
ua
re
 w
av
e
3
M
ax
 2
00
 V
52
 m
s
1 H
z
/
M
ax
 2
00
 V
0.
5 A
C
o n
st
an
t c
ur
re
nt
C
EL
LE
C
TR
A
 
20
00
–3
P
Sq
ua
re
 w
av
e
2 
Se
ts
 o
f 2
 p
ul
se
s
M
ax
 2
00
 V
52
 m
s
3 H
z
2 
Se
ts
 se
pe
ra
te
d 
by
 3
 s
M
ax
 2
00
 V
0.
2
A
 C
on
st
an
t c
ur
re
nt
In
tr
ac
el
TS
S2
0 
O
vo
dy
ne
Sq
ua
re
 w
av
e 
1–
99
9
(0
.1–
99
.9
) V
(1
–9
99
) m
s
(1
0–
99
90
) m
s
1–
99
9
99
.9
 V
10
0 m
A
 T
SS
20
10
00
 m
A
 E
P2
1
Le
ro
y 
Bi
ot
ec
h
EL
EC
TR
O
ve
t S
13
Sq
ua
re
 w
av
e 
pu
lse
 
ge
ne
ra
to
r
1–
10
,0
00
 o
r 
in
fin
ite
0–
13
50
 V
5–
50
00
 μs
 
0.
1–
10
,0
00
 m
s
0.
1–
10
,0
00
 H
z
13
00
 V
 10
 A
EL
EC
TR
O
ve
t E
Z
Sq
ua
re
 w
av
e 
pu
lse
 
ge
ne
ra
to
r
1–
10
,0
00
 o
r 
in
fin
ite
0–
15
00
 V
5–
50
00
 μs
 
0.
1–
10
,0
00
 m
s
0.
1–
10
,0
00
 H
z
15
00
 V
 2
5 A
EL
EC
TR
O
 ce
ll 
B1
0
Sq
ua
re
 w
av
e 
bi
po
la
r p
ul
se
 
ge
ne
ra
to
r—
hi
gh
 v
ol
ta
ge
 
lo
w
 v
ol
ta
ge
1–
10
,0
00
 o
r 
in
fin
ite
0–
10
00
 V
5–
50
00
 μs
 
0.
1–
10
,0
00
 m
s
0.
1–
10
,0
00
 H
z
10
00
 V
 10
 A
EL
EC
TR
O
 ce
ll 
S2
0
Sq
ua
re
 w
av
e 
pu
lse
 
ge
ne
ra
to
r
1–
10
,0
00
 o
r 
in
fin
ite
0–
20
00
 V
5–
50
00
 μs
 
0.
1–
10
,0
00
 m
s
0.
1–
10
,0
00
 H
z
20
00
 V
 2
5 A
(C
on
tin
ue
d)
86 Results and Discussion
258 Dosimetry in Bioelectromagnetics
TA
BL
E 
12
.2
 (C
on
tin
ue
d)
 
A
 R
ev
ie
w
 o
f C
om
m
er
ci
al
ly
 A
va
ila
bl
e 
El
ec
tr
op
or
at
io
n 
D
ev
ic
es
, I
nc
lu
di
ng
 Th
ei
r C
ap
ab
ili
tie
s a
nd
 C
ha
ra
ct
er
ist
ic
s
Pr
od
uc
er
D
ev
ic
e
Pu
lse
 
de
sc
rip
tio
n
Pu
lse
 n
um
be
r
Pu
lse
s a
m
pl
itu
de
Pu
lse
s d
ur
at
io
n
Pu
lse
s r
ep
et
iti
on
 
fr
eq
ue
nc
y
Pu
lse
 se
qu
en
ce
s
M
ax
im
um
 
vo
lta
ge
M
ax
im
um
 c
ur
re
nt
M
ol
ec
ul
ar
 D
ev
ic
es
A
xo
po
ra
to
r 8
00
 A
Sq
ua
re
 a
nd
 
bi
-le
ve
l p
ul
se
s 
w
ith
 p
os
iti
ve
 
an
d 
ne
ga
tiv
e 
po
la
rit
y, 
as
 
w
el
l a
s b
ip
ol
ar
Tr
ai
n 
du
ra
tio
n:
 
10
 m
s–
10
0 s
 
±(
1–
10
0)
 V
M
O
N
O
PO
LA
R:
 
20
0 μ
s–
1 s
BI
-P
O
LA
R:
 
40
0  μ
s–
1 s
BI
-L
EV
EL
: 
10
 m
s–
20
 s
M
O
N
O
PO
LA
R 
ftr
ai
n 
= 
(1
–2
00
0)
 
H
z
BI
-P
O
LA
R 
ftr
ai
n 
= 
(1
–2
00
0)
 
H
z
BI
-L
EV
EL
 
ftr
ai
n 
= 
(0
.0
24
–5
0)
 
H
z
Re
ct
an
gu
la
r 
pu
lse
Bi
po
la
r p
ul
se
Po
st
iv
e 
bi
-le
ve
l 
pu
lse
5 V
 p
ea
k 
to
 
pe
ak
±1
0.
0 μ
A
N
PI
EL
P-
01
D
Sq
ua
re
 w
av
e
/
(0
–1
10
) V
(0
–9
99
9.
9)
 m
s
(0
–9
99
9.
9)
 m
s
/
/
/
O
nk
oD
isr
up
to
r
O
nk
od
isr
up
to
r
El
ec
tr
op
or
at
or
/
/
/
/
50
 +
 50
 μs
Pa
us
e:
 10
 μs
 s
8 
Bi
ph
as
ic
15
00
 V
5 A
Su
pe
rt
ec
h 
In
st
ru
m
en
ts
SP
-4
a
W
ith
 R
C 
tim
e 
co
ns
ta
nt
 o
f t
he
 
ex
po
ne
nt
ia
l 
de
ca
y 
of
 w
av
e
0–
99
H
V:
 (2
00
–4
00
) V
LV
: (
0–
20
0)
 V
(1
–2
50
) m
s
(1
0–
60
,0
00
) m
s
Si
ng
le
 p
ul
se
 
m
od
e 
an
d 
bu
rs
t 
m
od
e 
(u
p 
to
 9
9 
pu
lse
s)
40
0  V
11
.9
 A
So
ur
ce
s: 
A
ng
io
dy
na
m
ic
s, 
ht
tp
://
w
w
w.
an
gi
od
yn
am
ic
s.c
om
/; 
BE
X
 C
o.
, 
Lt
d.
, 
ht
tp
://
w
w
w.
be
xn
et
.co
.jp
/; 
Bi
on
m
ed
 T
ec
hn
ol
og
ie
s, 
ht
tp
://
bi
on
m
ed
.d
e/
; 
BT
X
-H
ar
va
rd
 
Ap
pa
ra
tu
s, 
ht
tp
://
w
w
w.
bt
xo
nl
in
e.c
om
; 
C
yt
o 
Pu
lse
 S
ci
en
ce
, 
In
c.,
 h
ttp
://
w
w
w.
cy
to
pu
lse
.c
om
/; 
IG
EA
, 
ht
tp
://
w
w
w.
ig
ea
.it
/; 
In
ov
io
, 
ht
tp
://
w
w
w.
in
ov
io
.c
om
/; 
In
tr
ac
el
, 
ht
tp
://
in
tr
ac
el
.co
.u
k/
; 
Le
ro
y 
Bi
ot
ec
h,
 
ht
tp
s:/
/w
w
w.
le
ro
yb
io
te
ch
.co
m
; 
M
ol
ec
ul
ar
 
D
ev
ic
es
, 
ht
tp
://
w
w
w.
m
ol
ec
ul
ar
de
vi
ce
s.c
om
/; 
N
PI
 
ht
tp
://
w
w
w.
np
ie
le
ct
ro
ni
c.d
e/
; 
O
nk
oD
isr
up
to
r, 
ht
tp
s:/
/w
w
w.
on
ko
di
sr
up
to
r.c
om
; S
up
er
te
ch
 In
st
ru
m
en
ts
, h
ttp
://
w
w
w.
su
pe
rt
e.c
h/
El
ec
tr
op
or
at
or
.h
tm
l
No
te:
 W
e 
w
ro
te
 to
 a
ll 
lis
te
d 
pr
od
uc
er
s a
nd
 k
in
dl
y 
as
ke
d 
th
em
 to
 re
vi
ew
 th
e 
da
ta
 w
e 
fo
un
d 
in
 li
te
ra
tu
re
 a
nd
 o
n 
th
e 
In
te
rn
et
 a
nd
 u
pd
at
e 
if 
ne
ce
ss
ar
y. 
W
hi
le
 m
os
t o
f t
he
 
m
an
uf
ac
tu
re
rs
 w
er
e 
pl
ea
se
d 
to
 c
oo
pe
ra
te
, w
e 
di
d 
no
t 
ge
t 
in
fo
rm
at
io
n 
ab
ou
t 
pu
lse
 c
ha
ra
ct
er
ist
ic
s 
fr
om
 o
th
er
s. 
W
e 
ar
e 
st
ill
 m
iss
in
g 
al
l t
he
 in
fo
rm
at
io
n 
ab
ou
t 
pu
lse
 
 ch
ar
ac
te
ris
tic
s f
ro
m
, L
on
za
, T
riT
ec
h,
 Ic
ho
r M
ed
ic
al
 S
ys
te
m
s, 
Th
er
m
o 
Fi
sc
he
r, 
Ep
pe
nd
or
f, 
M
ax
cy
te
, a
nd
 O
nc
os
ec
.
3.1 Book chapter 87
259Dosimetry in Electroporation-Based Technologies and Treatments
equipment used and the process. Many papers describing/using electroporation have 
reported insufficient details, and quite often measurements are not reported (Batista 
Napotnik et al., 2016; Campana et al., 2016). The field of electroporation is in need of 
promoting reproducible research that can only be achieved by adequate measurements, 
standardized reports, and proper use of electroporators and electrodes.
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Abstract 22 
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Introduction: Skin electroporation is a promising treatment for transdermal drug delivery, gene 24 
electrotransfer, skin rejuvenation, electrochemotherapy, and wound disinfection. Although a 25 
considerable amount of in vitro and in vivo studies exists, the translation to clinics is not as fast as one 26 
would hope. We believe the reason lies in the non-standardized dosimetry, i.e. electrode configurations, 27 
pulse parameters and pulse generators used. Adequate dosimetry could be determined by 28 
mathematical modeling and would allow comparison of protocols and translation into clinics. 29 
Areas Covered: We introduce the mechanisms and applications of skin electroporation, review existing 30 
mathematical models and compare the influence of different model parameters. We review electrode 31 
configurations and pulse generators, prototypes as well as commercially available models. 32 
Expert opinion: The reasons for slow translation of skin electroporation treatments into clinics lie in 33 
uncontrolled and inadequate dosimetry, poor reporting rendering comparisons between studies 34 
difficult, and significant differences in animal and human skin morphology, often dismissed by 35 
researchers. Mathematical models enable comparison of studies, however, when the parameters of 36 
the pulses and electrode configuration are not adequately reported, as is often the case, comparisons 37 
are difficult, if not impossible. For each skin electroporation treatment, systematic studies determining 38 
the optimal parameters should be performed and treatment parameters standardized. 39 
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Article highlights 43 
1. Mathematical models of skin electroporation facilitate our understanding of the phenomena,44 
help to reveal relevant parameters for treatment efficacy decrease the number of in vitro and45 
in vivo experiments needed and enable predictions about the treatment efficacy.46 
2. The reasons for slow translation of skin electroporation into clinics are non-standard pulse47 
parameters, non-standard electrode configurations, generators not complying with their48 
technical specifications or having no technical specifications at all, lack of reporting on the49 
delivered waveforms, electric field distribution, not performing the current-voltage50 
measurements and significantly different skin structure of animals and humans,.51 
3. We ask the researchers to follow the guidelines for reporting the dosimetry. The use of high-52 
quality electroporation equipment, with reliable and traceable operation, together with53 
controlled dosimetry and predictive modeling raises the quality of studies and enables faster54 
development of the field and eventual translation into clinics.55 
4. We propose that the pulse parameters and electrode configurations for skin electroporation56 
should be determined and standardized with the use of mathematical models, taking into57 
account the electric field distribution, electrical, thermal and chemical damage, drug/plasmid58 
distribution and other parameters, deemed relevant for the treatment.59 
5. When designing new clinical as well as esthetic (for the use in cosmetics) pulse generators,60 
they should comply with existing standards. In Europe, it has to comply with a Medical Device61 
Regulation MDR 2017/745, and in the USA, the device should be approved by the FDA (Food62 
and Drug Administration). Also, new standards specific to electroporation devices should be63 
developed.64 
65 
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1. Introduction66 
When biological cells are exposed to short high-voltage pulses, electroporation occurs, i.e. pores are 67 
formed in the plasma membrane leading to transient permeability increase, and molecules, for which 68 
the cell membrane is usually impermeable, can pass across membrane [1]. Therefore, electroporation 69 
occurs due to high electric field imposed across a short distance (plasma membrane) causing above-70 
threshold induced transmembrane voltage. In a similar way, electric field across the stratum corneum 71 
(SC) causes electroporation of skin, i.e. application of electric pulses to the skin disrupts its barrier 72 
function by means of skin electroporation. 73 
The main mechanism behind skin electroporation is thus the disruption of the most resistive and 74 
impenetrable layer of the skin, the SC. When short high-voltage pulses are applied, small aqueous 75 
pores, i.e., local transport regions (LTRs), are formed within the lipids of the SC [2–4]. LTRs are areas 76 
of the increased electric conductivity and permeability. When pulses are longer, in the millisecond 77 
range, Joule heating causes melting of the lipids around the edge of LTRs as well as around the pre-78 
existing defects and appendages (sweat glands, hair follicles) in the SC, the size of the defects increases 79 
and LTRs grow to a few hundred micrometers in diameter. These newly formed defects in the SC 80 
decrease its normally very high impedance and allow the electric field to penetrate lower layers of the 81 
skin [5,6], thus causing electroporation of the living cells beneath the SC. Additionally, electric pulses 82 
cause electrophoretic transport of charged molecules through the LTRs, assisting their transdermal 83 
delivery [7]. Electroporation should be distinguished from iontophoresis, which is the application of 84 
continuous direct low electric currents to the skin. The two main transport mechanisms of 85 
iontophoresis are electrophoresis (moving of charged molecules through skin) and electroosmosis 86 
(movement of neutral molecules by convective flow) [8]. In iontophoresis, no LTRs are formed in the 87 
SC, most of the transport is through pre-existing defects and appendages and it is mostly used for 88 
transdermal delivery of small charged molecules. 89 
90 
Figure 1: Mechanism of skin electroporation. After high-voltage electric pulses are applied, local transport regions form 91 
through which the transport of larger molecules can occur. Here, local transport regions are imaged via calcein transport. 92 
Reprinted from Bioelectrochemistry and Bioenergetics, 47 / 1, Pliquett et al., Local transport regions (LTRs) in human 93 
stratum corneum due to long and short `high voltage' pulses, 151-161, Copyright (1998), with permission from Elsevier. 94 
95 
2.1 Applications of skin electroporation 96 
Transdermal or intradermal gene electrotransfer [9] is one of the most widely used and promising skin 97 
electroporation applications where short-term gene expression is successfully achieved, for example 98 
in gene transfer of antigen-presenting cells in immunotherapy such as DNA vaccination [9] or in 99 
transfection of skin cells to produce various proteins [10]. In transdermal drug delivery, the aim is a 100 
controlled transport of small therapeutic molecules across the skin, for example, to treat pain, 101 
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dementia, Parkinson’s disease [8,11–13]. In cosmetics, electroporation is used in the so-called 102 
‘needless mesotherapy’ or ‘mesoporation’ to rejuvenate the skin [14–16], although our measurements 103 
of some devices indicate that instead low-intensity radiofrequency (RF) pulses are delivered. In 104 
classical electroporation short, square wave, high voltage electric pulses are delivered to the tissue 105 
and the treatment is assumed as “non-thermal”, while RF-therapies base on controlled tissue heating 106 
with a high frequency alternating current. Pulses of irreversible electroporation are applied to remove 107 
the aged cells and to promote the growth of new cells, while extracellular matrix remains undamaged 108 
[17], and in superficial wound disinfection to kill the antibiotic-resistant bacteria [18,19]. In 109 
electrochemotherapy, cutaneous and subcutaneous tumors are treated with a combination of electric 110 
pulses and chemotherapeutic drug [20,21]. 111 
Although skin electroporation lends itself as a very promising approach for transdermal drug and gene 112 
delivery, the translation into the clinical setting is lagging behind the in vitro and in vivo studies [13]. 113 
In our review, we critically assess the existing applications of skin electroporation, discuss possible 114 
reasons for the slow transfer of skin electroporation into clinical use and suggest possible solutions for 115 
improving it. 116 
117 
2.2 Models of skin electroporation 118 
As the experimental setups of skin electroporation can vary significantly, direct comparison of results 119 
obtained by different electrode configurations and pulse generators are difficult, if not impossible. The 120 
models of skin electroporation could be instrumental in comparing results from them, facilitating also 121 
the transition from the in vitro to the in vivo and finally to the clinics as well as decreasing the number 122 
of experiments needed. Mathematical models of skin electroporation describe thermal [22,23] or 123 
electric [5,6,16,24–28] effects or both coupled together [29–36], primarily for the description of 124 
changes in the stratum corneum (SC) based on mechanisms of skin electroporation (formation of the 125 
defects in the lipid bilayers of the SC, LTR formation and growth [22,30,37], mehcanical deformation 126 
of the SC [28]). In the treatment planning of electroporation-based medical treatments, models can be 127 
used to calculate the electric field and thermal damage in the cutaneous/subcutaneous tumors and 128 
surrounding tissue [27,29,35,38–41], although for standard electrodes and pulses, the standard 129 
operating protocols obviate the need to calculate each case separately [20]. Electric and/or thermal 130 
models can be coupled to transport models via the diffusion and electrophoresis through the LTRs 131 
[30,31,42–45], the dual-porosity model [46], compartmental models [43] and/or regression models 132 
[47]. In case of the DNA transport, the electric properties of the injected plasmid DNA were taken into 133 
account [48], the efficiency of gene electrotransfer was evaluated according to the predicted plasmid 134 
DNA concentration inside the reversibly electroporated tissue [49] as well as taking into account the 135 
thermal stress and tissue damage during gene electrotransfer [50]. The extravasation of 136 
macromolecules in the size of antibodies or plasmid DNA from blood vessels into the surrounding 137 
tissue during skin electroporation was also calculated [51]. Most of the models treat the skin as a bulk 138 
tissue of a few layers of different dielectric properties [6,25,27,31,44], or as an equivalent circuit 139 
[32,52], however, also multi-scale model, i.e. model which takes into account the microstructure of 140 
the skin is available [5]. Recently, a computational study at the level of single lipids in the SC was 141 
performed, i.e., a molecular dynamics study, which showed that aqueous pores indeed form in the SC 142 
[53]. Some typical examples of the models, progressing from molecular level to elaborated mechanistic 143 
macroscale models, are shown in Fig. 2. For example, in a) the molecular dynamics study of pore 144 
formation, b) the equivalent circuit, c) electric field distribution in the bulk skin model, d) model of a 145 
single LTR or e) several LTRs in the SC, f) single cells from the multi-scale model and g) model of gene 146 
electrotransfer. 147 
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148 
Figure 2: Examples of different models of skin electroporation. 149 
a) Results of the molecular dynamics simulation of the pore formation in the stratum corneum. Reprinted with permission 150 
from Gupta R, Rai B. Electroporation of Skin Stratum Corneum Lipid Bilayer and Molecular Mechanism of Drug Transport: A 151 
Molecular Dynamics Study. Langmuir. 2018;34:5860–5870. Copyright (2018) American Chemical Society. 152 
b) An equivalent circuit of the skin. Above: the entire SC is modeled with one equivalent circuit. Rb represents the resistance 153 
of the bulk solution. The resistance of the skin is represented by two parallel branches with Rx being the pathway through 154 
the appendages, Rl through lipid bilayers in the SC and Rc the inner resistance of each compartment of the model. (This 155 
model assumes that SC is made of many hydrophilic compartments, separated by boundary bilayers.) Reprinted from 156 
Biophysical Journal, 68/3, Chizmadzhev et al., Mechanism of electroinduced ionic species transport through a multilamellar 157 
lipid system, 749-765, Copyright (1995), with permission from Elsevier. Below: Only one LDR (local dissipation region) in the 158 
SC is modeled with the equivalent circuit. Reprinted from Bioelectrochemistry, 57/1, Martin et al., Theoretical analysis of 159 
localized heating in human skin subjected to high voltage pulses, 55-64, Copyright (2002), with permission from Elsevier. 160 
c) A bulk numerical model of the subcutaneous tumor showing electric field distribution when 276 V are applied to parallel161 
plate electrodes. Adapted from [54]. 162 
d) The model of a single local transport region formation inside a layered skin model. Left: a layered model of the skin. 163 
Middle: The geometry of a pre-existing pore inside the SC. Right: Melting of the lipids around the pre-existing pore and164 
consequent increase in the radius of the LTR. Reprinted from Journal of Biomechanical Engineering, 129/5, Becker SM and 165 
Kuznetsov AV, Local Temperature Rises Influence In Vivo Electroporation Pore Development: A Numerical Stratum Corneum 166 
Lipid Phase Transition Model, 712-721, Copyright (2007), with permission from Elsevier. 167 
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e) A bulk model of the skin with included different dielectric properties of each skin layer and with a model of LTR 168 
formation inside the SC. Four three-dimensional slice plots of the conductivity distributions (S/m) represent four stages of 169 
the process in chronological order when 400 V is applied. © [2008] IEEE. Reprinted, with permission, from Pavšelj N, 170 
Miklavčič D. Numerical Models of Skin Electropermeabilization Taking Into Account Conductivity Changes and the Presence 171 
of Local Transport Regions. IEEE Transactions on Plasma Science. 2008;36:1650–1658. 172 
f) The geometry of the cells of the skin (corneocyte, keratinocyte, spheres in the papillary dermis) used in the multi-scale 173 
model of skin electroporation. From each cell, equivalent dielectric properties of the respective layer were obtained. © 174 
[2018] IEEE. Reprinted, with permission, from Dermol-Černe J, Miklavčič D. From Cell to Tissue Properties—Modeling Skin 175 
Electroporation With Pore and Local Transport Region Formation. IEEE Transactions on Biomedical Engineering. 176 
2018;65:458–468. 177 
g) A model of gene electrotransfer with subcutaneously injected plasmid after pulse application. Left: Skin patch with the 178 
injected plasmid. SC is shown in red with local conductive pathways in white. Right: Gray ellipsoid is the injected plasmid 179 
DNA. Electrophoretic movement of the plasmid DNA through reversibly electroporated volume of the skin tissue is shown 180 
as the trajectories of the plasmid DNA movement inside the volume of reversible electroporation due to the non-uniform 181 
electric field. © [2019] IEEE. Reprinted, with permission, from Forjanič et al. Electroporation-Induced Stress Response and 182 
Its Effect on Gene Electrotransfer Efficacy: In Vivo Imaging and Numerical Modeling. IEEE Trans. Biomed. Eng. 183 
2019;66:2671–2683. 184 
185 
2.3 Pulse generators and dosimetry 186 
In the existing studies, various electrode configurations from invasive to non-invasive are used for 187 
pulse application [55]. In Table 1, we summarize the custom prototype electrodes used in different 188 
studies and similar commercially available electrodes that researchers could use as well. Pulses of 189 
different lengths, shapes, and voltages (schemes are shown in Fig. 3) are applied with different pulse 190 
generators (electroporators), listed in Table 2. It needs to be emphasized that a clinical electroporator 191 
is a pulse generator, which has to follow the requirements appointed by the local medical regulations 192 
and meet the medical device standard IEC 60601 (a series of technical standards for the safety and 193 
effectiveness of medical electrical equipment). In Europe, it has to comply with a Medical Device 194 
Regulation MDR 2017/745 (which in 2017 replaced Medical Device Directives (93/42/EEC, 98/79/EC 195 
and 90/385/EEC) and is in a transition period until May 2020) and in the USA, the device should be 196 
approved by the FDA (Food and Drug Administration) for specific indication. In Europe, the area of 197 
cosmetic devices has not been well regulated until now but with the new MDR (EU 2017/745), also 198 
esthetic devices which present the same characteristics and risk profile as medical devices, are 199 
included under the scope of this Regulation. 200 
The design, development and quality assurance of an electroporator is challenging because the 201 
electrical characteristics of biological loads vary between tissues, samples from one tissue and parts of 202 
the body. SC has a significantly higher impedance than lower skin layers or muscle tissue, meaning that 203 
at the same electrode configuration and applied electric pulses the current between the electrodes is 204 
higher for invasive than for non-invasive electrodes. Additionally, the invasive and non-invasive 205 
electrodes present different risks and are therefore classified into different safety classes of the 206 
standards for medical devices. The electric field distribution is also electrode geometry dependent 207 
[56]; thus, the comparison of different electrode types and transition from in vitro to in vivo to the 208 
clinical use is only possible through modeling. 209 
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210 
Figure 3: Typical waveforms, applied in skin electroporation treatments. a) Square wave pulses with durations (tFWHM – the 211 
time of full width at half maximum) from a few nanoseconds to several hundred milliseconds and pulse amplitudes (A) from 212 
a few tens to several hundred volts. b) Exponential pulses with the time constant (τ) from one millisecond to a few hundred 213 
milliseconds. c) Sinusoidal waveform, with different periods (T) and amplitudes (A). d) Bipolar pulses with varying pulse 214 
durations (tFWHM), delays between half periods (i.e. inter-pulse delays tIPD) and delays between bipolar pulses (tPAUSE). 215 
216 
3. Conclusion217 
Skin electroporation is a promising modality for treating different conditions with transdermal drug 218 
delivery, gene electrotransfer, electrochemotherapy and irreversible electroporation. A considerable 219 
amount of in vitro and in vivo studies exists, which use significantly different electrode configurations, 220 
waveforms, and pulse generators. We presented some of the electrode configurations and pulse 221 
generators, prototype as well as commercially available, appearing in the literature and pointed out 222 
their advantages and drawbacks (see Table 2). Results from studies with different parameters are 223 
sometimes difficult (if not impossible) to be compared. Thus, we propose to use mathematical models. 224 
They are promising in combining different experimental results and enabling better treatment efficacy 225 
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prediction. Alternatively, reporting should follow recommendation and provide detailed description of 226 
pulses and electrodes [57–59], that should allow development of models by experts. 227 
228 
4. Expert Opinion229 
Skin electroporation is a safe, fast, and efficient method of delivering drugs or DNA across the skin and 230 
affecting skin structure. Unfortunately, the translation of skin electroporation protocols into clinics is 231 
not as fast as one would hope [13]. Already translation from the in vitro to the in vivo is difficult due 232 
to a significantly more complex environment in vivo. An interesting link between the in vitro and the 233 
in vivo studies is the in vitro 3D reconstructed human skin [60–62] which is more similar to in vivo 234 
human than rodent skin. Nevertheless, before entering into the clinics, the in vivo experiments must 235 
be up-scaled to humans, which can result in enormous amounts of drugs/plasmids needed, and scaling 236 
up of electrodes and pulse generators. 237 
We identified two main reasons for the hampered transition of skin electroporation into the clinics. 1) 238 
In vivo studies are usually done on animals (rodents, pigs, rabbits) with significantly different skin 239 
structure than humans, which is recognized by the researchers, but they have no way of translating 240 
the results. They differ in, among others, the thickness of the layers, their number, the density of the 241 
appendages, hydration. The structure of the skin varies significantly also between different people, 242 
among different body parts of one person or even of the same part of skin throughout the day. 2) The 243 
dosimetry of the delivered pulses is not well controlled. Pulses of various shapes, durations and 244 
amplitudes are applied to different electrode configurations with many pulse generators. Some 245 
electroporators have vague or non-existent technical specifications, meaning the researchers do not 246 
know the exact pulse parameters. The comparison of different devices and reproducibility of 247 
experiments are therefore difficult and sometimes impossible. Thus, we suggest making use of 248 
mathematical models of skin electroporation, which can be used to calculate and predict the 249 
differences among various protocols observed in the literature by taking into account different pulse 250 
parameters and skin structure. 251 
252 
4.1 The models of skin electroporation 253 
Models offer an insight into the mechanisms of skin electroporation, and we firmly believe in their 254 
significant contribution to the community by elucidating the steps in skin electroporation, the 255 
importance of different parameters and by decreasing the number of needed in vitro or in vivo 256 
experiments. In the models, the number and thickness of the layers, their dielectric, thermal and 257 
transport properties can easily be changed and various pulse combinations tested without expensive, 258 
ethically questionable and time-consuming experimental work. 259 
260 
From models, we can observe that small differences in the skin structure and parameters of applied 261 
pulses have a large influence on the treatment outcome. It was theoretically shown that small 262 
differences in the thickness of the stratum corneum (SC) affected the size of the LTRs and the 263 
electrophoretic force, pushing molecules across the skin [30] and thus, the treatment efficacy. 264 
Additionally, we conducted a parametric study of a model of electroporation of skin patch as a proof-265 
of-principle of how small changes in the skin or pulse properties can have a large effect on the 266 
treatment outcome. We modeled the non-invasive multi-electrode array with 570 V pulses applied 267 
between every two pins [10] (Figure 4). The initial parameters of the model (skin geometry and 268 
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dielectric properties) were obtained from [5], and electroporation was calculated sequentially as in 269 
[54]. The obtained results were our baseline. We modeled 1) the effect of skin hydration and/or age 270 
by varying the initial SC conductivity, 2) increase in SC conductivity after electroporation, 3) the body 271 
part by varying the thickness of SC, 4) different pulse generator by varying the applied voltage and 5) 272 
electric conductivity of all layers (Table 3). We calculated the reversibly and irreversibly electroporated 273 
volume and normalized them to the baseline. We observed that only a 2-fold difference in initial or 274 
electroporated SC conductivity, which can easily be expected in experiments, increased the 275 
electroporated volume up to 30%. Increasing the thickness of the SC to 40 µm instead of 20 µm 276 
increased the reversibly electroporated volume but surprisingly, not the irreversibly electroporated. 277 
Decreasing the voltage by half did not decrease the electroporated volumes by half as one could expect 278 
but to 45% (reversible) or only 15% (irreversible) of the baseline. We can thus see that already small 279 
differences in the skin structure, which are more than expected in experiments across different animal 280 
species or even in the same subject, could be responsible for the poor reproducibility in applying the 281 
in vivo results from animal studies to human studies and that modeling of skin electroporation is useful. 282 
283 
284 
Figure 4: A numerical model of skin electroporation, which we calculated in the scope of this paper. a) The geometry of the 285 
layered skin with the circles marking the pins of the multi-electrode array on the surface of the stratum corneum. 286 
b) Classical pulse application scheme usually used in gene electrotransfer studies. Numbers mark the order of pulses in our 287 
simulation. 288 
c) The electric field distribution 2 mm below the skin surface (in the hypodermis) when 570 V is applied when following the 289 
pulse application scheme on B. 290 
d) and e) show the side view of the logarithm of electric field distribution when the thickness of the SC is d) 20 µm or e) 40 291 
µm. We can see that a minor change in the thickness of one layer significantly influences the distribution of electric field 292 
even 2 cm below the surface in the muscle layer. 293 
294 
Although the mathematical models of skin electroporation are promising, they do come with their 295 
drawbacks. Currently, the largest drawback is the lack of reliable parameter values [5]. The values of 296 
the parameters used in the models of human skin, come from porcine skin [23], properties of 297 
keratinous fibers [22,23], ex vivo human cadavers frozen for different time [24,26,63], geometry of 298 
skin cells [5], are deduced from physical constants and/or are based on only a few measurements. 299 
Also, the place of the measurement is not always given and the measuring protocol not well described. 300 
The values of some parameters are only estimated, especially the dielectric properties of different 301 
layers after electroporation. Moreover, the dielectric properties of the skin are anisotropic, which is 302 
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only rarely considered in the models. Also, all models should be validated by actual measurement. The 303 
models of skin electroporation were mostly constructed for human skin, and some were also validated 304 
on it [24,42], however, others were validated on rat [25], porcine [5], mice skin [38], with analytical 305 
solutions [22,23,31,34] or were not validated [30]. It was already shown that skin layers differ vastly in 306 
their dielectric properties, which significantly affects the results of calculations [23]. However, some 307 
models still model skin as one organ of one layer with homogeneous properties [48,64,65], which can 308 
lead to erroneous results. 309 
In future, new models should be developed and existing ones improved. More good-quality 310 
measurements of properties of skin should be performed and made available. The modeling focus 311 
should go in the direction of mechanistic multi-scale modeling and linking the phenomena at different 312 
levels – molecular, single-cell, organ, and tissue [66]. The successfully permeabilized/transfected 313 
region should be predicted by taking into account the LTR and pore formation, thermal, chemical and 314 
electric tissue damage, the amount of the drug/DNA in contact with the cells [49,50], and other 315 
parameters, determined to be relevant for skin electroporation. Better models will enable a better 316 
treatment outcome prediction and more controlled treatment, which will pave the way to the routine 317 
use of skin electroporation in the clinical setting. 318 
319 
4.2 The dosimetry 320 
In the field of skin electroporation, many different pulse generators were used (listed in Table 2). 321 
Unfortunately, in most cases, the delivery of electroporation pulses was not properly monitored [67]. 322 
Measurement of electroporation pulses is crucial to determine and control their quality and delivery. 323 
Current through the electrodes should always be measured to make sure that the pulses were applied 324 
to the biological load. Additionally, pulse generators cannot always be trusted due to poor regulation 325 
and lack of standardization. Because of large variety of biological loads with significantly different 326 
dielectric properties, (also due to different electrode geometries used), pulse generators are not 327 
always able to deliver what they promise. In case of loads with low impedance and use of pulses 328 
parameters in the higher operation range, the delivered pulses can have a significant voltage drop due 329 
to the insufficient energy storage. On the other hand, the voltage amplitude can be limited because of 330 
current limitations. Some devices warn the user about the improper operation while others do not. 331 
Another problem is that pulse parameters of some devices cannot be changed and/or pre-332 
programmed setups without unknown pulse parameters are used. Consequently, studies often lack 333 
the information on pulse specifications (shape, duration, number, voltage, repetition frequency) and 334 
thus cannot be reproduced. 335 
Applied pulses are of different shapes, durations, voltages with their spectral energy contained within 336 
different parts of the spectrum. It is known that the dielectric properties of tissues are frequency-337 
dependent [68], which influences the electric field distribution across the skin layers and consequently 338 
electroporation efficiency [69]. Currently, there are no agreed standard operating procedure pulse 339 
parameters for skin electroporation, except for the treatment of cutaneous and subcutaneous tumors 340 
[20]. More studies should be performed, determining the most optimal waveform for skin 341 
electroporation. Although there is a significant number of pulse generators available on the market, 342 
versatile generators should still be developed, for example, for applying bursts of short bipolar pulses, 343 
i.e. the high-frequency irreversible electroporation (HF-IRE) pulses [70] to reduce pain and muscle344 
contraction during skin electroporation [13]. The generators, producing the optimal waveforms being 345 
applied to optimal electrode configurations should be reliable, simple to use, safe, with available 346 
technical specifications, feedback quality measuring system and, when used in the clinics, should 347 
comply with the standards for medical devices [71,72]. 348 
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Various electrode configurations are used in the skin electroporation studies, and the information on 349 
electrode geometry is often poor or lacking which additionally renders the dosimetry inaccessible. 350 
Moreover, in many studies, only the applied voltage is reported although it was shown that the electric 351 
field is the most important parameter influencing the efficiency of electroporation [73] and different 352 
electrode configurations cause significantly different electric field distributions [56]. The electrodes 353 
are of different materials (stainless steel, platinum, silver, silver chloride, brass, gold) which can cause 354 
different chemical reactions and metal release and could affect the treatment outcome [74–76]. 355 
Interestingly, it was experimentally shown that gene transfection of skin cells [77], as well as 356 
electrochemotherapy of subcutaneous tumors [78], could also be achieved contactless with pulsed 357 
magnetic fields (PEMF) which could decrease the chemical contamination and facilitate the use of non-358 
invasive techniques and is worth exploring in the future. Electric field distribution should be calculated 359 
and shown for each configuration separately enabling comparison of different electrode 360 
configurations. These calculations should be then used to reach an agreement on the most efficient 361 
electrode configuration for a chosen skin electroporation treatment. 362 
Various pulse shapes, generators and electrode configurations all contribute to vastly different 363 
dosimetry among the published studies, and the dosimetry is not always adequately reported. All this 364 
renders comparison of different studies difficult, if not impossible, especially if not all the details are 365 
presented. In electrochemotherapy, the pulse parameters and electrode configurations are now 366 
standardized to provide safe and efficient treatment for the patients [20]. A similar attempt should 367 
also be made in the field of other skin electroporation treatments. We thus ask the researchers to 368 
follow the instructions for reporting the dosimetry, as suggested in [57–59,71]. Using good quality 369 
pulse generators together with controlled dosimetry, and predictive modeling should increase the 370 
efficiency of skin electroporation treatments, enable comparisons between treatments and simplify 371 
the translation into clinics. 372 
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Annotations to references 380 
* Paper of interest381 
[5] A paper presenting mechanistic multiscale model of skin electroporation. 382 
[6] A paper presenting a bulk model of skin electroporation, taking into account the presence of 383 
separate local transport regions. 384 
[8] A paper reviewing different methods of increasing skin permeability, among them also 385 
electroporation. 386 
[31] A paper presenting the model of thermal local transport region expansion via melting of the387 
lipids of the stratum corneum. 388 
[50] A modeling paper on evaluating gene electrotransfer efficiency via electroporation efficiency389 
and electrophoretic transport of plasmid DNA. 390 
[53] A modeling paper showing pore formation in the stratum corneum with molecular dynamics391 
simulations. 392 
[57] A paper giving instructions on correct reporting of experimental factors in food and393 
biotechnological applications of electroporation. 394 
395 
** Paper of particular interest 396 
[1] An excellent review paper on mechanisms and models of electroporation. 397 
[58]  A paper giving instructions on correct reporting of experimental factors in biological398 
experiments on electroporation. 399 
[59] A paper giving instructions on correct reporting of experimental factors in clinical experiments400 
with electroporation. 401 
[71]  A book chapter on dosimetry in electroporation-based treatments, also giving instructions to402 
researchers on correct reporting of the delivered waveforms. 403 
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 p
ro
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at
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ra
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e 
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su
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at
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1]
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ag
e 
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N
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N
D
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TR
O
D
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al
 d
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g 
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er
y 
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ro
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ty
pe
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g 
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e 
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et
er
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5 
m
m
 a
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e 
di
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et
er
 1
5 
m
m
) 
ne
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le
 e
le
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ro
de
: 3
 c
m
 x
 3
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m
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ve
r 
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O
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EC
TR
O
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an
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er
m
al
 d
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g 
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er
y 
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 E
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m
en
t  
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 e
le
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ro
de
 2
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m
m
 in
 d
ia
m
et
er
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A 
[1
6]
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si
ve
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le
ct
ro
de
s 
N
EE
DL
E 
EL
EC
TR
O
DE
S 
Ge
ne
 e
le
ct
ro
tr
an
sf
er
 
El
ec
tr
oc
he
m
ot
he
ra
py
 
IG
EA
 
 7
  
he
xa
go
na
l c
on
fig
ur
at
io
n 
 D
ia
m
et
er
 0
.7
 m
m
, l
en
gt
h 
10
 m
m
, 2
0 
m
m
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m
m
 
m
ed
ic
al
 g
ra
de
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l 
[9
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IG
EA
 
8 
(2
 ro
w
s o
f 4
) 
lin
ea
r c
on
fig
ur
at
io
n 
 D
ia
m
et
er
 0
.7
 m
m
, l
en
gt
h 
10
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m
 o
r 
20
 m
m
 o
r 3
0 
m
m
 
m
ed
ic
al
 g
ra
de
 st
ee
l 
[9
3]
 
BT
X 
- H
ar
va
rd
 
Ap
pa
ra
tu
s 
2 3 
m
m
 ti
p 
le
ng
th
  
ul
tr
a 
th
in
 d
ia
m
et
er
 
pl
at
in
um
 
[9
4]
 
BT
X 
- H
ar
va
rd
 
Ap
pa
ra
tu
s 
8 
or
 1
2 
4 
or
 6
 m
m
 g
ap
 
le
ng
th
s:
 2
, 3
, 5
, 1
0,
 1
6,
 2
5,
  
st
ai
nl
es
s s
te
el
 
[9
5]
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ro
y 
8 
(t
w
o 
ro
w
s o
f f
ou
r)
 
Li
ne
ar
 c
on
fig
ur
at
io
n 
8 
m
m
 b
et
w
ee
n 
tw
o 
ro
w
s,
 e
ac
h 
ne
ed
le
 is
 2
 
m
m
 a
pa
rt
 
0.
88
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m
 d
ia
m
et
er
, 1
5 
m
m
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ng
 
st
ai
nl
es
s s
te
el
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4]
 
FO
RK
 E
LE
CT
RO
DE
S 
Ge
ne
 e
le
ct
ro
tr
an
sf
er
 
BE
X 
an
d 
N
EA
PG
EN
E 
4 
(3
 n
ee
dl
es
 +
 1
 p
la
te
) 
3 
x 
2.
5 
m
m
 n
ee
dl
es
 in
te
rv
al
s,
 le
ng
th
 3
 m
m
 
or
 5
 m
m
 o
r 1
0 
m
m
, d
ia
m
et
er
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.5
 m
m
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nl
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at
ed
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 p
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tin
um
 
[9
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M
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RO
N
EE
DL
E 
AR
RA
Y 
EL
EC
TR
O
D
ES
 
Ge
ne
 e
le
ct
ro
tr
an
sf
er
 
cu
st
om
 p
ro
to
ty
pe
 
py
ra
m
id
al
 sh
ap
e,
 ra
di
us
 o
f t
he
 ti
p 
is 
be
lo
w
 
1 
μm
 
ne
ed
le
s l
en
gt
h:
 2
00
 µ
m
 ±
 7
 μ
m
 (9
00
 
ne
ed
le
s p
er
 a
rr
ay
 a
nd
 1
21
 a
rr
ay
s p
er
 
w
af
er
. 
N
ee
dl
e 
sp
ac
in
g:
 9
0 
μm
 
 so
lid
 si
lic
on
 
gl
as
s 
tit
an
iu
m
 
ce
ra
m
ic
 
po
ly
m
er
 
[3
8,
98
] 
Im
ag
e 
fr
om
 [9
8]
 
G
RI
D 
EL
EC
TR
O
DE
S 
El
ec
tr
oc
he
m
ot
he
ra
py
 
cu
st
om
 p
ro
to
ty
pe
 
Fl
ex
ib
le
 su
pp
or
t a
nd
 6
7 
ne
ed
le
s,
 le
ng
th
 5
 
or
 1
0 
m
m
 
st
ai
nl
es
s s
te
el
 
[9
9]
 
Im
ag
e 
fr
om
 [9
9]
. 
N
A 
= 
no
t a
va
ila
bl
e 
63
0 
Co
py
rig
ht
s:
 
63
1 
L-
sh
ap
ed
 p
ro
to
ty
pe
 e
le
ct
ro
de
s:
 R
ep
rin
te
d 
fr
om
 Jo
ur
na
l o
f C
on
tr
ol
le
d 
Re
le
as
e,
 1
34
 /2
, M
az
èr
es
 e
t a
l.,
 N
on
 in
va
siv
e 
co
nt
ac
t e
le
ct
ro
de
s f
or
 in
 v
iv
o
63
2 
lo
ca
liz
ed
 c
ut
an
eo
us
 e
le
ct
ro
pu
lsa
tio
n 
an
d 
as
so
ci
at
ed
 d
ru
g 
an
d 
nu
cl
ei
c 
ac
id
 d
el
iv
er
y,
 1
25
-1
31
, C
op
yr
ig
ht
 (2
00
9)
, w
ith
 p
er
m
iss
io
n 
fr
om
 E
lse
vi
er
. 
63
3 
Ri
ng
 a
nd
 n
ee
dl
e 
el
ec
tr
od
es
: R
ep
rin
te
d 
fr
om
 E
ffe
ct
 o
f e
le
ct
ric
 fi
el
d 
on
 th
e 
en
ha
nc
ed
 s
ki
n 
pe
rm
ea
tio
n 
of
 d
ru
gs
 b
y 
el
ec
tr
op
or
at
io
n,
 9
0/
2,
 M
or
i e
t 
63
4 
al
., 
Ef
fe
ct
 o
f e
le
ct
ric
 fi
el
d 
on
 th
e 
en
ha
nc
ed
 sk
in
 p
er
m
ea
tio
n 
of
 d
ru
gs
 b
y 
el
ec
tr
op
or
at
io
n,
 1
71
-1
79
, C
op
yr
ig
ht
 (2
00
3)
, w
ith
 p
er
m
iss
io
n 
fr
om
 E
lse
vi
er
. 
63
5 
63
6 
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Ta
bl
e 
2:
 P
ul
se
 g
en
er
at
or
s 
us
ua
lly
 u
se
d 
in
 st
ud
ie
s o
n 
sk
in
 e
le
ct
ro
po
ra
tio
n.
 F
or
 e
ac
h 
m
an
uf
ac
tu
re
r, 
w
e 
lis
t t
he
 e
xi
st
in
g 
pu
lse
 g
en
er
at
or
s,
 th
e 
in
te
nd
ed
 u
se
, t
he
 
63
7 
w
av
ef
or
m
 ty
pe
, p
ul
se
 n
um
be
r, 
am
pl
itu
de
 a
nd
 d
ur
at
io
n,
 re
fe
re
nc
e 
to
 a
 st
ud
y 
or
 m
an
uf
ac
tu
re
r’s
 w
eb
pa
ge
 a
nd
 o
ur
 e
xp
er
t o
pi
ni
on
 o
n 
th
e 
ge
ne
ra
to
r. 
As
 w
e 
di
d 
63
8 
no
t h
av
e 
ac
ce
ss
 to
 a
ll 
th
e 
lis
te
d 
ge
ne
ra
to
rs
, s
om
e 
w
er
e 
no
t t
es
te
d 
or
 o
ld
er
 v
er
sio
ns
 th
an
 li
st
ed
 w
er
e 
te
st
ed
 a
s s
pe
ci
fie
d 
un
de
r e
ac
h 
ex
pe
rt
 o
pi
ni
on
. 
63
9 
M
an
uf
ac
tu
re
r 
Pu
ls
e 
ge
ne
ra
to
r 
U
se
d 
fo
r 
W
av
ef
or
m
 
ty
pe
 
Pu
ls
e 
nu
m
be
r 
Pu
ls
e 
am
pl
itu
de
 
Pu
ls
e 
du
ra
tio
n 
Re
fe
re
nc
e 
Ex
pe
rt
 o
pi
ni
on
 
Am
ic
o 
M
ez
of
or
te
 D
uo
* 
Co
sm
et
ic
s 
(m
es
ot
he
ra
py
) 
N
A 
N
A 
N
A 
N
A 
[1
00
] 
Th
e 
de
vi
ce
 w
as
 te
st
ed
 in
 o
ur
 la
bo
ra
to
ry
. I
t d
el
iv
er
s 
st
an
da
rd
 lo
w
 
vo
lta
ge
 ra
di
of
re
qu
en
cy
 (R
F)
 e
le
ct
ric
 p
ul
se
s t
o 
th
e 
sk
in
. T
he
re
 a
re
 th
re
e 
di
ffe
re
nt
 a
pp
lic
at
or
s 
av
ai
la
bl
e 
fo
r t
he
 d
ev
ic
e.
 O
ne
 fo
r R
F 
an
d 
tw
o 
fo
r 
m
es
ot
he
ra
py
 - 
”e
le
ct
ro
po
ra
tio
n”
. T
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 d
ev
ic
e 
al
lo
w
s u
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o 
se
t u
p 
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e 
du
ra
tio
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of
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e 
th
er
ap
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(m
in
ut
es
), 
to
 c
ha
ng
e 
th
e 
pr
og
ra
m
s (
fa
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od
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ha
nd
 ..
.) 
an
d 
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 c
ha
ng
e 
th
e 
in
te
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ity
 o
f t
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th
er
ap
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w
, s
ta
nd
ar
d,
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ig
h)
. I
t g
en
er
at
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 a
 
sin
us
oi
da
l o
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pu
t s
ig
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l w
ith
 o
f 8
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 k
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. T
he
 
sin
us
oi
da
l p
ul
se
s a
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 g
en
er
at
ed
 in
 b
ur
st
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(m
od
ul
at
ed
). 
Th
e 
du
ra
tio
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of
 th
e 
bu
rs
ts
 a
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 4
.3
 
m
s f
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 m
es
ot
he
ra
py
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 3
0 
m
s f
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F 
th
er
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de
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 b
et
w
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bu
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 8
.5
 m
s f
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m
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ot
he
ra
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 1
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s f
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 T
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 c
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ou
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 c
ha
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s d
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ch
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 p
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su
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tim
e 
of
 tr
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ra
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s a
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ve
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m
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r m
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 d
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 re
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de
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m
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re
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ce
 c
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 b
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e 
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bl
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, i
t l
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 d
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t a
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bl
e 
an
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or
e.
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 m
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 d
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 d
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w
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 T
he
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er
at
io
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re
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se
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at
io
n.
 T
he
y 
ca
n 
ho
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m
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 m
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 d
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Table 3: The volume of reversibly and irreversibly electroporated skin in the layered skin model as 642 
calculated in the scope of this paper. First, we calculated the volume of reversibly and irreversibly 643 
electroporated volume and then varied the parameters of the model. For each change in parameters, 644 
we normalized the results to the results with initial values of the parameters (the baseline) 645 
         Change of parameters 
Normalized volume 
Reversibly electroporated 
volume 
Irreversibly 
electroporated volume 
Baseline 100 % 100 % 
Increased SC conductivity (2-times) 124% of the baseline 122% of the baseline 
Increased electroporated SC 
conductivity 
123% of the baseline 130% of the baseline 
Increased SC thickness 120% of the baseline 98% of the baseline 
Decreased voltage (50% of the initial 
one) 
45% of the baseline 17% of the baseline 
Changed threshold of electroporation 
(increased 2-times) 
98% of the baseline 91%of the baseline 
Increased conductivity of all layers (2-
times) 
100% of the baseline 124% of the baseline 
SC = stratum corneum 646 
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Functional Requirements and
Quality Assurance Necessary for
Successful Incorporation of
Electroporation-Based Therapies
Into Clinical Practice
Electroporation-based therapies have a huge potential for implementation into clinical
practice in socioeconomically disadvantaged populations. Currently, the price of electro-
porators and electrodes is relatively high, but custom low budget devices can be devel-
oped. In the paper, we describe three most established applications in medicine, with the
focus on the basic mechanisms, which should be taken into account during the develop-
ment process of a clinical electroporator. Also, typical pulse parameters used in each of
the described applications are defined. In the second part of the paper, we describe tech-
nical functional requirements for a clinical electroporator and safety guidelines, with the
focus on medical device standard. At the end of the paper, the focus moves to a more gen-
eral problematic, such as quality assurance and the importance of measurement during
the pulse delivery, which we firmly believe is necessary for successful electroporation.
[DOI: 10.1115/1.4045837]
1 Introduction
Electroporation is a phenomenon in which cells that are
exposed to an intense pulsed electric field increase permeability
and conductivity of their membranes. Each biological cell is sur-
rounded by a cell membrane. The cell membrane consists mainly
of phospholipids, which in aqueous conditions, due to its proper-
ties, form a bilayer. The bilayer is a stable structure [1] and due to
its nonpolar interior, almost impenetrable for polar molecules, dis-
solved in the aqueous electrolyte. The resting transmembrane
potential is in a range of few tens of mV, due to the distribution of
ions between the cell exterior and interior [2]. If an external elec-
tric field is applied to a biological cell or tissue, the local electric
field in the cell and their surroundings is disturbed. The imposed
transmembrane voltage superimposes to the cell resting potential.
The electrical field “amplifies” in the cell membrane, as the elec-
tric potential difference is established across the membrane. The
induced transmembrane voltage is conditioned by the orientation
of the cell regarding the applied electric field and cell shape.
Therefore, due to the pulse application, transport through the cell
membrane can be affected, cells can be stimulated, and if the
applied electric field is high enough, pulse application can also
lead to electroporation of the cell membrane.
According to current understanding, the electroporation is
based on the formation of aqueous pores in the lipid bilayer [3–5].
Pores enable the ionic and molecular transport over otherwise
impermeable membranes during the pulse. Experimental observa-
tion of the pore formation was not successful with known techni-
ques, but molecular dynamic (MD) simulation and statistical
thermodynamics provide convincing corroboration of pore for-
mation. Recently, it was also shown that electric pulse exposure
causes chemical changes to the lipids, responsible for the trans-
port after the pulse, and modulation of membrane proteins’
function [3].
We distinguish between reversible and irreversible electropora-
tion. In the case of reversible electroporation, the cell after the
pulse application fully recovers. Thus, through the permeabilized
cell membrane, proteins and small or large molecules can be
delivered. Additionally, if two cells are close to each other, fusion
can occur, due to electroporation. But when the damage of the cell
membrane and to the cell is too excessive, the cell dies, presum-
ably due to the loss of cell homeostasis. Electroporation is a plat-
form technology with many applications in different fields [6–9].
It is well established in medicine, where electrochemotherapy
(ECT) has been studied for more than two decades [10]. With
time, new applications developed and now nonthermal tissue abla-
tion by means of irreversible electroporation (NTIRE) [11], DNA
1Corresponding author.
Manuscript received September 3, 2019; final manuscript received December 15,
2019; published online January 31, 2020. Assoc. Editor: Boris Rubinsky.
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vaccination [12], and gene therapy [13,14] are studied in detail. In
the field of bio- and food technology, electroporation is exploited
for inactivation of microorganisms, extraction of biomolecules,
fast drying of biomass, and even cooking [8,9].
This paper aims at presenting the electroporation and
electroporation-based therapies in medicine, as a prospect solution
for socioeconomically disadvantaged people and populations.
Because portable, battery-powered, cost-efficient clinical electro-
porator is not yet available on the market, we also provide guide-
lines for future developers.
In the first part of the paper, we describe three most established
applications in medicine, with the focus on the basic mechanisms,
which should be taken into account during the development pro-
cess of a clinical electroporator. Additionally, for each applica-
tion, we specify the range of used pulse parameters. In the second
part of the paper, functional requirements for each of the previ-
ously described applications, safety guidelines, where we focus on
compliance with medical device standard and FDA requirements,
are defined. In the end, the focus moves to quality assurance and
measurements.
2 Electroporation-Based Medical Applications
All electroporation therapies could be used at low cost and in
areas with limited resources. Electroporator can be transportable
and battery-powered and in case of wide pulse parameter range,
could be, in combination with custom made electrodes, used for
different medical applications (described below). Currently, elec-
trodes for ECT and IRE are for single-use and quite expensive;
however, this cost could and should be reduced with an increase
in the use. The electroporator user interface can be developed in a
way to facilitate the use; nevertheless, the device operator should
be familiar with at least basic mechanisms of electroporation,
meaning training is required. Electroporation-based therapies are
safe, with little or no side effects, reduce stays in the hospital, can
facilitate or replace surgeries and at the same time improve the
quality of patient’s life’s, can be performed in an outpatient basis,
and are therefore a promising application for introduction to the
clinical practice all around the world. In this section, three appli-
cations are described, with the focus on the used electrical pulse
characteristics (Fig. 1).
2.1 Electrochemotherapy. The leading electroporation-
based therapy is ECT, an antitumor therapy [15–17], at which
after injection of the chemotherapeutic drug, locally applied high
voltage electric pulses trigger transient permeabilization of cells
in a tissue. In the case of an adequate application, all tumor cells
[18] get permeabilized, meaning the diffusion, of previously
injected chemotherapeutic drug into the cells is thus facilitated.
This results in higher cytotoxicity [19] of injected drug. Bleomy-
cin is the most utilized drug for ECT and the intravenous infusion
is the most common, while Cisplatin is injected intratumorally
[20]. For the success of the application, drug concentration in the
treated area should be sufficient and the whole tumor should be
exposed to high enough electric field [21]. ECT can be easily
repeated, in case of tumor progression or in cases where tumor
does not completely respond to ECT after the first treatment. ECT
is highly effective, with complete response rates between 60%
and 70% and objective response rates about 80%, after a single
treatment [10]. It is suitable for the treatment of cutaneous and
subcutaneous tumors of different histotypes, both skin and non-
skin cancers, as well as metastases. In the last few years, ECT has
also been established in deep-seated tumors, including bone
metastases, liver malignancies, and pancreatic and prostate can-
cers, and gastrointestinal tumors. Additionally, lung and brain
tumors are currently studied as potential future targets [22]. ECT
is a treatment of choice especially when tumors are located close
to major blood vessels and consequently not manageable with sur-
gery [23]. European Standard Operating Procedures of Electro-
chemotherapy (ESOPE) have been established in 2006 [24];
however, SOP only defines ECT for skin tumors smaller than
3 cm in diameter. Therefore, an update of SOP was published in
2018, which provides guidelines for the treatment of primary and
metastatic tumors (also> 3 cm) of the skin, based on broad expe-
rience across treatment centers and medical specialties [20].
National Institute for Health and Care Excellence (NICE), in the
United Kingdom, has recognized ECT as an integral part of the
multidisciplinary treatment for patients with skin metastases of
nonskin origin and melanoma (NICE interventional procedure
guidance IPG 446) [25]. For easier understanding of the ECT pro-
cedure, we suggest watching the video published in the Journal of
Visualized Experiments [26].
A combination of ECT with immunotherapy, GET, radiother-
apy, as well as calcium electroporation are promising novelties on
the ECT field [22]. Calcium electroporation has been investigated
in vitro, in vivo, and in early clinical trials, and it lends itself as
safe inexpensive antitumor treatment [27]. A drastic increase of
intracellular calcium concentration triggers necrotic cell death,
due to acute energy depletion [28]. Calcium affects normal and
malignant cells differently (malignant cells are more sensitive to
calcium electroporation); it can be administered by other medical
professionals (not only oncologists), it is nonmutagenic, and has a
long durability [29]. Therefore, calcium ECT seems specifically
advantageous for economically and socially disadvantaged coun-
tries. However, calcium electroporation is currently performed
mainly for tumors localized to the skin and in combination with
intratumoral injection, additional attention should be paid to the
risk of necrosis. According to first results, calcium electroporation
response rates are comparable to bleomycin ECT rates [30] and
the same electroporation device can be used for both. In classical
Fig. 1 Three most established electroporation-based medical
applications: (a) ECT: after chemotherapeutic drug injection,
electroporation pulses are delivered to the cell. Electroporation
of cell membrane is triggered, which results in increased trans-
port of the drug in the cell interior. (b) IRE: after the pulse deliv-
ery, the cell dies, due to the loss of homeostasis. (c) GET: the
injected DNA migrates to the cell membrane, where it is due to
electroporation and electrophoretic force, transferred into the
cell interior. DNA then migrates toward the nucleus, where it is
transported across the nuclear envelope. Afterward, the result
of successful GET is gene expression, which can be used for
gene therapy and DNA vaccination.
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ECT and calcium electroporation, eight square wave 100 ls long
pulses with a repetition rate of 1Hz or 5 kHz are most commonly
used (To ensure electroporation, the electric field in tissue should
be higher than 400V/cm [31].). Pulse voltage amplitude is elec-
trode (distance between the electrodes) and target tissue-
dependent; in most cases, it is somewhere between 200 and
1000V in case of skin electroporation and up to 3 kV for deep-
seated tumors. Also, a 5 kHz pulse repetition rate is more common
due to shorter duration of electroporation; the sensation of only
one application of electric pulses (less pain), meaning muscle con-
traction is present after the pulse application and an electrode dis-
placement due to muscle contraction during pulse delivery is
therefore reduced. The SOP [20] in detail defines treatment
choices, including pretreatment examinations, anesthesia, drug
injection, electrode selection, and characteristic of electric pulses
for treatment with a Cliniporator device from IGEA. If a device or
electrodes from other manufacturers or custom-made electrodes
are used, the electric pulse characteristic should be adjusted to
comply with requirements in the SOP.
2.2 Irreversible Electroporation. IRE or NTIRE-
nonthermal irreversible electroporation is a promising application
for ablation of nontumor and tumor tissue. The cells primarily die
due to membrane permeabilization and not due to the increase of
tissue’s temperature [32,33]. However, a local temperature
increases around the electrodes and can be significant at higher
amplitudes, also due to the high number of pulses delivered to a
limited volume of tissue [34,35]. It was shown that IRE does not
cause denaturation of proteins and is not affected by blood flow.
Additionally, rapid activation of the immune system, no scarring,
and the potential ability to treat tumors near large blood vessels
were observed [11]. In case of irreversible electroporation of
tumor tissue, the same as in ECT, all tumor tissues should be cov-
ered with a high enough electric field; however, for IRE, the elec-
tric field should be above the IRE threshold, which is around
700V/cm [11,36] for approximately 100 pulses. Therefore, to
cross the IRE threshold, applied pulse amplitudes go as high as
3000V, meaning current amplitude values can reach up to 50A
[37] (similar values can also be reached at ECT of deep-seated
tumors). The number of applied pulses at IRE is most often above
90 and the pulse duration is around 100 ls. Because the standard
operating procedures are not yet defined for the IRE, the pulse
parameters of delivered pulses are much more diverse. In addition,
an individual treatment plan is required for each specific tumor
and is crucial for a successful outcome. IRE is mainly used for the
treatment of deep-seated tumors either during open surgery or per-
cutaneously in the liver, pancreas, kidney, lung, and other organs
[38]. Because electric fields applied in IRE can cause cardiac
arrhythmias, synchronization of pulse delivery with the refractory
period of the cardiac rhythm is necessary [39]. The additional
issue at IRE is muscle contractions [40], which are associated
with the high voltage amplitudes and a large number of pulses
delivered at a low repetition rate to avoid excessive tissue heating.
Therefore, general anesthesia and neuromuscular blocking agents
are necessary to prevent muscle contraction [11]. Recently, in a
series of studies, authors showed that by applying bursts of high-
frequency bipolar pulses also termed as H-FIRE (High-Frequency
IrReversible Electroporation) pulses, muscle contractions can be
avoided, without compromising the nonthermal mechanism of
cell death [41,42]. Every single monopolar pulse is replaced by a
burst of few microsecond long bipolar pulses, with a repetition
rate in ranges of few hundred kHz, while the repetition rate of the
burst stays the same as pulse repetition rate at IRE. Additionally,
in the case of H-FIRE, even the electric field distribution is more
homogeneous. Also, the transmembrane transfer of molecules
may be achieved with bursts of short few microsecond long
pulses; however, H-FIRE pulses need considerably larger voltage
amplitudes for cell disruption in comparison to longer monopolar
pulses [43]. Recent reports offer the possibility to use H-FIRE
pulses in electrochemotherapy, but again, at the expense of higher
electric fields than in classical ECT [44].
Tissue ablation with IRE would enable the ablation of previ-
ously unresectable tumors. Additional, IRE is in comparison to
other treatment modalities that are easy to perform, favorable,
because the procedure time is short, and it was also shown, IRE
has a low risk of bleeding and perforation [45].
2.3 Gene Therapy and DNA Vaccination. Gene electro-
transfection is a promising non-viral gene delivery method
[13,46], used for treatment of cancer and other diseases [47,48],
regulation of protein levels to enhance or reduce function, or the
amelioration of symptoms of iatrogenic or natural disease, DNA
vaccination [49,50], and genetic modification of organisms
[51,52]. Plasmids or oligonucleotides may also be delivered to
explore promoter or gene function [53]. Facilitation of gene
expression in vivo by electroporation of plasmid DNA has impli-
cations for both vaccine and gene therapy applications [12].
Electroporation promotes antigen, oligonucleotides, and immuno-
modulatory molecule delivery into tumor tissue, which then stim-
ulate the immune system or act on immunosuppressor genes [54].
Plasmid DNA should be injected before electroporation and
should be always delivered to the tissue placed between the elec-
trodes. After or during the electroporation, the cell membrane
interacts with injected plasmid and forms a DNA-membrane com-
plex, which is then transported through the cytoplasm to the
nucleus. The electroporation has to be reversible because, after
the pulse delivery, the cells have to express transferred genes [55].
Great variety of pulses with different pulse parameters are used in
this field, both high-voltage short-duration pulses (few hundred ls
long pulses and local electric fields around 400V/cm (HV)) or
low-voltage long-duration pulses (from few to hundreds ms long
pulses and local electric fields of few tens V/cm (LV)) or even the
combination of both. In some studies, it was suggested that HV
pulses are crucial for permeabilization of the cell membrane and
pore formation, while LV pulses electrophoretically drag nega-
tively charged DNA into the cell [56]. In other studies, the authors
proposed the change of electric field direction or orientation of the
electrodes during the pulse delivery; thus, the area of DNA entry
is enlarged (because DNA transfection occurs only in the part of
the membrane facing the cathode) [57]. Additionally, nanosecond
pulses with a duration from few to hundreds of nanoseconds and
electric field densities up to several tens of kV/cm are currently
studied, because it is believed that they affect internal cell mem-
branes and may contribute to increased delivery of plasmid to the
nucleus [58]. Overall, it was proven that longer electric pulses
give higher transfection efficiency, but they reduce cell viability
and shorter pulses give lower transfection efficiency and preserve
viability.
In the field of DNA vaccination by electroporation, mainly
intramuscular (IM) and intradermal (ID) delivery are studied. The
muscle is an attractive tissue for nucleic acid vaccination in a clin-
ical setting due to the accessibility and abundance of the target tis-
sue [59]. Skeletal muscles promote strong humoral and cellular
immune responses; however, muscle fibers are quite ineffective in
plasmid capture. Therefore, for a successful application, a large
volume of plasmid should be injected. The expression of plasmid
DNA in the muscles can be prolonged and increased by electropo-
ration. It was reported that by electroporation, the antigen delivery
increase up to a 1000 fold over naked DNA delivery alone can be
reached [50]. Currently, the development of delivery systems and
research in the field of DNA vaccination by electroporation are at
full swing [60]. Clinical studies of electroporation in the muscle
showed the procedure is well tolerated by patients.
HIV, Human papillomavirus (HPV), Hepatitis C, and cancer
DNA vaccination by electroporation are currently investigated
[14]. For cancer gene therapy, viral delivery methods such as
immune modulators, cell cycle regulators, suicide genes, anti-
angiogenic genes, and genes encoding toxins are used and
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electroporation mediated delivery is studied. It was shown that the
most successful cancer therapeutic genes, delivered by electropo-
ration, which results in significant tumor regression are IL-12 and
IFN-a [48,53]. However, studies [61,62] also determined that opti-
mization of electroporation pulse characteristics have a major
impact on the success of the application; therefore, further
research is necessary. Because vaccination is generally regarded
to be one of the most cost-effective interventions in public health,
we believe DNA vaccination with electroporation is the most
promising application for implementation into economically dis-
advantaged populations. DNA is more heat stable, easier to pro-
duce and store than current vaccines [63]. The transport from the
manufacturing to injection into the patient is easier and therefore
cheaper, because DNA is more heat stable, and easier to produce
and store than current vaccines.
3 Medical Devices for Electroporation
As presented in Sec. 2, different applications require different
pulse parameters, such as voltage amplitude, pulse width, pulse
repetition rates, and a number of pulses or even bursts of pulses
[64,65]. Therefore, specific pulse generators, i.e., electroporators,
have to be designed and developed for each application. When
designing an electroporation device, one should always keep in
mind that biological sample/tissue as a load has resistive–
capacitive nature and varies from sample to sample. Additionally,
also the impedance of a biological load decreases during the pulse
delivery, due to electroporation [66,67].
A considerable number of electroporation devices can be found
on the market, some designed for specific applications and
some for multifunctional laboratory use. Several reviews have
been published, in which pulse characteristics of commercially
available electroporators are described [68–70]. But for the incor-
poration of an electroporator into the clinical practice, an electro-
porator has to follow the requirements appointed by local medical
regulations and meet medical device standards. In Europe, it has
to comply with a Medical Device Regulation 2017/745 and in the
United States, the device should be approved by the FDA (Food
and Drug Administration). The process of incorporation of a med-
ical device in clinical practice in developed countries is thus well
established. After the development process and collection of con-
siderable scientific evidence for devices’ safety and effectiveness,
the first-in-human study is performed, followed by the evaluation
of the device in clinical trials, culminating in regulatory approval
for use and the adoption of the device [71]. The European CE
Mark adoption process requires demonstration of safety, quality,
and efficacy and nongovernmental notified bodies regulate the
approval and postapproval. While in the United States, demonstra-
tion of safety and efficacy is required and regulated by a central
governmental agency (FDA) [72]. All clinical trials, studies, or
testing have to be authorized by the FDA. And even after a medi-
cal device is made available on the market for use, regulations
have been established to ensure ongoing postmarket surveillance
of device safety and effectiveness [73].
In Europe, currently there are only five certified clinical electro-
porators, the Cliniporator 2 and Cliniporator VITAE (IGEA
S.p.A., Italy), available for ECT and GET, SENNEX (BionMed
Technologies, Germany), that is only used for ECT, NanoKnife
(AngioDynamics, USA), which may be used for soft-tissue abla-
tion and ePORE (Mirai Medical, Ireland) that is compatible with
the EndoVE, which enables a targeted treatment delivered within
minutes in an outpatient endoscopy setting. In the United States,
the FDA clearance was granted to NanoKnife (AngioDynamics,
USA), first for the soft-tissue ablation and recently also for
“Direct IRE Cancer Treatment” clinical study (DIRECT), for the
treatment of stage III pancreatic cancer. Nevertheless, it has not
received clearance for the therapy or treatment of any specific dis-
ease or condition. Unfortunately, none of those devices is actually
appropriate for implementation in economically disadvantaged
populations. The first issue is the cost, for example, a Cliniporator
device is sold for 100,000 e (without VAT) and each electrode
that is for single-use cost 1200 e and sometimes, more than one
set of electrodes per treatment are used. Few cost-effectiveness
studies of ECT have been done [74,75], but none of them have
taken into account also the increase in the quality of life of
patients after the ECT. Therefore, the use of ECT even in devel-
oped countries is sometimes hard to justify. Additionally, none of
the existing clinical electroporators is battery-powered or easy to
transport. Therefore, in the following part of the paper, we provide
guidelines for future electroporator manufactures, based on our
experiences. No relevant cost-effectiveness or economic studies
have been published yet; therefore, it is hard to evaluate its poten-
tial for implementation in economically disadvantages population.
However, in the case of the development of a low-cost electropo-
rator for all presented applications it can have potential for
implementation.
3.1 Functional Requirements. For successful electropora-
tion and development of a quality and reliable electroporator, it is
crucial to understand what needs to be achieved when applying
electric pulses. Because different applications require different
electric pulse characteristics, and because biological loads vary
considerably, specific electroporators are designed for each appli-
cation. However, it is possible to develop a device that could be
used for all presented medical applications. Micro- and milli-
second square wave pulses are usually generated by an HV power
supply switching circuit, with fast power MOSFET or IGBT used
as switches [76–79]. The simplest and most cost-efficient solution
is a square wave generator concept shown in Fig. 2. The solution
is similar to the capacitor discharge circuit; the voltage power sup-
ply V constantly charges the capacitor C. Pulse duration, pulse
repetition rate, and a number of pulses are defined by the switch-
ing sequence, meaning the switch has to be driven by a precise
and adequate driving/control system. The output pulse amplitude
is defined by the set amplitude of the variable power supply. To
minimize a voltage drop on the load, all the required energy must
be generated and stored in the capacitor before each pulse deliv-
ery. Meaning large capacitor or capacitor banks are needed, espe-
cially in the case of IRE, where applied pulse voltage amplitudes
are as high as 3 kV and at least 90 pulses are delivered. For the
development of a nanosecond electroporator, more complex cir-
cuit designs are required such as a transmission line approach
(Blumlein line) and diode opening switch and even faster switches
are needed, mainly Radio Frequency MOSFET (RF-MOSFET) or
Silicon Carbide MOSFET (SiC MOSFET) are used [80]. For the
bipolar pulse generation, an H-bridge solution is the most estab-
lished. The short rise time of high voltage pulses is provided by
modular generator and short fall times can be achieved by short-
circuiting of the load [81].
For specific treatments (i.e., applications, treatment locations),
special application-optimized electrodes are used. SOP [20]
Fig. 2 Square wave generator concept. Switch S discharges
capacitor C, through the load. The capacitor C is constantly
charged, by a variable voltage source V. The amplitude of the
generated pulse is equal to the set voltage of the source. The
voltage drop during the pulse is capacitance, load impedance,
and pulse duration dependent and should not exceed 10% of
the set voltage V.
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describes the appropriate use of different electrodes available for
ECT in combination with the Cliniporator device. An electropora-
tor should be compatible with different electrode types. However,
the device should recognize the electrode type and adjust the out-
put pulse parameters in accordance with the treatment modality.
For example, if the distance between the electrodes is larger, then
the pulse amplitude should be increased, to ensure the same elec-
tric field in the targeted tissue. An important part of the clinical
electroporator, from the prospect of the use, is a user interface.
Devices for the clinics should be as user-friendly as possible. To
prevent misuse and mistakes, the output pulse characteristic
should be preprogrammed for specific electrodes and treatment
protocols. Meaning the user only selects, i.e., electrode type.
However, in the case of deep-seated tumors, where anatomy is
more complex, or due to the inability to cover the whole tumor
due to its size, with standard electrodes, several single-needle
electrodes are used [82]. Special treatment plans are designed for
each therapy, to ensure the optimal configuration of the electrodes
that adequately cover the tumor with high enough electric field.
Meaning, a custom setting of the pulse parameter should be
enabled in this case. Due to safety reasons, clinical electroporators
are armed by the user, just before the pulse delivery. When
capacitors are charged, the device is ready for pulse delivery;
however, this active time is limited to a few seconds. If the device
is not triggered and pulses are not delivered, it should self-
discharge. In the case of IRE and ECT of deep-seated tumors, the
pulse delivery should also be synchronized with cardiac rhythm.
Both charge and delivery triggers should be made in the form of a
pedal or enabling button on the handle, in a way not to obstruct
the user. An electroporator should have a built-in measuring sys-
tem, with an adequate bandwidth. The current and voltage should
be constantly monitored to ensure the pulse delivery, with the
sampling frequency that is equal or higher to twice the highest fre-
quency contained in the measured signal. The real-time oscillo-
scope like display of the measurement is desirable but not
mandatory. Nevertheless, at least the measured amplitude values
of delivered voltage and current should be displayed as feedback
and saved for post-treatment analysis if necessary. The evaluation
of the delivered pulses is necessary, the device can self-evaluate
the delivered pulses, or this can be done by the operator if
adequate data are displayed.
3.2 Safety Guidelines. A clinical electroporator has to com-
ply with the general standard for basic safety and essential perform-
ance of medical devices, EN/IEC 60601-1 [83]. The manufacturer
should ensure that the risk is removed, or if not possible, the risk
should be minimized. Therefore, manufacturers have to pay
particular attention to choosing adequate voltage insulation, limit
leakage currents in accordance with the safety class, limit the output
voltage, current and energy and to ensure electromagnetic compati-
bility by following the standard EN/IEC 60601-1-2 EMC for medical
devices.
Safety class of the electroporator is defined by its most risky
application. We distinguish between invasive and noninvasive
electroporation. If the device is made for more treatment modal-
ities, it should be classified on the basis of the one that represents
the highest risk. The same applies to the location of treatment; if
the device can be used in surgery for deep-seated tumors, then the
location with the highest risk has to be taken into account. Both
Cliniporator EPS02 and Cliniporator VITAE have been in accord-
ance with EN 60601-1 classified as Class I regarding the protec-
tion against electrical risks and class BF regarding the protection
against electric shock. Cliniporator EPS02 in accordance with
MDD 93/42 CEE classified as IIa, while Cliniporator VITAE is in
class IIb. Additionally, also the following standards have to be
considered: ISO 14971 for risk analysis, ISO 13485 for the quality
management system, EN/IEC 60601-1-6 and ISO 62366 for
usability, ISO 62304 and IEC 80002-1 for medical device soft-
ware, and IEC 62311 in case of a battery power supply.
3.3 Quality Assurance. Currently, electroporation research
and applications are developing fast and growing; therefore, the
number of electroporators available on the market is increasing
even faster than before. Unfortunately, the quality of some devices
is questionable [70]. Some manufacturers intentionally conceal
the output pulse parameters of their devices, claiming that it is
their intellectual property. The critical point on the field of in vitro
gene transfection, where preprogrammed electroporation proce-
dures are most commonly used by researchers, without even
knowing basic pulse parameters such as amplitude and pulse dura-
tion [70]. The concealed operation of electroporation devices hin-
ders sharing, comparing, and reproduction of results; it limits and
restricts researchers and further development of the new knowl-
edge. In the electroporation field as well as in general biomedical
research, the increase in failed efforts to confirm other group’s
published papers work is significant [84]. We believe this is at
least in part due to poor quality assurance. Measurement of elec-
troporation pulses is crucial to adequately determine and control
the quality and the delivery of pulses. Even the International Med-
ical Device Regulators Forum (IMDRF) gave the harmonization
initiative and proposed mutual recognition encouraged by WHO.
They engage an external consultant to conduct a more detailed
study to examine overseas experience and practices of, and the
scope of control on the use of, electroporation medical devices.
We can conclude that standardization regarding quality is neces-
sary; however, electroporation is a platform technology, and spe-
cific testing protocols for each application or field should be
established eventually. Nevertheless, some basic technical specifi-
cations and tolerances can be applied to all electroporators. Cur-
rently, the manufactures often give ill-defined technical
specification, defined pulse parameter ranges cannot be used with
all biological loads and/or in all possible combinations. Meaning,
for example, in case of low impedance load the number of pulses
or pulse duration and the voltage range are limited. Therefore,
before actual experiment, the researchers cannot know, if the
device will be able to deliver what it promises. Thus, we address
the future developers of electroporator medical as well as labora-
tory to follow the recommended guidelines.
Each device is designed for precisely defined maximal current
and some limitation is necessary, for the protection of the device
itself. Manufacturers should define the maximal current and the
principle of current limitation. Some devices use a pre-pulse to
evaluate the load and then adjust the pulse parameter range, in a
way to disable the current to go over the limit. If pre-pulse is
used, the amplitude and pulse duration should be as low as possi-
ble, but the pause between the pre-pulse and preset electroporation
pulses should be long (All processes triggered by the pre-pulse
must be extinguished before the delivery of actual electroporation
pulses.). Pre-pulse parameters should be given in detail in techni-
cal specifications (e.g., the amplitude, pulse duration, and exact
timing of the pre-pulse regarding the electroporation pulses).
Other devices measure the current on the output and then stop the
pulse delivery when the current value is too high. Such a meas-
uring system should be fast enough to assure the disconnection
within the pulse rise time and in this case, the user should be
informed about the interruption of pulse delivery. The third solu-
tion is to build in an electroporator an additional impedance,
which limits the output current. Meaning that the device will
never be able to generate higher current than maximal current and
will, therefore, reduce the applied voltage. Again, in this case, the
user should be informed about the alternation. Therefore, we pro-
pose the following solution. The manufactures should define
applications for which the device is made, and then provide the
technical specification and tolerances in accordance with the typi-
cal load for those applications, e.g., voltage: 200–1000V (for
loads with impedance higher than 50 X and for pulse durations up
to 1ms (NMAX¼ 10); 200–2000V (for loads with impedance
higher than 100 X and for pulse durations up to 100 ls
(NMAX¼ 10);); …, where NMAX is the maximal number of pulses.
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On the base of the literature review [66,85–87], our experiences,
and current status of technology, we defined the tolerance of the
voltage amplitude and pulse duration. Meaning the requirements
could be easily fulfilled, with the available electronics and circuit
solutions. Published permeabilization and cell survival curves
[66,85–87] indicate that more than 15% deviation can result in
significantly different electroporation outcome. However, in case
of in vivo electroporation, an additional error can be present in
electrode placement, treatment planning, muscle contractions
(present during the pulse delivery) or other unexpected circum-
stances. Because the total tolerance is equal to the sum of all toler-
ances, which may exceed 15%, the developers of electroporation
devices should at least follow the state-of-the-art tolerances.
Meaning the requirements could be easily fulfilled, with the avail-
able electronics and circuit solutions. Therefore, the recom-
mended voltage amplitude tolerance is 10%; thus, the applied
voltage amplitude should not be lower than 90% or higher than
110% of preset voltage. Meaning also the voltage of the first to
the last pulse should be in this range. The pulse duration should
be defined as Full Width at Half Maximum (FWHM) and a devia-
tion from the preset value should not be higher than 8% [85,86],
as shown in Fig. 3. The proposed tolerances must be fulfilled,
from maximal to minimal settings, which are: maximal pulse
amplitude, maximal pulse duration, the maximal number of
pulses, and minimal pulse repletion rate when the pulse is applied
on a typical load for an application that it is made for. Meaning
the list of applications should be defined and a typical load for
each of those applications should be developed. Additionally, also
electrodes should be standardized and tolerances of the distances
between the electrodes, appropriate materials and in case of multi-
ple use, also sterilization and maintenance should be defined. A
clinical electroporator should constantly self-test the operation,
and periodic evaluation and calibration of the device are manda-
tory. The tolerances defined in this section address the “classical”
electroporation and are not applicable to the nanosecond electro-
poration, where pulse duration may be the dominant source of
deviation.
3.4 Usage Guidelines. Each user as well as developer, of
electroporation-based therapies, has to be familiar with basic elec-
troporation mechanisms; therefore, education (e.g., www.ebtt.org)
and training (e.g., ESSO course on ECT) are necessary. The
application can be successful, only if the applied electric field
covers the whole targeted area and if induced voltage is higher
than the reversible or irreversible electroporation threshold volt-
age. It should always be taken into account that the tissue is not
homogeneous, meaning the electric field, to which the biological
load was exposed during the pulse delivery, cannot be evaluated
simply by equation (E¼U/d), which defines an electric field as
the ratio of applied voltage amplitude and distance between the
electrodes. This equation is only valid if the load between the
electrodes is homogeneous and plate electrodes are used and the
distance between the electrodes is small with respect to electrode
dimensions. The operation of an electroporator has to be always
monitored; only by adequate measuring, the quality of the pulse
delivery can be assured. We need to measure because we need to
know, if the pulses were successfully delivered and we need to
know, what was delivered. If the current flows through a load,
delivery was more or less successful, but we still do not know
anything about the pulse characteristics of the delivered pulses. If
an electroporator has a built-in measuring system, the user has to
evaluate the quality of measurements displayed by the electropo-
rator. Due to the poor regulation of the electroporation field and
lack of standard, the quality of built-in measurement systems is
sometimes questionable. Because of a large variety in the electri-
cal characteristic of biological loads/tissues, the user has to be
familiar with common errors in pulse delivery. When biological
loads have low impedance, problems can occur because the pulse
generators cannot deliver “what they promise,” i.e., high voltage
pulses due to too high currents. Or the amplitude of successive
pulses can be lower with each successive pulse delivered, if the
pulse repetition rate is in the higher half of device operation range,
meaning that the electroporator’s energy storage is not sufficient.
In the worst case, the voltage amplitude can even be lower than
electroporation threshold voltage [70]. Additionally, also each
user should be familiar with the guidelines for reporting electropo-
ration clinical studies [25].
4 Discussion
Electroporation-based therapies have a huge potential for
implementation into clinical practice in socioeconomically disad-
vantaged populations. Electrochemotherapy is easy, quick to per-
form, and inexpensive. Only suitable room for patient preparation
and treatment, an electroporator with suitable electrodes, a physi-
cian in charge, and a nurse (and an assistant trained in handling
the electroporator) are required for treatment of cutaneous tumors
and skin metastases. Because the treatment is safe, with mainly no
side effects, a patient can wait for a while in the hospital for the
observation, but do not need to spend a night. The treatment can
be performed on any part of the body, on different tumor types
with the same electroporation device, only appropriate electrodes
have to be selected [88]. The SOP [20] should always be followed.
Calcium electroporation is even cheaper because calcium is com-
mercially available and regularly used in most hospitals. It can
administer by other medical professionals (not only oncologists);
it is nonmutagenic and has long durability. Additionally, calcium
has an excellent safety profile, both for use in patients and for
staff, and would not need administration by staff accredited to
administer chemotherapy [27]. However, calcium can only be
used for tumors localized in the skin and has to be administered
locally.
The main advantages of IRE are apoptotic cell death, the sharp
boundary between the treated and untreated areas, and the overall
time for the procedure is extremely short in comparison to bench-
mark ablation treatments. The pulse application lasts only a few
minutes; actual time can be calculated from the number of deliv-
ered pulses and average heart rate [89,90]. IRE also enables the
ablation of tumors in areas previously contraindicated for thermal
ablation [90].
Gene therapy by electroporation is a highly efficient method,
with delivery efficiency better than many non-viral vectors [91]. It
Fig. 3 The applied voltage amplitude should not be lower than
90% or higher than 110% of preset voltage. Meaning also the
voltage drop between the first and last pulse at the maximal
number of pulses should be in this range. The pulse duration
deviation from the preset value should not be higher than 8%.
The proposed tolerances must be fulfilled in case of maximal
settings, which are: maximal pulse amplitude, maximal pulse
duration, the maximal number of pulses, and minimal pulse
repletion rate when the pulse is applied on a typical load for an
application that it is made for.
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substantially increases DNA delivery and DNA vaccine potency.
The preclinical development of electroporation is focused on tis-
sues that are easily accessible and the application technique is
simple and takes only a few seconds after DNA injection. Electro-
poration is a useful strategy to improve DNA-based vaccination
protocols; it stimulates both the humoral and cellular immune
responses and if necessary, they can contain several antigen epi-
topes [49]. Additionally, DNA is more heat stable, easier to pro-
duce and store than current vaccines [63]. The transport from the
manufacturing to injection into the patient is easier and therefore
cheaper, meaning it is perfect for warm climates like the African
continent. They do not display an environmental hazard since
there is no risk of replication and only contain the antigen
encoded [63].
Because different applications require different electric pulse
characteristics, and because biological loads vary considerably,
specific electroporators are designed for each application. How-
ever, it is possible to develop a device that could be used for all
presented medical applications. But, the price of such a device
would rise, the certification process would be more challenging,
and the size and weight would increase in comparison to a single
application device. A battery-powered electroporator would ena-
ble DNA vaccination even in areas without electricity. Currently,
the price of electroporation is relatively high, but custom low
budget devices can be developed. Even cheap single-use electro-
des, with mass production or multiple-use electrodes with a
defined sterilization process, would significantly reduce the price
of electroporation.
5 Conclusions
Electroporation is a platform technology, with high potential, it
can reduce cost and facilitate treatment procedures. According to
the ongoing studies the electroporation-based therapies are safe,
with little or no side effects [7]. The clinical data published on
electroporation based applications are quite encouraging; there-
fore we believe, that in the future, electroporation will be indis-
pensable in cancer treatment, infection disease treatment,
intracardiac ablation [92], and vaccination [91]. Further develop-
ment of standard electroporation treatment protocols, regulation
of electroporator development, and user training, however, remain
essential for successful incorporation into clinical practice.
Electroporation-based therapies have a huge potential for imple-
mentation into clinical practice also in socioeconomically disad-
vantaged populations. Currently, the price of electroporation is
relatively high, mainly due to costly electroporators and electro-
des, but custom low budget devices can be developed. It is not
technically difficult to develop an electroporator, more challeng-
ing is the quality assurance, because biological loads characteris-
tics vary considerably from sample to sample and even more from
tissue to tissue. Therefore, measuring of applied electric pulses is
crucial for a successful application.
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“Electroporation-Based Technologies for Medicine: Principles, Applications,
and Challenges,” Annu. Rev. Biomed. Eng., 16(1), pp. 295–320.
[8] Kotnik, T., Frey, W., Sack, M., Haberl Meglič, S., Peterka, M., and Miklavčič,
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1 
Towards standardization of electroporation devices and protocols 
Aleksandra Cvetkoska, Eva Pirc, Matej Reberšek, Ratko Magjarević, Damijan Miklavčič 
Cell exposure to high-voltage, short-duration electric pulses can lead to temporary formation 
of hydrophilic pores in the plasma membrane and increase of membrane’s permeability which 
consequently increases the transmembrane transport of molecules that are otherwise unable to 
cross the membrane. This phenomenon termed as membrane electroporation is currently an 
applicable technique in different areas such as biomedicine, biotechnology, food technology 
and environmental applications. Electroporation pulses are generated by pulse power 
generators known as electroporators and delivered to the cells (in tissue) via electrodes. The 
objective of this paper is to review and compare characteristics of the electroporation 
applications and equipment described in literature and/or present on the market. Since there are 
no specific standards or regulations referring particularly to the safety of medical devices with 
intended medical use for electroporation, we propose guidelines for the design of clinical 
electroporators and define minimal requirements for their safe and efficient use which can be 
incorporated within the particular standard in the future. In order to facilitate the comparison 
of the data obtained by different research groups and to enable reproduction of results under 
the same conditions, we want to stress the necessity of defining the electroporator’s output 
parameters and define tolerances of electroporation parameters for electroporation-based 
therapies.  
Introduction 
The phenomenon of electroporation 
Each biological cell is protected from its surroundings by the plasma membrane which is 
composed of a two-molecule thick layer of lipids. The plasma membrane would be a mostly 
impenetrable barrier if there were not various proteins, which enable transport of specific 
molecules across the membrane. However, cell exposure to high-voltage, short-duration 
electric pulses can lead to temporary formation of hydrophilic pores in the bilayers and increase 
of plasma membrane permeability which consequently causes increase in transmembrane 
transport of molecules that are otherwise unable to cross the membrane [1]. This phenomenon 
termed as membrane electroporation/permeabilization can be either reversible, when the cell 
exposure to electric field is short enough for the cells to fully recover; or irreversible, when 
their exposure leads to cell death.  
Electroporation applications 
Electroporation has become a relevant technique in different areas such as biomedicine, 
biotechnology, food technology and environmental applications [2]. Reversible electroporation 
is already a well-established method in medicine, which combined with administration of 
otherwise low-permeant chemotherapeutic drugs to tumor cells, results in highly efficient local 
antitumor therapy called electrochemotherapy (ECT). Locally applied short, high-voltage (HV) 
pulses in the range of few hundreds of volts to few kilovolts increase the permeability of tumor 
cells membranes in order to facilitate cellular uptake of chemotherapeutic drugs like bleomycin 
and cisplatin, thus increasing their cytotoxicity [3]. Electroporation is also used for cell gene 
transfection, i.e. gene electrotransfer (GET), which is a non-viral gene delivery method that 
uses reversible electroporation for delivering DNA molecules to cells. Skin and muscle are 
promising targets for gene delivery, thus GET has been used in many medical applications, 
including vaccination, wound healing and cancer treatment. On the other hand, the potential of 
irreversible electroporation in medicine appeared as a nonthermal irreversible electroporation 
(NTIRE), also termed Pulsed Field Ablation (PFA), which has enabled the ablation of 
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undesirable (malignant or arrhythmogenic) tissue with minimal damage to blood vessels and 
nerve conduits in the treated area [4]. Furthermore, electroporation emerged in different 
applications of biotechnology [5] and it is efficiently utilized for heritable genetic modification 
of microorganisms (electrotransformation), extraction of biomolecules, inactivation of 
microorganisms, and improving the mass transport in food processes. Some of the applications 
of electroporation are presented on Fig. 1. 
Generating electrical pulses 
To achieve successful electroporation, cells have to be exposed to sufficiently high electric 
fields (related also to duration of exposure). Electroporation pulses are electrical pulses, which 
are generated by pulse power generators known as electroporators and delivered to the cells (in 
tissue) via electrodes. Electrode geometry and tissue dielectric properties define the electric 
field intensity. Regardless of the application, electroporators have one common task: electrical 
pulses generation and delivery.  
Fig. 1. Various electroporation applications. When exposure of the cell to sufficiently high electric field reaches 
the cell membrane threshold value, the cell gets permeabilized. Membrane electroporation/permeabilization can 
be either reversible, when the cell exposure to electric field is short enough for the cells to fully recover; or 
irreversible, when their exposure leads to cell death. In case of reversible electroporation, during the 
electroporation process, molecules can be introduced into the cell (electrochemotherapy (ECT), gene 
electrotransfer (GET)) or molecules can be extracted from the cell. 
Electroporation success depends on the parameters of the delivered electrical pulses. The 
parameters of electrical pulses at the output of commercially available electroporators may vary 
in shape, voltage/current amplitude, pulse duration, number of pulses in a pulse train, and pulse 
repetition rate [6]. In electroporation, series of pulses is most commonly used for the treatment. 
If all pulses in a train/series of pulses are similar, the definition of the characteristics of only a 
single pulse and its repetition rate is sufficient for defining the treatment. The amplitude of the 
generated pulses may range from a few tens of volts (e.g. for GET) to a few kilovolts (e.g. for 
IRE) and even tens of kilovolts for microbial inactivation in liquid food pasteurization, with 
durations that range from nanoseconds to milliseconds for single pulse or train of pulses with 
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predefined pulse repetition rate. Pulses may be preset for a specific application or precisely 
defined for a particular patient.  
An electroporation pulse generator comprises a HV power supply, a pulse generator, a control 
unit, a user interface and an output module (Fig. 2). The user interface enables setting of pulse 
parameters as required for a specific application. It is preferable that the device measures the 
parameters of delivered pulses and generates warnings in case of malfunction and/or incorrect 
operation. 
Fig. 2. Block diagram of an electroporator. An electroporator comprises a user interface, to enable setting of the 
pulse; a control unit; a high-voltage (HV) power supply and pulse generator for generation and forming of 
electrical pulses; an output module, and in case of multiple electrodes, a commutator for switching the voltage 
pulses to different electrodes. Measuring of the delivered pulses is preferable and warnings in case of malfunction 
and/or incorrect operation should be generated. 
For generation of electrical pulses, HV power supply and pulse generator (for pulse shaping) 
are needed. The output module consists of an output pulse measurement unit and a commutator 
for switching high voltage pulses to different electrodes (if multiple electrodes are used).  
Electroporators for specific applications 
Electroporators are mainly classified as clinical, industrial or laboratory [7]. Electrodes 
together with the biological sample define the load for the output stage of the electroporator. 
Thus, classification of the electrodes is according to targeted load, i.e. cells (single-cell 
chambers, micro-electrodes, macro-electrodes and flow-through chambers) or tissue (plate, 
parallel needle array, hexagonal needle, finger and adjustable electrodes). Since biological 
loads as well as the electroporated volume intrinsically differ in different electroporation-based 
applications, pulses with specifically predefined parameters have to be used. Therefore, 
electroporators are often designed and developed for specific applications, where quality and 
efficiency have to be assured [8].  
Clinical electroporators 
Electroporation-based medical/clinical applications such as ECT, GET, IRE and PFA, have so 
far been focused predominantly on cancer treatments. Electroporators used for medical 
treatments in clinics, i.e. clinical electroporators, have been developed to implement antitumor 
therapy using a limited number of predefined settings of electrical pulses in associations with 
chemotherapeutic drugs (ECT) or foreign substances such as DNA (GET) within protocols 
based on reversible electroporation or as stand-alone ablation treatment based on irreversible 
electroporation (IRE). The target, e.g. tumor tissue should be covered with sufficiently high 
electric field, which should be above the threshold of reversible or irreversible electroporation 
500-600 V/cm local electric field (which often requires pulse amplitudes up to 3000 V and
currents up to 50 A), to achieve the desired effect. Therefore, HV pulse generators are needed
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which should not present potential risk for hazardous event for the patient, operator and nearby 
devices.  
Clinical electroporators are considered to be medical devices and thus, patient and operator 
safety must be ensured under both normal and single-fault conditions. Furthermore, they are 
obligated to meet medical devices’ standards and follow the requirements defined by local 
medical regulations, e.g. Medical Device Regulation 2017/745 in Europe or CFR (Code of 
Federal Regulations) Title 21 in the United States (US), in order to get approval for selling the 
device on the market, e.g. certification mark (CE) in Europe or FDA (Food and Drug 
Administration) approval in the US. In spite of agreements signed between EU and the US, a 
clinical electroporator approved for use in Europe cannot be automatically used in the US and 
vice versa, because each country has different regulatory regimes. 
Based on our review, there are only few certified clinical electroporators on the market. The 
most used clinical electroporators are the Cliniporator and the NanoKnife System. In Europe, 
the Cliniporator (two different models: Cliniporator EPS02 and Cliniporator VITAE), 
manufactured by IGEA S.p.A. (Carpi MO, Italy), used for both ECT and GET was approved 
by the Italian notified body and has CE mark. Another certified clinical electroporator in 
Europe is SENNEX (BionMed Technologies, Germany), which is used only for ECT. 
Recently, a new CE approved clinical electroporation generator ePORE (Mirai Medical, 
Galway, Ireland) was developed for simple and reliable delivery of ultra-short electrical pulses 
up to 250 kHz to enable treatment on an outpatient endoscopy basis. On the other hand, in the 
US, the NanoKnife System, manufactured by AngioDynamics, Inc. (Queensbury, N.Y, U.S) 
was approved by the FDA for surgical ablation of soft tissue [9]. Additionally, it is CE marked 
for Europe and has license approval for Canada for soft tissue ablation. However, it does not 
have FDA clearance for other treatments and therapies for specific disease or condition.  
To help verify the safety of medical devices, electrical safety standards have been established 
in the US, European countries and other parts of the world. The first medical standard for 
medical electrical equipment, IEC 60601 was published in 1977 by the International 
Electrotechnical Commission (IEC) which is a family of technical standards whose scope 
covers the safety, essential performance and electromagnetic compatibility of medical 
electrical equipment and systems. As of 2011 it consists of a general standard for medical 
electrical equipment: 60601-1 (EN 60601-1:2006/A1:2013 in EU or IEC 
60601-1:2005/A1:2012 in the US), ten collateral standards and about sixty particular standards. 
Collateral standards (numbered 60601-1-X) define the general requirements for certain aspects 
of safety and performance, e.g. Electromagnetic Compatibility (IEC 60601-1-2). Particular 
standards (numbered 60601-2-X) define particular requirements for specific products or 
specific measurements built into products and add conditions not mentioned in 60601-1 or 
explain how to simplify implementation of 60601-1 to a particular device type, e.g. cardiac 
defibrillators (IEC 60601-2-4). In spite of the sixty particular standards, a particular standard 
for clinical electroporators currently does not exist. Therefore, it will be necessary to define 
additional rules for manufacturing and safe and efficient use of clinical electroporators as 
relatively new medical devices in addition to those defined by ISO and EN/IEC standards. 
Considering the general standard for medical devices EN/IEC 60601-1, key safety factors that 
have to be considered in electroporator’s design include: voltage and energy limits, adequate 
insulation, limitation of leakage currents, electromagnetic compatibility requirements as 
presented in the standard EN/IEC 60601-1-2 and consideration of fault operations while 
maintaining quality, efficiency and smooth operation of the device. Other standards to be 
considered for developing clinical electroporators are ISO 14971 for risk analysis, ISO 13485 
for quality management system, EN/IEC 60601-1-6 and ISO 62366 for usability, ISO 62304 
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and IEC 80002-1 for medical device software and IEC 62311 in case of a battery powered 
clinical electroporator. 
Industrial electroporators 
In biotechnology and even more in food processing technology, high-power and high-voltage 
electroporators are needed due to the requirement to electroporate large volumes of liquid. In 
food processing, electroporation is more frequently termed as pulsed electric field (PEF) 
treatment used for food structure modification or liquid food pasteurization. By PEF treatment, 
permeabilization of biological cells is achieved, mass transfer is improved, and therefore an 
efficient way for extraction of liquid and valuable substances from cells is enabled. PEF 
treatment systems are usually composed of a pulse power generator and a treatment chamber.  
Depending on the application, a suitable pulse generator has to be chosen with adequate 
parameters:  
• pulse shape;
• peak voltage, which is highly depended on the desired application;
• peak current, which is determined by the object and volume being treated;
• geometry of the treatment chamber;
• average power required, depended on the desired processing capacity (kilograms/h or
liters/h).
In terms of power requirements, scale-up from several kW for laboratory to more than 100 kW 
for continuous-flow industrial-level processing was achieved. Therefore, regular average 
power of contemporary PEF devices ranges between 30 kW and 400 kW [10]. Commercial 
PEF treatment applications are mostly set up in potato (tuber) industry, fruit juice preservation, 
and vegetable processing. For juice processing, electroporation treatment systems with 
continuous flow have already been established with capacity of 8000 liters/h, whereas for 
potato processing capacity ranges up to 50-80 tons/h.   
The use of new processes applied in food industry always requires appropriate process control 
options and set up of a systematic preventive approach to food safety – HACCP (Hazard 
Analysis Critical Control Point). HACCP has seven principles that need to be followed, stated 
in the international standard ISO 22000 FSMS 2011. In the US, the adoption of different 
technologies in food processing industry is also subject to the regulation of the FDA and in EU 
it falls under the Regulation EU 2015/2283 on novel foods.  Regarding safety of the device, 
protection against electric shock in case of insulation failure is important when using the device 
in wet environments. For this reason, wineries for example, are equipped with RCD (Residual 
Current Devices) responsive to a leakage current of about 30 mA. Furthermore, 
electromagnetic compatibility according to standards is recommended. Thus, the pulse circuit 
has to be shielded with metal housing and mains and leads to the control circuity should be 
protected against over-voltage [11].  
Laboratory electroporators 
For conducting experiments in the laboratory, users can choose between several commercially 
available laboratory electroporators. Choosing the right laboratory electroporator can be crucial 
for experiments and treatment protocols as some laboratory electroporators have limited range 
and control over pulse parameters.  
Important step to be considered during electroporation is to assure pulse measuring and 
monitoring because only few electroporators can report and provide accurate measurements. 
Large variation of load characteristics is another reason to measure. The electrical properties 
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of the sample between the electrodes might affect the current delivered (conductivity 
versatility). The resistance of the cuvette, for example, can vary depending on the conductivity 
of the media which can drastically change the required current.  
However, in laboratories where experiments are done, oscilloscopes and current probes are 
often not readily available. Therefore, built-in measurement systems should be provided in 
order to be used with laboratory electroporators. The device should be able to perform self-
tests to ensure flawless operation and detect single faults. Some use “test” pulses which should 
be specified and should not affect/change the sample or influence the outcome of the result. 
Furthermore, the device should be able to interact with the operator in order to ensure safe and 
efficient treatment and generation of output pulses, which ensure effective experiment. The 
accuracy of measurements should be specified in advance and measuring and comparison of 
results during experiments should be reported. Periodic calibrations of the device and 
equipment need to be made as well as electrode replacement based on predefined intervals. In 
case of using single-use electrodes or electroporation cuvettes, safe disposal after the 
experiment should be provided due to the chemical reactions that can change the electrical 
properties of the electrodes in the next experiment. Recently, nanosecond electroporators were 
introduces and are now being used in laboratory setups. Here measurement protocols and 
delivery of the pulses are more challenging. Special attention and more advanced measurement 
setups are required, as those electroporators mainly do not have built-in measurement system.  
All of these problems and requirements could be solved with implementation of a specific 
standard for electroporators based on the application. As laboratory electroporators are not 
considered to be medical devices, medical device standards do not apply and therefore, the 
only solution is gathering all previously mentioned requirements into one standard and 
agreeing on requirements that will be followed by all manufacturers to enable comparability 
and reproducibility of research and laboratory results. Additionally, electroporation cuvettes 
and electrodes should be standardized with defined tolerances and materials used.  
Recommendations for further research and standardization 
Nowadays, electroporation industry is ascending even faster than before. Taking into 
consideration the new technologies, treatment protocols, increased research intensity and 
knowledge, we already have well-established protocols, equipment and promising treatments.  
For achieving successful and efficient electroporation, it is necessary to have well defined 
output pulses and measure them in each treatment or experiment to make sure that the pulses 
are delivered as requested. Thus, suitable reproduction and comparison of results can be made 
if necessary. When delivering electrical pulses for electroporation, regardless of the 
application, it is very important to provide complete reports in order to enable comparability 
and reproducibility of the results [4], [12], [13], [14]. A description of pulses and how the 
electrical pulses were measured is necessary. The researchers must provide all specifications 
of the measuring equipment, the point of measurement and state if the pulses were delivered 
and measured in each experiment. Additionally, parameters and complete time-domain 
waveforms of the pulses should be provided with an appropriate description of the 
electroporator and electrodes used. For commercial equipment, the name of the company and 
model should be specified. If the pulse generator is a laboratory prototype or specially 
manufactured unit, suitable description of the components, electrical configuration, 
measurement and data acquisition systems should be provided. Lastly, the electric field induced 
by the delivered pulses inside the biological load should be calculated and/or all data describing 
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the electric field should be listed (i.e. electrode shape and their position with respect to the 
treated sample/tissue).  
Currently, we can say that we have a developing market for clinical electroporators and new 
electroporators designed for specific applications are coming up. However, the absence of 
industry, laboratory and medical specific standards may eventually become an obstacle for 
further development of approved electroporation devices and associated equipment. Papers 
calling for standardization for other applications of electroporation have already been 
published, e.g. for standardization of IRE techniques and protocols, in which authors propose 
a set of technical recommendations for the use of IRE for treatment of locally advanced 
pancreatic cancer [15]. Having a specific standard for each application will simplify the 
harmonization of all commercial, certified electroporators and improve the safety, quality and 
efficiency of these devices. Current problems like voltage drop during pulse delivery, unknown 
pulse parameters, insufficient electrical field, non-comprehensive reports can be solved by 
stating limits and recommendations for voltage/current, energy, load, electrodes used, 
insulation and design.  
The standard should define: 
• maximum tolerances of generated pulses compared to expected values by considering
the plasma membrane permeabilization of the load and technical limitations of
electroporation device development;
• how to provide technical specifications of the device, i.e. to provide specifications
together with conditions under which they are achieved, e.g. to define maximum
amplitude of the pulses together with the pulse duration range and load resistance at
which it can be achieved;
• pre-pulses (amplitude, pulse duration and exact timing regarding the preset sequence),
if used;
• how to implement safety features like galvanic isolation, current, energy and voltage
limitations, warnings if the pulse delivery was stopped or limited, or if any other
unforeseeable event or malfunction has occurred;
• by which load the electroporators should be tested to ensure effectiveness at specific
applications, or to ensure predictable operation or operation within tolerances (this can
be quite challenging in case of delivery of nanosecond pulses as pulse reflections can
occur due to the dynamics and variability of the biological load, i.e. conductivity
increase due to electroporation);
• which electroporation cuvettes and electrodes should be used;
• maximum tolerances of the distances between the electrodes.
The standard should also consider procedures for different materials used and recommend a 
way of defining a treatment volume and an electric field distribution between the electrodes. 
Recommendation for electrochemotherapy device standardization  
ECT is an established cancer treatment used in clinics [16] for safe and convenient treatment 
of cutaneous and subcutaneous tumors following standard operating procedure (SOP) [17], 
[18]. The pulses are delivered to target tissue via electrodes, which are considered to be medical 
accessories, used only in combination with a particular pulse generator (mostly used is the 
Cliniporator EPS02). If the electrodes are placed on the patient’s skin, e.g. plate or non-
penetrate electrodes, they are considered to be non-invasive medical accessories, used to treat 
cutaneous tissues. In case they are intended to be placed inside the patient’s body, e.g. needle 
electrodes, they are considered to be invasive, used to treat deeper tissues.  
144 Results and Discussion
8 
Fig. 3. Different types of electrodes (by IGEA S.p.A.). a) Plate electrodes. b) Linear (parallel needle) array 
electrodes (first top image), adjustable linear needle electrodes with needle-length adjustment with 5 mm 
increment (bottom two images). c) Finger electrodes with orthogonal linear needles (left) and longitudinal linear 
needles (right). d) Hexagonal needle electrodes (first top image), adjustable hexagonal configuration needle 
electrodes with needle-length adjustment with 5 mm increment (bottom two images). e) Endoscopic electrode 
EndoVE (Endoscopic Vacuum Electrode) which is mounted at the head of an endoscope and utilizes a vacuum 
source to drag the tissue alongside with the electrode. f) Individual (long) needle electrodes for variable electrode-
geometry (from 2 to 6 electrodes with 16- to 30 cm long needle and active tip of 3 or 4 cm).  
The updated SOP [18] defines five types of electrodes (made of stainless-steel) that are 
commercially available (IGEA S.p.A, Carpi MO, Italy) and can be used together with the 
Cliniporator depending on the treated area:  
• Plate electrodes with 8 mm gap in-between, used for superficial skin lesions (Fig. 3a).
• Linear array electrodes (parallel needle array) that have 2 arrays of 4 needles (with
needle length of 10-, 20- or 30 mm), separated by 4 mm distance, used for smaller
tumors (recommended to be used for tumors in the facial region) with local anesthesia
(Fig. 3b).
• Hexagonal needle electrodes with needle length of 10-, 20- or 30 mm, used for
treatment of larger areas, e.g. cutaneous metastases (Fig. 3d).
• Finger electrodes (longitudinal or orthogonal) with needle length of 5- or 10 mm, used
for treatment of mucosal tumors, e.g. in the oral cavity (Fig. 3c).
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• Adjustable electrodes (linear (Fig. 3b) or hexagonal (Fig. 3d)) allow adjustments in
needle length (from 5 mm to 40 mm with 5 mm increment) for better support in
treatments of tumors with heterogeneous size.
In addition, endoscopic electroporation system EndoVe (Mirai Medical, Galway, Ireland) was 
developed to be used with the ePORE electroporation generator, which is also suitable for the 
Cliniporator (Fig. 3e). Furthermore, long freely-placeable needle electrodes (Fig. 3f) were 
introduced and new minimally invasive laparoscopic expandable needle electrodes are being 
developed by IGEA S.p.A [3], [16].  
Pulse parameters are defined in the SOP as a result of numerous previously conducted studies. 
For each pulse delivering, 8 square-wave pulses of 100 µs with pulse amplitude of about 1000 
V (1000 V up to 1300 V) across 8 mm distance between plate electrodes should be delivered 
at repetition rate of either 1 Hz or 5 kHz. ECT with pulse repetition rate of 5 kHz is mandatory 
for hexagonal needle electrodes because the treatment (delivering 8 x 12 = 96 pulses) with 1 
Hz repetition rate would extend over prohibitively long time and high-frequency (5 kHz) pulses 
reduce the number of contractions. Nevertheless, several applications may be needed to cover 
the whole tumor volume in a single session. 
All electrodes which are commercially available and meant to be used with the Cliniporator 
are for single use for a particular patient and only for a single session (for one nodule or several 
similar nodules in the same patient). In case of more nodules of different sizes, more than one 
electrode type may be needed for a particular patient in the same session.  
The galvanic isolation of the output is preferably implemented in the power supply and not in 
the output module in order to have accurate measurement of the output signal. Output current 
and voltage are measured at the output of the pulse generator to implement current, energy and 
voltage limitations. The SOP should define the maximum expected current or minimal 
expected resistance of the load. The maximum current of the device should be 10 % or 20 % 
higher than the maximum expected current, which is 20 A for the Cliniporator EPS02. SOP 
defines the maximum treatment voltage as 1300 V/cm voltage-to-distance ratio times 8 mm 
which is equal to 1040 V. The maximum voltage is defined by the SOP and tolerances, and is 
1000 V for the Cliniporator EPS02. The maximum energy should be equal to the maximum 
treatment time, times maximum current, times maximum voltage. 
Considering the SOP, for square wave pulses (described by the amplitude and the pulse 
duration tFWHM (FWHM – Full Width at Half Maximum)) we propose the following tolerances: 
• the pulse amplitude between 15 % and 85 % of FWHM should not rise over or fall
below 110 % or 90 % of SOP amplitude (Fig. 4a);
• the FWHM should not be longer or shorter than ± 8 % of SOP FWHM;
• delivered number of pulses should be exactly the same as in the SOP and variations of
this parameter are not allowed;
• pulse repetition rate may deviate from SOP pulse repetition rate (for both options) for
maximum ± 5 %.
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Fig. 4. a) Electroporation square wave pulse – pulse parameters and tolerances. b) Permeabilization curve (solid 
line) and cell survival (dashed line) adapted from [19] – tolerances.  For amplitudes between 90 % and 110 % of 
the defined SOP amplitude will still be possible to achieve efficient treatment. With amplitudes values higher than 
110 %, cell survival will be increasingly lowered and can lead to IRE while with amplitudes values lower than 90 
%, the cell permeabilization will decrease and can lead to inefficient tumor treatment.  
For successful ECT it is important to keep within these tolerances as we calculated them to 
define the maximum deviations where it is still possible to achieve the desired effect. For 
example, higher (more than 110 % of the amplitude) or lower (less than 90 %) values of the 
SOP amplitude can lead to IRE or insufficient electric field for ECT, respectively. Based on 
the permeabilization curves (Fig. 2 from reference [19]), even for pulses with the lowest or 
highest defined tolerances (for pulse amplitude and pulse durations) will still be possible to 
stay on the part of the permeabilization curve where the treatment will be efficient (Fig. 4b).  
ECT device should work within the tolerances on zero load and on electronic emulator of ECT 
load. Operation of the limitation should be tested by the device on power up and conformity 
by using electronic emulator of biological load.  
All electrodes should be manufactured utilizing a biocompatible material, usually stainless-
steel. However, materials tested by the requirements stated in the ISO 10993 series of standards 
for biological evaluation of medical devices that come into direct or indirect contact with 
biological tissues (parts -1, -5 and -10 are the most important) may be allowed. 
Following the SOP all electrodes need to be for single use. We propose the option of using 
multiple-use electrodes. In this case, clear instructions for electrodes’ cleaning and 
maintenance after every treatment should be provided. Moreover, multiple-use electrode 
replacement on predefined intervals should be stated and provided in the instruction for use. 
The allowed tolerances for the diameters of the electrodes, the distances between the electrodes 
and the length of the needles should also be defined. 
Conclusions 
With implementation of a specific standard for particular application, the electroporation 
devices will be safer, treatments more efficient and results more reproducible, which will allow 
faster and more straight-forward progress of electroporation as well as treatments and therapies 
based on electroporation. By implementing a particular medical standard for 
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electrochemotherapy electroporation devices, the standard operating procedure will be 
improved which will result in better and more effective cancer treatment. 
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Abstract—Electroporation is an emerging technology, with
great potential in any different medical and biotechnological
applications, food engineering and biomass production. Large
variations of biological load characteristics, however, represent a
great challenge in electroporator design, which results in different
solutions. Because a medical electroporator is a medical device,
it must comply with medical device regulative and standards.
However, none of the existing standards directly address the
operation or electroporator’s performance requirements. In or-
der to evaluate clinical, laboratory and prototype electroporation
devices during the development process, or to evaluate their final
performance considering at least from the perspective of output
pulse parameters, we present a case study on the design of an
electronic emulator of biological load during electroporation. The
electronic load emulator enables constant and sustainable testing
and unbiased comparison of different electroporator’s operation.
We developed an analog electrical circuit that has equivalent
impedance to the beef liver tissue in combination with needle
electrodes, during high voltage pulse delivery and or electropo-
ration. Current and voltage measurements during electroporation
of beef liver tissue “ex vivo”, were analyzed and parametrized
to define the analog circuit equation. An equivalent circuit was
simulated, built and validated. The proposed concept of electronic
load emulator can be used for classical electroporator (i.e. not
nanosecond) performance evaluation and comparison of their
operation. Additionally, it facilitates standard implementation,
regarding the testing protocol and enables quality assurance.
Index Terms—electroporation, tissue conductivity change, stan-
dard nonlinear load, biological load, electroporation emulator
I. INTRODUCTION
E lectroporation is an emerging platform technology, withgreat potential [1], [2]. One of the most successful
electroporation-based applications in medicine is an anti-
tumor therapy, called electrochemotherapy (ECT). Through the
permeabilized cell membrane transport of chemotherapeutic
drug, bleomycin or cisplatin is increased and considerably
higher cytotoxicity is reached [8], [9], [10], [11]. According
to Standard Operating Procedure for ECT [14], [15] in clinical
practice, mainly eight square wave pulses of amplitudes up to
1000 V, 100 µs pulse duration each and repetition frequency
of 1 Hz or 5 kHz are applied to the tissue. A medical device
that enables electroporation is called an electroporator, it is
a high voltage pulse generator, that generates high voltage
pulses of a specific duration, pulse repetition frequency and
shape [12], [13]. From the view of an electroporator, the load
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is a tissue defined by the electrodes [16].
Despite facts, that biological load electric properties vary
considerably, tissue has an inhomogeneous composition
[17], [18], [19], different electrode type/geometry (different
distances between the electrodes) are used, and even though
that due to electroporation [20], [21], [22], tissue conductivity
changes during the pulse delivery, which results in a non-
linear current response of a biological load to a square
wave electric pulse [20], [23], [24], [25] the pre-set train
of pulses should be generated and delivered to the load, for
successful electroporation. Which represent a great challenge
in electroporator design that results in different solutions.
Problems mainly occur with low resistant loads, or when
the pulse repetition rate is in the higher half of the device’s
operation range, because some pulse generators cannot
deliver such high currents or energies on the output [13].
Electroporators are mainly not only pulse generators, but they
also have built-in protection systems for current and energy
limitation and systems for ensuring the effectiveness of the
therapy (for protection of patients, operators, and electronics),
the operation at boundary condition of safe operation area
may deviate from the expectations. But implementation of
protection systems is not straight forward, because at normal
operation, high displacement current spikes occur at the
beginning of the pulse (due to capacitive nature of biological
tissue as the load) and ringing is sometimes present at pulse
switching.
For more than a decade our group is evaluating
electroporation devices [13], [37], [38] and currently, a
rise in electroporation device providers, can be detected
on the market. But unfortunately the transitions between
devices from different manufacturers, or comparison of
results obtained by different researchers using different
electroporators, is becoming impossible, due to the pre-
programmed electroporation procedures (The researchers
do not even even know and therefore also do not report
basic pulse parameters (e.g. pulse shape, repetition rate, and
voltage amplitude) [26], [27].). The most stressful conditions
for an electroporator are short-circuit or discharge between
electrodes during the pulse delivery, which can be tested with
short-circuiting or very closely placed electrodes. However
until now, for the evaluation of an electroporator performance
within the safe operation area mainly a resistor or more
advanced, a resistor with a capacitance in parallel were
used. But those evaluations are considered over-simplifie.
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Since in the case of ECT a typical load is tissue, real tissue
or its model could be used [39]. Currently, however, there
are no available models on the market, which incorporates
inhomogeneous characteristics of tissue or are too expensive,
or for single-use and are thus inadequate, therefore some
researchers rather use for example, a potato [46], [47],
which might be a better solution than a resistor, because
at least a conductivity increase (due to electroporation) and
heating are present. We think that many problems concerning
electroporation devices have evolved due to the lack of
standard and evaluation protocol.
In the scope of this paper we present an idea of an analog
electrical circuit that emulates beef liver tissue in combination
with needle electrodes, undergoing high voltage pulse delivery
and/or electroporation. Current and voltage measurements
during electroporation of liver tissue “ex vivo”, were analyzed
and parameterized in a way to fit the proposed analog circuit
equation. An equivalent circuit was then simulated, built and
validated as a proof of concept. The developed equivalent elec-
tronic emulator can be used for electroporators performance
evaluation and comparison of the operation between different
electroporators, or of an electroporator over its lifetime. The
developed device emulates small volume beef liver tissue in
combination with needle electrodes (IGEA, Italy). However,
the proposed process/concept can be applied to any electropo-
ration measurements and specific emulators can be developed
e.g. for more conductive loads, loads with a higher threshold
voltage.
II. METHODS AND MATERIALS
For the development of an electronic emulation circuit,
high-quality measurements of current and voltage, during
pulse application to the biological tissue are needed. We used
“ex vivo” measurements, where smaller volume, beef liver
tissue, was treated because we do not have so accurate and
high sample rate “in vivo” measurements. Unfortunately, “in
vivo” measurements are mainly collected by means of the
ECT Cliniporator device, of which sampling frequency is too
low to accurately measure current spikes. Additionally, due to
muscle contractions (which are triggered with pulse delivery),
some noise can be present in “in vivo” measurements.
Therefore this study is based on measurements of already
published research by Langus et. al. [23]. They introduced
time-dependent effects into a finite element model developed
specifically for electroporation, which is able to predict the
time evolution of electric current, within a 5 % error. ”Ex
vivo” experiments on beef liver samples, were done, nine
different sequences of electric pulses were delivered to the
tissue, by commercially available needle electrodes (IGEA,
Carpi, Italy) with a 10 mm of active part, a diameter of 1.2
mm and the distance between the centers of the electrodes
being 10 mm. Applied voltage and current were monitored
and used for the development of the model. Current and
voltage measurements of eight pulses in a sequence, 1000 V,
750 V, and 500 V voltage amplitude with a pulse duration
of 100 µs, two different repetition frequencies 1 Hz and
4717 Hz, were re-processed and analyzed in order to model
and emulate electroporation load with an analog electric
circuit. Measurement data were imported into Matlab R2018b
(MathWorks, Natick, Massachusetts, USA) computing
environment, where values of optimal circuit elements were
calculated and then the circuit was simulated in PSpice AD
Lite (OrCAD, Cadence, California, USA). When pulsed
electric fields (PEF) are applied to a biological tissue, current
response has a typical time course which consists of a fast,
high capacitive current, followed by a slight amplitude rise
due to tissue electroporation, or more or less square wave
pulse, if tissue was not yet electroporated [40], [41], [42]
meaning, that applied voltage was lower than electroporation
threshold voltage (Fig. 1a).
(a)
I(t) = IR + IC + IE
IR = A
IC = B ∗ e−t/C
IE = D ∗
(
1 − e−tE
)+ +
(b)
Fig. 1: (a) Typical time course during PEF application to
the tissue (red) and three mathematical functions (black); (b)
Current is modeled as a sum of a square wave pulse and two
exponential functions, by following the equation (Eq. 1)
A. Mathematical model
A typical current time course, during PEF application to
tissue, is shown in the figure (Fig. 1a), where dynamics
associated with pulse rise and fall time have not been included
(indicated with the red dashed line). The dynamic of measured
current, during the pulse (pulse rise and fall time are not
included) can be roughly described as a sum of a square wave
pulse and two exponential functions, as presented with the
equation (Eq. 1) (Fig. 1b), where t represents time and A, B, C,
D, and E are abstract parameters that are in the circuit model
substituted by applied voltage and load parameters. Such a
form of the equation has been chosen, because it represents a
resistive, capacitive response and increase of conductivity due
to electroporation, but also because it can be easily converted
to an equation, which defines an analog electric circuit.
I(t) = A+B∗e−t/C+D∗(1−e−t/E),when 0 < t < Tpulse
(1)
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Where Tpulse is equal to the duration of the pulse. The
first element of the equation, a constant A, represents a real
(ohmic) part of the current, which is a result of resistive
tissue component. But as current in tissue is also reactive, two
additional elements are added. The second element B ∗e−t/C ,
an exponential decay function, represents a capacitive current
spike and can be modeled as the capacitor discharge. The
third element D ∗ (1 − e−t/E), an exponential rise function,
illustrates a conductivity growth during pulse delivery, which
is a result of tissue electroporation (pore formation) and
tissue heating [20], [21], [22].
B. Circuit model
The mathematical model (Eq. 1) can be easily substituted by
a circuit model (Fig. 2) with three parallel branches, namely,
resistive, capacitive and inductive, which models increase
of conductivity due to electroporation (Eq. 2). When the
applied voltage is lower than the electroporation threshold
voltage, the tissue is not electroporated and therefore the
conductivity is roughly constant. In the equivalent circuit
(Fig. 2) a Zener diode with breakdown voltage equal to the
electroporation threshold voltage, enables or disables an in-
ductive/electroporation branch. Additionally, at the end of each
applied pulse, the stored energy in the capacitor and inductor
will be released and will cause the transient exponential decay
current on the trailing edge of the current waveform, resulting
in a short negative value current spike. The negative spike
is also present in the case of biological load, but we only
modeled the dynamics of the pulse to facilitate calculations,
therefore we neglected the rise, fall time and post pulse
dynamics.
1) Single monopolar pulse model: For a single positive
monpolar pulse the following circuit is proposed (Fig. 2).
Vep
I(t)
R2
IC
C1
Uth
R3
L1
IE
R1
IR
Fig. 2: Single monopolar pulse circuit emulator: equivalent
circuit model of tissue during electroporation. Where Vep
represent applied electroporation pulse, with pulse voltage
amplitude Uamp and Uth electroporation threshold voltage.
The values of the circuit elements are calculated using the
following equations (Eq. 2, 3).
I(t) = IR + IC + IE
I(t) =
Uamp
R1
+
Uamp
R2
∗ e−t/τ1+
+
Uamp − Uth
R3
∗ (1− e−t/τ2), when 0 < t < Tpulse
(2)
C1 =
τ1
R2
L1 = τ2 ∗R3 (3)
Where Vep represents applied electroporation pulse, with pulse
voltage amplitude Uamp and Uth electroporation threshold
voltage. For the threshold voltage determination measurements
at different applied voltages are required. While all the other
values can be determined directly from the mathematical
model:
R1 =
Uamp
A
; R2 =
Uamp
B
τ1 = C; R3 =
Uamp − Uth
D
; τ2 = E
(4)
This solution is accurate only in case of one pulse applica-
tion, or when pulse repetition frequency is low (pause between
pulses is longer than 1 ms [43]) e.g. in our case 1 Hz, meaning
all the applied pulses in one sequence have approximately the
same current time course.
For numerical model, all measurement data (described
earlier [23]), were imported into Matlab R2018b (MathWorks,
Natick, Massachusetts, USA) computing environment, where
values of optimal circuit elements were calculated. Five
measurements of applied current and voltage for each preset
voltage 500 V, 750 V and 1000 V (pulse duration: 100 µs
and repetition frequency: 4.717 kHz), were averaged and
downsampled for further analyses. The capacitive current
spike part was due to its short duration - dynamics decimated
by 10 and others by 70, though, in the end, the half of values
represented a capacitive current spike and the other half
an inductive/electroporation part of the pulse. At first, the
real-time conductivity was calculated from applied current
and voltage measurement only for the first pulse in sequence.
With the Matlab’s curve fitting toolbox, optimal parameters
for proposed equation (Eq. 1) were determined, for each
applied voltage separately. Those values were then used as
initial values for the least square error (LSE) fit, which was
performed for each applied voltage separately. That is how
optimal electronic component values were calculated for
each applied voltage. Then using by (Eq. 2), LSE regression
was done for all three applied voltages together. Due to a
large number of variables and three applied voltages, each
variable range was predefined. For resistive components and
time constants, fifteen linearly distributed values between
a minimal and maximal proposed optimal values from
individual fit were used. While the threshold voltage was
limited between 200 V and 400 V, because in Langus et. al.
[23] optimal fitting maximum and minimum electric field
magnitude limit were set to 20000 V/m and 40000 V/m .
That is how all the values for single monopolar pulse circuit
(Fig. 2) emulator were determined.
2) Multiple monopolar pulse model: With a higher repe-
tition frequencies, in our case 4717 Hz, it was observed that
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the current reaches around 75% of the final amplitude at the
first pulse and percentage than exponentially rises with pulses,
while all pulses in sequence have the same shape and ampli-
tude in case of 1 Hz repetition frequency [23]. It was shown
that for pulse repetition frequencies above 1 kHz a significant
change in pulse shape occurs, meaning the following pulses
start at higher initial value [43]. Heat generation, diffusion and
pore lifetime could explain these phenomena [43], [44], [45].
Therefore in parallel to inductor L1 an additional resistor R4
and diode in series are added (Fig. 3). A diode emulates an
”electroporation” memory while resistor R4 emulates loss of
memory. For the first pulse in a pulse sequence with higher
repetition frequency, the situation is the same as for first/single
pulse or pulses with lower repetition frequency (Fig. 2). The
electroporation memory is not yet present. During the pulse,
the inductor L1 is magnetized and right after the pulse, during
the pause between pulses, the L1 current in the model regarded
as IM0 starts to flow through the new resistor R4 and the
inductor is in a demagnetization phase until the next pulse
arrival. IE is still present when the next pulse is generated
because the pause between the pulses is shorter than inductor
demagnetizing time. Therefore the IE increases, it is the sum
of inductor magnetize current and Imem memory current. The
inductor current for second and all other pulses is calculated
in accordance with equations (Eq. 5, 6):
IL(t, N) = (
Uamp−Uth
R3
− Imem(N)) ∗ (1− e−(t−(N−1)∗Tper)/τ2) + Imem(N)
(5)
Imem(N) = IM0(N) ∗ e−Tpause/τ3 (6)
In which, N is a pulse number, IM0 represents a current at
the end of the previous pulse, Tpause is equal to the duration
of the pause between pulses and Tper in pulse period (Tper =
Tpulse + Tpause).
L1 IE
Imem
R4
Fig. 3: Additional in series connected resistor R4 and diode
in parallel to the inductor L1, emulate an ”electroporation”
memory, which enables that the following pulse starts at the
higher initial value.
R4 which enables memory current was again defined with
LSE regression. In this case, the whole sequence, all eight
pulses were, included in the calculation. Because only one
variable R4, was left undefined, a range of potential R4
values was extended, meaning a lot higher number of potential
values were included in the regression. Theoretical final circuit
emulator (Fig. 4) and equations (Eq. 7, 8, 9, 10), are only
valid for the time of the pulse ((N − 1) ∗ Tper < t <
(N − 1) ∗ Tper + Tpulse), describe well the behaviour of
biological load, in our case liver tissue during monopolar ECT
pulse application.
Vep
R2
IC
C1
Uth
R3
L1
Imem
R4
R1
IR
IE
Fig. 4: Final electronic emulator of biological load during
electroporation.
I(t,N) =



Uamp
R1
+
Uamp
R2
∗
∗e−(t−(N−1)∗Tper)/τ1 , U < Uth
Uamp
R1
+
Uamp
R2
∗ e−(t−(N−1)∗Tper)/τ1+
+(
Uamp−Uth
R3
− Imem(N))∗
∗(1− e−(t−(N−1)∗Tper)/τ2)+
+Imem(N), U > Uth
(7)
Imem(N) = IM0(N) ∗ e−Tpause/τ3 (8)
IM0(N) =
{
I((N − 1) ∗ Tper − Tpause), N > 1
0, N = 1
(9)
C1 =
τ1
R2
; L1 = τ2 ∗R3; R4 = τ3 ∗ L1 (10)
Final load current for higher repetition frequencies is de-
scribed with discrete equation (Eq. 7), where N is the pulse
number, Tper period (pulse duration + pause). When the ap-
plied voltage is lower than the electroporation threshold volt-
age, the load current consists only of the ohmic and capacitive
components. However when the applied voltage is higher than
the electroporation threshold voltage, additionally to an ohmic
and capacitive component also the inductive/electroporation
current is added, which emulates conductivity rise during
electroporation (Eq. 7). In the second circuit (Fig. 4) an
additional memory current, which is pulse number dependent,
is added to the inductive component. At the first pulse, the
memory current is equal to zero because the inductor L1 is not
yet magnetized. Then with each successive pulse the memory
current is higher until it reaches the plateau (Eq. 8, 9), due
to inductor magnetization and demagnetization. From the time
constant also the last missing components (C1, L1 and R4) are
calculated and thus the circuit is fully defined (Eq. 10).
C. Electronic load emulator
Since electronic components with exactly the same values
as defined in the numerical model are not available, the
prototype’s components that have the most similar values,
available on the market, were used. The circuit with available
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components values was first simulated in PSpice AD Lite
(OrCAD, Cadence, California, USA) and the load current
compared in Matlab to the modeled and measured current.
For the measurements of prototype emulator, oscilloscope
(HDO6104A-MS, LeCroy, USA), high voltage differential
probe (HVD3206A, LeCroy, USA) and current Hall probe
(CP031A, LeCroy, USA) were used. The electric pulses, with
the same pulse settings and with the same electroporation
device (i.e. ELECTRO cell S20, β-teh, Leroy, France) as
in Langus et. al. [23], were applied to the electronic load
emulator.
III. RESULTS
A. Numerical calculations
For each applied voltage individual LSE-fit of the math-
ematical model, gave a precise fit of the time evolution of
electric current (Fig. 5a). However the aim was to develop a
prototype of electroporation load emulator, therefore the same
circuit should be used for all applied voltages. Meaning a fit
of a circuit model was done on all three voltages together and
a slightly higher deviation from the average measurement was
obtained. For both 1000 V and 750 V voltage amplitude, the
modeled current is however still within the standard deviation
of measurements (Fig. 5b).
(a) (b)
Fig. 5: Average of five current measurements of the first pulse
at 1 Hz (yellow) and 4717 Hz (green) repetition frequency.
(a) Modeled current (red), optimal circuit parameter values
were determined for each applied voltage separately; (b)
Modeled current (red), optimal circuit parameter values were
determined with the LSE method, all three currents at different
voltages were included into the cost function.
The first modeled pulse in a sequence with higher repetition
frequency, has the same time course as in a single monopolar
pulse model, while all consecutive pulses have higher initial
values (Fig. 6a, first row). Matching between measurement
and modeled current, slightly decreases with pulse number,
but it is still within the standard deviation (Fig. 5, blue line)
of measurements for 750 V and 1000 V applied voltage
amplitude. Optimal values of electronic components for a
single-first pulse circuit emulator and for a sequence of pulses
with higher repetition frequency are presented in table (TABLE
I).
TABLE I: Optimal values of electronic components for the
single positive monopolar pulse model are presented in the first
line and for multiple monopolar pulse model in the second.
R1[Ω] R2[kΩ] R3[kΩ] R4[Ω] C1[nF ] L1[mH]Uth[V ]
682.4 1.287 1.287 —— 0.998 57.5 400
682.4 1.287 1.287 171.1 0.998 57.5 366.7
TABLE II: Final component value table, of components which
were used in the PSpice simulation and prototype emulator.
R1[Ω] R2[kΩ] R3[kΩ] R4[Ω] C1[nF ] L1[mH]Uth[V ]
680 1.2 1.2 175 1 57.5 360
B. PSpice model and electronic emulator
With the help of the PSpice model, a prototype emulator
was built. Available component values (TABLE II) were im-
plemented into PSpice transient analysis. The analysis was run
for 1.6 ms. Coil internal resistance was set to measured winded
wire resistance 15 Ω. The input voltage, rise time was equal to
the average rise time of all applied voltage pulses, 0.358 µs and
the same was done also for fall time, which was considerably
slower 2.44 µs. The pulse width was set to 99.5 µs and period
to 212 µs in order to match the measurements. The PSpice
simulation results of the prototype device are presented in the
second row of Figure 6.
Zener diode was composed of two Zener diodes in series,
one with breakdown voltage 200 V (1N5388B, MULTICOMP)
and another with 160 V (1N5384B, MULTICOMP). In order
to implement the most suitable inductor, that would optimally
operate at the applied pulse frequency, the inductor was
manufactured especially for this application. An RM14-type
ferrite core made from N41 material grade with 1.9 mm gap
(EPCOS/N41/RM14, 160nH, 42.2 x 34.8 x 30.2mm), was
winded in a 0.25 mm thick copper wire (number of windings:
600). The inductor was analyzed with an LCR meter (E4980A,
Keysight, USA), at 5 kHz the serial inductance was 57.6
mH and serial resistance 15 Ω and at 10 kHz the serial
inductance was 57.8 mH and serial resistance 17.6 Ω (The
inductor maximal constant current is 150 mA). CREE Silicone
Carbide diode C2D05120 was used as a memory diode. Final
value list of components built-in a prototype, is given in the
table (TABLE II). Measurements of the prototype emulator
are presented in the following figure (Fig. 6c, third row).
An additional current measurement was added at the applied
voltage set to 200 V, in order to present a current response,
when the applied voltage is lower than the electroporation
threshold voltage.
and in performance summary table (TABLE III)
IV. DISCUSSION
The proposed numerical model slightly deviates from the
measured values. The best fit was reached for the current mea-
surement at the input voltage 750 V. This may be explained by
the fact that the electric field was due to needle electrode use,
slightly heterogeneous, meaning that cells that are closer to the
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Fig. 6: Average of five current measurements at 4717 Hz repetition frequency (green), (a) numerically modeled current by
Matlab (red, first row), (b) modeled current by a PSpice (blue, second row) and (c) measured current trough prototype emulator
(purple, third row). An additional current measurement in the case of the emulator was added at the applied voltage set to 200
V, in order to present a current response, when the applied voltage is lower than the threshold voltage. In the first column, the
current at 500 V in the second 750 V and third 1000 V applied voltage amplitude is presented.
Fig. 7: A physical prototype electronic emulator of biological
load during electroporation.
TABLE III: The performance summary table displays the
root mean square error between measurements on beef liver
and mathematical model (RMSEM ), or prototype emulator
(RMSEE) or resistor (RMSER) and mean standard devia-
tion of five measurements on beef liver (σliver).
SET VOLTAGE
REP. F
σliver
[mA]
RMSEM
[mA]
RMSEE
[mA]
RMSER
[mA]
500 V, 1 Hz 38.5 40.3 38 101.1
500 V, 4717 Hz 46.3 125.8 132.1 101.4
750 V, 1 Hz 115.1 111.6 106.2 72.6
750 V, 4717 Hz 124.7 41.4 40.7 471.4
1000 V, 1 Hz 116.1 192.7 189.5 131.6
1000 V, 4714 Hz 177 55.7 58.1 705.7
needles, electroporate at lower voltages. In the case of plate
electrodes, we believe the fit would be even better, because
of a more homogeneous electric field distribution. Also the
negative spike at the trailing edge of the current waveform
was not modeled. The biggest challenge in the post pulse
calculations is the impedance of the pulse generator. Almost
every time, after pulse generation, the impedance is changed
(due to the turn-off, of the switch in electroporator) and cannot
be defined from the current and voltage measurements, due to
high noise and low voltage.
PSpice model and the current measurement of the proto-
type emulator match finely. A Zener diode that defines the
electroporation threshold voltage behaves as expected and
therefore enables simulation of electric current before and
during electroporation. Meaning the proposed mathematical,
numerical and circuit models are an appropriate method for
the development of an electronic emulator of biological load
during electroporation. The performance summary table (TA-
BLE III) presents the root mean square error values, between
the measurements on beef liver and mathematical model or
prototype emulator or resistor and mean standard deviation
of five measurements on beef liver. For the comparison of
operation, the optimal resistance value from E24 resistance
value list was selected. The minimal square error criteria was
used and the value of 560 Ω gave the best match. Additionally,
to the three main features (capacitive spike, rise of conductivity
during the pulse and electroporation memory) the developed
emulator in comparison to the optimal resistor has significantly
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lower RMSE. Preliminary results show that the presented
circuit model could be upgraded for electroporation pulses of
both polarities, named also biphasic or bipolar pulses. The
last branch in the circuit should be doubled and mirrored as
shown in (Fig. 8). Current measurements of both polarities
should be however analyzed in detail in order to determine the
relation between both inductors. If there is a memory present
also between a positive and negative pulse inductors should
be coupled.
Vep
R2
IC
C1
Uth
R3
L1
Imem1
R4
IE
R1
IR
Uth
R5
L2
Imem2
R6
Fig. 8: Proposed emulator upgrade for electroporation with
both polarity pulses, but additional current measurements
should be analyzed in detail, to determine the relation between
both inductors (L1, L2).
The solution, presented in this paper, presents a novel
approach, which enables repeatable and unbiased testing and
evaluation of electroporator performance. However, the pro-
posed emulator has to be adjusted for each biological load
specifically i.e. cell-suspension in cuvettes, plate electrodes,
electrodes for a skin treatment or needle electrodes for deep-
seated tumors. Therefore, for each biological load, a separate
analysis should be done. At first, we have to collect accurate
measurements, with a high sample rate, and than parametriza-
tion in accordance with this paper should be done. Finally,
the circuit components should be modified accordingly to the
newly calculated values. But from the prospect of standardiza-
tion or evaluation and comparison of different electroporation
devices, each of the components in the proposed circuit could
be replaced with an adjustable value component. A series
of a different capacitor and Zener diode modulation would
incorporate flexibility and provide one versatile emulator. The
maximal voltage and current of an emulator are defined with
the maximal voltage and current of the selected components
and the frequency is limited by the selected inductor. Charac-
teristics of the ferrite core are frequency dependent and in case
of saturation the inductor would not work as desired. The study
in the paper is focused only on “classical” electroporation
pulses. However, recently a much broader range of pulse
duration is investigated and therefore the frequency spectrum
of induced transmembrane potential is getting more attention
[49]. With lower frequencies, the proposed concept can be
used, but in case of higher frequencies, actual physical com-
ponents should be thoughtfully selected with minimal parasitic
values, or if not possible, the parasitic contributions should be
added to the PSpice model. Also, a switch from circuital to
distributed models of pulse delivery would be needed.
V. CONCLUSION
The proposed concept of electronic emulator of biological
load during electroporation, accurately symulatethe current
during electroporation. It is a proof of concept with huge
potential. For each specific biological load, first voltage and
current measurements should be made and a specific model
should be however developed. But from the prospect of
standardization or evaluation and comparison of different elec-
troporation devices, each of the components in the proposed
circuit could be replaced with an adjustable value component.
A series of a different capacitor and Zener diode modulation
would incorporate flexibility and provide one versatile emula-
tor. However additional measurements on different biological
loads and different electrodes should be done and analyzed
for this purpose. The main innovation of the presented pro-
cess/concept of an emulator is that it enables sustainable, re-
peatable and unbiased testing, therefore, it facilitates standard
implementation. Additionally, the emulator can be used as
a load during the development of an electroporator, which
facilitates the development process. We believe this is the first
step towards the development of an electroporator tester. Such
devices are well known and indispensable in the defibrillation
field [50]. Even more in case of a defibrillator, a load is
well known and electrodes are well defined, while in case
of electroporation the same device can be used with different
electrodes and load can vary from the skin to liver, or even
vegetable tissue.
ACKNOWLEDGMENT
This study was supported by the Slovenian Research
Agency (ARRS) (MRIC UL IP-0510, P2-0249, funding for
Junior Researchers to Eva Pirc). The authors would like to
thank Anja Zajc for the help with coil winding and to the
agreement between Esigelec and the University of Ljubljana,
which enabled Bertrand Balosetti’s visit to the University of
Ljubljana.
REFERENCES
[1] M. L. Yarmush, A. Golberg, G. Serša, T. Kotnik, and D. Miklavčič,
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Miklavčič, “Sequential finite element model of tissue electropermeabi-
lization,” IEEE Trans Biomed Eng., vol. 52, no. 5, pp. 816–827, May
2005.
[21] A. Ivorra, B. Al-Sakere, B. Rubinsky, and L. M. Mir, “In vivo electrical
conductivity measurements during and after tumor electroporation: con-
ductivity changes reflect the treatment outcome,” Phys. Med. Biol., vol.
54, no. 19, p. 5949, 2009.
[22] R. E. Neal II, P. A. Garcia, J. L. Robertson, and R. V. Davalos, “Ex-
perimental Characterization and Numerical Modeling of Tissue Electrical
Conductivity during Pulsed Electric Fields for Irreversible Electroporation
Treatment Planning,” IEEE Transactions on Biomedical Engineering, vol.
59, no. 4, pp. 1076–1085, Apr. 2012.
[23] J. Langus, M. Kranjc, B. Kos, T. Šuštar, and D. Miklavčič, “Dynamic
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Nanosecond Pulse Electroporator With
Silicon Carbide MOSFETs: Development
and Evaluation
Eva Pirc , Damijan Miklavčič , and Matej Reberšek
Abstract—Nanosecond electroporation of cell organelles
is being studied since more than a decade, but it is still not
entirely understood. Unique prototype hardware equipment
and challenging measuring methods may also be a con-
tributing reason for this situation. In the scope of this paper,
we improve the performance of the high-voltage nanosec-
ond pulse generator by introducing silicon carbide (SiC)
MOSFETs. We developed a new high-voltage diode opening
switch (DOS)—nanosecond pulse generator for laboratory
use for in vitro experiments in electroporation cuvettes.
Analysis and comparison of the most commonly used
switching technologies in pulse generators were made. The
device is designed by two parallel two-stage Marx-bank cir-
cuits with SiC MOSFETs that generates up to 200 A in the
resonant network. A driving circuit for stable simultaneous
switching of SiC MOSFETs was developed. The developed
generator can deliver from 500 V to more than 6 kV, ap-
proximately 8 ns pulses to a 50 Ω load. Even though the
amplitude of the output pulse is not as high as expected,
the multiplication factor VOUT/VIN is still approximately 9,
which is an improvement compared to the previously pub-
lished linear DOS generator. Measurement and evaluation
process is described in detail. Additionally, we emphasize
on the size of an error that occurs during measurements.
Index Terms—Electroporator, nanosecond pulse gener-
ator, silicon carbide power MOSFET, diode opening switch
(DOS), nanosecond pulse measurement.
I. INTRODUCTION
E LECTROPORATION is a technique in which electricpulses are applied to tissue or cells, in order to increase
permeability of their membranes [1]–[3]. In case of reversible
electroporation themembrane becomes permeable tomolecules,
that otherwise cannot pass the barrier and can subsequently fully
recover, opposed to the main goal of irreversible electropora-
tion that is cell death. Electroporation is already established
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in medicine and biotechnology [4], [5], electrochemotherapy
(ECT) is used to introduce chemotherapeutic drug into cells
[6]–[8] and IRE (irreversible electroporation) to induce cell
death, thus to ablate tissue [9], [10]. Overall electroporation
is a technique with great potential [5], [11]–[16]. Applied elec-
tric pulses induce voltage across the cell membrane that is pulse
duration and amplitude dependent. The same amount of elec-
troporated cells can be reached, with shorter pulse duration, if
higher pulse amplitude is used [17]. The shorter the pulses are,
the easier they “penetrate” into cell interior and permeabilize
internal membranes of organelles [18]. The application requires
electroporator to generate and electrodes to deliver electrical
pulses to tissue or cells. An electroporator is a high-voltage
pulse generator that generates pulses of specific shape, ampli-
tude, duration, number and pulse repetition rate [19], [20]. It is
very important to adjust pulse parameters to specific tissues, cell
types, applications and desired outcomes. Most of the devices
available on the market generate pulses with lengths from 10 μs
to 10 ms, at an electric field strength in the range of several
hundreds of volts per centimeter. Pulses from 100 to 900 μs
duration, with similar electric field strengths are widely used
for electrochemotherapy. Nanosecond pulses (4–600) ns long,
with electric field strengths of several tens of kilo-volts per
centimeter, are able to affect membranes of internal organelles
[21]–[23].
There are fivemajor concepts of electroporator design, capac-
itor discharge, square wave pulse generator, analog generators,
pulse forming network, and diode opening switches [19], [20].
First three concepts are mostly, used to generate micro- and
milli- second pulses. For nanosecond pulse generation pulse
forming networks or transmission lines and DOS (Diode Open-
ing Switch) are more appropriate solutions. All pulse power de-
vices as well as electroporators work in two phases: charge and
discharge. During charging period switches are turned off and
transmission lines or capacitors are charged. When the switches
are turned on, capacitors discharge to the output load [19].
In electroporation device design, we are looking for switch-
ing elements that generate maximum load current in this short
on stage and are at the same time capable of fast synchronous
reproducible, switching at high-voltages and currents. Semicon-
ductor switching elements that weremost often used in nanosec-
ond pulse electroporators are radio-frequency (RF) MOSFETs in
pulse-forming network concepts and power MOSFETs or IG-
BTs in DOS concepts. RF MOSFETs enable fast switching while
0018-9294 © 2019 IEEE. Personal use is permitted, but republication/redistribution requires IEEE permission.
See http://www.ieee.org/publications standards/publications/rights/index.html for more information.
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Fig. 1. Basic schematics of Diode Opening Switch – DOS and its op-
eration. Diode D with a good repeatability transfers energy saved in the
second inductor L2 to the load RL (a). Diode must be forward and re-
verse pumped, with adequate anharmonic current ID and should stop
conducting when all energy is stores in L2 , at this time a maximal re-
verse current through the diode IMAX is equal to 1.7  IM IN . If all the
conditions are met, a short high-voltage pulse URL is induced on the
load (b).
power MOSFETs and IGBTs are slower, but enable high currents.
Between semiconductor materials that are used for construction
of switching elements that work from 1200 V to 6500 V, which
is area of our interest, wide energy band-gap materials such as
silicon carbide (SiC) are more and more commonly used [24],
[25]. Elements that are based on wide energy band-gap mate-
rials, have much lower leakage currents, higher operating tem-
peratures and better radiation hardness. Therefore higher critical
electric fields can be reached, consequently blocking layers can
be thinner and with higher doping concentration. Therefore,
SiC MOSFETs also have lower on-resistance and electrons in
saturation can reach higher velocities, which results in higher
operating frequencies. Additionally good thermal conductivity
enables operation at higher power densities [24], [26]. However,
modest transconductance and short channel effects are important
to be considered, when using the device. Due to their excellent
properties, SiC MOSFETs are replacing silicon IGBTs, mainly
because of their faster switching times, and power MOSFETs,
mainly because of their lower on-resistance.
DOS is a commonly used concept for a few nanosecond scale
pulse generation, because amplitudes can reach up to several
kilo-volts. The circuit operates so that the diode with a good re-
peatability transfers energy saved in the second inductor L2 , to
the load (Fig. 1). In the first, charging period of the generation,
the capacitor (C1) is charged through the resistor (R) by DC
voltage supply (VIN). In the beginning of the second discharg-
ing period, the switch (S) is turned ON and the energy in the
capacitor (C1) starts circulating in the resonant network (C1 ,
C2 , L1 , L2) [27]. If the diode matrix (D) is short-circuited, an
aharmonic oscillation of the current through the inductor L2 is
observed. If the D is not short-circuited, the resonant network
firstly pumps current through the diodes. During the forward
pumping, charge is accumulated in the diodes PN-junctions
[27], which is proportional to the amplitude of the current and
the minority carrier lifetime. After completing the half period,
the resonant network starts pumping the current through the
diodes in the reverse direction. With the charge still present in
the PN-junctions, the diodes resume conducting until the accu-
mulated charge is removed. The time which takes to remove the
charge is inversely proportional to the amplitude of the current.
The ideal DOS abruptly stops conducting and commutates all
the L2 current into the load. The resonant network must be de-
signed in a way that the majority of the energy, firstly stored
in C1 , is stored in L2 , during the current commutation. This is
achieved by doubling the reverse current in comparison to the
forward current. During the current commutation the inductor
L2 induces high-voltage pulse on the load in order to main-
tain the current flow, which is proportional to the RL  IMAX ,
where RL is the resistance of the load and IMAX is a maximal
reverse current through the diodes. The induced voltage on the
load is normally much higher than the charging voltage and
the ratio between them is determined by a multiplication factor.
The inductors in the resonant network can have ferromagnetic
saturable cores which improves the multiplication factor but the
generator then operates nonlinearly and only in a small range of
output voltages [28]. In contrast, the air-core inductors achieve
lower multiplication factor but work linearly from zero voltage
to the saturation of semiconductor switches [27].
Most of existing nanosecond pulse generators used for elec-
troporation experiments are based on the pulse forming net-
works and spark gaps or RF MOSFET switches [22], [29]–[33].
Some DOS pulse generators for electroporation experiments
have already been developed and have performedwell [23], [22].
Among others, Sanders [27] developed a 5 kV2.5 ns nanosecond
DOS electroporator, Kuthi developed a 1200V 3.5 ns generator
[28] and some simulations of the DOS generators have also been
done by Kranjc [34].
Measurement of micro- and milli- second electroporation
pulses is relatively straightforward as pulse reflections are
normally negligible. However, with high-voltage nanosecond
pulses, measurement becomes more challenging [23], [35].
Firstly, the electric losses and reflections in the wiring between
the generator and the load are no longer negligible, therefore, the
probe should be connected to the wiring in electrical proximity
to the load. The commercial high-voltage nanosecond probes
are costly and useful only in specific setups. Some probes may
be incorporated into transmission lines [36] or electrodes [37],
other setups may use 50Ω probes [38] and some must use high-
impedance probes [39]. High-voltage nanosecond probes can be
made of wide-band resistive voltage divider [39], D-dot sensor
[37], 50 Ω probe [38] or capacitive voltage divider [36].
Nanosecond electroporation is being studied for more than
a decade, nevertheless the trend still clearly shows increased
interest into effects of nanosecond pulses. It is also believed that
further investigations of nanosecond electroporation of cells will
gain important knowledge necessary for better understanding of
162 Results and Discussion
3528 IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING, VOL. 66, NO. 12, DECEMBER 2019
Fig. 2. Comparison of different semiconductor switching technologies
which are used for generating nanosecond pulses. Compared are the
amplitude (a) and the rise time (b) of the current through the switch-
ing element, derived from the data sheets. Currents generated by the
switching elements are by linear approximation normalized to the same
600 V supply voltage (red star dots).
dynamics and transport in classical electroporation [40]. Some
studies of basic electroporation principles and nanosecond elec-
troporation are still not confirmed or are even contradictory
[23]. In case of nanosecond electroporation this can be a re-
sult of unique prototype hardware devices, with narrow scope
of parameters, incorrect application, or even an incomplete de-
scription of used hardware and delivered pulsemeasurement and
characterization [35] or inappropriate measurement equipment
or inadequate delivery system. High-voltage nanosecond pulse
generators for laboratory use with reproducible pulse delivery
of wide range of parameters, as well as accurate high-voltage
nanosecond measurement systems are needed.
II. METHODS AND MATERIALS
In nanosecond pulse electroporator design, the main chal-
lenge is, to construct a generator that delivers very short and at
the same time very high power pulses. The development started
with the analysis and comparison between the most commonly
used semiconductor switching technologies in pulse generators
and silicon carbide (SiC) MOSFET technology (Fig. 2). The com-
parisonwasmadewith switching elements of similar breakdown
voltages and sizes, with less than 50 ns rise time, namelyDE275-
102N06A (RF MOSFET, IXYS, USA), APT37M100B2 (Power
MOSFET, Microsemi, USA), IRGPS60B120KDP (IGBT, Infi-
neon, USA) and C2M0025120D (SiC MOSFET, CREE, USA).
We have compared the rise time, specified in data sheet and the
current amplitude at fixed supply voltage. As different manufac-
turers test their elements at different supply voltages, we have
at first by normalized linear approximation, define test current
at rise time data acquisition, which was 600 V (Fig. 2a). SiC
technology stand out by the current amplitude. However, with
the nanosecond pulses we are also interested in the rate of the
current increase. Therefore, we plotted the normalized test cur-
rent amplitude on the rise time axis (Fig. 2b) on which it can
be observed that the current in the SiC MOSFET rises slower
than in the RF MOSFET and quicker than in the power MOSFET
or IGBT.
Fig. 3. Basic schematic of DOS generator with two parallel two-stage
Marx- banks. Two-stage Marx-bank is used to deliver double voltage to
the resonant network in comparison to the breaking voltage of the switch
and power supply voltage. Two Marx-banks are used in parallel to deliver
higher current to the resonant network. Resonant network (C and L) and
DOS (D) are the same as in Sanders linear DOS generator [27].
A. Pulse Generator Design
Further on we focused on DOS generator, which we believe
is the most suitable topology for SiC MOSFET based nanosecond
pulse generators. With the advantage of using SiC MOSFETs we
aimed at developing linear DOS generator that could be used to
deliver short nanosecond pulses with wide range of high-voltage
amplitudes to the cuvettes. To achieve such high-voltages maxi-
mization of IMAX , which is proportional to theVIN ∗
√
C1/L2 ,
is required. However only VIN can be maximized in this equa-
tion, asL2 defines the pulse duration, which should be optimized
in accordance with desired biological effect and not for the out-
put voltage. And as C1 should be calculated so that the reverse
recovery time, of the diodes is equal to the π2
√
C1 ∗ L2 which
consequently enables generation of the output pulse at IMAX .
VIN is however, always limited by the breakdown voltage of
the switching elements. Therefore, in order to increase theVIN ,
stacking of the switching elements in series is required. Not
to increase the power supply voltage (VP S ), a two-stage Marx-
bank circuit was used, to stack the switches and twoMarx-banks
were used in parallel to generate double current in the resonant
network (Fig. 3), in comparison to the Sanders linear DOS gen-
erator [27]. As we used the same Step Recovery Diodes (SRD)
for the DOS (D, CN25M, EIC, Thailand) as Sanders and we
did not want to change the pulse duration, the capacitance and
inductance of the elements in the resonant network are the same
as in the Sanders linear DOS generator. Inductors are air coils,
made specially for this application, calibrated with LCR meter
(4284A, Agilent), at 1 MHz frequency and 2 V settings.
CN25M diodes have reverse recovery time of 50 ns, max-
imum repetitive peak reverse voltage 1000 V and maximum
average forward current 25 A. Because the maximum reverse
voltage of one diode is too low for our application, several
diodes must be stacked together in series and as 1000 V divided
by 25 A is almost 50 Ω, n × n matrix of CN25M diodes is the
most appropriate for 50Ω load, where n is the number of diodes
in series and in parallel in the matrix. A compact 8 × 8 diode
matrix (Fig. 4) was made by gluing the was made by gluing the
diodes together by conductive adhesive (MG chemicals, 8330-
19G, 8330S-21G) in order to minimize stray inductance and
all parasitic properties of lines connecting the load. The diode
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Fig. 4. (a) 8× 8matrix of CN25Mdiodes glued together with conductive
adhesive used in order to minimize stray inductance. (b) Ratio between
load current (calculated from the measured voltage) and L2 current is
lower with higher diode matrix size, due to their non-ideal characteristics.
Fig. 5. Schematic of two-stage Marx-bank circuit implemented in the
DOS generator. During the charging phase, capacitors (C) are charge
parallelly through the resistors (R), and during the discharge phase. SiC
MOSFETs connect capacitors in series and discharge them through the
resonant network. Two Marx-bank circuits are implemented in parallel to
generate high enough current for the resonant network. EachSiCMOSFET
has its own driving circuit galvanically separated from each other.
matrix was glued as close as possible to the load and second
inductor L2 . On the (Fig. 4), we can see the ratio between load
current (calculated from the measured voltage) and L2 current.
The ratio is lower with higher diode matrix size, due to their
non-ideal characteristics. Additionally, all diodes do not stop
conducting at exactly the same moment and this may also result
in a lower output pulse amplitude as expected. For DOS it would
be the best to use custom made diodes.
B. Marx-Bank Circuit
Two-stage Marx-bank circuit (Fig. 5) was developed to en-
able charging of the resonant network with up to 2000 V. The
energy storage capacitors (C) are a part of theMarx-bank circuit
and also of the resonant network. During the charging phase the
capacitors are parallelly charged through the resistors (R) by the
external high-voltage power supply. And during the discharge
phase SiC MOSFETs connect capacitors in series and discharge
them through the resonant network (Fig. 3). C2M0025120D
Silicon Carbide Power MOSFET with N-channel enhancement
Fig. 6. Block diagram of SiC MOSFET driver circuit. Galvanic separation
of the driver is made by isolated DC–DC converters and optocoupler.
The driver is supplied by +24 V and −5 V. Power supply capacitors
C01 and C02 stabilize the power supply voltage during switching. Gate
resistor Rg is used for stable simultaneous switching of all four SiC
MOSFETs.
mode (Cree, Inc., USA) were chosen because of their high
drain-source breaking voltage, and their high and fast current
rise (Fig. 2). It was empirically determined that at least two
Marx-bank circuits must be implemented in parallel, to enable
generation of high enough currents for the resonant network,
before SiC MOSFET reach saturation. Charging resistors have a
high value of 2 kΩ to ensure that the capacitors are in the major-
ity discharged through the resonant network. However, due to
high resistance of the charging resistors, the energy storage ca-
pacitors cannot be instantly recharged and the maximum pulse
repetition rate is therefore 3.5 kHz.
C. SiC MOSFET Driving Circuit
When designing a driving circuit for SiC MOSFET (Fig. 6),
it is important to consider SiC MOSFETs special characteristics
[24]. Due to low transconductance, they must be driven with
higher voltage difference than IGBTs or Si MOSFETs. At least
22 V voltage difference is desired for recommended operation,
voltage for on stage is 20 V and for off stage from −2 V to
−5 V. It is important that the upper limit of 25 V and the
lower limit of −10 V are not crossed. Selected SiC MOSFETs
start conducting at 2.5 V, but are not totally opened until Vgs
reaches 16 V. Therefore, high dV/dt of the Vgs is needed for
fast switching times that means driving circuit should have low
impedance. For optimal switching of the SiC MOSFET, stray
impedance of the driving circuit must be minimal, therefore,
lines connecting the MOSFET driver to power supply capacitors
and gate terminal should be as short as possible. Even though
the stray impedance is minimized, it can still lead to excessive
output oscillations, which can lead to unintentional MOSFET
switching that can be suppressed by appropriate gate resistor
Rg . The Rg is also important for the simultaneous switching of
all four SiC MOSFETs, as asynchronous switching in Marx-bank
circuit may overcharge and harm the switches. During the pulse
generation, the source (S) electric potential of the first stage
switches in the Marx-banks (SiC MOSFET1 and SiC MOSFET2)
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Fig. 7. Final prototype, with open (left) and closed enclosure (right).
The cuvette holder is directly connected to the diode matrix in order to
minimize parasitic effects.
stay on the same level as the GND (Fig. 5), while the source
electric potential of the second stage switches (SiC MOSFET3
and SiC MOSFET4) have to fall to the −Vin electric potential
of the bottom capacitor (C). The second stage switches must
though also charge the stray capacitance, therefore the current
through the second stage switches is higher, which slows down
their turning on time. To achieve simultaneous switching of the
second and first stage switches, the Rg resistance, of the second
stage switches, must thus be lower. However, a small difference
in rise times should not affect or destroy the MOSFETS, since they
operate up to 1200 V. If one of MOSFETS turns on slower, that
should not be harmful, until the switching is still fast enough,
to prevent the voltage rise of any MOSFET’s Vds over 1200 V.
In our Marx-bank circuit, we have empirically determined the
resistanceRg of the second stage MOSFET’s to be 1Ω, and of the
first stage to be 2 Ω (Fig. 6), to achieve simultaneous switching
of all MOSFET’s.
Two isolated DC-DC converters (RP-0512D and RP-0505S,
RECOM, Germany) are used to power supply the driving circuit
and to galvanically separate it from the main power supply lines
(Fig. 6). The two DC-DC converters and the source of one
SiC MOSFET are connected together to form a 0 V potential for
the gate driver. One DC-DC converter then supplies the driver
with +24 V and the other with −5 V. Optocoulper (HCPL-
0723, Avago USA) is used to galvanically separate the digital
trigger signal (trig), and the SiC MOSFETs are driven by an
ultrafast MOSFET driver (IXDD609SI, IXYZ,USA). Driver can
be supplied with up to 35 V, it can deliver up to 9 A output
current and has output resistance of up to 1 Ω. The ground of
the optocoupler and the driver are connected to the −5 V. The
optocoupler is then supplied with 0 V potential for the 5 V
supply difference, and the driver with +24 V to have 29 V of
operating voltage range. Power supply capacitors C01 and C02
are added to the power supply lines to stabilize the power supply
voltage during the switching. As capacitors with different values
have different resonant frequencies, C02 is composed of three
different capacitors, which result in wider frequency blocking
range and better stability of optocoupler’s power supply.
D. Fabrication and Assembly
The device (Fig. 7) was implemented on 6U (Eurocard) sized
PCB card, it is double sided with 105 μm copper layer and sol-
der stop mask. If available, SMD electrical components were
preferably chosen, trigger input connector is a 50 Ω BNC and
a holder for the electroporation cuvette is made for the output.
During the PCBdesign, special attentionwas given tomake lines
in the resonant network and in the output stage spaced enough
for the high-voltage, and at the same time as short as possible
and wide enough for the high currents. The device is triggered
by a function generator (33220A, Agilent Technologies, USA)
set to: VPP = 2.5 V, f = 1 kHz, pulse length 10 μs and offset
1.25 VDC. High-voltage generator (MCP 350-1250, FuG Elek-
tronik GmbH, Germany) and low voltage generator (NG310,
UNIWATT, Germany) that supply 5V/3A DC are used for high
and low voltage power supply, respectively. Not to damage the
DOS in case of too high-impedance of the load, a 100Ω resistor
(TFSF100RJE- ND, Ohmite, USA) is added in parallel to the
load. If there would not be any load present at pulse generation,
DOS would commutate L2 current to high impedance and L2
would induce very high voltage, which would damage the DOS
and additionally high dv/dt could also damage the optocuplers.
E. Voltage and Current Measurements
For all the voltage and current measurements, an oscillo-
scope (Wavepro 7300A, LeCroy, USA) was used. Driver cir-
cuit was evaluated with differential probes LeCroy ADP305
(1 kV, 100 MHz, LeCroy, USA). The L2 current in the reso-
nant network was measured by high-frequency current trans-
former (1 kA, 500 MHz, Bezgoz, France). For the output pulse
measurement several different voltage probes were used. The
high-voltage output pulse was measured with different com-
mercial probes (HVD3605, PPE20kV, PPE6kV and ADP305,
LeCroy, USA), high-voltage commercial attenuators (N-type,
J01026A0009, 2.5 kV20 dB± 0.8 dB; andBNC, J01006A0837,
20 dB ± 1 dB; both 50 Ω, 1GHz, Telegartner, Germany).
III. RESULTS
The nanosecond pulse generator performance was evaluated
in three steps. In the first step, driving circuits in the Marx- bank
generators were tested for stable simultaneous switching of all
four SiC MOSFETs. In the second step, the current in the resonant
network was evaluated for the desired waveform and amplitude.
And in the third step, the output pulse was measured.
A. SiC MOSFET Driving Circuit
Falling of the voltage VDS on SiC MOSFETs, during the
switching, is synchronous. Therefore, no extra voltage is redis-
tributed to the adjacent SiC MOSFETs in the Marx- bank circuits
during the switching and the probability for the SiC MOSFET
breakdown during the switching is thus minimized. If the power
supply voltage, VIN is approximately 700 V or more, VDS
after reaching the zero voltage, during the switching, slightly
increases because of SiC MOSFET saturation that is due to drain
current (ID ) rise. Therefore, the current in the resonant network
will not significantly rise with increasing the VIN over 700 V.
After the pulse generation, VDS exponentially rises to the sup-
ply voltage in approximately 280 μs because capacitors C1 are
recharging. Therefore, the maximum pulse repetition rate of the
generator that can be reached is 3.5 kHz.
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Fig. 8. The waveform of the L2 current, in the resonant network, is a
function of the power supply voltage (VIN ). For the analyzes the output
of the generator was short circuited. At its maximum, the L2 current
reaches 200 A and the ratio between its first minimum and maximum
is 1.7.
B. Resonant Network
The output of the generator was short-circuited and the L2
current was measured (Fig. 8) to analyze the operation of the
resonant network. By increasing the power supply voltage (VIN )
the L2 current linearly increases up to 600 V of VIN and at
700 V it saturates as predicted from the SiC MOSFET switching
analyzes. At its maximum the L2 current reaches 200 A and the
ratio between its first current minimum and maximum is 1.7,
which meets the expectations and is adequate for nanosecond
pulse generation by diode opening switch (DOS) [27].
C. Output Pulse
Measurement of the output pulse of the generator is not
straight forward, due to the short duration and at the same
time high-voltage. Commercially available high impedance,
high voltage probes for measuring voltage amplitudes up to
15 kV have bandwidth in range of 50–70 MHz (−3 dB). Dif-
ferential 100 MHz probes that can measure up to 6 kV are a
better choice for nanosecond pulse measurements, but can still
be too slow, due to their rise time, which is around 3 ns. The
best choice among commercially available probes for measur-
ing nanosecond pulses are high voltage pulse attenuators that
have bandwidths in GHz range and can measure up to 16 kV
(Barth electronics, USA), but they are expensive compared to
other previously described probes and thus not easily available
to all researchers working on nanosecond electroporation field.
Therefore, for the evaluation of developed device, a commer-
cially available probes with additional calibration were used. A
50 Ω commercial attenuators were tested to measure the output
pulse. The final attenuator was assembled from two N-type at-
tenuators and one BNC attenuator to achieve 60 dB ± 2.8 dB
attenuation. The factory graded accuracy of the attenuator is still
not satisfying, but at least it is possible to calibrate the atten-
uator satisfactorily, namely, the assembled attenuator measures
31 ± 2% lower amplitude. The 50 Ω input of the attenuator
of course influences the measurement, but in our case, the load
was replaced by the attenuator. With such attenuator, the output
pulses of the generator were measured (Fig. 9a). The shape of
the pulses is Gaussian, with insignificant reflections. However,
because the attenuators graded for 2.5 kVmaximum voltage and
in our case it broke at 4 kV. Consequently, a commercial high-
voltage differential probe (HVD3605, 6 kV, 100 MHz, LeCroy,
USA) was used to measure the output voltages over 4 kV. When
Fig. 9. Output pulse measurements by assembled attenuator (a) and
HVD3605 probe (b) as a function of the power supply voltage (VIN ).
Calculated output pulses taking into account the calibration constants
31% for the assembled attenuator and 5% for the HVD3605 probe.
Fig. 10. Duration (a) and rise time (b) of the output pulses in case of
assembled attenuator and in case of HVD3605 probe as a function of
the power supply voltage (VIN ).
the HVD3605 probe is compared with the assembled attenuator
a 5% loss in the amplitude is observed and reflections of the
pulse arises (Fig. 9b). Measured pulse duration and rise time are
shorter if measured with assembled attenuator in comparison to
HVD3605 probe (Fig. 10). Pulse duration vary from 7 to 10 ns,
while rise time vary from 4 to 10 ns. By increasing the power
supply voltage VIN up to 600 V, the amplitude of the output
pulse linearly rises (Fig. 11). Over the 600 V of VIN , due to the
saturation of the SiC MOSFETs, the rise in the output pulse am-
plitude gradually declines by increasing the VIN and at 900 V
of VIN the rise almost stops. The multiplication factor of the
input voltage VOUT /VIN is around 9 in the linear space and in
the saturation gradually falls to 7, at 900 V of VIN (Fig. 11).
On the figure (Fig. 12) we can see the output pulse amplitude
and the FWHM (duration of the pulse) dependency on the load
of the developed device. Our generator works as expected, also
with cuvette, the amplitude is slightly lower in case of electro-
poration cuvette than on a 50 Ω load, while the pulse duration
is a bit longer, mainly due to a smaller absolute reactance of the
load at generated pulse frequency spectrum [41].
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Fig. 11. Output pulse amplitude VOUT as a function of the power
supply voltage VIN with linear and saturated space of operation. And
the multiplication factor of the input voltage VOUT /VIN .
Fig. 12. The comparison of the output pulse amplitude (a) and FWHM
(b) generated on different loads. In first two cases we used 100 Ω and
50 Ω load resistor (TFSF100RJE-ND, Ohmite, USA). In second case
we added in parallel to 100 Ω load resistor an electroporation cuvette
with 1 mm and 2 mm spacing between the electrodes, filled with KPB
(Potassium phosphate buffer).
IV. DISCUSSION
The design of the generator is based on a SiCMOSFETs,Marx-
bank circuit and DOS. The RF MOSFETs, are still the most ap-
propriate for short nanosecond pulses generated by transmission
lines, which require fast rising times (Fig. 2). Whereas the SiC
technology is the most suitable technology for longer nanosec-
ond pulses or DOS generators as less elements are needed to
generate higher currents. For a SiC MOSFETs a special driver
circuit had to be develop that delivers the negative voltage on
the gate during the off stage. For the correct operation of the
Marx-bank circuit, the power supply and the control signal of
the driver have to be properly galvanically isolated and the gate
resistors have to be optimized for simultaneous switching of
all four SiC MOSFETs. Otherwise, electrical elements could be
damaged during the switching, especially the SiC MOSFETs and
the optocouplers. The current in the resonant network could be
increased by embedding one or two more Marx-bank circuits
in parallel. Nevertheless, 200 A appeared to be enough for our
aim [42] However, the resonant network and DOS configuration
that were taken from the previous publication [27] did not work
as expected. The rise time of the output pulse was much longer
than expected, consequently, also the amplitude of the output
pulse was not as high as expected. The causes for this under
performance could be a mismatched frequency of the resonant
network with reverse recovery time of the DOS, or the stray
impedance on the generator’s output. Even though, the ampli-
tude of the output pulse was not as high as expected, the mul-
tiplication factor VOUT /VIN is approximately 9, which is still
an improvement compared to the previously published linear
DOS generator [27]. The improvement was achieved primar-
ily through the use of SiC MOSFETs which enable more current
and Marx-bank circuit which in the same time delivers double
voltage to the LC oscillator. If the DOS would work as fast as
in the previous publication of the linear DOS generator, it is
expected that the multiplication factor would be 14. However,
the biggest challenge was to adequately evaluate the output
pulse. Researchers in the field of nanosecond electroporation
use various methods to measure the high-voltage nanosecond
pulses [36]–[39]. Due to conditional usability and high costs,
of commercial probes, the researchers often develop their own
high-voltage nanosecond probes. Also more costly commercial
high-voltage differential probes, for example HVD3605 probe
(LeCroy, USA), can be used for high-voltage nanosecond pulse
measurement. These probes are very accurate in theirwide band-
width, however, at the limit of the bandwidth, due to not themost
suitable connection terminals, the pulse reflection occurs and the
probe loses accuracy, but not more than −3 dB. For this rea-
son, we evaluated measuring error that occurs during the output
pulse measurement. The commercial calibrated RF attenuators
and the HVD3605 differential voltage probe were evaluated.
Because HVD3605 is not very accurate at high-frequency sig-
nals, we would suggest that a high voltage−20 dB attenuator is
made, or bought and then calibrated. And also that the commer-
cial wide band 50Ω attenuators are used to attenuate the signal to
the oscilloscope’s voltage level. Thus, each attenuator could be
accurately calibrated and the measurement of the high-voltage
nanosecond pulse would be more accurate. For the high-voltage
attenuator, we suggest using capacitive voltage divider if we do
not want to influence the measured signal, otherwise the 50 Ω
attenuator should be the most accurate and appropriate.
V. CONCLUSION
A nanosecond pulse generator was develop for “in vitro”
electroporation experiments using standard electroporation cu-
vettes. The generator can deliver from 500 V to more than
6 kV, approximately 8 ns pulses to a 50 Ω load. Two in par-
allel two-stage Marx-bank circuits can generate up to 200 A
current in the resonant circuit. As the SiC MOSFETs already go
into saturation at 600 V (Fig. 11). However, the biggest chal-
lenge in this study was to accurately measure the high-voltage
short nanosecond pulses. We have already emphasized [23] that
accuratemeasurement of the delivered nanosecond pulses is cru-
cial for the unbiased nanosecond electroporation experiments.
But it should be also emphasized that the bandwidth of the
probes ends at −3 dB which means that the probe at the end
of its bandwidth has a −29% error. A −29% error may be ac-
ceptable for electronics, however, a 29% different amplitude
may have a significantly different biological effect [43], [44].
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Because permeabilization and cell survival are sigmoid func-
tions of voltage, more than 10% difference in voltage may result
in a significantly different biological effect. For example, if we
focus on permeabilization curve, a ±29% deviation from the
real voltage amplitude result in totally different outcome. In one
case the majority of cells can be intact (i.e., not permeabilized)
while in other case, the majority of the cells can be permeabi-
lized [43], [44]. Whenever we are using measuring probes, we
have to be aware of themeasuring error. Commercially available
probes have the measuring error specified in a data sheet, but
it is still sometimes overlooked, while prototype probes have to
be correctly calibrated and measuring error evaluated.
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Germany: Springer, 2017.
[36] T. J. Camp et al., “Bioelectric studies with subnanosecond pulsed electric
fields,” in Proc. IEEE Pulsed Power Conf., 2009, pp. 876–879.
[37] A. Silve et al., “Implementation of a broad band, high level electric field
sensor in biological exposure device,” inProc. IEEE Int. PowerModulator
High Voltage Conf., 2010, pp. 711–714.
[38] P. Leveque and D. Arnaud-Cormos, “Measurement and characterization
of exposure systems for high-frequency, ultrashort pulses,” in Handbook
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Abstract
Background: Currently, high-frequency irreversible electroporation studies are in
full swing, but limited to a few research groups with custom made laboratory
prototype electroporators. According to the review of electroporators and
economic evaluations of electrochemotherapy and irreversible electroporation, we
came to the conclusion, there is still a potential area of pulse parameters that
needs to be investigated. The development of an asymmetric bipolar pulse
generator with a maximum voltage of 4 kV and minimum duration time of few
hundred nanoseconds, would enable in vivo evaluation of biological effects of
high-frequency electroporation pulses. First high-frequency electrochemotherapy
was performed in in vitro, by Scuderi et. al. and the developed device enables the
translation to in vivo.
Methods: In the paper we made an analysis and comparison between the most
commonly used drivers and optical isolation in high voltage pulse generators and
described in detail circuit topology of the developed device. The effectiveness of
electrochemotherapy with high-frequency electroporation pulses and ”classical”
electrochemotherapy pulses was compared.
Results: The developed device is able to generate 4 kV pulses, with theoretical
maximal current 131 A and 200 ns minimal pulse duration, the maximal pulse
repetition rate is 2 MHz and the burst maximal repetition rate being 1 MHz. The
device was validated also in vivo, electrochemotherapy with high-frequency
electroporation pulses was performed, which proved at least as effective as
electrochemotherapy with ”classic” well-established electric pulses, resulting in 86
% and 50 % of complete responses, respectively. Contrary to numerous reports,
muscle contractions were comparable between the two protocols.
Conclusions: The device enables research of still unknown effects, it facilities
further research of cancellation and sensitization effects in vivo. The desired
performance was reached and first in vivo high-frequency electrochemotherapy
was performed.
Keywords: electroporation; electroporation device; high frequency; bipolar;
asymmetric; SiC MOSFET; high voltage generation; pulse generator
Background
Electroporation is a phenomenon, whereby, due to the exposure to high voltage elec-
tric pulses, biological cells become permeable to molecules, which otherwise could
not cross the cell membrane [1]. We distinguish between reversible and irreversible
electroporation. If the cell membrane is able to fully recover, after the electric pulse
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application, the electroporation is reversible, but when the damage is too extensive,
the cell dies and we name it irreversible electroporation (IRE) [2]. Electroporation
is already well established in medicine and food processing [3, 4]. Additionally, the
technology holds great promise also in other fields, such as biomass production [5].
Different electroporation based applications require particular pulse parameters i.e.
voltage amplitudes, pulse width, a number of pulses or bursts and pulse repetition
rate [6, 7, 8]. Therefore specific pulse generators, i.e. electroporators have to be
designed and developed for each application. Additionally, electrical properties of
biological loads considerably vary and their conductivity changes during the pulse
application, due to electroporation [9, 10, 11, 12]. Therefore when designing an elec-
troporator, one should always keep in mind that, biological sample as a load has
resistive–capacitive nature and can vary from sample to sample and in addition the
impedance of a biological sample decreases during pulse delivery [13, 14]. In a recent
study [15] authors showed that because biological tissue is frequency-dependent, dif-
ferences in pulse frequency spectrum reflect in the induced transmembrane voltage.
In medicine, electrochemotherapy (ECT), an antitumor therapy, in which elec-
troporation introduces the chemotherapeutic drug into cells is well established [16].
According to the standard operating procedure intratumoral or intravenous delivery
of the chemotherapeutic drug bleomycin or cisplatin is followed, by the application
of eight high voltage pulses, which are monopolar, 100 µs long, with pulse repetition
rate 1 Hz or 5 kHz and voltage amplitudes between 1000 V and 1300 V (depending
on the electrode type) [17, 18, 19]. IRE is also an emerging medical application, used
as non-thermal ablation of normal and tumor tissue, as cells primarily die due to
membrane permeabilization and not due to increase of tissue’s temperature [20, 21].
It was shown that IRE does not cause the denaturation of proteins or scarring and
does not damage blood vessels. Therefore it has a potential ability to treat tumors
near large blood vessels. Additionally, the rapid activation of the immune system
was observed [22]. However, a local temperature increases around the electrodes can
be significant at higher amplitudes and due to a high number of pulses delivered
to a limited volume of tissue [23]. Also, nerve stimulation and muscle contractions
are associated to high voltage pulse delivery [24, 20]. These are also observed and
reported in ECT and require additional management (In order to reduce move-
ment, muscle relaxants are administered prior to treatment, but the dosage of those
relaxants should be monitored throughout the procedure [25, 26]) and synchronisa-
tion of pulse delivery with ECG, which complicates the treatment procedure [27].
Recently it was suggested that by applying high-frequency, bursts of bipolar pulses,
named H-FIRE (High-Frequency IRreversible Electroporation), muscle contractions
during IRE can be reduced without compromising the non-thermal mechanism of
cell death [28, 29] and at the same time, render electric field distribution in tissue
more homogeneous [28]. It was shown in vitro that the transmembrane transfer
of molecules may be achieved with the same type of pulses [30]. However, H-FIRE
pulses need considerably larger voltage amplitudes for cell disruption in comparison
to longer monopolar pulses [30]. With the potential advantages of IRE over current
ablation modalities, the technology seems uniquely suited also for cardiac ablation.
Currently, the research of electoporation as a potential treatment modality of atrial
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fibrillation (AF), which is the most commonly ablated arrhythmia, is in full swing
[31, 32]. A term ”Pulsed field ablation” (PFA) is defined as IRE that uses a train
of bipolar and biphasic pulses of high voltage and short duration to create tissue
injury without significant heating and therefore reduces the injury to nontargeted
tissues [33] .
Recently it was also demonstrated that it is possible to use HF-EP (high-frequency
electroporation) pulses in electrochemotherapy, but again, at the expense of higher
electric fields than in classical ECT. Scuderi et. al. [34] determined that in high-
frequency electrochemotherapy (HF-ECT) a higher electric field, equal to 3 kV/cm,
has to be established than in ”classical” ECT (1.3 kV/cm) to obtain comparable
effectiveness in vitro.
Previous studies indicated, that advantage of those specific high frequency elec-
troporation pulse characteristics might be in reducing muscle contraction and pain
sensation during high voltage pulse delivery [28, 29, 35]. It was shown that the elec-
tric field threshold for muscle contraction is two times lower than the threshold for
electroporation (for 100 mus long pulses) [35]. It was already reported that bipolar
pulses [36] in ECT and H-FIRE pulses [29] reduce muscle contraction and it was
also shown that IRE can be performed with a pulse duration of 1 µs by increas-
ing the number of electric pulses and voltage amplitude [29, 37, 38]. Also recent
reports have been describing the phenomena of electrical cell sensitization [39, 40]
and cancellation effect [41, 42] in the range of microsecond and sub-microsecond
pulse duration. These effects i.e. sensitization, cancellation and nerve and muscle
decreased excitation effects of the electroporation are still not well understood and
further studies are needed in particular in vivo, due to inconclusive results obtained
in vitro [43, 44]. Additionally, van Es et. al. [45] introduce a novel asymmetric, high-
frequency electroporation for HF-IRE and concluded that the use of the asymmetric
pulses enhances the feasibility of the HF-IRE method. Therefore, the development
of an asymmetric bipolar electroporator, with variable setting of pulse duration and
voltage amplitude for each half period of the pulse, would enable a new insight and
interesting investigations of cancellation and sensitization effects.
For the generation of electric pulses, with high voltage amplitudes, up to sev-
eral kV, there are basically three different circuit concepts used: a modular pulse
generator [46]; generator with serial switches [47]; Marx generator [48].
A simple solution is a generator with serial switches, where an array of n connected
switches is connected to a source. In this case, the synchronization of the switches is
necessary, for proper operation, the maximum generated voltage amplitude is equal
to the power supply voltage. In Marx generator topology, n capacitors are charged
in parallel and then, by switching on switches simultaneously, all capacitors are
discharged in series through the load. The maximal generated voltage amplitude
is equal to the power supply voltage multiplied by the number of capacitors. For
the generation of bipolar pulses a serial H-bridge generator is used, where in series
connected array of high voltage switches is connected to the H-bridge [49]. Also
a modular square wave pulse generator, can generate bipolar pulses if transistor
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bridge, that enables polarity change, is added at the output. The diagonal bridge
transistors in case of adequate control, change the polarity of the output voltage
[50]. But for the generation of asymmetric bipolar pulses, a serial H-bridge genera-
tor is the simplest and economically most reasonable solution.
Until now in all H-FIRE studies, custom made laboratory prototype electropora-
tors were used. Each research group has developed its own prototype device, with
specific topology, which is based on an H-bridge. Therefore the research is limited
only to a few research groups that have the knowledge to build such custom device.
However clinical bipolar electroporator should be designed and certified before the
implementation into clinical practice. In literature pulse delivery systems are most
often only briefly mentioned and not described in detail. Arena et. al. were one of
the first who developed a custom pulse generator, with maximal output rating of
the system equal to ±450 V and with a sufficient level of charge to deliver 20 A over
a 100 µs bursts [28]. In more recent studies of the same group [51], the burst con-
sisted of a train of 100 pulses of 1 µs duration and alternating polarity, with a delay
of 2 µs between each pulse, and also the amplitude was increased to 800 V. While
Sano et. al. managed to reduce the minimal pulse duration to 250 ns, the minimal
delay between the change of pulse polarity was still 1 µs. Their device is also able
to generate asymmetric pulse durations of negative and positive half period and the
voltage amplitude was increased up to 5 kV [52, 37, 53]. Yao et al. developed a IRE
bipolar electroporator and electrodes, the voltage amplitude is the study changed
in the range from 800 V to 2 kV. The device can generate pulses with constitutive
pulse widths from 1 µs up to 100 µs, but the burst repetition rate is equal to 1
s [54], similar device was used in the first clinical study using H-FIRE pulses by
Dong. et. al. [38]. Grainys et. al developed a bipolar symmetrical and asymmetrical
electroporator (± 1kV, 100 A) for in vitro electroporation and presented it in the
paper [49]. But for in vivo experiments, higher voltage amplitudes are required.
Mirai Medicals developed a CE approved clinical electroporation generator named
ePORE, it enables a simple and reliable delivery of ultra-short electrical pulses up
to 250 kHz and claim it eliminates he muscular contractions and pain associated
with the technology [55, 56].
According to the electroporators review [13, 57] and economic evaluations of ECT
and IRE [58, 59], that have been published, we came to the conclusion, there is still a
potential area of pulse parameters that needs to be investigated. The development
of an asymmetric bipolar pulse generator with a maximum voltage of 4 kV and
minimum duration time of few hundred nanoseconds, would enable in vivo evalu-
ation of biological effects of HF-EP pulses. In the paper, the work is presented in
three sections, in the methods and material part of the paper the importance and
the process of electronic component selection is described. Then the concept and
topology of developed electroporator are presented. In the results measurements
and evaluation of the developed device and in vivo use, with the focus on high
frequency electrochemotherapy.
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Results
Device Performance
For the evaluation of developed device we first used 80 Ω resistor as load, we con-
nected a 33 Ω resistor (AZ330KE, Ohmite, USA) and 47 Ω resistor (AZ470KE,
Ohmite, USA) in series. This value was chosen because mainly in vivo the resis-
tance of the tissue in combination with the needle electrodes is close to 80 Ω [60].
The measurement of monopolar and bipolar pulses with minimal pulse duration are
displayed in Figure 1. The capacitor charging voltage was set to 500 V and then
raised up to 4 kV with a step of 500 V. In order to reach expected 4 kV, we were
forced to increase the pulse trigger width to 260 ns, meaning the electroporator’s
minimal pulse duration increased to 200 ns. On Figure 1 (b) also a negative half
period was added, the delay between the trigger of the positive and negative half
period on digital delay generator was set to 200 ns. The pulse amplitude of de-
veloped device reaches desired 4 kV, and complete symmetry between both pulse
polarities can be observed.
In Figure 2. an asymmetric pulse generation is presented. The pulse width of a
positive and negative half period can be independently changed from 200 ns up to
1 ms (Figure 2(a)). The same applies also to the pulse amplitude (Figure 2(b)).
In Figure 2(a) the capacitor charging voltage was set to 4 kV and trigger pulse
duration was set to 260, 400 and 800 ns for both half periods. It can be observed
the pulse amplitude comes closed to 4 kV with the extension of pulse duration,
also the pause between both half periods is reduced with the extension of pulse
duration. While in Figure 2(b) the first half period was in all cases the same (4 kV
and trigger duration 260 ns), and the duration of trigger (260 ns, 400 ns, and 800
ns) and charging voltage of the second half period was changed (4 kV , 2 kV and 1
kV). Figure 2 demonstrates that the minimal pulse duration and highest amplitude
of the first half period has a good repeatability and can be followed by the pulse of
opposite polarity of any pulse duration or amplitude from the operation range.
The monopolar pulse measurements from Figure 2 were studied in detail. The rise
and fall time, as well as pulse duration and relative amplitude error, were calculated
for each measured voltage. The results are displayed in Figure 3. As expected both
rise and fall time of the pulse rises with pulse amplitude, however the maximal
value is still under 150 ns, which allows us to generate pulses with minimal pulse
duration of 200 ns at maximal voltage amplitude. The maximal relative voltage
amplitude error is 5 % which confirms the desired performance is reached.
High frequency electrochemptherapy in vivo
Finally, the device was tested ”in vivo”. In Figure 4 current and voltage measure-
ment of one HF-EP are displayed. Additionally, in the Figure 5 the measurement
of accelerations during the pulse delivery is presented. We compared the acceler-
ations in case of classical ECT pulses (eight monopolar, 100 µs long, 1 Hz pulse
repetition rate, and pulse amplitude 780 V) with eight burst of high frequency
1-1-1-1 µs (duration of a positive half period - pause between pulse half periods
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- duration of a negative half period - pause between bipolar pulses) long bipolar
pulses, with the same burst repetition rate as classical ECT pulse repetition rate,
but higher voltage amplitude 1950 V. No significant difference in the muscle con-
tractions was observed. Furthermore, the therapeutic effect of electrochemotherapy
with bleomycin in combination with HF-ECT pulses was compared. Both, ”classi-
cal” and HF-ECT electric pulses, significantly (p <0.05) potentiated the antitumor
effect of bleomycin. Namely, ”classical” ECT with bleomycin resulted in 50 % (3/6
mice) of complete responses and HF-ECT with bleomycin in 86 % (6/7 mice) of
complete responses. The difference between these two groups is however not signif-
icantly different. Survival of animals from these groups was significantly prolonged
compared to non treated control group or only EP treated groups. HF-ECT elec-
tric pulses significantly (p <0.05) prolonged the survival of animals compared to
control group. However, the difference between the two types of electric pulses was
not significant (Figure 6). Both, ”classical” ECT and HF-ECT were well tolerated
by animals. After the treatment, their body weights did not vary more than 5 %
(data not shown), and no treatment-related mortality was observed.
Discussion
Device Performance
The developed device is able to generate 4 kV pulses, with theoretical maximal cur-
rent 131 A and 200 ns minimal pulse duration, the maximal pulse repetition rate
is 2 MHz and the burst maximal repetition rate being 1 MHz. The device was first
evaluated on an 80 Ω resistor. Monopolar, as well as symmetric and asymmetric
bipolar pulse generation, was successfully demonstrated (Figure 1). Rise and fall
time increased with the capacitor charging voltage amplitude and therefore, also the
shape of the pulse is less squared and more bell-shaped, for 200 ns pulses as pulse
duration increases, i.e. FWHM decreases with voltage amplitude. The maximal rel-
ative error between the capacitor charging voltage and measured load voltage was
at maximum equal to 5 %, but with the extension of pulse duration, error decreases
and pulse shape is also more square shaped (Figure 2(a)). However, a slight volt-
age amplitude drop can be seen in Figure 2(a), which occurs due to the lack of
stored energy, the capacitor bank was not yet used in this first level of evaluation.
Figure 3(d) shows that relative error can be reduced also with the reduction of
the applied capacitor charging voltage. Because of a poor hardware reporting of al-
ready developed bipolar electroporators comparison is difficult, however parametric
comparison is possible. From the prospect of output pulse parameters, the main
innovation of presented device is ability to generate bipolar asymmetric pulses. We
also believe the minimal pulse duration in combination with such high voltage (4
kV) and asymertry was improved. Maximal output pulse amplitude is 4 kV, Sano
et. al. [52, 53, 37] reached 5 kV, however, we believe our device, with a 131 A
maximal current, can also be used for IRE.
The design proposed in this paper enables faster development and spread of the
high frequency electroporation (H-FIRE, and HF-ECT). Because the developed
electroporator also has an option of asymmetrical pulse delivery it enables research
of still not well investigated pulse parameter space in vitro and due to high maxi-
mum current also in vivo. The developed generator consists of newest component
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technologies presented in methods and material section, that enable even faster
switching times didt than previously described solutions [30, 49].
High frequency electrochemptherapy in vivo
On the second level of evaluation, the developed device was used in an in vivo ex-
periment treating subcutaneous tumors on mice to evaluate tumors responses and
muscle contractions present during HF-ECT. Therefore, accelerations of mice hind
leg during the pulse delivery was measured. Only a half of capacitor bank (four
capacitors) was used, because we used symmetric pulses. No voltage drop was de-
tected in in vivo measurements in Figure 4, meaning energy storage was sufficient.
In vitro experiments by Scuderi et. al. [34], showed that HF-EP could be used in
ECT. According to the Arena et. al. [28], high-frequency fields have the potential
to overcome impedance barriers posed by low conductivity tissues, which could
result in more homogenous and predictable treatment outcomes in heterogeneous
systems. Additionally one of the main benefits of high-frequency fields is potentially
alleviated muscle contractions and pain.
In the scope of this study we present the first in vivo experiments of HF-EP in
ECT. Scuderi et. al. [34] determined in vitro that in HF-ECT a higher electric field
(3 kV/cm), has to be applied than in ”classical” ECT (1.3 kV/cm) to obtain com-
parable cytotoxicity, therefore we applied the electric pulses with amplitude of 1950
V, which resulted in 3.25 kV/cm (voltage to distance ratio). ECT with bleomycin
and HF-EP proved at least as effective as ECT with classic well-established electric
pulses where 86 % and 50 % of complete responses were observed, respectively.
Additionally, preliminary data on ECT with cisplatin and HF-ECT pulses (n=2)
indicated that ECT with HF-EP is as effective as classical ECT, resulting in 100
% of complete responses. Contrary to numerous reports, muscle contractions were
comparable between the two protocols. These findings, in the case of HF-EP, are
not in compliance with published results of Ringel-Scaia et al. [61], where H-FIRE
caused no muscle contractions in comparison to IRE pulses delivered with nee-
dle electrodes. But we are the first who used plate electrodes in combination with
HF-EP. Direct translation from in in vitro to in vivo is thus not possible. In the
future the voltage amplitude should be optimized for in vivo HF-ECT, with plate
electrodes, which could result in reduction of muscle contractions.
Conclusions
The developed device operates in accordance with expectations, the maximal out-
put voltage is 4 kV and the theoretical maximal current 131 A and 200 ns minimal
pulse duration. The maximal pulse repetition frequency is 2 MHz. It generates
asymmetric bipolar pulses (amplitude and duration), pulse duration asymmetry,
as voltage amplitude asymmetry can be simultaneously provided. The device thus
enables research of still unknown effects, in poorly investigated µs range of pulse
parameters including further research of high-frequency electroporation therapies
in vivo.
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The device was first tested on a 80 Ω resistor and then in vivo on mouse tumor
model. In both cases the desired performance was reached. Additionally, accelera-
tion of mice leg during the pulse delivery was measured in order to evaluate muscle
contractions. More in vivo measurements should be done, before any final conclu-
sions can be made, but contrary to existing reports, we observed similar muscle
contractions in both protocols used. Most importantly, HF-ECT with bleomycin
and cisplatin proved as effective as the established ”classical” ECT with bleomycin
and cisplatin.
Methods and Materials
The output stage of a developed device is a custom made serial asymmetric H-bridge
generator which is in detail described in this section of the paper and presented in
the Figure 9. The capacitors are charged with a high voltage power supply MCP
350-1250 (FuG Elektronik GmbH, Germany) and then discharges through two series
of three SiC MOSFET’s connected in an H-bridge. Each MOSFET has its own
driving circuit, which are galvanically separated from each other. Two digital inputs
trigger the positive and negative output pulse generation. A logic circuit controls
triggers, in a way that only one can be active at the same time. In our previously
published paper [62] we already made an analysis and comparison between the most
commonly used semiconductor switching technologies in pulse generators. We again
chose the Silicon Carbide (SiC) MOSFET technology, which we believe is the most
suitable for high voltage and high current short pulse duration generators. Since the
manufacturer started to produce even more suitable SiC MOSFETs (C2M0045170D,
Cree, USA) with a drain to source voltage 1700 V and pulse drain current 160 A.
Thus only three MOSFET in series are needed in order to generate desired 4 kV
pulses on the output. When designing a driving circuit for SiC MOSFET it is
important to consider SiC MOSFETs special characteristics [63]. SiC MOSFET’s
have low transconductance, therefore must be driven with high voltage difference.
For fast switching times high dVdt of the Vgs is needed, meaning driving circuit should
have low impedance. For optimal switching also stray impedance of the driving
circuit must be minimal, therefore, lines connecting the SiC MOSFET driver to
power supply capacitors and gate terminal should be as short as possible.
The development of a versatile pulse generator started with the selection of the
appropriate electronic components. In this paper we desire to upgrade the driving
circuit presented in Pirc et.al [62], mainly by reaching higher dVdt , meaning we can
generate shorter pulses on the output. Therefore, we analyzed available drivers and
optical isolations.
Driver and optical isolation
In order to develop a generator that would be able to generate few hundred nanosec-
onds wide square wave pulses, with the best possible repeatability (good time pre-
cision) and at the same time high accuracy, we made an analysis and comparison
between the most commonly used drivers and optical isolation in high voltage pulse
generators. We were looking for a driver and optical isolation with a short mini-
mal FWHM (Full-Width Half-Maximum) and at the same time high common-mode
transient immunity (CMTI - dVdt ), because minimal FWHM and high CMTI define
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the electoporator’s output minimal pulse width. Additionally, the pulse width jitter
should be low for good time precision. Therefore we evaluated the minimal FWHM
and calculated the pulse width jitter of each component separately.
On the basis of the following characteristics: maximum working isolation volt-
age, CMTI, maximum pulse width distortion, maximal propagation delay skew
and maximal propagation delay, collected from the datasheets, we picked the fol-
lowing optical isolators: HCPL-0723(Avago Technologies, Brodcom, USA), HFBR
0508Z (Broadcom, USA), ADuM210N0BRIZ (Analog Devices, USA); and drivers:
IXDN609SI(IXYS, USA), MIC4422YM (Micrel, USA), UCC27531DBVT (Texas
Instruments, USA). Additionally, we evaluated also ADuM4223 (Analog Devices,
USA) and Si826BAD-C-IS (Silicon labs, USA), which are a combination of a driver
and optocoupler in one chip. For the evaluation we used an evaluation board of-
fered by the manufacturer (if available), otherwise, we made a custom board in
accordance with the manufacturer’s instructions or similar to other designs.
All the components under test were triggered with a function generator (33220A,
Agilent Technologies, USA) set to: 5 Vpp, with 2.5 Vpp offset, frequency 10 Hz, pulse
rise time 5 ns, pulse width 20 ns and number of pulses 30. The minimal trigger
FWHM is 20 ns if the component under test did not generate the output pulse, the
trigger FWHM was increased by steps of 10 ns. In the case of optical isolation eval-
uation, the output was measured with a high precision differential probe TDP1000
(Tektronix, USA) and displayed on the oscilloscope MSO4104 (Tektronix, USA).
While for the evaluation of driver, the MOSFET in series connected to a charged
capacitor and 100 Ω load resistor (TFSF100RJE- ND, Ohmite, USA), was added
and the pulse on the MOSFET was measured, with a high voltage differential probe
ADP305 (Lecroy, USA) and displayed on the oscilloscope Wavepro7300A (Lecroy,
USA). The capacitor was charged with a high voltage generator MCP 350-1250
(FuG Elektronik GmbH, Germany).
Minimal measured FWHM and jitter for optical solutions are shown in the Table
1 and for drivers in Table 2. The minimal FWHM in the Tables 1, 2 is defined
as an average of thirty measured FWHM’s at minimal trigger FWHM and jitter
is defined as the difference between maximal and minimal measured FWHM at
minimal trigger FWHM. Further in the paper for easier reading instead of FWHM
term pulse width is used.
The test showed ADuM4223 and Si826BAD-C-IS are less suitable for our appli-
cation, due to high pulse width. Therefore we excluded them from further testing.
HCPL-0723 has the highest jitter and according to the datasheet, also the lowest
CMTI, which is only 10 kVµs . HFBR 0508Z is actually a set of fiber optic trans-
mitter and receiver connected with a plastic fiber optic cable. Due to the higher
output pulse width and design complexity of HFBR 0508Z we finally deiced to use
ADuM210N0BRIZ in our electroporator, because of its high CMTI, which is 100
kV
µs and its best test performance.
IXDN609SI was the only driver that can be triggered with a 20 ns pulse, however,
it has the biggest jitter. Because we wanted to develop a device that would be
able to generate pulses as short as 200 ns, IXDN609SI is for our goal the most
appropriate component among the tested devices. Final driving circuit topology was
almost the same as presented in Pirc et.al [62]. Only two isolated DC-DC converters
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were replaced with one isolated DC-DC converter MGJ2D052005SC (Murata Power
Solutions, Japan) and optocoupler was changed. Optimal gate resistor value was
determined through testing in accordance with the performance requirements.
MOSFETs in series
After the selection of appropriate components, a monopolar prototype was built.
We connected three MOSFETs in series in order to evaluate the high voltage (4 kV)
switching, the feasibility of the series and selected components. On Figure 7, a basic
topology of the series is presented. Capacitors C1 (940C20W1K-F, Cornell-Dubilier,
USA) are charged by an HV power supply HCP350-6K5 (FuG Elektronik GmbH,
Germany) and when triggered discharged by a Rload 150 Ω resistor (AZ151KE,
Ohmite, USA). In parallel to each SiC MOSFET, a resistor R1 (SM102031004FE,
Ohmite, USA) is added, which ensures the uniform distribution of voltage over all
three MOSFETs. In order to be able to generate pulses as short as 200 ns on the
output load, rise and fall time should be lower than 50 ns. Trough the testing we
determent the minimal gate resistor (Rg) value that still keeps the circuit stable is
6.8 Ω. We tested also different compositions eg. turning on lower MOSFET slower
than the other two, however, in the end, the optimal results were obtained when all
three MOSFETs had the same value of Rg.
The circuit was triggered with a digital delay generator DG645 (Stanford Re-
search Systems, USA), the trigger pulse width was set to 100 ns. Output pulse was
measured with the oscilloscope HDO6104A-MS (Lecroy, USA), high voltage differ-
ential probe HVD3605 (Lecroy, USA) and current probe CP031A (Lecroy, USA).
The outstanding performance was reached, pulse voltage amplitude was 3.98 kV
and pulse current amplitude was 28.45 A, while the pulse rise time was only 40.8
ns and fall time 47 ns, meaning minimal FWHM that can be generated is 100 ns as
shown in Figure 8.
Asymmetric H-bridge
Four series of three MOSFETs presented in the previous section were connected in
an asymmetrical H-bridge in order to enable the generation of asymmetric bipolar
pulse. In Figure 9 the topology is presented, each block marked with S represents
one MOSFET series from the previous section (in Figure 7 marked with dashed
line). But now the divider resistors R1 were enlarged to 100 MΩ (SM102031006FE,
Ohmite, USA), with the intention to reduce the current through resistors and
therefore the voltage between the electrode in an off state, is kept bellow elec-
trode potential. Load resistor was also enlarged to 300 Ω and capacitor bank was
extended. Five C2 = 5 µF (B58033I9505M001, TDK, Japan) and C1 = 0.25 µF
(B58031U9254M062, TDK, Japan) capacitors were connected in series in a block
with R2 = 10 MΩ resistors for generation of each half period, meaning altogether
there are two blocks. The additional logical circuit (NOR gate (MC74AC02DG))
at the input ensured that only one trigger (for a positive or negative half period)
pulse is present at the same time. Because each MOSFET has maximal pulse drain
current equal to 160 A, the maximal theoretical output current of the device is
evaluated to be 131 A. We reduced the 160 A for 10 % and for the current flowing
through the electroporator (current flowing through the electroproator at 4 kV is
≈ 13 A, because load resit is equal to 300 Ω).
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Fabrication, assembly and measurements
The device displayed in Figure 10 was implemented on 6U (Eurocard) sized PCB
card, it is double-sided with 140 µm copper layer and solder stop mask. If available,
SMD electrical components were preferably chosen, trigger input connectors are
a 50 Ω SMA. During the PCB design, special attention was given to make lines
spaced for the high-voltage, and at the same time as short as possible and wide
enough for the high currents. As a trigger digital delay generator DG645 (Stanford
Research Systems, USA), generates two trigger pulses, one for positive and one for
negative half period generation Output pulse was measured with the oscilloscope
HDO6104A-MS (Lecroy, USA), high voltage differential probe HVD3605 (Lecroy,
USA) and current probe CP031A (Lecroy, USA). Capacitors were charged with a
high voltage generator MCP 350-1250 (FuG Elektronik GmbH, Germany). The mea-
surements were analyzed in Matlab R2018b (MathWorks, Natick, Massachusetts,
USA). The rise/fall time was defined as the time required for a pulse to rise/fall
from 10/90 % to 90/10 % of the maximal measured voltage. Pulse width is defined
by FWHM a time passed between the first crossing and second crossing of 50 %
of the maximal measured voltage. And the pulse voltage amplitude was defined as
an average value above the 95 % of the maximal measured voltage. Additionally, a
relative error was determined as a difference between capacitor charge voltage and
calculated maximal measured pulse voltage amplitude.
In vivo experiments
Animals
Animal experiments were conducted in accordance with the principles and proce-
dures outlined with the guidelines for animal experiments of the EU directives and
the permission from The Administration of the Republic of Slovenia for food safety,
veterinary and plant protection (permission No.: U34401-1/2015/43). In vivo exper-
iments were performed on 8-week-old female Balb/c mice (Envigo, Udine, Italy) that
were maintained under specific pathogen-free conditions at constant room temper-
ature in a 12-hour day/night light cycle. Food and water were provided ad libitum.
One day prior to tumor induction, mice were shaved on their right flanks. Approx-
imately 7 days after the subcutaneous injection of 0.5 ∗ 106 CT26 cells (American
Type Culture Collection, Manassas, VA, USA) or when the tumors reached 40 mm3,
mice were divided into experimental groups (6-7 animals) and electrochemotherapy
with bleomycin or cisplatin was performed.
Treatment protocol
Two electrochemotherapy protocols with bleomycin or cisplatin were compared
in vivo: electrochemotherapy with well-established ”classical” ECT pulses and
electrochemotherapy with HF-ECT pulses. Treatment consisted of intratumoral
bleomycin (Bleomycin medac, Medac, Wedel, Germany; 5 µg; 40 µL) or cisplatin
(Cisplatina Kabi, 1 mg/mL, Fresenius Kabi AG, Bad Homburg, Germany; 40 g; 40
l) injection followed by electroporation 2 minutes later. For application of electric
pulses, plate parallel stainless-steel electrodes 6 mm apart were used. A water-based
gel was used to ensure good conductivity at the point of contact between electrodes
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and the skin overlaying the tumors. Physiological solution (40 µL) was used instead
of bleomycin or cisplatin in the control group and groups with electric pulses only.
During treatment mice were under inhalation anesthesia.
In case of ”classical” ECT, electric pulses were delivered with a commercially
available BetaTech electroporator (Electro cell B10, Leroy, France). Electric pulse
parameters: 780 V, 1.3 kV/cm voltage over the distance between the electrodes,
eight 100 µs long pulses were applied in two perpendicular direction (4+4) at 1 Hz
repetition frequency. HF-ECT were delivered by the newly developed electropora-
tor. One combination of parameters of electric pulses was tested, eight, 100 µs long
bursts of bipolar square wave pulses 1 µs - 1 µs - 1 µs - 1 µs (duration of a positive
half period - pause between pulse half periods - duration of a negative half period -
pause between bipolar pulses) were applied with plate electrodes. The pulse voltage
amplitude was set to 1950 V (3.25 kV/cm voltage to distance ratio). For this a
capacitor bank was added, which consists of eight capacitors 947D501K112BJMSN
(CDE- Cornell Dubilier, USA) connected in two independent series. Four in series
connected capacitors, are discharged at positive and the other four at negative pulse
generation. The capacitor bank stores a sufficient amount of energy, to prevent an
increase of voltage drop over 5 % of the preset voltage.
The therapeutic effect was followed three times per week by measuring tumor vol-
ume using a vernier caliper. Tumor volume was calculated by the following formula:
V = a ∗ b ∗ c ∗ π6 , where a, b and c were three mutually orthogonal tumor diame-
ters. Mice were humanely sacrificed when the tumor volume reached 350 mm3. A
Kaplan–Meier survival plot was constructed with the tumor volume of 300 mm3
representing the endpoint event.
In the scope of this study we also evaluated the muscle contractions during pulse
delivery. Therefore a triple axis accelerometer BMA220 (DFRobot, China), was
connected to Arduino UNO (Arduino, USA) on which software captured and saved
the measurements, which were analysed post festum in Matlab. The absolute ac-
celeration was calculated and gravitation was not excluded. The accelerometer was
taped with a micropore tape to the right hind foot during pulse delivery, which
caused no pain.
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9. Langus, J., Kranjc, M., Kos, B., Šuštar, T., Miklavčič, D.: Dynamic finite-element model for efficient modelling
of electric currents in electroporated tissue. Scientific Reports 6 (2016)
10. Neal 2nd, R.E., Garcia, P.A., Robertson, J.L., Davalos, R.V.: Experimental characterization and numerical
modeling of tissue electrical conductivity during pulsed electric fields for irreversible electroporation treatment
planning. IEEE Transactions on Biomedical Engineering 59(4) (2012)
11. Ivorra, A., Al-Sakere, B., Rubinsky, B., Mir, L.M.: In vivo electrical conductivity measurements during and after
tumor electroporation: Conductivity changes reflect the treatment outcome. Physics in Medicine Biology
54(19), 5949 (2009)
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23. Cornelis, F.H., Cindrič, H., Kos, B., Fujimori, M., Petre, E.N., Solomon, D.M.S.B., Srimathveeravalli, G.:
Peri-tumoral metallic implants reduce the efficacy of irreversible electroporation for the ablation of colorectal
liver metastases. Cardiovasc Intervent Radiol. (2019)
24. Davalos, R.V., Mir, L.M., Rubinsky, B.: Tissue ablation with irreversible electroporation. Ann Biomed Eng
33(2), 223 (2005)
25. Ball, C., Thomson, K.R., Kavnoudias, H.: Irreversible electroporation: A new challenge in out of operating
theater anesthesia. Anesthesia Analgesia 110(5), 1305–1309 (2010)
26. Landström, F.J., Nilsson, C.O., Crafoord, S., Reizenstein, J.A., Adamsson, G.B., Löfgren, L.A.: Electroporation
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Figures
Figure 1 Output pulse measurement The measurement of monopolar (a) and bipolar (b) pulse
on a 80 Ω load resistor. The capacitor charging voltage was set to 500 V and then raised to 4 kV
with a step of 500 V.
Figure 2 Output pulse measurement An example of symmetric (a) and asymmetric (equal
charge) (b) bipolar pulse generation, the pulse width of a positive and negative half period can be
independently changed and as well also the pulse amplitude.
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Figure 3 Output pulse measurement The rise (a) and fall time (b), as well as pulse duration
(FWHM)(c) and relative amplitude error δU (d) for each measured monopolar pulse from the
Figure 5(a).
Figure 4 In vivo measurement In vivo measurement of applied voltage and current trough the
electrodes: (e) Fourth burst of 1-1-1-1µs long bipolar pulses with the voltage amplitude set to
1950 V; (d) Measured fourth burst of current trough the electrodes; (c) Eight 100 µs long bursts
were applied with the pulse repetition rate equal to 1 Hz (bursts were sequentially measured,
meaning the pause between bursts was not measured). (a) and (b) are zoomed in measurements
of (c) and (d), which demonstrate that, no voltage drop during the pulse was present.
Tables
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Figure 5 Mice leg acceleration measurement Measured absolute acceleration, of mice leg in case
of: (a) classical ECT pulses, (b) bursts of bipolar pulses. Blue and orangre represent two individual
measurements. Some noice is present in the pause between pulses, which was most likely caused
by the person holding the mice and electrodes.
Figure 6 Animal survival Survival of animals treated with electrochemotherapy with bleomycin
(BLM) using classical ECT pulses or HF-ECT pulses.
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Figure 7 MOSFETs in series Basic topology of three MOSFETs in series, each MOSFET has its
own driving circuit which is in the figure presented as a box marked with initials D.C.. Dashed
line, defines a a box S, four of those boxes are for the purpose of bipolar pulse generation
connected in H-bridge (Figure 3)
Figure 8 Measurement of the output pulse Measurement of the output pulse, generated by
series of three MOSFETs: (a) Measured voltage on the 150 Ω load resistor. (b) Measured current
trough the 150 Ω load resistor.
Figure 9 Basic topology of H-bridge Each block marked with S represents one MOSFET series
from the previous section (in Figure 1 marked with striped line). Additional logical circuit (NOR
gate (MC74AC02DG)) at the input ensured that only one trigger pulse is present at the same
time.
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Figure 10 The developed device The developed H-bridge circuit is implemented on double-sided
PCB 6U board and installed on a custom made capacitor bank.
Table 1 OPTICAL ISOLATORs: Mean values of minimal FWHM further defined as pulse width and
jitter for a set of 30 measurements, for different optical isolators under test.
component set/masured trigger width [ns] output pulse width [ns] jitter [ns]
HCPL-0723 20/19.10 18.53 1.04
ADuM4223 50/49.45 40.98 0.75
Si826BAD-C-IS 30/28.65 13.84 0.29
HFBR 0508Z 20/19.25 30.2 0.93
ADuM210N0BRIZ 20/21.37 18.28 0.26
Table 2 DRIVERs: Mean values of minimal FWHM and jitter for a set of 30 measurements, for
different drivers under test.
component set/measured trigger width [ns] output pulse width [ns] jitter [ns]
IXDN609SI 20/20.4 44.36 9.45
ADuM4223 70/69.99 67.53 1.98
UCC27531DBVT 110/109.23 57.27 3.8
MIC4422YM 40/39.82 125.26 2.55
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Abstract
Final goal of the study is to estimate the cost-effectiveness of electrochemotherapy 
for the tre-atment of basal-cell carcinoma and skin melanoma. Paper consists of 
two parts: the first part presents basic principles and concepts of health technology 
assessment and cost-effectiveness analysis, and the second part reports an early 
cost-effectiveness analysis of electrochemothe-rapy for the treatment of basal-cell 
carcinoma and skin melanoma that we are developing. Few cost-effectiveness 
analyses of electrochemotherapy have already been done, but with a lack of 
information about intervention effectiveness in terms of quality of life, which may 
result in inac-curate or even inadequate conclusions. In order to obtain the most 
realistic results, two general Markov models and their reduced versions for initial 
calculations are presented. The models were designed specifically to assess 
electrochemotherapy of basal-cell carcinoma and skin me-lanoma. Also, data 
required for successful calculations have been identified, some of which are missing 
and will be collected within different studies which are still under way, including 
rando-mized control trials. Additionally, recommendations for data collection 
process and follow-up reporting are made. With this paper we want to raise 
awareness about the importance of nume-ric quality of life reporting and 
usefulness/meaning of EQ-5D questionnaire that might not be self-evident at first 
sight, but are crucial for cost-effectiveness analysis.
Izvleček
Končni cilj projekta je izdelava analize stroškovne učinkovitosti (angl. Cost-
Effectiveness Analysis) elektrokemoterapije za zdravljenje bazalnoceličnega 
karcinoma in kožnega melano-ma. Prispevek je sestavljen iz dveh delov. V prvem 
delu prispevka so predstavljeni osnovni kon-cepti in postopki vrednotenja 
tehnologij v zdravstvu (angl. Health Technology Assessment) in analize stroškovne 
učinkovitosti, v drugem delu pa poročamo o zgodnji stroškovni analizi (angl. early 
Cost-Effectiveness Analysis) elektrokemoterapije, kot terapije za zdravljenje 
bazalnocelič-nega karcinoma in kožnega melanoma, kar je predmet naše študije. 
Nekaj stroškovnih analiz je že nastalo vendar zaradi pomanjkanja podatkov o 
učinkovitosti zdravljenja, v smislu povečanja kakovosti življenja bolnikov (angl. 
Quality of Life ), zaključki ne morejo biti točni. Da bi izdelali čimbolj relevantno 
analizo, v članku predstavljamo dva splošna Markova modela in njuni poe-
nostavljeni različici, ki ju bomo uporabili za začetne izračune. Modela sta bila 
zasnovana posebej za analizo elektrokemoterapije bazalnoceličnega karcinoma in 
kožnega melanoma. Dodatno so opredeljeni tudi potrebni podatki za uspešne 
izračune. Manjkajoče podatke bomo zbrali v okviru različnih študij, ki še vedno 
tečejo, vključno z randomiziranimi kliničnimi študijami. Predstavlje-no je tudi 
priporočilo za poročanje, ki bi olajšalo zbiranje podatkov. S tem prispevkom 
predvsem želimo dvigniti splošno ozaveščenost o pomembnosti številčnega 
poročanja o kakovosti življe-nja in uporabnosti oziroma pomenu vprašalnikov 
EQ-5D, ki na prvi pogled morda nista samou-mevna, vendar sta bistvenega pomena 
za analizo stroškovne učinkovitosti.
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1. Introduction
Electroporation is an evolving tech-
nique with many applications (1-4); in 
this article the focus is on one of the 
most successful, i.e. electrochemothe-
rapy (ECT). ECT is an antitumor the-
rapy that increases the cytotoxicity of 
chemotherapeutic drugs such as bleo-
mycin and cisplatin by the help of appli-
ed electric pulses. Electroporator is a de-
vice that generates high-voltage electric 
pulses, which are delivered to the tissue 
trough electrodes (5). If the electric fi-
eld generated between the electrodes is 
sufficient, the permeabilization of the 
target (tumor) cells is triggered and en-
trance of the previously injected che-
motherapeutic drug into cells (within 
the tumor) is enabled (6). As a result, 
electrochemotherapy is a highly efficient 
treatment, with complete response rates, 
based on a single treatment between 60 
to 70 % and objective response rates up 
to 80 % (7).
Basal-cell carcinoma (BCC) is the 
most common form of skin cancer 
and its incidence is still increasing 
mainly due to the population ageing. 
Worldwide, every year two to three 
million patients are diagnosed with 
non-melanoma skin cancer (8). The 
current gold standard for the treatment 
of BCC (and other skin malignancies) 
is surgical excision (9), but for patients 
that are unsuitable for conventional tre-
atments, ECT offers a good alternative. 
Specifically, in the treatment of BCC, 
the objective response rates after a sin-
gle ECT session are close to 100 % (75). 
Upon that, the surrounding tissue re-
mains undamaged and, consequently, a 
good cosmetic outcome is obtained. In 
most cases, ECT can be performed as an 
outpatient procedure under sedation or 
local anaesthesia. Therefore, treatment 
with ECT results in a considerably 
shorter hospital stay, faster recovery 
and reduced health care costs (10). ECT 
diminishes the need for surgery, it can 
be a feasible treatment option for cuta-
neous lesions resistant to other therapi-
es or can serve as an adjunct to other 
therapies. The UK National Institute for 
Health and Care Excellence (NICE) de-
emed that ECT was a safe treatment for 
primary BCC, however it also warned 
about the limited evidence for its effica-
cy (11).
In western countries the incidence 
of melanoma has been increasing for 
as long as recorded (12). Melanoma 
spreads by lymphogenous and also by 
hematogenous route. ECT is a stan-
dardised procedure for the treatment 
of superficial metastases of melanoma 
resistant to other treatments. Skin me-
tastases of melanoma occur in 2–20 % 
of melanoma patients (13). ECT has se-
veral advantages: the treatment can be 
administered in an outpatient setting 
under local anaesthesia and deep seda-
tion; it can also be scheduled as a day-
-care or day-hospital procedure under
general sedation; repeated sessions can
be performed with a minimum inter-
val of one to two weeks (14-17). Overall
ECT can be considered as “patient
friendly” procedure with effective-
ness consistently reported throughout
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the reports. Its effect can be localised, 
thus reducing side effects. Later in the 
article, the focus is mainly on the co-
st-effectiveness of ECT, which will fa-
cilitate a comparison of ECT to other 
treatment options, not only with re-
spect to its effectiveness but also its 
cost effectiveness.
Screening and evaluation of medical 
technologies is becoming crucial, as in 
most of the developed countries health 
care expenditures are constantly increa-
sing, while at the same time budgets are 
getting tighter (18). In Slovenia, health 
care spending is currently estimated 
below the European average (19,20). 
Between years 2002 and 2008, health 
care spending in Slovenia amounted to 
between 7.49 % and 8.08 % of GDP. It 
spiked in year 2009 to 8.56 % of GDP 
and has been between 8.5–8.73 % of 
GDP ever since (19,21). Unfortunately, 
based on demographic data, the fo-
recast is not reassuring. In year 2017, 
18.7 % of Slovenian population is older 
than 65 years (22). The projections show 
that this number is going to be approxi-
mately 33.6 % by 2060, what will una-
voidably result in a significant increase 
in health care expenditure. Simulations 
show that health care expenditure 
will increase from 0.5 % up to 2.8 % of 
GDP per year, by the year 2060 (23). 
Independently of the relative or abso-
lute expenditure per year, the health 
care national budgets are in any case li-
mited. Therefore, decision makers have 
to consider carefully all public money 
spending, especially since, in limited 
budget scenarios, the introduction of a 
new technology may result in the exclu-
sion of an old one. There are however 
cases where innovations were inclu-
ded into the medical practice, without 
any previous economical evaluations 
and had to be abandoned later due to 
economic inefficiency (73). The intro-
duction of new technologies in the 
Slovenian public health care system is 
still relatively arbitrary. Each innovati-
on is evaluated according to three cri-
teria: i) health effectiveness (the more 
severe the disease is the more points it 
gets); ii) professional justification of the 
program (meta-analyses and systematic 
literature reviews get the most points, 
regardless of the results); iii) economic 
efficiency (only price is considered here, 
the cheaper the innovation is, the more 
points it gets). All innovations are than 
ranked on a priority list according to 
the number of points collected (24).
Therefore, an efficiency improve-
ment of health care systems is necessary. 
Choices about providing health care in-
terventions, based on available evidence 
regarding safety, effectiveness and cost 
effectiveness thus have to be made (18). 
Widely used in most developed coun-
tries is a Health Technology Assessment 
(HTA) evaluation process. HTA is a 
structured process aiming to inform 
decision makers about choices which 
can be used to allocate healthcare bud-
get (25). In the majority of cases, HTA 
provides an estimate of the incremental 
cost-efficacy ratio (ICER), which infor-
ms decision makers about the gain in 
terms of quality of life per cost that the 
introduction of a new technology will 
produce (77). This article reports on an 
early cost-effectiveness analysis (eCEA) 
of ECT for the treatment of BCC and 
skin melanoma that we are developing. 
The first part of the paper introduces 
basic concepts of HTA and CEA, while 
the second part reports on a case study 
of electroporation based treatments, in 
particular ECT for BCC and skin mela-
noma.
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2. Health technology
assessment
According to the World Health 
Organization (WHO), Health technology 
assessment (HTA) refers to the systema-
tic evaluation of properties, effects, and/
or impacts of health technology. It is a 
multidisciplinary process to evaluate the 
social, economic, organizational and et-
hical issues of a health intervention or 
health technology. The main purpose of 
conducting an assessment is to inform a 
policy/decision maker (26). The evalua-
tion can be applied to systems, general 
equipment, instruments, hardware and 
software as well as to procedures, stan-
dards, norms, staff skills, professional 
knowledge, drugs, public health pro-
grams, etc. However, HTA is currently 
manly employed for the pharmaceuti-
cals. Slowly it is being claimed also for 
biomedical devices, where slightly di-
fferent methods or at least some modi-
fications of currently used methods are 
required (27). Main outcome of such 
evaluation should provide information 
about the costs /economic effectiveness, 
savings, performance, safety, ethical and 
social impacts and improvements of the 
investigated treatment/drug. Finally, the 
question that needs to be answered is: 
“Do we really need this technology and 
why?”.
The formal proof of HTA can be fo-
und in systematic reviews, meta-analy-
ses and randomized controlled clini-
cal trials (28). A multi criteria decision 
analysis is suggested by which one can 
evaluate the cost-effectiveness through 
the benefits of quality adjusted life ye-
ars (QALY). One of these analyses is the 
Cost-Effectiveness Analysis (CEA); its 
basics concepts and principles are pre-
sented in the following section.
Unlike drugs, which cannot be 
commercialised if sufficient evidence 
on their effectiveness is not collected, 
medical devices can be marketed after 
their safety has been proven. As a con-
sequence, decision makers are called to 
make choices while cost-efficacy evi-
dence is not fully available, especially 
for innovative technologies. Therefore, 
in the past years there has been a signi-
ficant diffusion of early HTA (eHTA) or 
early economic analyses (78,79). In those 
cases, the limited clinical evidence that 
is available is projected using statistical 
methods, the costs are estimated assu-
ming the worst case (i.e., max costs) and 
the uncertainty is quantified using sta-
tistical techniques. As a result, an eHTA 
informs the decision makers about the 
incremental risk-opportunity ratio, whe-
re risk is considered as a potential cost 
and the opportunity is considered as po-
tential effectiveness. An eHTA assumes 
that proper HTA analyses are preformed 
when sufficient clinical data are availa-
ble. The alternative would be to just wait 
and postpone the introduction of medi-
cal devices that can potentially save lives 
or increase significantly life quality, but 
this is not feasible with medical devices 
because their lifecycle is much shorter 
than that of drugs.
2.1.  Cost-Effectiveness 
Analysis
There is a wide variety of approaches 
to economic evaluations of health tech-
nologies, one of them being cost-effecti-
veness analysis (CEA), which measures 
the incremental resources required for a 
new intervention in monetary units and 
the technology impact on patient health 
using different scales. In this paper, the 
focus is on the CEA, which measures 
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impact on health in terms of quality 
of life, which is known as cost - utility 
analysis (29).
2.1.1. Quality of life 
(QoL) and QALY
In HTA it is assumed that people in 
their life move through different he-
alth states, each of those states has a 
specific value attached to it - Quality 
of life (QoL). QoL describes a quality 
of individual’s daily life, including so-
cial, emotional and physical aspects. 
For evaluating QoL, health care indi-
ces that provide information how he-
alth care influences patients, known as 
Health Adjusted life Years (HAYs), are 
used. One of them is Quality Adjusted 
Life Years (QALY), which is a gene-
ral index (i.e., not disease specific), 
and a unit of health care outcome 
that merges length of life with quali-
ty of life. QALYs are used in the Cost 
Effectiveness Analysis (CEA) to deter-
mine the ratio of incremental costs (i.e., 
new technology versus a benchmark) 
to QALY gained. The index is defined 
as the value-weighted time-life-years, 
weighted by their quality-accumulated 
over the time (30). QoL is normalized 
to a standardized scale with ranges 
from 0.0 (death) to 1.0 (perfect health). 
According to some authors, negative 
values can also be reached, describing 
states worse than dead (e.g., dementia 
and coma are often considered equal to 
or worse than death (31)). Widely used 
and translated into most languages is 
the EuroQol (EQ-5D) evaluation tool 
(questionnaire), which is a standardi-
zed instrument for use as a measure of 
health outcome (The study/trial/project 
that use EQ-5D should be registered; 
see also: https://euroqol.org/support/
how-to-obtain-eq-5d/) (32,33). It is also 
one of the measures recommended for 
use in cost-effectiveness analyses by the 
Washington Panel on Cost Effectiveness 
in Health and Medicine (34) and NICE 
(National Institute for Health and Care 
Excellence) (35). The health status is 
measured in five dimensions: mobility 
(walking ability); self-care (ability to 
wash or dress); usual activities (such as 
“work, study, housework, family or le-
isure activities”); pain/discomfort; and 
anxiety/depression. The respondents 
rate each dimension. There are two 
versions with a three-level (EQ-5D-3L, 
which rate each dimension using three 
values: ‘0’, indicating no problems, ‘1’ in-
dicating some problems, or ‘2’ indicating 
huge problems) and a five-level (EQ-
5D-5L) scale. On the basis of patients’ 
evaluation of their physical, social and 
cognitive functions final index – value 
is calculated. Therefore, the EQ-5D-3L 
defines 243 potential health states (i.e., 
35), which together with two additional 
states for dead or unconscious give a to-
tal of 245 health states. For example, a 
year of perfect health is worth 1 and all 
non-perfect health years are worth less 
than 1, depending on the burden of the 
disease to the patient (36). Thus an in-
tervention that generates six additional 
years in a health state valued at 0.65 will 
generate more QALYs than compara-
ble technique that generate seven years 
in health state estimated at 0.5. There 
are also some other measurement in-
struments available that are frequently 
used in parallel or alternatively, such as 
Nottingham health profile, Quality of 
life Scale (QUOLS) and others (37-40). 
Since healthcare budget is always limi-
ted (sometimes scarce) and the intro-
duction of a new technology may result 
in the exclusion of another, it is impor-
tant to use a general index (e.g. QALY) 
in order to quantify the benefit on the 
whole national population (41,73).
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Figure 1: Incremental cost-effectiveness plane/diagram (70). 
The resulting ICERs are presented graphically as a ratio 
between costs and the effectiveness/utility or as a distribution 
with uncertainty in cost-effectiveness plane. Four quadrants 
represent all combinations of possible outcomes. The more 
effective outcomes are located further right on the x-axis, and 
with the rise of y-axis the cost of the outcome rises (69). An 
ICER of an innovation that is more costly and more efficient 
then the benchmark is located in the first quadrant; in case of 
a more costly and less efficient technology, ICER is in second 
quadrant. Other options can be derived from the figure.
2.1.2. Incremental 
cost ratio (ICER)
The result of CEA is presented with 
incremental cost ratio (ICER). ICER is 
defi ed as the additional cost per addi-
tional benefit/utility that is measured 
in QALY. Because QALY has a normal 
distribution and a sum of two normal 
variables is also normally distributed, 
ICER can be calculated as a ratio of two 
asymptotically normal variables (42). 
In the following equation (Eq. 1) tre-
atment B represents a gold standard or 
benchmark to which new treatment X, 
e.g. electrochemotherapy, is compared.
(1)
The visualization of ICER is a dis-
tribution over a sample population, it 
is presented with a four quadrant cost-
-effectiveness plane that illustrates the
relation between an incremental levels
of effectiveness (utility gained) of an
outcome and additional total cost of
implementing this outcome (Figure 1).
In case when new technology is more
effective and cost efficient (fourth qu-
adrant in Figure 1), compared to the
benchmark, i.e. treatment B, than the
innovation, i.e. treatment X, is for sure
more suitable and worth of adopting.
More commonly the outcomes of CEA
of new technologies are divergent, for
example the innovation is more effecti-
ve but also more costly (case 1 and 2 in
Figure 1). It should be decided whether
the incremental utility is worth the cost
and sustainable (43).
Maximum acceptable ceiling ra-
tio (max ICER) is the threshold or the 
maximum amount that a decision-ma-
ker is prepared to pay for one incremen-
tal QALY. It is drawn in the cost-effecti-
veness plane, as a threshold line (Figure 
1, red line). If the calculated ICER falls 
below this line, the new technology is 
considered cost effective and is adopted 
(cases 1 and 4 in Figure 1), otherwise it 
is rejected based on its cost-ineffecti-
veness (cases 3 and 2 in Figure 1) (44). 
Decisions, which apply to the public 
health care thresholds and acceptable 
outcomes of maximum ICER, are sug-
gested by the WHO, however the pro-
blem remains how to apply these thre-
sholds to each specific case. As analyses 
are often made by commercial entities 
with vested interests, the results may 
favor the new technology. It thus ne-
eds to be taken into account that the 
evaluator’s subjective impact is always 
present. Another question that is also 
present is, how much the society shou-
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ld pay for a QALY. According to the ge-
nerally present opinion, e.g. in the UK, 
a QALY is worth somewhere between 
£20,000 and £30,000  (44). In Slovenia, 
rather than having a maximum value 
defined, each innovation is placed on 
a priority list of admission based on 
the evaluation of the following crite-
ria: health effectiveness; quality of ju-
stification of recommended program; 
economic effectiveness (high scores 
correlate with lower costs); population 
perspective (more patients more po-
ints); and organizational efficiency. The 
quality of life is not considered in the 
evaluation.
CEA always includes a comparison 
of a new technology to the benchmark 
technology, if available. The innovati-
on cannot be cost effective by itself, it 
has to be cost effective compared to the 
benchmark. In a CEA, a treatment pro-
ducing an additional 0.5 QALY at an in-
cremental cost of €3,000 per patient, is 
considered having a cost of €6,000 per 
QALY (i.e. €3,000 /0.5 QALY = €6,000 /
QALY) (36).
2.1.3. Discounting
It should always be taken into acco-
unt that values of costs and outcomes 
change with time (29). Because the CEA 
are projected through a certain period of 
time discounting is necessary. Cost and 
outcomes should be discounted relative 
to their present value at the rate of 3 % 
or up to 5 %, per year (29). The cost di-
scount rate can be estimated from the 
equation (Eq. 2). Some authors suggest 
a common rate for costs and outcomes 
and others prefer a lower rate for ou-
tcomes. NICE discounting guidance for 
cost effectiveness analysis (45) requires 
that both costs and health outcomes are 
discounted at 3.5 % (46).
(2)
For example, if the present value of 
cost is €2,500 and a 5 % discount rate 
is used, one year in the future, the cost 
will be €2,375 and 5 years in the future 
the expense will be only €1,875. The same 
procedure is used for the discounting of 
health care outcomes.
2.1.4. Sensitivity analysis
The degree of uncertainty is a subject 
to variables used in CEA. To estimate 
plausible variations, a sensitivity analysis 
should always be performed. Such sensi-
tivity analysis provides information on 
how a variation of a certain variable 
affects the result of the CEA. We distin-
guish between deterministic and proba-
bilistic sensitivity analysis. Deterministic 
sensitivity analysis uses an approach in 
which one or more parameters are chan-
ged manually across a pre-specified ran-
ge (range should correspond to the un-
certainty defi ed in literature). Results 
are than analysed and the extent of the 
impact of input parameter variation on 
the output values is defined. Probabilistic 
sensitivity analysis captures uncertainty 
of all input variables, it is characterized 
through the use of probability distributi-
ons, translated to uncertainty and results 
in means and standard error for the in-
cremental costs (47). If a correlation of 
input variables is present and available, it 
should also be considered and incorpo-
rated into the model (48).
2.1.5. Data collection and 
decision-making models
Most often, data collection metho-
ds used in HTA are: systematic litera-
ture review; meta-analysis; modelling; 
group judgment; unstructured litera-
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ture review; and expert’s opinions (29). 
Sometimes it happens that for a speci-
fic new medical device or an innovati-
ve technique there is not yet sufficient 
evidence available, apart from data pro-
ving its safety. When only few or low 
quality studies are available, potential 
source of bias must always be conside-
red and documented (29). Additionally, 
in order to incorporate conditionality 
and uncertainty of data collected, de-
cision models are used to simulate ad-
justments of projections of the existing 
primary data. With modeling patients 
conditions, treatment efficacy, treatment 
and maintenance costs and incidence 
of the disease, projections to a future 
costs and outcomes of the treatments 
or innovations can be made. Decision 
making trees, fuzzy logic and state tran-
sition modeling, such as Markov model 
and Monte Carlo simulation, are most 
often used (49). Markov models are wi-
dely used in HTA and health-economy 
studies, and recently Craven et al. (50) 
showed that this approach can also be 
used in pre-market HTA studies for me-
dical devices.
In the CEA, each state in the model 
represents a specific state of health, or 
stage of disease between which the pa-
tient migrates. There is always one state 
that represents death, which is consi-
dered an absorbing state as it does not 
have a return path. Each state is associa-
ted with an average QALY, reflecting the 
quality of life of patients in this health 
status, a cost that is reflecting the cost 
needed to maintain the patient in this 
state (e.g., avoid deteriorations) and the 
probability to move from the current 
health state to another, or the stay in 
the same state in the following period 
of time (usually one year). Health sta-
tes are defined according to the disea-
se being studied. The model’s structure 
should be as simple as possible, as it is 
not necessary to model the full com-
plexity of the disease. Moreover, since 
the CEA focuses on incremental costs 
and QALY, only those states in which 
the technology under assessment is ma-
king real differences are relevant for the 
model. Model complexity (i.e. number 
of parameters and model order) should 
always be limited by the quantity and 
quality of data available (51). However, 
more aggregated structure that still 
includes fundamental disease process 
and interventions is often the best so-
lution (47).
3. Case study on
electrochemotherapy (ECT)
Electroporation is an evolving tech-
nique with many applications (1-4). 
In our study the focus is on electro-
chemotherapy of basal-cell carcinoma 
(BCC) and skin melanoma, as these two 
therapies are used for the longest time 
and have a very high success rate. Few 
cost-effectiveness analyses have already 
been done (52,53), but due the lack of 
information obtained, especially about 
QoL increase, the results are incomp-
lete, inadequate and/or inaccurate. 
Numerical data about QoL increase are 
not available, QoL is reported only as 
”better”, ”highly improved”, ”significan-
tly better”, or using similar descriptors. 
Most probably the main reason that 
QoL was not acquired in previous stu-
dies is due to poor reporting. Our study 
originates from a previous one (52) and 
uses innovative eCEA methods (54). 
In order to facilitate result compari-
sons with benchmark technologies, 
cancer type specific analyses are done. 
For the scope of this paper, models for 
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both studied cancer types are designed 
and presented. In addition, required 
and missing data are defined and pre-
sented (Table 1). In the near future we 
plan to collect all missing data trough 
randomized control trials and different 
studies which are still under way. With 
this paper we also want to raise gene-
ral awareness about the importance of 
numeric QoL reporting and useful-
ness/meaning of EQ-5D questionnaires 
that might not be self-evident at first 
sight. If despite our effort the data will 
still not be available, simulations will be 
done to acquire the missing data. Our 
main aim is to build a general model 
that will allow us – with minimal chan-
ges – to also simulate/project the cost 
efficiency for patients with better initial 
survival options and to also stimulate 
similar studies for other cancer types 
treated with ECT.
Cancer patients that are treated with 
innovative technologies (which have not 
yet been introduced into clinical pra-
ctice) in most cases have severe cancers 
and are not suitable for any other alre-
ady established treatment. In fact they 
are usually without other treatment 
options. However, the goal of several 
emerging applications in oncology, such 
as ECT, is to be used in early-diagnosed 
patients with better survival options. 
Measurement of QoL increase in pati-
ents with severe cancer is more deman-
ding and biased. QoL of a patient with 
severe cancer and poor survival opti-
ons after the therapy cannot be equally 
compared with the QoL of patients, with 
better survival options before the pro-
cedure. Their quality of life before tre-
atment was not the same, therefore we 
can assume that only a minimum incre-
ase in the quality of life could be obser-
ved (56).
Regarding the benchmark, there are 
different options. Some authors compare 
the innovative technology with the most 
recent cost-effective technology while 
others compare it with the gold standard/
benchmark in order to make the analysis 
more replicable. For skin cancer, compe-
titive technologies are: surgical excision, 
topical intralesional therapy, photoche-
motherapy and radiotherapy (14,55). In 
our study, the ECT treatment of BCC 
and skin melanoma will be compared 
to surgery and radiotherapy. We assume 
ECT is considerably cheaper than radi-
otherapy while having at least compara-
ble effect (10,14,52).
3.1.  Constructing the model
While the structure of the mo-
del should reflect the essential featu-
res of the disease and its interventi-
ons irrespective of data availability, 
it is expected that in some cases data 
availability may aff ct choices regar-
ding model structure (29). In order to 
Figure 2: A general eight state Markov model of skin 
melanoma. The model should always reflect the 
essential features of the disease and its outcomes (40).
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Figure 3: A reduced – initial Markov model for skin 
melanoma, only the states that are relevant for the new 
technology, in this case ECT, are included.
use the most appropriate models that 
would give the most realistic results, 
models are designed in advance and 
the data needed will be obtained sub-
sequently in the near future (56). Two 
general models, for each cancer type, 
are presented in this paper (Figure 2, 
4), covering whole complexity of the 
disease and its essential features. Those 
two models will be used for final simu-
lations that could provide the cost-e-
ffectiveness evaluation of electroche-
motherapy as a treatment also used in 
patients with less severe cancer stages. 
For the initial analysis, however, models 
are simplified/reduced (e.g. aggregating 
states) (Figure 3, 5), in order to faci-
litate the calculations and focus only 
on states that are relevant for the new 
technology (i.e. where ECT is currently 
used). Models for different cancer types 
differ from each other with respect to 
the number of states; their defi ition 
and flow through the model are con-
ditioned by disease characteristics and 
possible outcomes.
Because cancer may be a recurrent 
disease, Markov model approach is 
used for modeling (57). The first gene-
ral model was made for BCC (Figure 4). 
It is simple, it has only seven states and 
much less possible state transitions 
than the second general model that was 
made for skin melanoma (Figure 2) 
which has nine states. The initial states 
in both general models represent popu-
lation without cancer. (These two states 
will be eliminated at the initial calcula-
tions, because they are not relevant for 
the new technology - ECT.) The fol-
lowing states represent different cancer 
stages, such as primary tumor, distant 
metastases, metastases in the lymph 
nodes, distant metastases with predo-
minantly cutaneous symptoms and di-
stant metastases without predominan-
tly cutaneous symptoms in case of skin 
melanoma. Because all patients are not 
diagnosed with cancer at its initial sta-
te, some might enter the model with the 
disease that combines several states in 
the model. Clinical stages of skin mela-
noma are defined as follows: at stages I 
and II patients only have a primary tu-
mor; stage IIIa,b means that a patient 
has a primary tumor and metastases in 
the lymph nodes; stage IIIc combines 
a primary tumor, local metastases and 
metastases with predominantly cutane-
ous symptoms. The last and most severe 
stage IV includes a primary tumor and 
distant metastases (76).
Electrochemotherapy is at the time 
of writing manly used in stage IIIc and 
IV patients (10,14), therefore a reduced 
- initial models for initial calculations
consist only of states relevant for those
two cancer stages. A reduced BCC model
is slightly different and simpler. There are
only three possible outcomes: complete
response, residual disease and progressi-
ve disease. In the case of BCC, electro-
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chemotherapy is used only in patients 
with bigger and recurrent tumors (10,14). 
Both general models also have the same 
two absorbing states, one is death due to 
cancer and the other is death from other 
causes; for initial calculations these two 
states will be merged into one state (pa-
tients can move to these two states from 
any other state, arrows are not drawn 
in the models for clarity (Figure 2, 4)). 
The probability of staying in dead state 
is always one and the cost zero. As seen 
from the model, all states are numera-
ted and have two additional parameters: 
QALY and cost. The time step at which 
patients migrate between states is set in 
accordance with disease characteristi-
cs (58). Because signifi ant changes in 
QoL of patients treated with electroche-
motherapy are detected already within 
few months after the treatment (34,59), 
the time step for the study is set to three 
months. In all models (Figure 2–5) num-
bers in the circles enumerate states, for 
example the state without cancer in both 
general models designates the state 1. The 
letter P in both general models (Figure 2, 
4) represents a probability of transition
between two states. The fi st undersigned
number represents the state from which
a transition is made and the second un-
dersigned number provides the informa-
tion to which state it is moving. Finally,
in order to correctly include data in the
model, a conditioned probability calcu-
lation will be performed (58).
3.2.  Data collection approach
For each state represented in the mo-
del, three data are needed for a success-
ful cost-effectiveness analysis:
1. The probability of transition between
different states in a defi ed time step
(ExampleBCC g. model: P23 represents the
probability of a complete response
three months after the treatment.);
2. The cost of staying for three months
in each state (ExampleBCC g. model:
cost2 represents the sum of all expen-
ses a health care provider has in the
selected time step, such as medical
examinations, medications, therapies,
etc. in case patient has an untreated
BCC);
3. The utility of patients in each
state, expressed in QALY
(ExampleBCC g. model: QALY3 represents
the average result of an EQ-5D qu-
estionnaire filled out by the patients
with complete response).
For the initial calculations, initial mo-
dels that reflect only the impact of the 
technology under investigation (ECT) 
will be used. In case any of above listed 
information is not available, those data 
will have to be estimated using the best 
possible approach, including:
1. The transition probability between
states or QoL data can be adapted
from randomized control trials te-
Figure 4: A seven state general Markov model of basal-
cell carcinoma (BCC).
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sting the most similar technology 
in the most possible similar cancer 
(Figure 6: Case 1 and 2). The missing 
values can be estimated by fitting 
probabilistic distribution and then 
calculating mean and standard devi-
ation, which are also useful for sensi-
tivity analysis that will be performed 
later.
2. Alternatively, the missing data can be
derived from interviews with expert
clinicians and fitting the results with
statistical distribution (Figure 6: 
Case 3).
3. The missing data for a general model
can be simulated or predicted from
initial calculations, made on reduced
models that include only states rele-
vant for the new technology. (The si-
mulation will also provide the CEA
estimation in case ECT would be
used in early-diagnosed patients with
greater survival options.)
Once the data for initial models will
be collected, an incremental analysis will 
be run in order to determine the incre-
mental cost-effectiveness ratio and its 
confidence interval. Finally, two steps 
will conclude the first stage of this study:
1. Sensitivity analysis (the model will be
run using a deterministic approach
by changing the input parameter va-
lue)
2. Statistical analysis (i.e. using Monte
Carlo simulation, each subject will
move from one state to another
according to the given transition pro-
bability.)
3.3.  Field of interest
1. Probability of transition between
states: Response rates for initial calcula-
tions / probabilities for the electroche-
motherapy treatments and other com-
parable technologies will be collected at 
fi st from different oncological trials in 
Slovenia. In case these data will have a 
high standard deviation, or there will not 
be enough of them for a representative 
pattern, we will expand our study requ-
esting data and support from InspECT 
database (60). (Probability values will be 
defined from study reports; the use of a 
table (Table1) is suggested for easier data 
collection). Finally, we would also like to 
make some possible outcome predicti-
ons, in case that the technique will/wou-
ld also be used in patients with earlier 
cancer stages and better survival options; 
for these purposes general models were 
developed. Cancer incidence data that 
will define the probability P12 (in both 
general models) for skin melanoma will 
be obtained from the Cancer Registry of 
the Republic of Slovenia (61). In case of 
BCC, the incidence should be multiplied 
by 1.3, because non-melanoma skin can-
cers are usually not properly included in 
the cancer registries (62). Also, the fact 
that the incidence of BCC continues to 
increase should be taken into account in 
general calculations.
Figure 5: A reduced – initial Markov model for BCC, only the 
states that are relevant for the new technology, in this case 
ECT, are included.
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Because most databases are made on 
an annual basis, the collected data will 
be projected on a three-month scale, if 
needed. Other probabilities will be si-
mulated from initial calculations and 
expert’s opinions. In case of skin me-
lanoma, patients can be diagnosed at 
different cancer stages or might be in a 
state that is a combination of two sta-
tes in the model; for example, they can 
have a primary tumor and distant me-
tastases with predominantly cutaneous 
symptoms. In order to properly fit tho-
se probabilities in the model, statistical 
methods will be used.
2. Quality of life evaluation: alre-
ady after a brief literature survey, it has 
become obvious that most of the re-
levant reports are missing data about 
EQ-5D results even though these shou-
ld be collected as stated at clinical trial 
specifi ations (63,64). The quality of life 
is reported only as ”better”, ”highly im-
proved”, ”significantly better”, or using 
similar descriptors (65,66,71,72). For the 
Markov model analysis, however, nume-
ric data are required. This is one of the 
main reasons why we have decided to 
postpone the analysis, as we want to co-
llect real data instead of implementing 
expert’s estimations of QALY increase. It 
seems more rational to collect EQ-5D re-
sults, as only numerical values will pro-
vide us with adequate/useful results. At 
first we will try to collect the test results 
from already completed clinical trials. 
Most likely, if EQ-D5 were done, the re-
sults were collected at 3 and 8 months af-
ter the treatment, as specified in clinical 
trial documentation, so the rescaling on 
a time step basis will be necessary to fit 
into the model. Then we will ask physici-
ans who are involved in trials including 
electroporation treatments to include 
the EQ-5D evaluation tool into their stu-
dies if they are not already included, and 
use the developed table template (Table 
1)for reporting.
3. Incremental cost evaluation: co-
sts depend on the specific application 
protocol, disease stages and severity. 
The first necessary and inevitable cost, 
which is common to all applications, 
is staff (e.g., nurses, doctors). Local or 
general anesthesia is also used in some 
procedures. In case of electrochemothe-
rapy, the cost of intratumoral or intra-
venous application of chemotherapeu-
tics cistplatinum or bleomycin must be 
considered. The cost of patient’s hospita-
lization, the necessary medical examina-
tions before the procedure and any other 
specific treatment that may entail side 
effects must also be taken into account.
The second necessary cost is the 
electroporator and electrodes. IGEA 
S.p.A. (Italy) produces a Cliniporator
device, appropriate for electrochemothe-
rapy of smaller cutaneous or subcutane-
ous tumors. Cliniporator VITAE is an
upgrade, which has higher pulse ampli-
tude and can also be used for electro-
chemotherapy of deep-seeded tumors
or irreversible electroporation (IRE).
Figure 6: Visualization of data collecting and data 
simulating process.
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In the USA, AngioDynamics produces 
NanoKnife, which is mainly used for 
IRE. For successful application, electro-
des are needed that may be for single or 
multiple use. IGEA offers many different 
electrode types. NanoKnife has only ne-
edle electrodes; from one up to six per 
treatment can be used. The amortiza-
tion expense or annual lease of the de-
vice must also be considered. The cost 
of electrochemotherapy has already 
been evaluated for Italy by Colombo et. 
al. (52), a cost-effectiveness analysis has 
also been done, but without the quality 
of life consideration. All the collected 
data thus must be rechecked and upda-
ted for further evaluations. The authors 
calculated an average use of 1.3 electro-
de per procedure. In a further study, 
the number of available electrode types 
may significantly change because there 
are several new electrode configurations 
available. Maintenance was estimated 
biannually at €6,000 and annual lease 
of the device at that time was €12,000. 
The device lifespan is 8 years, and for all 
further calculations Colombo et. al. (52) 
assumed that at least 100 patients are tre-
ated per year with a single device, which 
may be an overly optimistic assumption. 
The cost is then calculated per patient. 
Electroporator and electrode price must 
be divided by its lifespan and the num-
ber of patients treated on a yearly basis. 
The cost of being in each state needs to 
be defi ed. The cost evaluation of being 
in initial state (having cancer) will be ta-
ken from the literature; for the USA, UK 
estimations of specific cancer types on a 
yearly basis are available (67,68). In case 
of expanding the data collection to other 
countries, we should consider the issue 
of different living standards, as the stan-
dard of living and money value is not the 
same everywhere. To align the costs, data 
collected from all around the world will 
be calibrated if needed. The adjustment 
will be made on the basis of living co-
sts (74).
3.4.  Data collection proposal
To facilitate initial data collection, a 
table template (Table 1) is proposed. The 
table refers to reduced models; in case of 
BCC there are five possible states and in 
case of skin melanoma only three. For 
each patient, every three months the cli-
nician is supposed to:
• defi e the medical interventions;
• assess patient state by circling the
appropriate number in the table;
• obtain EQ-5D questionnaire and re-
port numerical value;
• record all medical interventions or
examinations that patient had in
the last period, including the type of
anesthesia during ECT, days spend in
hospital, biopsy, blood analysis and
radiological assessment;
• report about all drugs prescribed to
the patient for his/her condition, also
for the management of side effects,
analgesics, wound care dressing…
• report any other potential costs.
4. Conclusion
In the scope of this paper two gene-
ral Markov models for CEA have been 
developed, one for skin melanoma and 
the other for BCC. Initially, both mo-
dels are reduced in such a manner that 
they consists only of states that are re-
levant for the current use of new tech-
nology, i.e. electrochemotherapy. But for 
a cost-effectiveness analysis, the data on 
quality of life increase on a time step 
scale are also needed, which in our case 
represents a problem. Researchers are 
currently only reporting that quality of 
life is increased after the treatment, but 
Pregledni znanstveni članek
3.8 Paper 7 203
36 Zdrav Vestn | januar – februar 2018 | Letnik 87
the numerical data that are crucial for 
successful cost-effectiveness analysis 
are missing (65,66,71,72). In this paper, 
the data needed for the evaluation of 
cost-effectiveness of electrochemothe-
rapy treatment of skin melanoma and 
BCC are clearly identifi d. Additionally, 
recommendations for data collection 
process and follow-up reporting are 
made.
Because electrochemotherapy is an 
emerging technology, it is still not used 
in all patients, but as the proof of con-
cept rises, it is gradually moving up the 
cancer staging scale. A realistic cost-e-
ffectiveness analysis for a specific cancer 
type will facilitate equipment purcha-
se and clinical practice implementati-
on. Additionally, the prediction of cost 
effectiveness can also influence the next 
round of fund raising. In our opinion, an 
additional incentive from a good cost-
-effectiveness analysis would definitely
also benefit other electroporation-based
therapies. The biggest obstacle is Quality
of life data, which will be overcome by
obtaining the EQ-5D questionnaires
in the near future. Because the time
step is set to three months, we believe a
two-year data will give a representative
pattern. Furthermore, specific models
should be developed for each disease
separately in order to include all speci-
fic phenomena in a specific cancer type.
Electrochemotherapy must be compa-
red to well established procedures that
are cancer-type, location and size depen-
dent.
Table 1: A table template proposed for the initial data collection.
patient code: 
0001/2017
Pre-operative 
evaluation
Procedure Follow-up at 3 months Follow-up at 6 months
BCC/ skin melanoma
Medical interventions 1 visit at the 
specialist
Ect in general 
anesthesia, chest 
x-ray
2 visits at the 
specialist
3 visits at the 
specialist
state (reduced model) 1 , 2 , 3 , 4 , 5 1 , 2 , 3 , 4 , 5 1 , 2 , 3 , 4 , 5 1 , 2 , 3 , 4 , 5
eQ_5d 0.45 0.43 0.38 0.33
Biopsy Y / n Y / n Y / n Y / n
Blood analysis Y / n Y / n Y / n Y / n
radiological assessment no / us / Ct / Mr /
pet-Ct
no / us / Ct / Mr /
pet-Ct
no / us / Ct / Mr /
pet-Ct
no / us / Ct / Mr /
pet-Ct
days of hospitalization 0 2 0 2
Wound care dressing
(product name)
NO NO YES: XY© NO
prescribed drugs NO Paracetamol 
500 mg tablets 
3 X 1
NO NO
other potential costs
(describe)
NO NO NO NO
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Abstract 16 
Purpose: Electrochemotherapy is increasingly entering into national and international 17 
guidelines, requiring formal evaluation of treatment costs and cost-effectiveness to ensure 18 
that their uptake actually provides value for money to budget-constrained health care 19 
systems. The study aims to conduct an early cost-effectiveness analysis of 20 
electrochemotherapy with Cliniporator™ in patients with stage IIIc and IV skin melanoma 21 
in Slovenia. 22 
23 
Methods: The study enrolled 23 patients, treated with electrochemotherapy at the Institute 24 
of Oncology Ljubljana. The average cost of electrochemotherapy was estimated using 25 
patient-specific cost data on electrochemotherapy procedure and subsequent follow up. 26 
Quality adjusted life years were estimated by collecting EQ-5D questionnaires at baseline; 27 
after complete or partial response following the treatment; and after a relapse of skin 28 
lesions. A discrete-time Markov model was built to estimate the lifetime costs and 29 
consequences of using electrochemotherapy compared to standard of care, from the 30 
perspective of the Slovenian health care system. The analysis was conducted separately for 31 
the whole patients' sample and for the subset of patients with bleeding lesions. 32 
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Deterministic and probabilistic sensitivity analysis were conducted to test model 33 
assumptions and characterize the uncertainty around model parameters. 34 
35 
Findings: In the whole patient population, electrochemotherapy of skin melanoma stage 36 
IIIc and IV is expected to increase the quality of life by 0.29 QALYs (95 % Credible 37 
interval 0.097, 0.498), at the higher cost of €6,568 (95% CrI 4,593, 8,928) in comparison 38 
to the standard of care. At the cost-effectiveness threshold of €20,000 per QALY, the 39 
probability of electrochemotherapy being cost-effective compared to standard of care is 40 
estimated to be 0.30 and 0.91 for the whole patient sample and the patients with bleeding 41 
lesions respectively. For the whole sample population, a reduction in the price of the 42 
electrodes by half is expected to increase the probability of being cost-effectiveness from 43 
0.30 to approximately 0.64. 44 
45 
1. Introduction46 
47 
 Electroporation is a phenomenon by which the transport of otherwise impermeant 48 
molecules through the cell membrane is facilitated1–3. Electroporation is becoming 49 
increasingly recognized in medicine4–6 and also in food technology and biotechnology7–50 
9. In medicine, electroporation is used for the treatment of solid tumors, either in51 
combination with chemotherapy (electrochemotherapy) or alone (irreversible 52 
electroporation). Electrochemotherapy (ECT) is a local antitumor therapy that increases 53 
the toxicity of chemotherapeutic drugs bleomycin or cisplatin4. Nonthermal irreversible 54 
electroporation (IRE) enables the ablation of undesirable (malignant) tissue, with 55 
minimal damage to blood vessels and nerves10. Additionally, electroporation is also a 56 
promising delivery method for the introduction of genetic material for DNA 57 
vaccination11. Published studies demonstrated that the electric field established by 58 
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applied high voltage, short-duration electric pulses, increases the plasma membrane 59 
permeability2. Electroporation can be performed as a reversible or irreversible 60 
electroporation. In the case of reversible electroporation, the cells fully recover after 61 
electric pulse application, while in case of irreversible electroporation after the pulse 62 
application cells die, due to the loss of the cell homeostasis. The device that generates 63 
and enables the delivery (via the application-specific electrodes) of electroporation 64 
pulses to biological tissue, is named an electroporator12,13. 65 
 With the development of the electroporation field, new medical therapies, new 66 
clinical electroporators, and innovative delivery systems, questions regarding cost-67 
effectiveness arise. In fact, while the technology is entering into national and 68 
international guidelines14, however, its value for money remains largely unexplored in 69 
mostly all settings. Indeed, not many electrochemotherapy cost-effectiveness analyses 70 
have been published to date15, and due to the lack of information obtained, especially 71 
about the quality of life increase, results are incomplete16. The UK National Institute for 72 
Health and Care Excellence (NICE) deemed that electrochemotherapy is a safe 73 
treatment for primary basal cell carcinoma and primary squamous cell carcinoma, 74 
however, it also warned about the limited evidence around its efficacy17. 75 
Electrochemotherapy treatment of skin melanoma and basal cell carcinoma has been 76 
uptaken broadly in Slovenian clinical practice and therefore there is a need to discuss 77 
whether the treatment is cost-effective and whether the price of the electrodes is 78 
appropriate. The aim of this study was to perform an economic evaluation of 79 
electrochemotherapy , with the Cliniporator™ as a treatment modality for stage IIIc and 80 
IV skin melanoma skin melanoma in Slovenia.  81 
82 
1.1 Electrochemotherapy of skin melanoma 83 
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From all forms of skin cancer types, cutaneous melanoma is the most deadly and 84 
sixth most common cancer type in Slovenia (3.84 % among all cancer types)18.. 85 
Melanoma spreads by lymphogenous and also by the hematogenous route. The AJCC 86 
(American Joint Committee on Cancer) stages of skin melanoma are defined as follows: 87 
localized melanoma (stage I and II), meaning patients only have a primary tumor; stage 88 
III for regional metastatic melanoma, where IIIa/b includes patient with a primary tumor 89 
and metastases in the lymph nodes; stage IIIc combines a primary tumor, local 90 
metastases, and metastases with predominantly cutaneous symptoms. The most severe 91 
stage IV includes patients with a primary tumor and distant metastases19. Progression 92 
of the disease and survival rate highly depend on the stage at which melanoma is 93 
diagnosed and treated20. Cutaneous metastases of melanoma occur in 2–20 % of skin 94 
melanoma patients21 and are one of the most common malignancies in the world. 95 
Electrochemotherapy is at the time of writing manly used in stage IIIc and IV 96 
patients22,23. 97 
Electrochemotherapy is a standardized procedure for the treatment of superficial 98 
metastases of melanoma resistant to other treatments. European Standard Operating  99 
Procedures of Electrochemotherapy (ESOPE) have been established in 200624, for 100 
cutaneous and subcutaneous tumors and updated in 201825. National Institute for Health 101 
and Care Excellence (NICE), in the UK, has recognized electrochemotherapy as an 102 
integral part of the multidisciplinary treatment for patients with skin metastases of non-103 
skin origin and melanoma (NICE interventional procedure guidance IPG 446)26. 104 
Electrochemotherapy of skin melanoma is a highly effective treatment, with complete 105 
response rates, based on a single treatment between 60 to 70 % and objective response 106 
rates up to 80 %27,14. The main advantages of the treatments are: i) it can be administered 107 
in an outpatient setting, under local anesthesia or deep sedation and is therefore simple 108 
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to perform; ii) the procedure is assumed as daily intervention, as it is finished within 109 
half of an hour; iii)  in case of low or no response, it can be repeated after a month 110 
(however, the cumulative dosage of bleomycin should not be exceeded) or later when 111 
new metastases develop; iv) and also has a good cosmetic outcome, because the 112 
surrounding tissue remains undamaged28,29. Overall electrochemotherapy is considered 113 
a safe procedure with little or no side effects27,30,31. Electrochemotherapy diminishes the 114 
need for surgery and is, a feasible treatment option for cutaneous lesions resistant to 115 
other therapies. 116 
117 
2. Methods and materials118 
2.1 Patients 119 
We enrolled 23 patients, treated with electrochemotherapy at the Institute of 120 
Oncology Ljubljana in Slovenia between June 2014 and March 2019. Patients were 121 
treated according to Slovenian Recommendations for the treatment of patients with 122 
cutaneous melanoma. At the time of writing 8 of the patients were still ongoing patients 123 
while the other 15 died or refused further treatment. The average patient age at the first 124 
electrochemotherapy procedure was 78.1, with a standard deviation of 12.3 years, range 125 
from 48 to 96 years. Patients were diagnosed with stage IIIc or IV malignant melanoma 126 
and were not amenable to other treatments. In Slovenian guidelines for the treatment of 127 
skin melanoma, electrochemotherapy indicated as a treatment modality for recurrence 128 
at the extremities where simple excision is not possible (> 3–5 metastases) or for 129 
recurrent relapses (sooner than 3–6 months)32. Patients were treated with 130 
electrochemotherapy in accordance with standard operating procedure with the 131 
CliniporatorTM device24,25. Follow up examinations were conducted 14 days after the 132 
intervention and after 1, 2, 4, 8 and 12 months. Altogether 38 electrochemotherapy 133 
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procedures were performed, meaning on average each patent was treated 1.6 times, 134 
range 1 to 5 procedures per patient. At each electrochemotherapy procedure, all skin 135 
lesions present at the time of procedure were treated. electrochemotherapy was repeated 136 
when new lesions were presented or when only a partial response was obtained. 137 
138 
2.2 Cost analysis 139 
2.2.1 The cost of electrochemotherapy 140 
The average cost and standard deviation of single electrochemotherapy procedure 141 
were estimated using patient-specific data on resource consumption during 142 
electrochemotherapy procedure and subsequent follow-ups and attaching the 143 
corresponding unit costs. All the costs are presented in euros and valid for Slovenia. 144 
Costs related to the hospital and procedure were obtained from the Institute of Oncology 145 
Ljubljana, whereas IGEA S.p.A. provided prices related to the medical device. The 146 
overall cost of electrochemotherapy is presented in TABLE 1.  147 
148 
TABLE 1. : Costs included in the evaluation of the cost of electrochemotherapy in 149 
Slovenia 150 
Unit Cost per unit (€)
Overnight stay in the hospital 
(one night after electrochemotherapy + one day) 
240 
Price of intervention and cost of staff 
(average duration: 45 minutes to1 hour) 
          Staff one hour of procedure 128.25 
          Supplies for personnel and venue 66.13 
          Consumables during operation 99.25 
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          Depreciation of apparatus in an operating room 22.57 
Chemotherapeutic drug 
Bleomycin vial 30 
Cisplatin bottle 23 
Anesthesia 
General anesthesia 225.88 
Local anesthesia 4.4 
Sedation 14.60 
Spinal block 15.90 
Electrodes EPS series 1,200 
151 
The average cost of single electrochemotherapy procedure was estimated to €2,757 152 
with the standard deviation €707.3. Additionally to the individual costs of specific items 153 
reported above in TABLE 1, the Institute of Oncology also provided an exact expense 154 
for eight electrochemotherapy procedures. The error between the exact amount and our 155 
evaluation was less than 10 %, therefore we concluded that the assessment method was 156 
appropriate. 157 
General anaesthesia was used in 25 out of 38 treatments.. On average 1.5 to 2 158 
bleomycin vials and one cisplatin bottle per patient was used, and the cost of bleomycin 159 
was thus set to €52.5 per procedure. The cost of cisplatin is less, but was only used in 160 
two electrochemotherapy procedures. Electrodes represent almost half of the price for 161 
electrochemotherapy procedure and new versions of electrodes (EPSA series) are even 162 
more expensive, with a price of €1600 per single electrode (VAT excluded). All 163 
electrochemotherapy electrodes manufactured by IGEA S.p.A are for single-use, 164 
meaning one electrode can be used for one patient, but for multiple metastases, however, 165 
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in some cases more than one electrode geometry is used due to the difference in 166 
metastases. In the scope of our study 1.19 electrodes per patient were used, in range 167 
from 1 to 2 per procedure. Also, other patient-specific costs were analysed and 168 
evaluated, such as analgesics or antibiotics, but because these costs did not exceed €10 169 
per treatment, they were neglected in the analysis. Follow-up specialist visits were 170 
conducted after 1, 2, 4, 8 and 12 months following the intervention with an estimated 171 
cost of €22.5 per examination. 172 
CliniporatorTM device, manufactured by IGEA S.p.A. is essential part to perform 173 
electrochemotherapy. The price of the device CliniporatorTM EPS02 is €100,000 (VAT 174 
excluded). The maintenance cost is €3,000 and the maintenance is due every 24 or 36 175 
months according to the country specific (e.g. Germany: 24 months, while Italy, U.K. 176 
and Slovenia: 36 months). The CliniporatorTM device is considered as a highly stable 177 
device, therefore IGEA as a manufacturer requires the maintenance only every 36 178 
months. The device lifetime is specified as 500 treatment sessions or 10 years (based 179 
on user manual).  180 
2.2.2 Cost of skin melanoma 181 
Following an extensive literature review, we couldn’t identify baseline cost data for 182 
skin melanoma in the Slovenian setting. However, an extensive cost of illness study is 183 
available for Croatia33. Because Croatia and Slovenia are neighboring countries and not 184 
long ago, were even both part of the same country, data collected for Croatia were 185 
considered in this study. For the calculations, the average cost per single patient for 186 
stage IV melanoma was set to €4,333 per year. This value is also in accordance with the 187 
European average34 and close to value available for Italy35. With the help of Slovenian 188 
palliative experts, we evaluated the worst-case cost of care for a patient with bleeding 189 
lesions to be € 3,450 per patient per year (includes only the care of bleeding wounds). 190 
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This cost can be completely eliminated after the electrochemotherapy procedure, 191 
however, only 5 % of melanoma patients develop bleeding lesions.   192 
2.3 Quality of life 193 
Patients were given an EQ5D questionnaire at each examination, and the following 194 
results were obtained: before the procedure the average quality of life was equal to 0.65, 195 
the patient that responded to electrochemotherapy had an increase in quality of life to 196 
0.72 and in case of relapse of metastases, the quality of life decreased to 0.66. A 197 
significant increase in quality of life was expected only in patents with bleeding nodes, 198 
which after ECT gain the most, however, only 5 % of all melanoma patients have 199 
bleeding lesions, meaning 1.15 patients in our study. The quality of life for patient with 200 
bleeding lesions was in initial state thus reduced to minimal obtained quality of life, 201 
which was equal to 0.4.  202 
203 
2.4 Cost-effectiveness analysis 204 
A cost-effectiveness analysis was conducted to estimate the lifetime costs and 205 
consequences of using electrochemotherapy in the target patient population from the 206 
perspective of the Slovenian health care system. The model used a time horizon of 10 207 
years, which was considered to appropriately reflect the average survival time in this 208 
patients population. All future costs and consequences were discounted at a 3.5% 209 
discount rate.  210 
Patients included in the study are mostly elderly with stage IIIc and IV skin 211 
melanoma and are generally not amendable to any other treatment option. Therefore, in 212 
the present study, electrochemotherapy was compared to the standard of care (SOC) 213 
consisting of symptomatic therapy and palliative treatment. The cost-effectiveness of 214 
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electrochemotherapy compared to standard of care was expressed in terms of 215 
incremental net health benefit (iNHB) which is calculated based on:  216 
𝑖𝑁𝐻𝐵𝐸𝐶𝑇 𝑣𝑠 𝑆𝑂𝐶 =  𝛥𝑄𝐴𝐿𝑌 −  𝛥𝐶𝑜𝑠𝑡/𝑘 217 
Where 𝛥𝑄𝐴𝐿𝑌 and  𝛥𝐶𝑜𝑠𝑡 are the differences in the expected QALYs and costs 218 
between electrochemotherapy and standard of care, and k is a constant value 219 
representing the cost-effectiveness threshold36. Electrochemotherapy is then considered 220 
cost-effective for any value of the iNHB greater than 0.  The value of the cost-221 
effectiveness threshold for Slovenia was assumed to be equal to the 2018 Slovenian real 222 
Gross Domestic Product (GDP) per capita, and set equal to €20,000 per QALY37.  223 
The CEA analysis was conducted separately for the whole patients’ sample and for 224 
the subset of patients with bleeding lesion, because of the higher procedure costs and 225 
higher potential improvement in the quality of life was observed.  226 
2.5 Markov model for electrochemotherapy of skin melanoma 227 
A discrete-time Markov model was used to model patients’ lifetime costs and 228 
consequences of either electrochemotherapy or standard of care. A Markov model of 229 
skin melanoma16 was suggested, however it had to be modified to better fit the disease 230 
progression of  patients with stage IIIc  and IV skin melanoma after 231 
electrochemotherapy. The model is presented in Figure 1. In the initial state, patients 232 
have predominately cutaneous symptoms and are treated with electrochemotherapy, 233 
they can either not respond (i.e. they remain in the same state) or move to a response 234 
state if they experience complete or partial response (response to electrochemotherapy). 235 
Patients then remain in the response state unless they develop new metastases, then they 236 
are moving to a relapse state, where they can again receive repeated 237 
electrochemotherapy. The cycle length used in the model is two months. 238 
239 
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240 
Figure 1: Four state Markov model of skin melanoma, adopted for electrochemotherapy treatment 241 
of stage IIIc and IV melanoma. 242 
243 
Bimonthly transitions probabilities between states were directly derived from fully 244 
observed patient-level data collected during the study. First, the total person-months of 245 
exposure in each state and the number of transitions to any other state were used to 246 
calculate a 4 by 4 transition-rate matrix Q in a Bayesian framework using the data from 247 
the study and uninformative prior distributions. The model was run using OpenBugs 248 
Markov Chain Monte Carlo (MCMC) software38 (Appendix A). In the model, an initial 249 
run of 10,000 iterations was considered as ‘burn in’ (these values were discarded). 250 
Subsequently, two independent chains, starting from randomly assigned values were 251 
run, and convergence was monitored by looking at the ratio of the within-chain to 252 
between-chain variance to be about one, and by using Heidelberger-Welch39 and 253 
Gelman-Rubin40 diagnostics. Second, the transition-probability matrix P(t) was 254 
estimated by taking the matrix exponential  𝑃(𝑡) = 𝐸𝑥𝑝(𝑄𝑡) using the exmp package 255 
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in Rstudio41. The estimated transition probabilities and their credible intervals for 256 
electrochemotherapy are provided in TABLE 2.  257 
258 
TABLE 2:  Two-month transition probabilities for patients receiving 259 
electrochemotherapy 260 
Transition probabilities with electrochemotherapy 
Mean 95% credible interval 
From State 1 to: 
State 1 0.147 0.06 - 0.279 
State 2 0.608 0.48 - 0.717 
State 3 0.11 0.07 - 0.161 
State 4 0.135 0.06 - 0.26 
From State 2 to: 
State 1 0 - 
State 2 0.726 0.64 - 0.809 
State 3 0.196 0.13 - 0.268 
State 4 0.079 0.04 - 0.134 
From State 3 to: 
State 1 0 - 
State 2 0.236 0.13 - 0.359 
State 3 0.54 0.39 - 0.683 
State 4 0.224 0.11 - 0.363 
261 
In the absence of electrochemotherapy, patients were assumed to remain in state 1 262 
until they die, with probability, which was assumed to be equal to one of relapsed 263 
patients in the electrochemotherapy group (state 3 to state 4). Lastly, transition 264 
probabilities were assumed to be the same for both the whole sample and the subgroup 265 
of patients with bleeding lesions.  266 
2.5.1 Scenario and sensitivity analysis 267 
268 
Probabilistic sensitivity analysis (PSA) was performed by assigning probability 269 
distributions to all parameters used in the cost-effectiveness model. For transition 270 
probabilities, samples were taken directly from the joint posterior distribution of the 271 
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transition probability matrix, calculated with the MCMC simulation in OpenBugs. For 272 
costs and QALY data, samples were derived from Gamma and Beta distributions 273 
respectively, which were previously characterised using mean and standard deviation 274 
estimates from the study data and the literature. Mean estimates and 95% credible 275 
intervals for costs and QALY data are reported in TABLE 3. The results of the 276 
probabilistic sensitivity analysis are then reported in a cost-effectiveness plane and used 277 
to calculate cost-effectiveness acceptability curves for electrochemotherapy compared 278 
to standard of care.  279 
In addition, the probability of electrochemotherapy being cost-effective has been also 280 
estimated as a function of the cost of the electrodes used for each electrochemotherapy 281 
procedure in both patients subgroups, because the cost of one electrode geometry 282 
represent almost half of the estimated electrochemotherapy procedure cost. 283 
Lastly, since electrochemotherapy is usually considered to be a daily procedure, not 284 
requiring hospitalization, the results of a scenario analysis are reported, where 285 
electrochemotherapy procedures were assumed to be provided in an outpatient care 286 
setting, without any hospitalization costs.  287 
288 
TABLE 3:  Costs and QALYs values and credible intervals used in the model (1-289 
year values) 290 
Mean 95% Credible interval 
Cost state 1 
All patients 4333 € 4139 - 4533 
Patients with bleeding lesions 7784 € 7586 - 7978 
Cost state 2 4333 € 4139 - 4533 
Cost state 3 4333 € 4139 - 4533 
Cost of ECT 2757 € 2095 - 3690 
QALY state 1 
All patients 0.66 0.54 - 0.744 
Patients with bleeding lesions 0.4 0.23 - 0.58 
QALY state 2 0.72 0.66 - 0.804 
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QALY state 3 
All patients 0.66 0.54 - 0.744 
Patients with bleeding lesions 0.4 0.23 - 0.58 
291 
292 
3. Results293 
In the whole sample, electrochemotherapy is expected to improve quality of life by 294 
0.29 QALYs (95 % CrI 0.097, 0.498) over patients lifetime, at an increased cost of 295 
6,568 € (95 % CrI 4,593, 8,928). The expected NHB of electrochemotherapy compared 296 
to standard of care is equal -0.037 QALYs (95 % CrI -0.19, 0.11), meaning that at the 297 
used cost-effectiveness threshold of €20,000 per QALY gained, electrochemotherapy is 298 
slightly less cost-effective compared to standard of care, although the uncertainty over 299 
this estimate is quite large. For the subgroup of patients’ with bleeding lesions, 300 
electrochemotherapy is expected to yield a higher quality of life by 0.34 QALYs (95 % 301 
CrI 0.18, 0.56) at a higher cost of 4,863 € (95 % CrI 2,479, 7,177). Compared to the 302 
whole sample, providing electrochemotherapy only to patients with bleeding lesions is 303 
expected to be more cost-effective with an expected iNHB of 0.10 (95 % CrI -0.06, 304 
0.27).  305 
The results of the probabilistic sensitivity analysis show a considerable uncertainty 306 
on the incremental costs and QALYs of electrochemotherapy for both patient groups 307 
with the simulated costs and QALYs pairs being spread widely in the cost-effectiveness 308 
plane. However it must be noted that most of the simulations remain in the first quadrant 309 
of the cost-effectiveness plane, meaning that electrochemotherapy is highly likely to be 310 
more effective and more costly compared to standard of care (Figure 2, panel a). The 311 
probability of electrochemotherapy being cost-effective is estimated to be 30% for the 312 
whole sample, and 91% in patients with bleeding lesions (Figure 2, panel b) 313 
314 
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315 
Figure 2: (a) Cost-effectiveness plane; (b) The probability of electrochemotherapy being cost-effective 316 
for all patients and patients with bleeding lesions. 317 
318 
A reduction in the cost of the electrodes used in the electrochemotherapy procedure 319 
is not going to greatly affect the probability of cost-effectiveness in patients with 320 
bleeding lesions, since in this patient population, electrochemotherapy is already highly 321 
likely to be the best treatment option even at the base case cost of the electrodes. 322 
However, the cost of the electrodes has a considerable impact when considering the 323 
whole patient sample (Figure 3). For example, a reduction by half in the average cost 324 
of the electrodes used during the electrochemotherapy procedure would increase the 325 
probability of cost-effectiveness from 0.30 to approximately 0.64.  326 
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327 
Figure 3: The probability of electrochemotherapy being cost-effective as a function of electrode cost for 328 
both patients groups. 329 
330 
Finaly, in the scenario without hospitalization costs, the expected incremental costs 331 
of electrochemotherapy were estimated to be 16 % lower compared to the base case 332 
analysis, which in turn resulted in a higher iNHB of 0.014 (95 % CrI - 0.12, 0.15) and 333 
a higher probability of being cost-effective equal to 0.58. (Figure 4), for the whole 334 
patient sample. 335 
336 
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Figure 4: (a) Cost-effectiveness plane, in case of elimination of hospitalization price; (b) The 337 
probability of electrochemotherapy being cost-effective for all patients and patients with 338 
bleeding lesions, without hospitalization costs. 339 
340 
4. Discussion341 
Ten percent of skin melanoma patients develop in transit melanoma metastases 342 
during the course of cutaneous melanoma treatment. Most often in transit metastases 343 
develop on the lower limbs. Traditional methods of treatment differ among countries 344 
and are surgery, radiotherapy, topical imiquimod, isolated limb perfusion, systemic 345 
therapy or symptomatic therapy. Surgical excision is a reasonable treatment option only 346 
in case when a patient has a small number (<3) of skin lesions. However, researches 347 
show that even then, only 19% of patients remain without evidence of recurrence, within 348 
a median follow‐up of 40 months42. Other treatment option including 349 
electrochemotherapy are thus used in case of a higher number of skin lesions. New 350 
systemic therapies are promising, nevertheless, due to the high cost, as well as to the 351 
treatment-related side effects, it is still advised to treat skin lesions locally, for as long 352 
as possible43. 353 
Since the average age of the patients included in our study is 78.1, those patients are 354 
often not suitable candidates for new systemic treatments due to comorbidities. For 355 
elderly patients, topical or local therapy is the most advantageous, as it is safe and has 356 
no side effects.  Because our study includes mainly elderly with severe cancer, which 357 
are not amendable to any other treatment options, electrochemotherapy can improve 358 
their quality of life in comparison to symptomatic therapy or palliative treatment 359 
(natural course of the disease).  However, the cost of electrochemotherapy is relatively 360 
high, the main contributor is the high cost of electrodes and electroporation device. In 361 
the future, a greater need for electrochemotherapy can be expected, despite the great 362 
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promise of systemic therapy. Because due to different cell clones in cutaneous 363 
metastases, the management of individual strains, which do not respond to systemic 364 
therapy, remains necessary. 365 
In the scope of this paper, the first cost-effectiveness analysis of 366 
electrochemotherapy based on the real-world study is presented. To our knowledge this 367 
is the first study to report detailed primary data on the cost QALYs of 368 
electrochemotherapy in this patient population. Previous studies44–50 have reported 369 
increases in quality of life after electrochemotherapy, however, quantitative information 370 
is often lacking or not sufficiently detailed to allow estimation of the cost-effectiveness 371 
of electrochemotherapy in patients with stage IIIc and IV skin melanoma. For example, 372 
even when quality of life estimates were reported, it was not possible to differentiate 373 
between cancer types and stages51,52. The primary data collected in this study aims to 374 
fulfil this gap; however, the study has a number of limitations. First, by only collecting 375 
data on patients receiving electrochemotherapy, improvements in QALYs were 376 
measured using a before and after evaluations, which is prone to biases. Second, the 377 
estimation of the relative effectiveness of electrochemotherapy compared to standard of 378 
care is based on the assumption that patients not receiving treatment would remain with 379 
the same baseline utility values for the rest of their life, which may not be the case. 380 
Third, EQ_5D questionnaires were collected at each examination, but some patient data 381 
were missing. Nevertheless, the QALY estimates are consistent with the existing 382 
literature and were judged plausible by the clinicians who collected the data in the first 383 
place.   384 
When considering all patients with stage IIIc and IV skin melanoma, 385 
electrochemotherapy is expected to be less cost-effective compared to palliative care 386 
and symptomatic treatment (iNHB -0.037 QALYs, with probability of being the most 387 
3.9 Paper 8 227
cost-effective strategy equal to 0.32). Conversely, electrochemotherapy is expected to 388 
be more cost-effective in patients with bleeding lesions as both the relative improvement 389 
in QALYs after successful electrochemotherapy and the expected savings in 390 
management costs are expected to be higher, although with a considerable uncertainty 391 
in the model estimates. It should be also noted that the NHB estimates are calculated 392 
using a cost-effectiveness threshold of €20,000 per QALY, equal to approximately the 393 
2018 Slovenian per capita GDP. While the use of thresholds based on GDP has been 394 
recommended by the WHO37, other estimates have also been proposed in the literature. 395 
For example Woods et al. provide country specific values using empirical estimates of 396 
the threshold for the UK; estimates of the relationship between country GDP per capita 397 
and the value of a statistical life; and a series of explicit assumptions53. For Slovenia the 398 
authors estimate a threshold in a range between $11,374 and $15,690 purchasing power 399 
parity (PPP) which correspond to a range in Euro between €6,710 and €9,257. It is 400 
expected that electrochemotherapy wouldn’t be considered cost-effective in any case at 401 
these lower thresholds.  402 
Electrochemotherapy is in theory, a daily procedure, but due to the age of some of 403 
patients involved in this study, most of them were hospitalized for a day or two, some 404 
patients had even longer hospitalizations up to 8 days, due to other disease related 405 
complications (not related to electrochemotherapy). Also, one of the advantages of 406 
electrochemotherapy is that it can be performed under local anesthesia, but in our study 407 
65.8% of patient received general anesthesia, due to the high number of metastases 408 
treated in a patient. 409 
 In case electrochemotherapy would be used also on younger patients or patients 410 
with less severe cancer stage, the number of procedures would increase and an increase 411 
in quality of life after electrochemotherapy might be higher than for patients included 412 
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in our study. However, in this case, the cost-effectiveness analysis of 413 
electrochemotherapy should include other treatment options for this patient population, 414 
including surgery, radiotherapy, and immunotherapy. The cost of immunotherapy is 415 
significantly higher than the costs of electrochemotherapy procedures while the quality 416 
of life increase might be comparable. For example, it was estimated that the cost of 417 
immunotherapy in Slovenia may be up to €60,000 per year. Electrochemotherapy in 418 
case of reasonable electrode price, is also expected to be cheaper than surgery, because 419 
it is a daily procedure is lasting no more than 45 minutes in case of less severe cancer 420 
stages. Increases in quality of life and treatment response rates are also likely to be 421 
higher in this patient population. Therefore, one could arguably assume that the 422 
probability of electrochemotherapy being cost effective is potentially higher for less 423 
severe cancer stages compared to their more severe peers.  424 
Nevertheless, the cost of electrodes remains a critical issue that may hinder a broader 425 
adoption of electrochemotherapy in clinical practice. Indeed, electrodes represent 426 
almost half of the procedure costs, and this study showed the extent to which their price 427 
is likely to affect electrochemotherapy’s value for money. This study also shows that 428 
cost-effectiveness of electrochemotherapy is highly dependent on which patients’ 429 
subgroups are considered in the analysis, suggesting that the optimal price of the device 430 
is likely to be indication specific. More research is needed to estimate the cost-431 
effectiveness of electrochemotherapy in other less severe patient populations. 432 
Systematic collection of EQ_5D questioners or any other quantitative reporting of 433 
quality of life during the electrochemotherapy treatment are essential for further 434 
economic evaluations of electrochemotherapy. It seems that even if it is obligatory to 435 
collect quality of life data, it is not done on a regular basis, as it is not considered 436 
important. 437 
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438 
5. Conclusions439 
Electrochemotherapy of skin melanoma stage IIIc and IV increases the quality of life 440 
after the procedure. The probability of electrochemotherapy (with hospitalization) being 441 
cost-effective for the patient with stage IIIc and IV skin melanoma is just above 30 %, 442 
which implies the prices of the device and electrodes should be reduced for successful 443 
implementation into clinical practice. However, if patients have bleeding lesions than 444 
electrochemotherapy is more likely to be cost-effective (probability rises to 0.91).  In 445 
order to simulate the probability of electrochemotherapy being cost-effective for 446 
patients with less severe cancer stages, the hospitalization cost was removed from the 447 
cost of the procedure, as electrochemotherapy can be performed as a daily procedure. 448 
The probability of being cost effective for all patients included in the study raised, 449 
however, the cost effectiveness can be easily increased with the reduction of the 450 
electrode price, which represents almost half of the whole procedure cost. 451 
452 
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Appendix A: Code used in OpenBugs to estimate the transition-rate matrix 581 
model{ 582 
#estimate rates from fully observed data 583 
#loop for any state except for the death state 584 
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for (i in 1:3){ 585 
# model transitions from each state to any other state as a 586 
poisson distribution 587 
temp[i]<-lambda[i]*E[i] 588 
m[i]~dpois(temp[i]) 589 
#estimate conditional probability to go to one of the two 590 
possible other states (conditional on leaving state i) 591 
tr[i,1]~ dbin(condP[i],m[i]) 592 
} 593 
#define rate-transition matrix 594 
G[1,1]<--G[1,2]-G[1,4] 595 
G[1,2]<-lambda[1]*condP[1] 596 
G[1,3]<-0 597 
G[1,4]<-lambda[1]*(1-condP[1]) 598 
G[2,1]<-0 599 
G[2,2]<--G[2,3]-G[2,4] 600 
G[2,3]<-lambda[2]*condP[2] 601 
G[2,4]<-lambda[2]*(1-condP[2]) 602 
G[3,1]<-0 603 
G[3,3]<--G[3,2]-G[3,4] 604 
G[3,2]<-lambda[3]*condP[3] 605 
G[3,4]<-lambda[3]*(1-condP[3]) 606 
#define priors for rates and conditional probabilities 607 
for (s in 1:3){ 608 
lambda[s]~dgamma(0.1,0.1) 609 
condP[s] ~dbeta(1,1)} 610 
} 611 
#data 612 
list(m=c(24,27,19), 613 
E=c(724,4271,1635),  614 
tr=structure(.Data=c(22,24,11,2,3,8),.Dim=c(3,2))) 615 
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4 Conclusions
Electroporation is a platform technology, which is already established in many
different fields. When dealing with electroporation, measuring is crucial for
achieving effective electroporation, because quality assurance can only be provided
by appropriate measurements, i.e., measuring the voltage and current using an
oscilloscope. The biggest challenge is to accurately measure the high-voltage short
nanosecond long pulses. It should be emphasized that the bandwidth of the probes
ends at -3 dB which means that the probe at the end of its bandwidth has a -29 %
error. A -29 % error may be acceptable for electronics, however, a 29 % different
amplitude may have a significantly different biological effect [103, 104]. Because
permeabilization and cell survival are sigmoid functions of voltage, more than
10 % difference in voltage may result in a significantly different biological effect
[103, 104]. Whenever we are using measuring probes, we have to be aware of the
measuring error. Commercially available probes have the measuring error specified
in a data sheet, but it is still sometimes overlooked, while prototype probes have to
be correctly calibrated and measuring error evaluated.
Unfortunately in the field of electroporation, failed efforts to confirm other pub-
lished paperwork are increasing [30]. We believe the main reason for this situation
is, that methods in many papers describing/using electroporation are reported in
insufficient details, and quite often measurements of output pulses are not reported
[18, 31]. The field of electroporation is in need of promoting reproducible research
that can only be achieved by adequate measurements, standardized reports, and
proper use of electroporators and electrodes. For example, skin electroporation
is a promising modality for treating different conditions with transdermal drug
delivery, gene electrotransfer, electrochemotherapy and irreversible electroporation.
A considerable amount of in vitro and in vivo studies exists, which use significantly
different electrode configurations, waveforms, and pulse generators. Results
from studies with different parameters are sometimes difficult (if not impossible)
to be compared. The reasons for slow translation of skin electroporation into
clinics are non-standard pulse parameters, non-standard electrode configurations,
generators not complying with their technical specifications or having no technical
specifications at all, lack of reporting on the delivered waveforms and electric field
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distribution, not performing the current-voltage measurements, and significantly
different skin structure of animals and humans. Nevertheless, it was shown that
electroporaton can reduce cost and facilitate treatment procedures. According to
the ongoing studies the electroporation based therapies are safe, with little or no
side effects. The clinical data published on electroporation-based applications are
quite encouraging, therefore we believe, that in the future, electroporation will
be indispensable in gene therapy, cancer treatment, infection disease treatment,
intracardiac ablation, and vaccination. However, further development of standard
electroporation treatment protocols, regulation of electroporator development and
user training, remain essential for successful incorporation into clinical practice.
Electroporation based therapies have a huge potential for implementation into
clinical practice also in socioeconomically disadvantaged populations. Currently,
the price of electroporation treatments is relatively high, mainly due to costly elec-
troporators and electrodes, but custom low budget devices can be developed. It is
not technically difficult to develop an electroporator, more challenging is the quality
and safety assurance, because biological loads characteristics vary considerably
from sample to sample and even more from tissue to tissue. Therefore, due to the
huge variation in biological load characteristics, delivered pulses may significantly
deviate from the pre-set. Low impedance of a load (tissue or cell suspension)
requires large power/currents, which quite often leads to significant voltage drop on
the load. Protocols in which a larger number of pulses (or long pulses) are delivered,
can result in reduced amplitude of pulses. With implementation of a particular
standard for particular application, the electroporation devices will be safer,
treatments more efficient and results more reproducible, which will allow faster
and more straight-forward progress of electroporation as well as treatments and
therapies based on electroporation. By implementing a particular medical standard
for clinical electroporation devices, the quality of clinical devices will be improved
which will result in better and more effective cancer treatment. But in order to
propose particular standard for electroporator, first technical specifications and
tolerances have to be determined, then, testing protocols have to be established.
We proposed the tolerances in the scope of the paper 2 and 3 and a possible
solution for establishment of testing protocol in paper 4. Because biological loads
are nonlinear resistive capacitive loads, ad hoc biological loads (e.g. potato tuber)
and resistors are not appropriate for electroporation device evaluation, because
they are not adequate approximation of therapeutic biological load. Therefore, we
develop an electronic emulator of a biological load during electroporation, which
allows sustainable and constant testing of electroporation devices and an objective
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comparison of the operation of different electroporators or of an electroporator over
its lifetime. We believe the developed emulator represents the first step toward the
development of standard and the testing or evaluation protocol, which we believe
will contribute to scientific and overall progress in the field of electroporation.
Defining the load is an important step in electroporator development, which was/is
often neglected. Illdefined load makes the development process more challenging
and can result in non-optimal solutions. Now, with high-quality measurements, a
load can be defined and an emulator can be developed, which raises the quality of
the development process.
The electroporation device developed in the scope of this Ph.D thesis operates
in accordance with expectations, the maximal output voltage is 4 kV and the
theoretical maximal current 131 A and 200 ns minimal pulse duration, the maximal
pulse repetition frequency is 2 MHz. It generates asymmetric bipolar pulses,
as well as pulse duration asymmetry, as voltage amplitude asymmetry can be
simultaneously delivered. Therefore, the device enables research of still unknown
effects, it facilities further research of cancellation and sensitisation effects, high
frequency electroporation and due to high maximal current also in vivo experiments
with bursts of bipolar pulses. The device was tested in vivo on mice. In both cases
the desired performance was reached. Additionally, acceleration of mice lag during
the pulse delivery was measured in order to evaluate muscle contractions. More
in vivo measurements should be done, before any final conclusions can be made,
but for now, we can only summarize, that muscle contractions were present also
in case of high frequency bursts and were significant. Importantly, HF-ECT with
bleomycin proved as effective as well established ”classical” ECT with bleomycin.
Two general Markov models for CEA have been developed, one for skin
melanoma and the other for Basal cell carcinoma (BCC). Initially, both models
are reduced in such a manner that they consist only of states that are relevant
for the current use of new technology, i.e. electrochemotherapy. Because elec-
trochemotherapy is an emerging technology, it is still not used in all patients, but
as the proof of concept rises, it is gradually moving up the cancer staging scale. A
realistic cost-effectiveness analysis for a specific cancer type facilitates equipment
purchase and clinical practice implementation. Additionally, the prediction of
cost-effectiveness can also influence the next round of fund raising. Furthermore,
specific models should be developed for each disease separately in order to include
all specific phenomena in a specific cancer type. Electrochemotherapy must be
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compared to well established procedures that are cancer-type, location and size
dependent.
As part of the doctoral dissertation, cost-effectiveness for electrochemotherapy
of stage IV and IIIc skin melanoma was evaluated. The results show that elec-
trochemotherapy increases the quality of life of patients after the intervention, but
the probability of being cost-effective is quite low (approximately 50 %), which
means that the price should be reduced for successful implementation in clinical
practice. However, if patients have bleeding lesions the ECT can be assumed
cost-effective (probability rises to 0.97). Cost-effectiveness would be best achieved
by reducing the cost of the electrode, which accounts for almost half of the total
cost of the intervention.
5 Original Scientific Contributions
Evaluation of electroporators and recommendations for standardization
of electroporator as a standalone medical device
The electroporation device manufacturers are currently hindering the development
of electroporation field by concealing the output pulse parameters of their devices,
designing them in a way to disable output pulse measuring, specifying charac-
teristics which device cannot deliver, and making devices that do not warn the
user when pulse delivery fault occurs. Consequently, reports of electroporation
studies are missing data that are essential for the reproduction of studies. In
order to properly understand the current situation and trends of development on
the electroporation field, a new review of commercially available devices, their
characteristics, limitations, and weaknesses was made. Also an expert opinion
about the electroporation devices used in skin electroporation was provided. The
quality of the pulse delivery was evaluated, by checking if the delivered pulses were
adequately addressed and measured in the electroporation studies, with the focus
on the field of nanosecond electroporation, where the delivery and measuring is
the most challenging. With the evaluation of commercially available devices and
their use, we would like to raise the awareness of the importance of measuring,
and influence on the manufacturers to stop obscuring pulse parameters and enable
measuring – quality control. Additionally, recommendations for standardization,
mainly focusing on the evaluation of electroporators proper or improper operation
were proposed and electronic emulator of the biological load during electroporation,
which enables constant and sustainable testing and unbiased comparison of different
electroporators operation, was developed.
Development of a novel bipolar high-frequency high-voltage pulse gener-
ator - electroporator
Recent insights on high-frequency irreversible electroporation (H-FIRE), and sen-
sitization and cancellation effects drive us to develop high frequency, high voltage,
bipolar, square wave pulse generator. We developed such a generator by using and
improving the latest pulse generator designs. The developed 4 kV pulse generator,
generates high voltage pulses with minimized switching time between positive and
negative pulse. The minimal pulse duration is 200 ns and maximal repetition rate
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2 MHz. The new generator allows us to study uptake and excitation effect in
vivo by high frequency pulses and test hypothesis related to more uniform tissue
electroporation and reduction of nerve and muscle excitation and pain sensation. It
is also able to generate asymmetrical bipolar pulses that enable us to study in detail
the sensitization and cancellation effects. The developed device was tested in first
in vivo high frequency electrochemotherapy (HF-ECT), in which HF-ECT with
bleomycin and cisplatin was proved to be as effective as well established ”classical”
ECT with bleomycin and cisplatin.
Cost-effectiveness analysis of electrochemotherapy for treatment of basal
cell carcinoma and skin melanoma
Cost-Effectiveness Analysis (CEA) has already been made for some ECT and IRE,
nevertheless, they were made without acquiring the quality of life (QoL) experienced
by the patients, which is crucial for adequate and accurate Health Technology
Assessment (HTA). The main reason that QoL was not acquired in previous studies
is most likely poor reporting, numerical data are not available. In our study, we
focused on electrochemotherapy of skin melanoma and basal cell carcinoma (BCC)
as these two therapies are used for the longest time and are also very successful.
We developed two Markov models, one for each therapy. For each of our Markov
models, we defined which data are needed. We collect these data (by data collection
methods) for the skin melanoma and conducted a CEA of ECT of stage IV and IIIc
skin melanoma. The cost-effectiveness of electrochemotherapy of stage IV and IIIc
skin melanoma was calculated for patients treated at the Institute of Oncology in
Ljubljana using the Cliniporator device and associated electrodes. We also provide
suggestions on how to improve the cost-effectiveness of the therapy. The realistic
CEA enriches health technology developers, with a better understanding of the
field, and provides a cost framework for a successful implementation in clinics. The
HTA also provides a basis for assessment of allowable costs for developing a new
product i.e. medical device.
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its correlation with electroporation-mediated molecular transport,” J. Membr.
Biol., vol. 236, no. 1, pp. 3–13, 2010.
[17] M. Isokawa, “Membrane time constant as a tool to assess cell degeneration,”
Brain Research Protocols, vol. 1, no. 2, pp. 114–116, 1997.
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L. A. Löfgren, “Electroporation therapy of skin cancer in the head and neck
area,” Dermatologic Surgery, vol. 36, no. 8, pp. 1245–50, 2010.
[101] I. Daskalov, N. Mudrov and E. Peycheva, “Exploring new instrumentation
parameters for electrochemotherapy. attacking tumors with bursts of biphasic
pulses instead of single pulses,” IEEE Engineering in Medicine and Biology
Magazine, vol. 18, no. 1, pp. 62–66, 1999.
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the electroporation thresholds of lipid bilayers: Molecular dynamics simulation
investigations,” Journal of Membrane Biology, vol. 246, no. 11, pp. 843–850,
2013.
References 253
[114] A. Golberg, M. Sack, J. Teissie, G. Pataro, U. Pliquett, G. Saulis, T. Stefan,
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Davalos, “Quantification of cell membrane permeability induced by monopo-
lar and high-frequency bipolar bursts of electrical pulses,” Biochimica et Bio-
physica Acta (BBA) - Biomembranes.
[119] J. C. Weaver, K. C. Smith, A. T. Esser, R. S. Son and T. R. Gowrishankar,
“A brief overview of electroporation pulse strength-duration space: A re-
gion where additional intracellular effects are expected,” Bioelectrochemistry,
vol. 87, pp. 236–243, 2012.
[120] A. Ivorra, B. Al-Sakere, B. Rubinsky and L. M. Mir, “In vivo electrical con-
ductivity measurements during and after tumor electroporation: Conductivity
changes reflect the treatment outcome,” Physics in Medicine Biology, vol. 54,
no. 19, pp. 5949, 2009.
[121] M. Sack, C. Schultheiss and H. Bluhm, “Triggered marx generators for the
industrial-scale electroporation of sugar beets,” IEEE Transactions on Indus-
try Applications, vol. 41, no. 3, pp. 707–714, 2005.
[122] M. A. Elgenedy, A. Darwish, S. Ahmed and B. W. Williams, “A transition
arm modular multilevel universal pulse-waveform generator for electropora-
tion applications,” IEEE Transactions on Power Electronics, vol. 32, no. 12,
pp. 8979–8991, 2017.
254 References
[123] A. Elserougi, A. Massoud and S. Ahmed, “Conceptual study of a bipolar
modular high voltage pulse generator with sequential charging,” IEEE Trans-
actions on Dielectrics and Electrical Insulations, vol. 23, no. 6, pp. 3450–3457,
2016.
[124] V. Novickij and et al., “High-frequency submicrosecond electroporator,”
Biotechnology Biotechnological Equipment, vol. 30, pp. 1–7, 2016.
[125] A. Elserougi, A. Massoud and S. Ahmed, “High-power bipolar multilevel
pulsed electroporator,” Instrumentation Science Technology, vol. 44, no. 1,
pp. 65–72, 2016.
[126] M. Cheng and W. H. Organization, “Medical device regulations: Global
overview and guiding principles,” Overview and Guiding Principles. World
Health Organization, 2003.
[127] J. L. Martin, B. J. Norris, E. Murphy and J. A. Crowe, “Medical device
development: The challenge for ergonomics,” Applied Ergonomics, vol. 39,
no. 3, pp. 271–283, 2008.
[128] D. B. Kramer, S. Xu and A. S. Kesselheim, “Regulation of medical devices
in the united states and european union,” New England Journal of Medicine,
vol. 366, no. 3, pp. 848–855, 2012.
[129] M. van Tulder, “Health technology assessment (hta) increasingly important in
spine research,” European Spine Journal, vol. 20, no. 7, pp. 999–1000, 2011.
[130] Analiza zdravstvenega sistema v Sloveniji, Povzetek in ključne ugotovitve:
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